# EDGAR Filing Document

**Accession Number:** 0000051253
**File Stem:** 0000051253-26-000006
**Filing Date:** 2026-2
**Character Count:** 680853
**Document Hash:** 89c6fdf4addf67904ef579e322a4ad35
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000051253-26-000006.hdr.sgml**: 20260227

**ACCESSION NUMBER**: 0000051253-26-000006

**CONFORMED SUBMISSION TYPE**: 10-K

**PUBLIC DOCUMENT COUNT**: 169

**CONFORMED PERIOD OF REPORT**: 20251231

**FILED AS OF DATE**: 20260227

**DATE AS OF CHANGE**: 20260227

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** INTERNATIONAL FLAVORS & FRAGRANCES INC
- **CENTRAL INDEX KEY:** 0000051253
- **STANDARD INDUSTRIAL CLASSIFICATION:** INDUSTRIAL ORGANIC CHEMICALS [2860]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 131432060
- **STATE OF INCORPORATION:** NY
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-04858
- **FILM NUMBER:** 26701808

**BUSINESS ADDRESS:**
- **STREET 1:** 521 W 57TH ST
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019
- **BUSINESS PHONE:** 212-765-5500

**MAIL ADDRESS:**
- **STREET 1:** 521 W 57TH ST
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** VANAMERIGEN HAEBLER INC
- **DATE OF NAME CHANGE:** 19680426

?xml version='1.0' encoding='ASCII'? iff-20251231

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-K**

---

| | |
|:---|:---|
| ☑ | **ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** |

---

**For the fiscal year ended December 31, 2025**

**OR**

---

| | |
|:---|:---|
| ☐ | **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** |
| **For the transition period from _______ to _______** | **For the transition period from _______ to _______** |

---

**<u>Commission File Number 1-4858</u>**

**INTERNATIONAL FLAVORS & FRAGRANCES INC.**

*(Exact name of registrant as specified in its charter)*

---

| | |
|:---|:---|
| **New York** | **13-1432060** |
| *(State or other jurisdiction<br>of incorporation or organization)* | *(I.R.S. Employer Identification No.)* |

---

**521 West 57th Street, New York, NY 10019-2960**

**200 Powder Mill Road, Wilmington, DE 19803-2907**

*(Address of principal executive offices) (Zip Code)*

**Registrant's telephone number, including area code (212) 765-5500**

**SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT:**

---

| | | |
|:---|:---|:---|
| **Title of Each Class** | **Trading Symbol** | **Name of Each Exchange on Which Registered** |
| Common Stock, par value 12 1/2¢ per share | IFF | New York Stock Exchange |
| 1.800% Senior Notes due 2026 | IFF 26 | New York Stock Exchange |

---

**SECURITIES REGISTERED PURSUANT TO SECTION 12(g) OF THE ACT:** None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☑ No ☐

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☑

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☑ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
| | | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☑

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☑

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to § 240.10D-1(b). ☑

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑

The aggregate market value of the voting stock held by non-affiliates of the Registrant was $18,848,336,277 as of June 30, 2025.

As of February 20, 2026, there were 255,477,487 shares of the registrant's common stock, par value 12 <sup>1</sup>/2¢ per share, outstanding.

**DOCUMENTS INCORPORATED BY REFERENCE**

Portions of the registrant's proxy statement for the 2026 Annual Meeting of Shareholders (the "IFF 2026 Proxy Statement") are incorporated by reference in Part III of this Form 10-K.

------

**INTERNATIONAL FLAVORS & FRAGRANCES INC.**

**TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
| | | **PAGE** |
| | **PART I** | |
| ITEM 1. | <u>[Business](#i5239245a6bb24ffbb6af4395e0b30886_13)</u> | <u>[3](#i5239245a6bb24ffbb6af4395e0b30886_13)</u> |
| ITEM 1A. | <u>[Risk Factors](#i5239245a6bb24ffbb6af4395e0b30886_16)</u> | <u>[10](#i5239245a6bb24ffbb6af4395e0b30886_16)</u> |
| ITEM 1B. | <u>[Unresolved Staff Comments](#i5239245a6bb24ffbb6af4395e0b30886_19)</u> | <u>[21](#i5239245a6bb24ffbb6af4395e0b30886_19)</u> |
| ITEM 1C. | <u>[Cybersecurity](#i5239245a6bb24ffbb6af4395e0b30886_22)</u> | <u>[21](#i5239245a6bb24ffbb6af4395e0b30886_22)</u> |
| ITEM 2. | <u>[Properties](#i5239245a6bb24ffbb6af4395e0b30886_25)</u> | <u>[23](#i5239245a6bb24ffbb6af4395e0b30886_25)</u> |
| ITEM 3. | <u>[Legal Proceedings](#i5239245a6bb24ffbb6af4395e0b30886_28)</u> | <u>[23](#i5239245a6bb24ffbb6af4395e0b30886_28)</u> |
| ITEM 4. | <u>[Mine Safety Disclosures](#i5239245a6bb24ffbb6af4395e0b30886_31)</u> | <u>[23](#i5239245a6bb24ffbb6af4395e0b30886_31)</u> |
| | **PART II** | |
| ITEM 5. | <u>[Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](#i5239245a6bb24ffbb6af4395e0b30886_37)</u> | <u>[23](#i5239245a6bb24ffbb6af4395e0b30886_37)</u> |
| ITEM 6. | <u>[\[Reserved\]](#i5239245a6bb24ffbb6af4395e0b30886_40)</u> | <u>[24](#i5239245a6bb24ffbb6af4395e0b30886_40)</u> |
| ITEM 7. | <u>[Management's Discussion and Analysis of Financial Condition and Results of Operations](#i5239245a6bb24ffbb6af4395e0b30886_43)</u> | <u>[24](#i5239245a6bb24ffbb6af4395e0b30886_43)</u> |
| ITEM 7A. | <u>[Quantitative and Qualitative Disclosures About Market Risk](#i5239245a6bb24ffbb6af4395e0b30886_61)</u> | <u>[43](#i5239245a6bb24ffbb6af4395e0b30886_61)</u> |
| ITEM 8. | <u>[Financial Statements and Supplementary Data](#i5239245a6bb24ffbb6af4395e0b30886_64)</u> | <u>[44](#i5239245a6bb24ffbb6af4395e0b30886_64)</u> |
| ITEM 9. | <u>[Changes in and Disagreements with Accountants on Accounting and Financial Disclosure](#i5239245a6bb24ffbb6af4395e0b30886_67)</u> | <u>[44](#i5239245a6bb24ffbb6af4395e0b30886_67)</u> |
| ITEM 9A. | <u>[Controls and Procedures](#i5239245a6bb24ffbb6af4395e0b30886_70)</u> | <u>[44](#i5239245a6bb24ffbb6af4395e0b30886_70)</u> |
| ITEM 9B. | <u>[Other Information](#i5239245a6bb24ffbb6af4395e0b30886_73)</u> | <u>[44](#i5239245a6bb24ffbb6af4395e0b30886_73)</u> |
| ITEM 9C. | <u>[Disclosure Regarding Foreign Jurisdictions that Prevent Inspections](#i5239245a6bb24ffbb6af4395e0b30886_76)</u> | <u>[45](#i5239245a6bb24ffbb6af4395e0b30886_76)</u> |
| | **PART III** | |
| ITEM 10. | <u>[Directors, Executive Officers and Corporate Governance](#i5239245a6bb24ffbb6af4395e0b30886_82)</u> | <u>[45](#i5239245a6bb24ffbb6af4395e0b30886_82)</u> |
| ITEM 11. | <u>[Executive Compensation](#i5239245a6bb24ffbb6af4395e0b30886_85)</u> | <u>[45](#i5239245a6bb24ffbb6af4395e0b30886_85)</u> |
| ITEM 12. | <u>[Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters](#i5239245a6bb24ffbb6af4395e0b30886_88)</u> | <u>[45](#i5239245a6bb24ffbb6af4395e0b30886_88)</u> |
| ITEM 13. | <u>[Certain Relationships and Related Transactions and Director Independence](#i5239245a6bb24ffbb6af4395e0b30886_91)</u> | <u>[45](#i5239245a6bb24ffbb6af4395e0b30886_91)</u> |
| ITEM 14. | <u>[Principal Accountant Fees and Services](#i5239245a6bb24ffbb6af4395e0b30886_94)</u> | <u>[45](#i5239245a6bb24ffbb6af4395e0b30886_94)</u> |
| | **PART IV** | |
| ITEM 15. | <u>[Exhibits and Financial Statement Schedules](#i5239245a6bb24ffbb6af4395e0b30886_100)</u> | <u>[45](#i5239245a6bb24ffbb6af4395e0b30886_100)</u> |
| ITEM 16. | <u>[Form 10-K Summary](#i5239245a6bb24ffbb6af4395e0b30886_235)</u> | <u>[116](#i5239245a6bb24ffbb6af4395e0b30886_235)</u> |
| <u>[SIGNATURES](#i5239245a6bb24ffbb6af4395e0b30886_238)</u> | <u>[SIGNATURES](#i5239245a6bb24ffbb6af4395e0b30886_238)</u> | <u>[117](#i5239245a6bb24ffbb6af4395e0b30886_238)</u> |

---

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

**PART I**

*In this report, we use the terms "IFF," "the Company," "we," "us" and "our" to refer to International Flavors & Fragrances Inc. and its subsidiaries.*

**ITEM 1.&nbsp;&nbsp;&nbsp;&nbsp;BUSINESS.**

We are a leading creator and manufacturer of products for application in food, beverage, health & biosciences, and scent, as well as complementary adjacent products, including natural health ingredients, all of which are used in a wide variety of consumer and end-use products. Our products are sold principally to manufacturers of dairy, meat, beverages, snacks, savory, sweet, baked goods, grain processors and other foods, personal care products, soaps and detergents, cleaning products, perfumes, dietary supplements, food protection, infant, elderly and animal nutrition, functional food, bio-fuel, and oral care products. As a result, we hold global leadership positions in the Food & Beverage, Home & Personal Care and Health & Wellness markets, and across key Tastes, Textures, Scents, Nutrition, Enzymes, Cultures, Soy Proteins and Probiotics categories, among others.

Sales in 2025 were $10.890 billion. Our business is geographically diverse, with sales in the U.S. representing approximately 28% of sales in 2025. No other country represented more than 10% of sales. In 2025, no customer accounted for 10% or more of sales.

**Our Product Offerings**

During the year ended December 31, 2025, our business consisted of five segments: Taste, Food Ingredients, Health & Biosciences, Scent and, until the completion of the divestitures of both the Pharma Solutions and Nitrocellulose disposal groups in May 2025, Pharma Solutions. Effective January 1, 2025, our former Nourish segment was restructured into two newly designated operating segments: Taste and Food Ingredients.

***Taste***

Our Taste segment consists of the development and production of a range of flavor compounds and natural taste solutions that are ultimately used by our customers in a diverse variety of products, including savory products (soups, sauces, meat, fish, poultry, snacks, etc.), beverages (juice drinks, carbonated or flavored beverages, spirits, etc.), sweets (bakery products, candy, cereal, chewing gum, etc.), and dairy products (yogurt, ice cream, cheese, etc.). Taste also includes value-added spices and seasoning ingredients for meat, food service, convenience, alternative protein and culinary products.

***Food Ingredients***

Our Food Ingredients segment consists of a diversified portfolio across natural, artificial and plant-based specialty food ingredients that provide functional properties solutions for food and beverage products, as well as specialty soy and pea protein with value-added formulations, emulsifiers and sweeteners. Natural food protection ingredients consist of natural antioxidants and anti-microbials used for natural food preservation and shelf-life extension for beverages, cosmetic and healthcare products, pet food and feed additives. Food Ingredients also includes savory solutions (such as spices, marinades, and mixtures) and inclusion products (such as products combining flavorings with fruit, vegetables and other natural ingredients).

***Health & Biosciences***

Our Health & Biosciences segment consists of the development and production of an advanced biotechnology-derived portfolio of enzymes, food cultures, probiotics and specialty ingredients for food and non-food applications. Among many other applications, our portfolio includes cultures for use in fermented foods such as yogurt, cheese and fermented beverages, probiotic strains, household detergents, animal feed, ethanol production and brewing. Health & Biosciences is comprised of Health, Food Biosciences, Home & Personal Care, Animal Nutrition and Grain Processing.

*Health* provides ingredients for dietary supplements, functional food and beverage, specialized nutrition and pharma.

*Food Biosciences* provides products that aim to serve the global demand for healthy, natural, clean label and fermented food for fresh dairy, cheese, bakery and brewing products. Such products contribute to extended shelf life, stability, taste and texture, helping our customers to improve their product offerings. The business's enzyme solutions also allow our customers to provide low sugar, high fiber and lactose-free dairy products.

*Home & Personal Care* produces enzymes for laundry and dishwashing detergents, cleaning and textiles to help enhance the product and process performance of products in the fabric and home care, textiles and industrials and personal care markets. The business also produces patented enzymatic polymers that are renewable, biodegradable alternatives to functional ingredients used in home cleaning and beauty care products.

*Animal Nutrition* produces feed enzymes and animal health solutions that help to improve nutrition, welfare, performance and sustainability of livestock animal farming.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

*Grain Processing* produces yeasts and enzymes for biofuel production and carbohydrate processing.

***Scent***

Our Scent segment creates fragrance compounds and fragrance ingredients that are integral elements in the world's finest perfumes and best-known household and personal care products. Consumer insights, science and creativity are at the heart of our Scent business, along with our unique portfolio of natural and synthetic ingredients, global footprint, innovative technologies and know-how, and customer intimacy. The Scent segment is comprised of Fragrance Compounds and Fragrance Ingredients.

*Fragrance Compounds* are unique and proprietary combinations of multiple fragrance ingredients that are ultimately used by our customers in their consumer goods. Our creative and commercial teams within fragrance compounds are organized into two broad categories: fine fragrances and consumer fragrances.

Our fine fragrances focus on perfumes and colognes, creating global and local namesake brands, from high luxury to mass market, from market leading to ultra-niche products.

Our consumer fragrances include three end-use categories of products:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Fabric Care, including laundry detergents, fabric softeners and specialty laundry products;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Home Care, including household cleaners, dishwashing detergents and air fresheners; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Body Care, including personal wash, hair care and toiletries products.

*Fragrance Ingredients* are natural and synthetic, and active and functional ingredients that are used internally and sold to third parties, including competitors, for use in the preparation of compounds. While the principal role of our fragrance ingredients facilities is to support our fragrance compounds business, we utilize excess manufacturing capacity to manufacture and sell certain fragrance ingredients to third parties, enabling us to leverage our fixed costs while maintaining the security of our supply for our perfumers and ultimately our customers.

***Pharma Solutions***

Our former Pharma Solutions segment produced, among other things, a vast portfolio of cellulosics and seaweed-based pharmaceutical excipients, used in prescription and over-the-counter pharmaceuticals and dietary supplements. We completed the divestiture of our Pharma Solutions disposal group, which included certain adjacent businesses, on May 1, 2025 and we divested our nitrocellulose business, which was within our Pharma Solutions segment, on May 9, 2025.

**Consumer Insights, Research and Product Development Process**

The markets in which we operate require constant innovation to remain competitive. Consumer preferences tend to drive change in our markets, and as science advances and sustainability continues to be an important factor to customers and consumers, we continue to strengthen our consumer insights and research and development platforms.

*Consumer Insights*

Innovation begins with understanding the consumer and anticipating emerging industry trends. Through our consumer insight programs, we develop a deep understanding of what consumers value, enabling us to focus our research, development, and creative efforts effectively.

Our consumer science, insights, and marketing teams interpret trends, monitor product launches, analyze quantitative market data, and conduct numerous consumer interviews annually. Leveraging this information, we design proprietary programs to evaluate potential products and uncover the emotional connections between consumers and prospective offerings. This ability to predict product success enhances brand equity, drives market share growth, and delivers greater returns for both our customers and IFF.

*Research and Development*

We consider our research and development infrastructure to be one of our key competencies and critical to our ability to provide differentiated products to our customers. We have strong product and application development pipelines built upon a global network of research and development, as well as regulatory and product stewardship capabilities.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

We invest substantial resources in the research and development of new and innovative molecules, compounds, formulations and technologies and the application of these to our customers' products. Guided by our consumer insights programs and business unit priorities, we strategically align our resources around key research and development platforms that address or anticipate consumer needs. These platforms reflect growth themes driven by consumer insights, such as improving home and personal care, empowering wellbeing and healthy lives, transforming food systems and accelerating climate solutions. By aligning our capabilities with these platforms, we ensure the proper support for each initiative, enabling successful commercialization of our products.

As of December 31, 2025, we have 849 granted U.S. patents, and 451 pending U.S. patent applications, as well as thousands of other granted patents and pending patent applications around the world. We have developed unique molecules and delivery systems for our customers that serve as the foundations of successful products around the world.

Our principal basic research and development activities are located in Union Beach, New Jersey; Wilmington, Delaware; Palo Alto, California; Brabrand, Denmark; and Leiden, The Netherlands. These centers, in collaboration with our global research and development network, drive:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• discovery of new materials;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• development of new technologies, such as delivery systems;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• creation of new compounds; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• enhancement of existing ingredients and compounds.

As of December 31, 2025, we employed approximately 3,000 people globally in research and development activities (including innovation, creation and design activities).

*Creative Application*

Through our global network of creative centers and application laboratories, we transform the Taste, Health & Biosciences, Scent and Food Ingredients (and, prior to its disposition, Pharma Solutions) products that we have developed in the research and development process into commercially viable solutions for our customers. Our creative teams, composed of marketing, consumer science, insights, and technical experts collaborate closely with customers to deliver experiences that meet consumer expectations in markets around the world.

New product development is driven by customer requests for specific solutions or IFF internal initiatives informed by consumer insights. Our product development team partners with our scientists and researchers to optimize consumer appeal and relevance of our product offerings. This collaborative process ensures offerings are refined and ready for integration into final consumer products. Beyond creating new products, our teams advise customers on improving existing formulations, whether by substituting ingredients for cost efficiency, enhancing yield, or improving functionality. These efforts often result in stronger value propositions for our customers.

Most of our formulas are treated as trade secrets and remain proprietary assets. Our business is not materially dependent upon any individual patent, trademark or license.

**Supply Chain**

*Procurement*

Our products rely on both natural and synthetic ingredients. As of December 31, 2025, we sourced approximately 20,000 different raw materials from a broad network of domestic and international suppliers and distributors.

Natural ingredients are derived from flowers, fruits and other botanical products, as well as from plant, animal and marine products, and commodity crops like wheat, corn and soy. These materials contain diverse organic chemicals that are responsible for the fragrance, flavor, antioxidant properties and nutritional value. We purchase natural products directly from farms or in processed and semi-processed forms. Some are used as-is, while others undergo additional processing. Natural products, combined with various chemicals, also serve as raw materials for the manufacture of synthetic ingredients through chemical processes.

To ensure a reliable supply of raw materials, achieve favorable pricing and provide timely pricing information to our customers, we continue to focus on:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• negotiating contracts with fixed or formula-based pricing for defined periods

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• hedging raw materials that can be linked to liquid commodity assets

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• building strategic supplier relationships to access critical materials

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• implementing indexed pricing models

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• reducing formulation complexity

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• evaluating make-versus-buy decisions for ingredients

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• sourcing locally through in-country procurement professionals

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• periodically assessing our supply base to drive cost efficiency and improvement

*Manufacturing and Distribution*

As of December 31, 2025, we had approximately 170 manufacturing facilities, creative centers and application laboratories located in approximately 30 different countries. Our major manufacturing sites are located in the United States, The Netherlands, Spain, Germany, Indonesia, Turkey, Brazil, Mexico, Slovenia, China, India, Ireland, Norway, Finland, Denmark, Belgium and Singapore.

For more detailed information about risks related to our supply chain, please refer to Item 1A, "Risk Factors" – *"Trade wars, tariffs, sanctions, geopolitical developments, supply chain disruptions, environmental events, natural disasters, public health or human rights crises, and other events may adversely affect our sourcing of raw materials, and our development, manufacturing, distribution or sale of our products*.*"*

**Sustainability** 

Our approach to sustainability is rooted in our Company's purpose statement and our ongoing commitment to 'Do More Good' for people and planet. This aligns with our Company's strategy for long-term growth and value creation. Through this commitment, we focus on the interconnected pillars of conscious sourcing, partnerships of impact, intentional innovation and operating for the future.

Across these four pillars, our Company continued to achieve notable recognitions in 2025. For example, we were recognized in 2025 by EcoVadis, receiving a Gold sustainability rating that places our Company among the top five percent of companies assessed. In addition, we maintained our position as a constituent of the Dow Jones Sustainability Indices, North America, a best-in-class benchmark for investors who recognize that sustainable business practices are critical to generating long-term shareholder value. We continue to support transparency and accountability through our submission to CDP Climate Change, Water Security and Forests, specifically named to CDP's A list for climate change for the tenth time since 2015. Lastly, we continue to be listed in the FTSE4Good Index series as well as being named as one of America's Most Responsible Companies by Newsweek.

**Governmental Regulation** 

We develop, produce and market our products in a number of jurisdictions around the world which are subject to federal, regional and local legislation and regulations in various countries.

Our products used in industries such as food and beverage, dietary supplements, home and personal care, and animal feed, must comply with strict quality, regulatory, and environmental standards.

These requirements have become increasingly stringent in recent years, impacting both existing and new products, and compliance with these standards can result in high capital expenditures, which may be significant in certain periods. We continuously monitor existing and emerging regulations, and although the impact of future changes cannot be predicted with certainty, compliance has not had, and is not expected to have, a material adverse effect on our capital expenditures, earnings, or competitive position.

Our products and operations are regulated by governmental agencies in the local markets in which we operate. These agencies include (1) the Food and Drug Administration and equivalent international agencies that regulate flavors and other ingredients in consumer products, (2) the Environmental Protection Agency and equivalent international agencies that regulate our manufacturing facilities, as well as fragrance products (including encapsulation systems), (3) the Occupational Safety and Health Administration and equivalent international agencies that regulate the working conditions in our manufacturing, research laboratories and creative centers, (4) local and international agencies that regulate trade and customs, (5) the Drug Enforcement Administration and other local or international agencies that regulate controlled chemicals that we use in our operations, (6) the Chemical Registration/Notification authorities that regulate chemicals that we use in, or transport to, the various countries in which we manufacture and/or market our products, and (7) the U.S. Department of Agriculture and equivalent international authorities with respect to, among other things, labeling of consumer products. We have seen an increase in registration and reporting requirements concerning the use of certain chemicals in a number of countries, such as Registration, Evaluation, Authorization and Restriction of Chemicals ("REACH") regulations in the European Union, as well as similar regulations in other countries.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

In addition to product-specific regulations, we are subject to health, workplace safety, and environmental standards at both local and international levels. Our manufacturing facilities worldwide must comply with environmental regulations governing air emissions, wastewater discharge, hazardous material usage, waste disposal, and remediation of existing contamination.

In recent years, there has been an increase in the stringency of environmental regulation and enforcement of environmental standards, and the costs of compliance have risen significantly, a trend we expect will continue in the future.

For more detailed information about risks related to governmental regulation applicable to the Company, please refer to Item 1A, "Risk Factors" – *"If we are unable to comply with regulatory requirements and industry standards, including those regarding product safety, quality, efficacy and environmental impact, we could incur significant costs and suffer reputational harm which could adversely affect results of operations."*

**Competition**

The markets for our products are part of a larger market that supplies a wide variety of ingredients and compounds used in consumer products. Our products are sold principally to manufacturers of dairy, meat, beverages, snacks, savory and sweet goods, baked goods, grain processors and other foods, personal care products, soaps and detergents, cleaning products, perfumes, dietary supplements, food protection, infant, elderly and animal nutrition, functional food, and oral care products.

The global market for our products has expanded, primarily as a result of an increase in demand for, and in the variety of, consumer products.

The market for our products is highly competitive. Our main competitors consist of (1) other large global companies, such as Givaudan, Novonesis, DSM-Firmenich, Symrise, Kerry, and ADM, (2) mid-sized companies, (3) numerous regional and local manufacturers and (4) consumer product companies who may develop their own competing products.

We believe that our ability to create products with the sustainability-related attributes customers expect and compete successfully in the various sub-markets is based on, among other things:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our in-depth understanding of our customers and consumers,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• vertical integration,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• innovation and technological advances from our research and development activities and, as applicable, our scientists,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to tailor products to customers' needs, and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to manufacture products on a global scale.

In certain industries, large multi-national customers and, increasingly, mid-sized customers, may limit the number of their suppliers by placing some on "core lists," giving them priority for development and production of their new or modified products. To compete successfully, we must make continued investments in customer relationships and tailor our research and development efforts to anticipate customers' needs, provide effective service and secure and maintain inclusion on these "core lists."

Private label manufacturers, mostly medium-sized, local or small food manufacturers, constitute a growing segment in certain markets where we are active. Over the last decade, with the strengthening of supermarket chains, online platforms and growing consumer price consciousness, consumption of private label products has grown at a faster rate than the brand food industry rate. We believe that new business opportunities will continue to arise from these clients as they are increasing their demand for products that are similar to existing products in the market, distinctive premium products, as well as more innovative products.

**Our People**

The success of our business is built on our talented employees. As of December 31, 2025, we had approximately 21,500 employees worldwide, of whom approximately 5,500 are employed in the United States. We continue to invest in our workforce, culture and leadership and development programs to support employee engagement and performance.

*Culture and Values*

Our culture is based on our four corporate values of passionate, partners, persistent and principled, and the expression of these values can be seen and felt throughout our history. Our employees appreciate that they contribute to products that touch and enhance the lives of millions of people around the world. IFF strives to have a culture of inclusion and belonging where all employees can thrive. Our programs focus on inclusive talent processes, employee experiences, and external engagement. Our robust culture ambassador and colleague community program engage a broad portion of the IFF community in building common identity and shared purpose as well as strengthening engagement and motivation by providing programming on IFF values and recognition of individuals who exemplify them.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

*Leadership and Development*

Our leadership development efforts empower employees to become forward-looking, inspiring and capable decision-makers, agents of change and great leaders. A full portfolio of proprietary leadership development programs and an overarching talent management system is in place to support growth of leaders and at all levels. To cultivate our employees' talent and build sustainable long-lasting careers at IFF, we provide tools that enable our employees to envision their career journeys and facilitate internal mobility. We offer corresponding development opportunities to include specialized courses for employees globally by partnering with leading institutions and universities to help provide the latest training and development offerings at all levels. We also offer our employees an extensive library of on-demand courses and materials on leadership, management and professional skills development. Those learning resources are integrated into our human capital platform, allowing managers and employees to establish digitalized learning plans that are ultimately captured as a part of their employee profile. Further, those offerings complement our talent acquisition strategy and organized and personalized feedback process, supported by industry-leading assessment tools.

*Occupational Health & Safety*

Employee safety is one of the cornerstones of our business. Our occupational health and safety management system requires and encourages employees and supervised contractors at sites globally to uphold IFF's protocols, report any incidents and suggest improvements that improve the safety of work sites. Our safety management system is based on U.S. Occupational Safety and Health Administration ("OSHA") standards which apply to all our sites in conjunction with any local regulations. We emphasize safety governance (setting and updating comprehensive safety policies and procedures), training (based on IFF policies and local regulatory requirements) and culture (characterized by awareness and communication) to support an injury-free workplace.

**Availability of Reports**

We make available free of charge on or through the "Investors" link on our website, www.iff.com, all materials that we file electronically with the Securities and Exchange Commission ("SEC"), including our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports, filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, as soon as reasonably practicable after electronically filing such materials with, or furnishing them to, the SEC.

The SEC maintains an Internet website, www.sec.gov, that contains reports, proxy and information statements and other information that we file electronically with the SEC. Information on, or accessible through, our website is not incorporated by reference into this Form 10-K.

A copy of our By-Laws, Corporate Governance Guidelines, Codes of Conduct, and the charters of the Audit Committee, Human Capital & Compensation Committee, Governance & Corporate Responsibility Committee and Innovation Committee of the Board of Directors are posted on the "Investors" section of our website, www.iff.com.

Our principal executive offices are located at 521 West 57th Street, New York, New York 10019 and 200 Powder Mill Road, Wilmington, Delaware 19803.

**Executive Officers of Registrant**

Below is a list of the executive officers of the Company and other significant employees who are members of our Executive Leadership Team as of February 27, 2026.

---

| | | |
|:---|:---|:---|
| **Name** | **Age** | **Position** |
| J. Erik Fyrwald<sup>(1)</sup> | 66 | Chief Executive Officer and member of our Board of Directors |
| Yuvraj Arora<sup>(1)</sup> | 54 | President, Taste and Chief Commercial Officer |
| Deborah Borg<sup>(1)</sup> | 49 | Executive Vice President, Chief People & Culture Officer |
| Michael DeVeau<sup>(1)</sup> | 45 | Executive Vice President, Chief Financial Officer |
| Ralf Finzel<sup>(1)</sup> | 62 | Executive Vice President, Global Operations Officer |
| Leticia Gonçalves Lourenço<sup>(1)</sup> | 51 | President, Health & Biosciences |
| Stephen Landsman<sup>(1)</sup> | 66 | Executive Vice President, General Counsel |
| Ana Paula Teles de Mendonça<sup>(1)</sup> | 57 | President, Scent |
| Andres Muller<sup>(1)</sup> | 61 | President, Food Ingredients |
| Vivek Verma | 57 | Executive Vice President, Chief Information Officer |

---

_____________________

(1)These individuals are executive officers and file reports under Section 16 of the Securities Exchange Act of 1934.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*J. Erik Fyrwald* has served as our Chief Executive Officer and a member of our Board of Directors since February 2024. Mr. Fyrwald joined us from Syngenta, where he served as Chief Executive Officer since 2016. Prior to his role at Syngenta, Mr. Fyrwald served as Chief Executive Officer of Univar Solutions from May 2012 until May 2016, as Chairman and Chief Executive Officer of Nalco from 2008 until 2011, when Nalco merged with Ecolab Inc., and following the merger, he served as President of Ecolab. Mr. Fyrwald began his career at DuPont starting in 1981. During his 27 years at DuPont, Mr. Fyrwald held a number of positions, including Group Vice President of the Agriculture and Nutrition Division at DuPont and Vice President and General Manager of DuPont's Nutrition and Health Business.

*Yuvraj Arora* has served as our Chief Commercial Officer and President, Taste since January 2025. Prior to this role, Mr. Arora served as Executive Vice President and President, Nourish since June 2023. Mr. Arora joined IFF from Kellogg North America, where he served as the President of the company's six U.S. categories since April 2021. He was with Kellogg for more than 20 years, beginning in India in 2002 where he held roles in marketing and category management. He later assumed roles of increasing responsibility in marketing, brand management and general management upon his relocation to the United States in 2005 and in Singapore from 2012-2015.

*Deborah Borg* has served as our Executive Vice President, Chief People & Culture Officer since August 2022. Ms. Borg joined IFF from Bunge Limited, where she served as Chief Human Resources and Communications Officer since 2016. Prior to joining Bunge, she served in a variety of business leadership and Human Resources roles in Australia, Switzerland and the U.S. for Dow Chemical between 2000 and 2015. She began her career at General Motors Australia.

*Michael DeVeau* has served as our Executive Vice President, Chief Financial Officer since January 2025. Mr. DeVeau served as our Senior Vice President, Corporate Finance and Investor Relations from December 2022 to December 2024 and had previously served as Senior Vice President, Chief Investor Relations & Communications Officer from February 2021 to December 2022, Vice President, Investor Relations, Communications, and Chief of Staff from September 2014 to February 2021, as well as Divisional Chief Financial Officer, Scent from 2018 to 2020 and Head of Corporate Strategy from 2016 to 2018. Since joining the Company in 2009 as Head of Investor Relations, Mr. DeVeau has held various roles of increasing scope and responsibility in communications, finance and strategy. Prior to joining the Company, he served in leadership positions in investor relations, finance and corporate development at PepsiCo. Mr. DeVeau began his career as an Equity Research Analyst at Citigroup Investment Research.

*Ralf Finzel* has served as our Executive Vice President, Global Operations Officer since November 2022. Previously, Mr. Finzel served as Vice President of Integrated Supply Chain for Honeywell International Performance Materials and Technologies Business Group in Houston since 2020. Prior to that, he served as Vice President of Integrated Supply Chain for Honeywell International Building Technologies Business Group from July 2017 to March 2020. He first joined Honeywell in Germany as an operations manager in 1999, and held various roles of increasing responsibility and scope in Europe and the U.S. Prior to joining Honeywell, he worked in research and plant management roles for Hoechst AG.

*Leticia Gonçalves Lourenço* has served as our President, Health & Biosciences since March 2025. Previously, Ms. Gonçalves Lourenço was ADM's President, Precision Fermentation and ADM Ventures from December 2023 to February 2025. Prior to that, Ms. Gonçalves Lourenço served as President, Specialty Ingredients and Global Foods from February 2020 to November 2023. Prior to joining ADM, Ms. Gonçalves Lourenço served for more than 25 years at Monsanto, now part of Bayer, in a variety of senior leadership roles, including Senior Vice President, U.S. Country Division Head and President for Europe and the Middle East.

*Stephen Landsman* has served as our Executive Vice President, General Counsel since July 2025. From August 2024 to July 2025, Mr. Landsman served as our Executive Vice President, Business Development. Previously, Mr. Landsman served as Group General Counsel from May 2018 to July 2024 and Global Head of Mergers and Acquisitions from June 2017 to May 2018 with Syngenta. Prior to joining Syngenta, Mr. Landsman served as Executive Vice President, General Counsel and Corporate Secretary for Univar, Inc. from 2013 to 2017. Prior to that, Mr. Landsman served as Vice President, General Counsel and Corporate Secretary at Nalco Company from 2003 to 2013, following various leadership positions within Nalco since 1990.

*Ana Paula Teles de Mendonça* has served as President, Scent since April 2024. Previously, Ms. Mendonça served as our Senior Vice President, Commercial Excellence from December 2022 to February 2024. Prior to that, she served as Vice President, President Global Ingredients & Regional General Manager, North America, Consumer Fragrances since February 2022, and, before that, as Vice President, Regional General Manager, North America, Consumer Fragrances since January 2016. Ms. Mendonça joined IFF more than 30 years ago, and her broad experience expands across Category Management (Fine Fragrance, Home, Fabric, and Beauty), Global Marketing, and Product Innovation.

*Andres Muller* joined IFF in December 2024 and has served as our President, Food Ingredients since January 2025. Mr. Muller joined IFF from Corbion where he served as President, Sustainable Food Solutions since March 2020 and was a member of the Executive Committee since January 2015. Previously, Mr. Muller served as SVP Global Sales, Innovation and Marketing at DuPont from 2013 to 2015 and held various leadership roles in marketing and sales within Sensient and DuPont Nutrition

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

and Health, formerly Danisco from 2001 to 2013. Mr. Muller began his career at Sabores y Fragancias in 1984 as a fragrance compounder. After numerous R&D and sales roles, he formed his own flavors and fragrances company, which Bush Boake Allen later acquired in 2000.

*Vivek Verma* has served as our Executive Vice President, Chief Information Officer since February 2021 and had previously served as our Senior Vice President, Chief Information Officer from 2016 to February 2021. Before joining the Company, Mr. Verma served as Vice President of Global Infrastructure Operations at American Express, a multinational financial services company. Prior to that, Mr. Verma held several other leadership positions at American Express as well as Vice President, Division CIO and management consulting roles with GlaxoSmithKline, Bristol Myers Squibb and PricewaterhouseCoopers.

**ITEM 1A.&nbsp;&nbsp;&nbsp;&nbsp;RISK FACTORS.**

**Risk Factor Summary**

*The following summary highlights some of the principal risks that could adversely affect our business, financial condition or results of operations. This summary is not complete and the risks summarized below are not the only risks we face. These risks are discussed more fully further below in this section entitled "Risk Factors" in Item 1A. of this report. These risks include, but are not limited to, the following:*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Consumer demand and preferences, as well as regulatory trends may impact demand for our products, which may have a negative effect on our operating results and future growth.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our business is highly competitive, and if we are unable to compete effectively our sales and results of operations will suffer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• If we are unable to successfully execute our strategic transformation, or enter into or close collaborations, joint ventures, partnerships, acquisitions, or divestitures, it may have a material adverse effect on our business, results of operations and financial condition.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our performance may be adversely impacted if we are not successful in managing our inventory and/or working capital balances.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our results of operations may be negatively impacted by the outcome of uncertainties related to legal claims, disputes, investigations and litigation, including the ongoing antitrust and competition investigations and related class action lawsuits.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Trade wars, tariffs, sanctions, geopolitical developments, supply chain disruptions, environmental events, natural disasters, public health and human rights crises, and other events may adversely affect our sourcing of raw materials, and our development, manufacturing, distribution or sale of our products.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Increases in input costs, including raw materials, transportation, and energy, have been exacerbated by recent inflationary pressures.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• A significant data breach or other disruption to our information technology systems could disrupt our operations, result in the loss of confidential information or personal data, and adversely impact our reputation, productivity, business or results of operations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We are exposed to AI-related risks and opportunities that if we fail to properly manage, could result in material liabilities, or otherwise materially adversely affect our business, results of operations, and financial condition.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The impact of currency fluctuation or devaluation in the international markets in which we operate may negatively affect our results of operations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• International economic, political, legal, compliance and business factors could negatively affect our financial statements, operations and growth.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our inability to recruit, retain or transition employees could adversely affect our ability to compete and achieve our strategic goals.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Any impairment of our tangible or intangible long-lived assets, including goodwill, may adversely impact our profitability.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We are subject to customer, consumer, shareholder and regulatory focus on sustainability, which may result in additional costs in order to meet new requirements, including adversely affecting our stock price, results of operations and access to capital.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our ability to declare and pay dividends is subject to certain considerations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We have a substantial amount of indebtedness that could materially adversely affect, among other things, our financial condition, our ability to return capital to our shareholders, needed investments into our business and our credit ratings. Indebtedness and related covenants could adversely affect our liquidity, flexibility, and cost of capital.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our funding obligations for our pension and postretirement plans could adversely affect our earnings and cash flows.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• A disruption in our manufacturing operations could adversely affect our profitability.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• If we are unable to comply with regulatory requirements and industry standards, including those regarding product safety, quality, efficacy and environmental impact, we could incur significant costs and suffer reputational harm which could adversely affect results of operations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Failure to comply with environmental protection laws may cause us to close, relocate or operate one or more of our plants at reduced production levels, and expose us to civil or criminal liability, which could adversely affect our operating results and future growth.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We could be adversely affected by violations, by us or our counterparties, of U.S. or foreign anti-bribery, international trade, anti-corruption, antitrust or competition laws and regulations, applicable sanctions or employment and human rights or employment regulations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our ability to compete effectively depends on our ability to protect our intellectual property rights.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Changes in our tax rates, the adoption of new U.S. or international tax legislation, or changes in existing tax laws could expose us to additional tax liabilities that may affect our future results.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The N&B Transaction could result in significant tax liability, and we may be obligated to indemnify DuPont for any such tax liability imposed on DuPont.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• If we fail to comply with data protection laws in the U.S. and abroad, we may be subject to fines, penalties and other costs.

**Risk Factors**

*We routinely encounter and address risks in conducting our business. Some of these risks may cause our future results to be different - sometimes materially different – than in the past or than we presently anticipate. Below are some of the risks we have identified that could adversely affect our business. How we react to material future developments, as well as how our competitors and customers react to those developments, could also affect our future results.*

**<u>Risks Related to Our Business and Industry</u>**

**Consumer demand and preferences, as well as regulatory trends may impact demand for our products, which may have a negative effect on our operating results and future growth.**

Many of our products are ingredients or components in consumer products which are sold to end-users throughout the world. Demand for such consumer products depends on consumer preferences that are driven by a variety of factors, such as the increasing use of weight management pharmaceutical products, increasing health and wellness awareness, greater transparency in product labeling, and changes in global, regional or local economic conditions (such as inflation, unemployment, salaries and wage rates stagnation, low growth rates, and impacts of supply disruptions, climate events, or geopolitical developments). At the same time, increased regulatory requirements, statements or questions around certain of our products, may result in changes in customer orders or delays in developing, manufacturing or marketing of new or existing products. Moreover, given that the timing or volumes in our customers' orders are generally at our customers' discretion, customers may cancel, reduce or postpone orders with us on relatively short notice.

These and other consumer and regulatory trends may continue to affect the demand for our products and impact our ability to meet certain productivity levels. If we are unable to anticipate or react to these trends in a timely and cost-effective manner, our productivity, results of operations and future growth may be adversely affected.

**Our business is highly competitive, and if we are unable to compete effectively, our sales and results of operations will suffer.**

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

We face intense global competition from multinational and specialized companies across our product offerings, as well as consumer product companies developing their own alternatives. Competitors may have greater resources, proprietary technologies, or benefit from recent industry consolidation, enabling them to respond more effectively to customer or market demands. As we expand into adjacent markets, such as functional foods and specialty fine ingredients, we encounter additional risks, including price sensitivity and lower margins. Our ability to compete depends on, among other things, innovation, product quality, regulatory compliance, pricing, logistical efficiency, digital proficiency, customer service, and intellectual property protection. Failure to invest in growth, scale new concepts, or adapt to technological advancements could erode our competitive position. Increased competition, including aggressive pricing, may lead to lost sales, margin pressure, and reduced profitability. We may not be in a position to allocate the appropriate level of investment in research and development efforts, due to other macroeconomic pressures, and such investments may not yield expected returns due to poor execution or delays by our customers in launching relevant products, changing consumer trends, or disruptive competitor innovations. These factors are beyond our control and could negatively impact our results of operations.

Additionally, a significant portion of our sales comes from a relatively small number of large multinational customers. In 2025, our 25 largest customers, a majority of which were multinational consumer products companies, collectively accounted for approximately 32% of our sales. Multinational customers have been facing their own competitive challenges, such as pressures by new smaller companies and specialty players that cater to or are more adept at adjusting to the latest consumer trends, including towards natural products and clean labels, changes in the retail landscape (including e-commerce and consolidation), and increased competition from private labels, which have resulted and may continue to result in decreased demand for our products. Multinational and increasingly middle market customers also rely on "core lists" of suppliers, requiring more favorable terms for inclusion, such as rebates, which could adversely affect our margins. If we fail to secure or maintain such "core list" status, our sales and margins could be adversely affected.

Beyond large multinational customers, our customer base continues to be diverse. Based on fiscal-year 2025 sales, we had approximately 20,000 customers, approximately 69% of which are small and mid-sized companies. This diversity requires ongoing adjustments to product development, manufacturing, distribution, marketing, and infrastructure to support varied go-to-market models. Managing a geographically and operationally diverse portfolio adds complexity, and failure to maintain relationships or gain market share with these customers could adversely affect our growth.

**If we are unable to successfully execute our strategic transformation, or enter into or close collaborations, joint ventures, partnerships, acquisitions, or divestitures, it may have a material adverse effect on our business, results of operations and financial condition.**

As part of our strategic transformation and portfolio optimization, we have completed several divestitures in recent years and continue to evaluate additional transactions, including strategic alternatives for our Food Ingredients segment. Successfully completing such transactions depends on factors beyond our control, such as industry and macroeconomic conditions, third party interest and financing, underlying asset performance, regulatory approvals, and entanglements with the rest of our businesses. Moreover, such transactions are complex, costly, and time-consuming, and may divert management's and employees' attention, lead to significant stranded and separation costs, and dis-synergies, risk of assuming liabilities, failure to meet business case objectives for such transactions, as well as employee turnover, and negative impacts on customer and supplier relationships. Strategic transactions often involve post-closing obligations under supply, manufacturing, licensing, or transitional service agreements that may bind us for extended periods, during which market conditions may change.

At the same time, we also continue to pursue collaborations, joint ventures, partnerships, acquisitions to enhance innovation, expand our product portfolio, and support growth, but these transactions also involve significant risks. Negotiating and implementing such arrangements is similarly complex and time-consuming, and we may fail to close deals, agree on favorable terms, or avoid post-closing disputes. Revenue from collaborations depends on our partners' performance, and these arrangements may not lead to timely or successful product development or commercialization. Acquisitions present additional risks, including integration challenges, failure to achieve anticipated synergies, cost savings, or revenue growth, and exposure to incremental liabilities or contractual obligations to minority investors. We may also incur impairment charges if acquired businesses underperform.

Failure to enter into such transactions or complete them on time, manage costs, or negotiate favorable terms could increase expenses, hinder our portfolio strategy, and negatively affect our financial condition. Even when successful, expected benefits may not be realized or may take longer than anticipated, and failure to meet these challenges could materially impact our business and results of operations.

**Our performance may be adversely impacted if we are not successful in managing our inventory and/or working capital balances.**

We manage inventory based on shelf life, sourcing levels, and anticipated demand. Effective inventory control is critical to meeting customer needs without incurring excess storage costs. If we fail to accurately forecast customer demand, it may lead

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

to excess or obsolete inventory, requiring markdowns or disposal charges that negatively impact our financial results. Supply chain disruptions and other global risks could also cause raw material shortages and inventory depletion, while excess raw materials with short shelf lives may increase shrinkage risk. If we are not successful in managing our inventory balances, our results of operations and cash flows may be negatively affected. Relatedly, we also sell certain accounts receivable on a non-recourse basis to unrelated financial institutions under "factoring" agreements, some of which are sponsored by certain customers. Should we choose not to participate, or if these programs were no longer available, it could reduce our cash flows from operations in the period in which the arrangement ends. Similarly, our failure to maintain proper control over collection of receivables and payment of payables could similarly impact our cash flows and results of operations.

**Our results of operations may be negatively impacted by legal claims, disputes, investigations and litigation, including the ongoing antitrust and competition investigations and related class action lawsuits.**

We are or may be, from time to time, involved in legal claims, regulatory investigations, and litigation, including matters related to competition and antitrust, environmental issues, intellectual property, product liability, personal injury, commercial disputes, employment and labor matters, false or deceptive advertising, and indirect taxes. For instance, product liability claims may arise from supplying ingredients to food, beverage, and personal care industries, while the operation of our facilities may expose us to environmental and personal injury claims, regulatory actions, and fines. Poor results of operations, liquidity or financial condition-particularly as we work towards implementation of our ongoing strategic transformation and our portfolio optimization strategy-may also increase litigation risk.

As further described in our consolidated financial statements, we are currently subject to antitrust investigations in a number of countries and class action lawsuits in the U.S. and Canada alleging antitrust violations by us and certain of our competitors. Additional suits and investigations may follow, and outcomes are uncertain. Enforcement actions could result in regulators imposing significant fines, penalties, or business restrictions, adversely affecting results of operations, liquidity, or financial condition, and overall business.

Our insurance coverage may be insufficient to protect us from potential material expenses related to pending and future claims and unavailable at reasonable cost in the future. Unfavorable outcomes in these or future matters could materially affect our profitability and financial condition.

**Trade wars, tariffs, sanctions, geopolitical developments, supply chain disruptions, environmental events, natural disasters, public health or human rights crises, and other events may adversely affect our sourcing of raw materials, and our development, manufacturing, distribution or sale of our products.**

We operate in a complex global environment and we are exposed, directly or indirectly through our suppliers, to risks, inherent in global development, manufacturing, distribution or sale of goods, including agricultural products. These include trade wars (including tariffs and duties), sanctions, geopolitical developments, supply chain disruptions, environmental events, natural disasters and public health crises, terrorism, industrial accidents, labor disputes, political or economic crises, as well as other external factors over which neither our suppliers nor we have control.

Our products depend on a wide range of raw materials sourced globally, such as essential or vegetable oils, botanical extracts, animal products, organic and petroleum-based chemicals. For certain materials, we rely on a limited number of suppliers or regions, making us vulnerable to shortages, delays, and price volatility. Tariffs and trade restrictions, sanctions, and geopolitical tensions (e.g., U.S.-China relations, Russia-Ukraine war, Middle East conflicts), as well as supply chain disruptions, along with energy price fluctuations, may further strain operations and margins. Environmental and climate-related events, including severe weather, droughts, floods, and water scarcity, can also impact crop yields, transportation, and energy costs, increasing sourcing challenges or prices of input costs.

Many of our manufacturing and research and development sites are highly specialized, and some are the sole location for producing certain products or uniquely situated to support our innovation efforts, respectively. Disruptions affecting these sites, including due to the risks outlined above, could lead to costly delays, reformulations, or relocation expenses. While we maintain strategic stock levels of certain raw materials and seek alternative sources when needed, these measures may not fully mitigate risks. If we are not able to successfully mitigate such risks, we could experience disruptions in production, which may result in decrease in our gross margin or reduced sales, and have a material adverse effect on our productivity, business, results of operations and financial condition.

Increases in input costs, including raw materials, transportation, and energy, have been exacerbated by recent inflationary and tariff pressures. If we are unable to increase the prices of our products to our customers to offset increased input cost trends, or if we are unable to achieve cost savings to offset such cost increases, our profits and operating results could be adversely affected. Our ability to price our products competitively is critical to maintain and grow our sales. However, possible increases in prices of our products to customers or the impact of the broader macroeconomic environment on our customers may continue to lead to declines in demand and sales volumes. We may also be unable to accurately predict or hedge cost fluctuations or anticipate the impact of price increases, while competitors may adapt more effectively. Persistent cost volatility could lead

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

customers to seek alternative suppliers or reformulate products, resulting in long-term sales declines or loss of market share. Additionally, inflationary or deflationary trends may affect the financial health of customers and suppliers, further impacting demand and supply. These factors are beyond our control and may materially affect our business and financial condition.

**A significant data breach or other disruption to our information technology systems could disrupt our operations, result in the loss of confidential information or personal data, and adversely impact our reputation, productivity, business or results of operations.** 

We rely on information technology systems, including third-party providers, to support critical business processes such as product development, manufacturing, sales, distribution, financial reporting, regulatory compliance, and data storage. To mitigate risks, we maintain an information security program with updated technology, policies, controls, insurance, governance, training, monitoring, and testing. While these measures mitigate cybersecurity risks, potential threats are constantly evolving and becoming more sophisticated, and conducted by a diverse group of actors, such as foreign governments, cyber terrorists, cyber criminals, malicious employees and other insiders and outsiders. The risks and potential threats can take many forms, such as code anomalies, "Acts of God," data leakage, hardware or software failures, human errors, cyber extortion, password theft or introduction of viruses, malware and ransomware, including through phishing emails. Geopolitical conflicts, such as those in the Middle East and Russia-Ukraine, further heighten cyber risk.

A significant IT disruption or breach of our systems or those of our third party providers could result in loss of confidential data, operational downtime, litigation, regulatory penalties, damages, reputational harm, and substantial remediation costs. Increased reliance on cloud computing, AI, and hybrid work arrangements adds complexity and risk, including through unauthorized access or disclosure of personal and proprietary information. Integration of acquired systems and divestitures also create transitional vulnerabilities. Privacy laws such as GDPR and CCPA that allow private actions increase our litigation exposure related to potential cyber incidents.

&nbsp;&nbsp;&nbsp;&nbsp;We have experienced threats to our data and our systems and although we have not experienced a material incident to date, there can be no assurance that these measures will prevent or limit the impact of a future incident. Additionally, while we have insurance coverage designed to address certain aspects of cyber risks in place, such insurance coverage may be insufficient to cover all losses or all types of claims that may arise.

**We are exposed to AI-related risks and opportunities that if we fail to properly manage, could result in material liabilities, or otherwise materially adversely affect our business, results of operations, and financial condition.**

We have been increasingly using AI tools in our operations, research and development and other areas. Many of our third-party partners also utilize AI tools. We may be exposed to AI-related risks in cases where we, our employees, or our third party partners, in each case whether or not known to us, use AI tools, as well as in cases where we fail to adopt AI tools at a pace or breath as our competitors.

The use of AI by us, our employees or any of our third-party partners may create risks, such as unauthorized disclosure of personal data, privacy risks, trade secrets, or confidential information, and potential receipt or use of third-party proprietary data, which could lead to intellectual property loss or disputes. AI may also weaken IP rights, where AI-generated inventions or creations may not be properly attributed to the rightful inventors, potentially resulting in additional disputes over intellectual property ownership and inventorship rights. The use of AI to draft patent applications may lead to inaccuracies or omissions in the applications, potentially resulting in weakened patent protection or possible outright rejection based on intellectual property ownership and inventorship. Separately, analyses, results or business processes relying on AI may also be deficient, inaccurate, or biased and we may fail to identify in a timely fashion or at all, if or to the extent that is the case. Furthermore, as discussed above, AI can amplify cybersecurity and IT risks and introduce compliance challenges as regulations evolve. Such risks may result in loss of confidential information, litigation, regulatory penalties, damages, reputational harm.

At the same time, AI is already changing the way we and our competitors do business by, among other things, accelerating research and development, creating efficiencies, improving supply chain, productivity and other processes, customer experience, talent management and decision-making. Any failure to capitalize on the AI benefits to the same degree or with the same speed as our competitors may put us in a disadvantageous position.

**The impact of currency fluctuation or devaluation in the international markets in which we operate may negatively affect our results of operations.**

We have significant operations outside the U.S., the results of which are reported in the local currency and then translated into U.S. dollars at applicable exchange rates for inclusion in our consolidated financial statements. The exchange rates between these currencies and the U.S. dollar have fluctuated and will continue to do so in the future, with the fluctuations being particularly pronounced in certain emerging markets. Changes in exchange rates between these local currencies and the U.S. dollar will affect the recorded levels of sales, profitability, assets and/or liabilities. Along with other macroeconomic uncertainty, we have experienced and continue to expect volatility in global foreign currency exchange rates. Changes to interest rate policy as managed by the Federal Reserve Bank or other central banks and potential changes in trade policy may

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

further impact such exchange rates. Further volatility or unfavorable movements in currency exchange rates may adversely impact our financial condition, cash flows or liquidity. Although we employ a variety of techniques to mitigate the impact of exchange rate fluctuations, including sourcing strategies and a limited number of foreign currency hedging activities, we cannot guarantee that such hedging and risk management strategies will be effective, and our results of operations could be adversely affected.

**International economic, political, legal, compliance and business factors could negatively affect our financial statements, operations and growth.**

We operate on a global basis, with manufacturing sites, supply arrangements and sales presence in the U.S., Europe, Africa, the Middle East, Latin America, and Greater Asia. We also continue to expand our presence in emerging markets across the world. In 2025, approximately 72% of our combined net sales were to customers outside the U.S., and we intend to continue expansion of our international operations.

As a result, our business is increasingly exposed to risks inherent in international operations. These risks, which can vary substantially by location, include the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• governmental laws, regulations and policies adopted to manage national economic and macroeconomic conditions, such as increases in taxes, austerity measures that may impact consumer spending, monetary policies that may impact inflation rates, employment regulations, currency fluctuations or controls and sustainability of resources;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• changes in environmental, health and safety permits or regulations, such as regulations related to biodiversity or the continued implementation and evolution of the European Union's REACH regulations and similar regulations that are being evaluated and adopted in other markets, or the ban on microplastics recently adopted by the European Commission ("EC") and the burdens and costs of our compliance with such regulations which may differ significantly across jurisdictions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• increased product labeling and ingredient prohibitions in specific markets that may impact consumer preferences, products costs and/or customer acceptance;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the imposition of or changes in customs, tariffs, quotas, trade barriers, other trade protection measures, import or export licensing requirements, and sanctions on trade with certain countries, imposed by the U.S. or other countries, which could adversely affect our cost or ability to import raw materials or export our products to other markets;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• risks and costs arising from our ability to cater to local demand and customer preferences, language and cultural differences;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the movement for increased unionization and collective labor activity in the U.S. and internationally may lead to labor instability, employee turnover, increased labor costs or production and operation disruptions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• changes in the laws and policies that govern foreign investment in the countries in which we operate, including the risk of expropriation or nationalization, the costs and ability to repatriate the profit that we generate in these countries;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• risks and costs associated with negative publicity on social media as a result of increased regulatory scrutiny, potential misinformation and/or targeted campaigns;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• risks and costs associated with complying with anti-money laundering and counter-terrorism financing laws;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• risks and costs associated with complying with the U.S. Foreign Corrupt Practices Act, similar U.S. or foreign anti-bribery and anti-corruption laws and regulations, applicable sanctions or competition laws and regulations in the jurisdictions in which we operate or ethical business practices and related laws and regulations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• risks and costs associated with political and economic instability, bribery and corruption, anti-American sentiment, and social and ethnic unrest in the countries in which we operate;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• difficulty in recruiting and retaining trained local personnel;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• natural disasters, global or local health crisis, pandemics (such as the COVID-19 pandemic), epidemics or international conflicts (such as the Russia-Ukraine war and Israel-Hamas war) or geopolitical tension (such as deteriorating U.S.-China relations), including trade wars, terrorist acts, political crisis, national and regional labor strikes in the countries in which we operate, which could endanger our personnel, interrupt our operations or adversely affect the demand for our products, the results of certain regions or our global supply chain; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the risks of operating in developing or emerging markets in which there are significant uncertainties regarding the interpretation, application and enforceability of laws and regulations and the enforceability of contract rights and intellectual property rights.

The occurrence of any one or more of these factors could increase our costs and adversely affect our results of operations.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

**Our inability to recruit, retain or transition employees could adversely affect our ability to compete and achieve our strategic goals.**

Attracting, developing, and retaining talented employees, including our management team and senior employees, is essential to the successful delivery of our products and meeting our productivity goals. Our ongoing strategic transformation initiatives, 2025 reportable segment reorganization and corporate cost reallocations have impacted and may continue to impact employees' roles and responsibilities. Competition for skilled labor particularly in scientific, tech and specialized fields may pose a risk to continued business operations, or increased labor costs. If we are unable to successfully transition, integrate, motivate and reward our employees, we may not be able to retain them or attract new employees. Thus, our ability to effectively compete with our competitors and to grow our business could be adversely affected.

In addition, the loss of any member of our senior management could materially adversely affect our ability to execute our business plan and strategy. We may not find an adequate replacement in a timely fashion, or at all, and any replacement may view the business differently than current members of management. Future executives may make changes to our strategic focus, operations, business plans or financial guidance and outlook, with corresponding changes in how we report our results of operations. We can make no assurances that we would be able to properly manage any shift in focus or that any changes to our business would ultimately prove successful.

**Any impairment of our tangible or intangible long-lived assets, including goodwill, may adversely impact our profitability.**

A significant portion of our assets consists of long-lived assets, including tangible assets such as our manufacturing facilities, and intangible assets, including goodwill and customer relationships.

As of December 31, 2025, we had $14.3 billion of intangible assets and goodwill, primarily arising from the acquisitions of Frutarom and N&B. Our results of operations and financial position in future periods could be negatively impacted should future impairments of our long-lived assets, including intangible assets or goodwill occur.

At least annually, we assess goodwill for impairment. We test for impairment by comparing the estimated fair value of a reporting unit with its carrying amount. If the carrying amount of a reporting unit exceeds its estimated fair value, we record an impairment charge based on the difference between the two. Intangible assets with finite lives are also tested for impairment when events or changes in circumstances indicate the carrying value may not be recoverable. Such events and changes in circumstances could include a sustained decrease in our market capitalization, increased competition or unexpected loss of market share, increased input costs beyond projections (for example due to regulatory or industry changes), our inability to recognize the anticipated benefits of acquisitions, unexpected business disruptions (for example due to a natural disaster, public health crisis, such as pandemics or epidemics or loss of a customer, supplier, or other significant business relationship), acts by governments and courts, operating results falling short of projections, or significant adverse changes in the markets in which we operate.

Effective January 1, 2025, our Nourish segment was restructured into two newly designated operating segments and reporting units: Taste and Food Ingredients. This change in management reporting necessitated the reallocation of goodwill between the two reporting units and the performance of a goodwill impairment test both prior to and subsequent to the change. We recorded an impairment charge of $1.153 billion within the Food Ingredients operating segment as a result of the change in the Company's segments, which is reflected in the Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) during the year ended December 31, 2025. Any future restructuring or other changes in reporting may result in additional impairment charges. Refer to Part II, Item 7 and Note 1 and Note 12 to the Consolidated Financial Statements for additional information.

Fair value determinations require considerable judgment and are sensitive to changes in underlying assumptions, estimates and market factors. Estimating the fair value of reporting units requires us to make assumptions and estimates regarding our business performance, future plans, future annual net cash flows, income tax considerations, discount rates and growth rates based on industry, economic, regulatory conditions and other market factors. Moreover, management will make significant accounting judgments and estimates for the application of acquisition accounting under GAAP, and the underlying valuation models. IFF's operating results could be materially and adversely impacted in future periods if IFF's accounting judgments and estimates related to these models prove to be inaccurate.

To the extent any of our businesses do not perform as anticipated and our underlying assumptions and estimates related to their fair value determination are not met, whether due to internal or external factors, the value of goodwill and other long-lived assets may be negatively affected and we may be required to record impairment charges.

**We are subject to customer, consumer, shareholder and regulatory focus on sustainability, which may result in additional costs in order to meet new requirements, including adversely affecting our stock price, results of operations and access to capital.**

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

Our customers, consumers and shareholders continue to be sensitive to environmental-related and other long-term sustainability issues. At the same time, we face increasing regulatory reporting requirements related to sustainability topics.

The increased focus on sustainability has resulted and may continue to result in new and changing regulations, including the need to comply with different regulatory regimes in different jurisdictions, and customer requirements that could affect us. These could cause us to incur additional capital expenditure and other costs or to make changes to our operations or reporting systems in order to comply with any new regulations and customer requirements. We could also lose revenue, including as a result of negative publicity, if our customers divert business from us because we have not complied with their sustainability requirements. Increased regulatory scrutiny, consumer or customer legal actions, shareholder activism with respect to sustainability, shifting public and investor sentiment on environmental, social and governance matters could also lead to increased costs and disruption to operations. These potential costs, changes and loss of revenue could have a material adverse effect on our business, results of operations and financial condition.

**Our ability to declare and pay dividends is subject to certain considerations.**

Dividends are authorized and determined by our Board of Directors in its sole discretion and depend upon a number of factors, including:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• cash available for dividends;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our results of operations and anticipated future results of operations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our financial condition, including our current or forecasted future cash flows provided by our operating activities (after deducting anticipated future capital expenditures and other commitments required to carry out our operations and business strategy);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our operating expenses;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• potential restrictions in our financing documents that may be instituted from time to time; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• other general and economic conditions or other factors our Board of Directors deems to be relevant.

We expect to continue to pay dividends to our shareholders; however, our Board may reduce, suspend or discontinue the payment of dividends at any time. For instance, we announced in February 2024 that we had updated its dividend policy, reducing the expected quarterly dividend approximately 50% to enable faster deleveraging of the balance sheet and provide improved financial flexibility.

Any reduction in the amount of dividends we pay to shareholders could have an adverse effect on the trading price of our common stock.

**We have a substantial amount of indebtedness that could materially adversely affect, among other things, our financial condition, our ability to return capital to our shareholders, needed investments into our business and our credit ratings.**

Our indebtedness and related covenants could adversely affect our liquidity, flexibility, and cost of capital. As of December 31, 2025, our total debt was approximately $5.994 billion. Required principal and interest payments, pricing grids tied to our credit ratings, and financial covenants under our revolving credit facility could limit our ability to obtain additional financing, invest in our business, or return capital to shareholders. A downgrade of our credit ratings could increase borrowing costs and reduce market access. A deterioration of our financial condition may lead to additional restrictions, including limitations on dividends and share repurchases and mandatory prepayments from certain asset sale proceeds. If we are unable to maintain compliance with covenants, manage maturities, or preserve investment grade ratings, our liquidity, financial condition, and cost of capital could be adversely affected.

**Our funding obligations for our pension and postretirement plans could adversely affect our earnings and cash flows.**

Our funding obligations for our pension plans are impacted by the performance of the financial markets, particularly the equity markets and interest rates. Funding obligations are determined under government regulations and are measured each year based on the value of assets and liabilities on a specific date. If the financial markets do not provide the long-term returns that are expected under the governmental funding calculations, we could be required to make larger contributions. The equity markets can be very volatile, and therefore our estimate of future contribution requirements can change dramatically in relatively short periods of time. Similarly, changes in interest rates and legislation enacted by governmental authorities can impact the timing and amounts of contribution requirements. An adverse change in the funded status of the plans could significantly increase our required contributions in the future and adversely impact our liquidity.

Assumptions used in determining projected benefit obligations and the fair value of plan assets for our pension and other postretirement benefit plans are determined by us in consultation with outside consultants and advisors. In the event that we determine that changes are warranted in the assumptions used, such as the discount rate, expected long-term rate of return on

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

assets, or expected health care costs, our future pension and postretirement benefit expenses could increase or decrease. Due to changing market conditions or changes in the participant population, the assumptions that we use may differ from actual results, which could have a significant impact on our pension and postretirement liabilities and related costs and funding requirements.

**<u>Risks Related to Legal and Regulatory Considerations</u>**

**If we are unable to comply with regulatory requirements and industry standards, including those regarding product safety, quality, efficacy and environmental impact, we could incur significant costs and suffer reputational harm which could adversely affect results of operations.**

Our products are subject to extensive and evolving regulatory, safety, and compliance requirements across multiple jurisdictions. These requirements govern product development, manufacturing, labeling, marketing, and sale, and include standards related to product safety, quality, efficacy, environmental impact, sustainability, and animal welfare. Compliance obligations may arise from government authorities, industry bodies, non-governmental organizations, or contractual commitments to customers. Regulatory frameworks continue to expand and become more complex, particularly in highly regulated markets, and may involve modernization of food safety laws, heightened scrutiny of certain ingredients (including synthetic or biotechnology-derived components). Emerging technologies, such as protein engineering, gene editing, and novel uses of biotechnology, are also prompting new or stricter regulatory approaches. These developments may require us to reformulate products, remove or replace certain substances, or modify manufacturing processes, potentially resulting in significant costs, capital expenditures, or operational changes that could adversely affect margins and profitability.

Recent regulatory actions illustrate these trends. For example, the European Commission's ban on microplastics in personal care products, detergents, and cosmetics requires us to innovate and reformulate affected products. Similarly, the European Green Deal's Chemicals Strategy for Sustainability ("CSS") has driven updates to key regulations such as the EU Classification, Labeling and Packaging regulation ("CLP") and the EU Detergent Regulation, introducing hazard-based risk management and grouping of substances to accelerate regulatory decisions. Revisions of the EU Cosmetic and Chemicals regulations have been deferred to the new EU Commission, but are still possible. These changes may negatively impact certain products we offer, including enzymes and fragrance ingredients. In the US, under the Toxic Substances Control Act ("TSCA") chemicals regulation, companies experience significant challenges to bring new substances to the market, with major delays experienced with US EPA assessments and very restrictive release conditions being established for substances that make it through these reviews. Failure to adapt promptly and cost-effectively to these changes could result in increased costs to reformulate affected products and in loss of business to competitors with compliant products, operational disruptions, customer claims, regulatory fines, litigation, or reputational damage.

We may also be exposed to serious adverse health claims related to undetected poor quality of raw materials, internal system failures to adequately reduce or eliminate certain hazards (such as pathogens, allergens, contaminants, pesticides, physical hazards, etc.) or products that are not in line with required or agreed specifications.

Compliance risks are further compounded by operational complexities. Gaps in our processes, or those of suppliers and distributors, could lead to non-compliant or unsafe products, mislabeled or contaminated goods, or failures to meet agreed specifications. Supply chain challenges, aging infrastructure, human error, and inadequate hazard controls (e.g., for pathogens, allergens, contaminants, pesticides, or physical hazards) may exacerbate these risks. Such events could potentially harm consumer health and safety and may trigger recalls, regulatory enforcement actions, penalties, lost profits, reputational harm, productivity losses, property damage, personal injury, other liability or litigation. Our contracts often require us to indemnify customers for costs associated with non-compliance events, including penalties, remediation, litigation, and lost sales. Insurance or supplier indemnification may be unavailable or insufficient to cover these liabilities. Additionally, negative publicity, whether based on actual or perceived safety or quality concerns, could immediately impact sales and customer relationships and require substantial resources to restore confidence in our products and brand. Any of these factors could adversely affect our business, financial condition and our results of operations.

**Failure to comply with environmental protection laws may cause us to close, relocate or operate one or more of our plants at reduced production levels, and expose us to civil or criminal liability, which could adversely affect our operating results and future growth.**

Our business operations and properties procure, make use of, manufacture, sell, and distribute substances that include known and potentially unknown hazards and are therefore subject to extensive and increasingly stringent federal, state, local and foreign laws and regulations pertaining to protection of the environment, including air emissions, sewage discharges, the use of hazardous materials, waste disposal practices and clean-up of existing environmental contamination.

Failure to comply with these laws and regulations or any future changes to them may result in significant consequences to us, including the need to pause or cease production, close or relocate one or more of our production facilities, administrative, civil and criminal penalties, fines, sanctions, litigation, costly remediation measures, liability for damages and negative publicity. If we are unable to meet production requirements, we can lose customer orders, which can adversely affect our future

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

growth or we may be required to make incremental capital investments to ensure supply. Idling of facilities or production modifications has caused or may cause customers to seek alternate suppliers due to concerns regarding supply interruptions and these customers may not return or may order at reduced levels even once issues are remediated. If these non-compliance issues occur, we may lose business and may be required to incur capital spending above previous expectations, close a plant, or operate a plant at significantly reduced production levels on a permanent basis, and our operating results and cash flows may be adversely affected.

**We could be adversely affected by violations, by us or our counterparties, of U.S. or foreign anti-bribery, international trade, anti-corruption, antitrust or competition laws and regulations, applicable sanctions or employment and human rights or employment regulations.**

The global nature of our business, our size and workforce, the significance of our international revenue, our focus on emerging markets, and our presence in regulated industries expose us to complex domestic and international regulatory challenges and risks associated with global operations. We are subject to the U.S. Foreign Corrupt Practices Act ("FCPA") and similar anti-bribery and anti-corruption laws in other jurisdictions, which generally prohibit companies and their intermediaries from making improper payments to foreign officials to obtain or retain business or secure other commercial advantages. U.S. public companies must also maintain accurate books and records and implement adequate internal accounting controls. Under the FCPA, U.S. companies may be held liable for corrupt actions by directors, officers, employees, agents, or other partners. Failure to comply with the FCPA or similar laws could result in substantial civil or criminal fines and penalties, materially adversely affecting our business, reputation, operating results, and financial condition.

We operate and may pursue opportunities in jurisdictions such as China, India, Brazil, Russia, and certain African countries, which present elevated risks of fraud, corruption, and internal control challenges. In certain regions, compliance with anti-bribery laws may conflict with local customs and practices. We periodically conduct internal investigations, compliance reviews, and control testing, and implement remedial actions as appropriate to help ensure compliance. Detecting, investigating, and resolving actual or alleged violations of anti-bribery laws is costly, time-consuming, and may divert senior management attention. Allegations of non-compliance could disrupt operations, damage relationships with third parties, and negatively impact our financial condition and results of operations. A determination that we violated such laws could result in severe civil or criminal penalties, significant fines, loss of licenses or permits, and reputational harm.

Given our global footprint, we also sell certain products to countries subject to U.S. and other jurisdictions' sanctions under general licenses and authorizations. For example, the U.S., European Union, and other jurisdictions have imposed sanctions and export controls on Russia, Belarus, and occupied regions of Ukraine. As a result, we have restricted exports to these regions to permitted products that meet essential needs. Compliance with sanctions laws is highly technical and requires rigorous oversight. Any inadvertent breach by us, our subsidiaries, or suppliers could have a material adverse effect on our business.

In addition, antitrust and competition laws and regulations continue to be actively enforced by competition authorities in the U.S., the European Union and other jurisdictions where we are active. Our failure to comply with competition laws and regulations can expose us to, among other things, high fines, damage actions (including private causes of action), reputation harm, and disruptions to our business, and expose our employees to civil or criminal penalties. See, also "*—Our results of operations may be negatively impacted by legal claims, disputes, investigations and litigation, including the ongoing antitrust and competition investigations and related class action lawsuits.*"

Similarly, the enforcement of international trade laws, including duties, tariffs, licensing requirements, anti-boycott, dumping and others is relevant to our broad and worldwide business. Our compliance failures related to any international trade laws or regulations could result in fines, damages, reputational harm and other negative impacts on the financial results of the Company.

Finally, our reputation and customer relationships depend in part on compliance by our suppliers, distributors, and other counterparties with ethical employment practices and legal requirements, including those related to child labor, wages and benefits, forced labor, discrimination, workplace safety, and human rights. While we generally expect adherence to our vendor code of conduct, we do not control third parties and cannot guarantee compliance. Failure by counterparties to meet applicable standards could harm our reputation and brand, expose us to litigation, investigations, enforcement actions, monetary liability, and additional costs, and adversely affect our business, financial condition, results of operations, and prospects.

**Our ability to compete effectively depends on our ability to protect our intellectual property rights.**

We rely on patents, trademarks, copyrights and trade secrets to protect our intellectual property rights. We often rely on trade secrets to protect our products, manufacturing processes, extract methodologies and other processes, as this does not require us to publicly file information regarding our intellectual property. From time to time, a third party may claim that we have infringed upon or misappropriated their intellectual property rights, or a third party may infringe upon or misappropriate our intellectual property rights. We could incur significant costs in connection with legal actions to assert our intellectual property rights against third parties or to defend ourselves from third-party assertions of invalidity, infringement,

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

misappropriation or other claims. Any settlement or adverse judgment resulting from such litigation could require us to obtain a license to continue to use the intellectual property rights that are the subject of the claim, or otherwise restrict or prohibit our use of such intellectual property rights. Any required licensing fees may not be available to us on acceptable terms, if at all. For those intellectual property rights that are protected as trade secrets, this litigation could result in even higher costs, and potentially the loss of certain rights, since we would not have a perfected intellectual property right that precludes others from making, using or selling our products or processes. The ongoing trend among our customers towards more transparent labeling could further diminish our ability to effectively protect our products.

We vigilantly protect our intellectual property rights, including trade secrets. We have designed and implemented internal controls intended to restrict access to and distribution of our respective intellectual property. Despite these precautions, our intellectual property is vulnerable to unauthorized access through employee error or actions, theft and cybersecurity incidents, and other security breaches, including due to increasing use of AI tools. See, also *"—We are exposed to AI-related risks and opportunities that if we fail to properly manage, could materially adversely affect our business, results of operations, and financial condition."* Protecting intellectual property related to biotechnology is particularly challenging because theft can be difficult to detect and biotechnology can be self-replicating. Accordingly, the impact of such theft can be significant.

For intellectual property rights that we seek to protect through patents, we cannot be certain that these rights, if obtained, will not later be opposed, invalidated or circumvented. In addition, even if such rights are obtained in the U.S., the laws of some other countries in which our products are or may be sold may not protect intellectual property rights to the same extent as the laws of the U.S. For instance, we may be unable to obtain or defend intellectual property rights in new and inventive technology developed in whole or in part by relying on AI tools. If other parties were to infringe on our intellectual property rights, or if our intellectual property rights were the subject of unauthorized access leading to competitive pressure or if a third party successfully asserted that we had infringed on their intellectual property rights, it could materially and adversely affect our future results of operations by, among other things, (i) us being required to cease production and marketing or reducing the price that we could obtain in the marketplace for products which are based on such rights, (ii) increasing the royalty or other fees that we may be required to pay in connection with such rights, (iii) limiting the volume, if any, of such products that we can sell or (iv) resulting in significant litigation costs and potential liability.

**Changes in our tax rates, the adoption of new U.S. or international tax legislation, or changes in existing tax laws could expose us to additional tax liabilities that may affect our future results.**

We are subject to taxes in the U.S. and numerous foreign jurisdictions. Our future effective tax rates could be affected by changes in the mix of earnings in countries with differing statutory tax rates, changes in the valuation of deferred tax assets and liabilities, changes in liabilities for uncertain tax positions, cost of repatriations or changes in tax laws, regulations, or their interpretation. Any of these changes could have a material adverse effect on our operating results.

We have and will continue to implement transfer pricing policies among our various operations located in different countries. These transfer pricing policies are a significant component of the management and compliance of our operations across international boundaries and overall financial results. Many countries routinely examine transfer pricing policies of taxpayers subject to their jurisdiction, challenge transfer pricing policies aggressively where there is potential non-compliance and impose significant interest charges and penalties where non-compliance is determined. We could suffer significant costs related to one or more challenges to our transfer pricing policies.

We are subject to the continual examination of our income tax returns by the Internal Revenue Service, state tax authorities and foreign tax authorities in those countries in which we operate, and may be subject to assessments or audits in the future in any of the countries in which we operate. The final determination of tax audits and any related litigation could be materially different from our historical income tax provisions and accruals, and while we do not believe the results that follow would have a material adverse effect on our financial condition, such results could have a material effect on our income tax provision, net income or cash flows in the period or periods in which that determination is made.

In December 2021, the Organisation for Economic Co-operation and Development ("OECD") released the Pillar Two model rules to reform international corporate taxation that aim to ensure that applicable multinationals (global revenue exceeding €750 million) pay a minimum effective corporate tax rate of 15%. The rules are being passed into national legislation based on each country's approach, and some countries have already enacted or substantively enacted the rules. A framework on Safe Harbours and Penalty Relief was released in 2022 providing details on the transitional reliefs available to businesses over the initial years of Pillar Two implementation. The OECD released administrative guidance in February 2023 aiming to provide clarity over contentious areas of the model rules and aiming to provide greater certainty for businesses impacted by Pillar Two. We continuously evaluate these developments and the potential impact of the Pillar Two framework, subject to legislative adoption by individual countries.

In August 2022, the U.S. government enacted legislation commonly referred to as the "Inflation Reduction Act", which, among other things, imposed a minimum "book" tax on certain corporations effective for taxable years beginning after

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

December 31, 2022 and created a new excise tax on stock repurchases made by certain publicly traded corporations after December 31, 2022.

In July 2025, the United States enacted the One Big Beautiful Bill Act ("OBBBA") which, among other things, extended key provisions of the Tax Cuts and Jobs Act of 2017 and allowed for immediate expensing of certain business expense. Provisions are applicable beginning in 2025 with many provisions applicable beginning in 2026. We continue to evaluate the impact of the OBBBA on our future cash taxes and effective tax rate.

Changes in tax laws or regulations, including further developments in connection with the IRA and OBBBA; changes enacted in response to the action items provided by the OECD under Pillar Two, and continued scrutiny on the taxation of large multinational companies all increase tax uncertainty and could impact the Company's effective tax rate and provision for income taxes. These changes are unpredictable and as such, it is difficult to predict the cumulative effect of such tax laws and regulations on our operating results.

**The N&B Transaction could result in significant tax liability, and we may be obligated to indemnify DuPont for any such tax liability imposed on DuPont.**

The 2021 N&B Transaction was a Reverse Morris Trust ("RMT"), treated as tax-free for U.S. federal income tax purposes by Dupont. Dupont received an opinion of counsel that the transaction qualified as a tax-free reorganization.

In connection with the N&B Transaction, IFF, N&B, and Dupont entered into a Tax Matters Agreement, a form of which is attached to IFF's registration statement on Form S-4 (Registration Number 333-238072) ("TMA"). Under the TMA, IFF and N&B are required to indemnify Dupont for any taxes resulting from a "Spinco Tainting Act." A Spinco Tainting Act is generally any action (or inaction) within our control or under the control of N&B or their affiliates, any event involving our common stock or the common stock of N&B or any assets of N&B or its subsidiaries, or any breach by N&B or any of its subsidiaries of any factual representations, assumptions, or undertakings made by it, in each case, that would affect the non-recognition treatment of the RMT (or other internal reorganizations prior to the N&B Transaction) to Dupont. If we were required to indemnify DuPont under the TMA, this indemnification obligation may be substantial and could have a material adverse effect on us, including with respect to our financial condition and results of operations.

Moreover, we are not indemnified by Dupont for most tax liabilities related to periods prior to the N&B Transaction. Tax liabilities could increase as an outcome of final determination of tax examinations and could adversely impact our financial results.

**If we fail to comply with data protection laws in the U.S. and abroad, we may be subject to fines, penalties and other costs.**

Legal requirements relating to the collection, storage, handling, use, disclosure, transfer, and security of personal data continue to evolve, and regulatory scrutiny in this area is increasing around the world. This regulatory environment is increasingly challenging and may present material obligations and risks to our business, including significantly expanded compliance burdens, restrictions on transfer of personal data, costs and enforcement risks. Many governments have enacted or are enacting new or updated data protection laws, including data localization laws that require personal data to stay within their borders. All of these evolving compliance and operational requirements, restrictions on use of personal data, as well as the uncertain interpretation and enforcement of laws, impose significant costs and regulatory risks that are likely to increase over time. Our failure to comply with these evolving regulations or to otherwise protect personal data from unauthorized access, use or other processing, could expose us to litigation claims, legal or regulatory proceedings, investigations, fines, sanctions, penalties and other costs that could harm our reputation and adversely impact our business.

**ITEM 1B.&nbsp;&nbsp;&nbsp;&nbsp;UNRESOLVED STAFF COMMENTS.**

None.

**ITEM 1C.&nbsp;&nbsp;&nbsp;&nbsp;CYBERSECURITY.**

**Risk Management and Strategy**

Our comprehensive Incident Response Plan outlines processes to identify, detect, assess, respond to and recover from threats, including cybersecurity threats. We follow those processes to manage material risks from cybersecurity threats, including risks relating to disruption of business operations or financial reporting systems, intellectual property theft; fraud; extortion; harm to employees or customers; violation of privacy laws and other litigation/legal risk; and reputational risk, as part of our overall risk management system and processes.

In addition, our Enterprise Risk Management ("ERM") program is designed to identify and assess our global risks and to develop steps to mitigate and manage risks. As part of our risk management practices, we, under the direction and ownership of the Executive Leadership Team, have established risk champions and ambassadors throughout the organization to identify,

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

assess, map, and mitigate these exposures on a regular basis in discussion with functional risk owners. The Board receives regular reports on the ERM process and the risk mitigation activities, including reports focused on compliance, human capital, cybersecurity, and sustainability risks.

Our Chief Information Officer ("CIO") is responsible for delivering on the Company's global Information Technology ("IT") strategy, including infrastructure, data and analytics, application delivery, end user services, cybersecurity risk management and the digital technology transformation program. The IT leadership team leads the implementation of the IT strategy and the day-to-day operations. Under the guidance of the CIO, our Chief Information Security Officer ("CISO") leads Information Security ("InfoSec"), which includes the Cyber Fusion Center, Infrastructure Security, including network segmentation, firewalls and intrusion detection and prevention systems, Identity and Access Management, Application Security, Data Security and InfoSec Governance, Risk and Compliance. InfoSec is overseen by the InfoSec Steering Committee, comprised of senior leaders representing all corporate functions and business units, and the InfoSec Governance Review Board, comprised of the IT leadership team and the InfoSec leadership team. InfoSec is governed in coordination with IFF's ERM Committee and is aligned to the U.S. National Institute of Standards and Technology ("NIST") Cybersecurity Framework.

In addition to our dedicated leadership team overseeing InfoSec, we view InfoSec as a shared responsibility, and to best protect our network, computers and data from threats, we empower our employees to be our first line of defense. To that end, all employees globally complete annual mandatory InfoSec training on email security, password security and our Acceptable Use Policy. We use email security, endpoint security, logging and monitoring, remote access, application security and other tools to deter threat actors, block malicious/phishing emails and avoid IT system interruptions.

Our comprehensive InfoSec Incident Response Plan is updated at least annually, and provides guidance for detecting, containing, eradicating and recovering from potential incidents. It outlines escalation procedures, reporting requirements, incident severity levels, a materiality assessment and roles and responsibilities for key partners, including IT, Legal/Employee Relations, Corporate Communications, Human Resources and other senior leaders. Our escalation procedures include escalation to our Executive Leadership Team, Audit Committee, Disclosure Committee, and Board of Directors, and reporting to regulators, customers, investors, and others. We also maintain cybersecurity insurance, regularly evaluate the effectiveness of our systems, and test our contingency plans by conducting vulnerability analysis and tabletop exercises with both technical incident responders and senior leaders.

Based on industry baselines and discussions throughout our membership in various global InfoSec communities, we believe that these preventative actions are designed to reduce cybersecurity risk and the likelihood and impact of potential information security incidents. Given the evolving nature of InfoSec incidents, we regularly engage with our peers on threat intelligence and collaborate with organizations both in our industry and across industries to share best practices.

In connection with our InfoSec risk management processes, we engage third-party assessors and outside counsel. Our program includes review and assessment by external, independent third parties, who assess and report on our overall InfoSec program and identify areas for continued focus and improvement. Our CIO, CISO and GC oversee our technology risk management and privacy teams, which work in partnership with our Internal Audit team to review IT-related controls as part of the overall internal controls process and regulatory requirements. We consult with outside counsel to advise our team and our Board of Directors on best practices for InfoSec oversight, and the evolution of that oversight over time. InfoSec employees regularly speak at and attend industry events to ensure awareness of evolving threats and innovative prevention and remediation techniques. Further, our InfoSec risk management processes extend to the oversight and identification of threats associated with our use of third-party service providers through relationship due diligence, InfoSec assessments and contractual provisions.

Our business strategy, results of operations and financial condition have not been materially affected by risks from cybersecurity threats, including as a result of previous cybersecurity incidents, but we cannot provide assurance that they will not be materially affected in the future by such risks and any future material incidents. For more detailed information about risks related to our cybersecurity, refer to Item 1A, "Risk Factors" *—"A significant data breach or other disruption to our information technology systems could disrupt our operations, result in the loss of confidential information or personal data, and adversely impact our reputation, productivity, business or results of operations."*

**Governance**

The Board of Directors is responsible for overseeing and reviewing with management the Company's InfoSec risks and the policies and practices established to manage such risks. In that effort, the Board of Directors delegates certain responsibilities to our Audit Committee. This committee-level focus on InfoSec allows the Board to further enhance its understanding of these issues as it continues to have overall oversight responsibility for risk.

The Audit Committee assists the Board of Directors in its oversight by staying apprised of our InfoSec programs, strategy, policies, standards, architecture, processes and material risks, and by overseeing response to InfoSec incidents. Our Audit Committee receives from management updates, at least quarterly, on material security risks, including any material incidents, relevant industry developments, threat vectors and material risks identified in periodic penetration tests or vulnerability scans.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

These updates also include material legal and legislative developments concerning InfoSec, our approach to complying with applicable law and material engagement with regulators concerning IT and InfoSec.

The Board of Directors receives regular reports from the Audit Committee which detail (a) InfoSec initiatives, (b) reviews of the policies and practices established to manage these processes, and (c) reviews of the Company's procedures for monitoring compliance with applicable laws. Additionally, the Board of Directors also receives updates on the Company's risks through ERM program reports, which include management's approach to mitigating and managing InfoSec risks.

Members of the Board of Directors stay apprised of the rapidly evolving cyber threat landscape and provide guidance to management, as appropriate, to address the effectiveness of our overall data privacy and cybersecurity program. Recently, members of the Board of Directors and Executive Leadership Team participated in a Cybersecurity Exercise led by our CIO and CISO as training, and, to prepare for incident response. The Board of Directors and Audit Committee also receive regular cybersecurity posture reports from an external third-party, and outside counsel advises the Board of Directors on best practices for the Board's oversight of InfoSec and the evolution of that oversight over time. Additionally, two members of our Board of Directors and Audit Committee have experience in InfoSec matters.

Our Board of Directors and Audit Committee's principal role is one of oversight, recognizing that management, led by our CIO and CISO, is responsible for the design, implementation and maintenance of an effective program for identifying, detecting, protecting against, responding to, recovering from and mitigating data privacy and InfoSec risks. Our CIO has more than 30 years of technology experience, including leadership across a variety of enterprise technologies, including InfoSec, and across multiple industries. Our CISO has more than 20 years of experience in InfoSec, across multiple industries, and is a Certified Information Systems Security Professional (CISSP). The CIO and CISO provide, at least, annual updates on IT and InfoSec initiatives to the Board of Directors and quarterly updates to the Audit Committee.

**ITEM 2.&nbsp;&nbsp;&nbsp;&nbsp;PROPERTIES.**

Our principal owned and leased properties, as of December 31, 2025, are as follows:

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Europe, Africa & the Middle East** | **Europe, Africa & the Middle East** | **North America** | **North America** | **Greater Asia** | **Greater Asia** | **Latin America** | **Latin America** | **Total** | **Total** |
| | **Owned** | **Leased** | **Owned** | **Leased** | **Owned** | **Leased** | **Owned** | **Leased** | **Owned** | **Leased** |
| Plant | 37 | 12 | 17 | 7 | 19 | 4 | 13 | 3 | 86 | 26 |
| Office | 1 | 43 |  | 2 | 1 | 12 |  | 2 | 2 | 59 |
| Laboratory | 3 | 16 | 2 | 11 | 2 | 19 | 1 | 6 | 8 | 52 |
| Warehouse | 2 | 15 |  | 7 |  | 3 | 1 | 4 | 3 | 29 |
| Other | 7 | 1 |  | 4 | 7 | 2 | 2 | 1 | 16 | 8 |
|  | 50 | 87 | 19 | 31 | 29 | 40 | 17 | 16 | 115 | 174 |

---

Our principal executive offices are located at 521 West 57th Street, New York, New York and 200 Powder Mill Road, Wilmington, Delaware. Our principal sites include facilities which, in the opinion of our management, are suitable and adequate for their use and have sufficient capacity for its current business needs and expected near-term growth.

**ITEM 3.&nbsp;&nbsp;&nbsp;&nbsp;LEGAL PROCEEDINGS.**

We are subject to various claims and legal actions in the ordinary course of our business. The Company's material legal proceedings are described in Part II, Item 8 of this Form 10-K in the Notes to Consolidated Financial Statements in Note 21, "Commitments and Contingencies" under the heading "Litigation." For more detailed information about risks related to legal proceedings, refer to Item 1A, "Risk Factors" – *"Our results of operations may be negatively impacted by the outcome of uncertainties related to legal claims, disputes, investigations and litigation, including the ongoing antitrust and competition investigations and related class action lawsuits."*

**ITEM 4.&nbsp;&nbsp;&nbsp;&nbsp;MINE SAFETY DISCLOSURES.**

Not applicable.

**PART II**

**ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.**

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

**Market Information.**

Our common stock is principally traded on the New York Stock Exchange under the ticker symbol "IFF."

While we have historically paid dividends on a quarterly basis to shareholders of our common stock, the declaration and payment of future dividends will depend on many factors, including, but not limited to, our earnings, financial condition, business development needs and regulatory considerations. Our Board of Directors may reduce, suspend or discontinue the payment of dividends at any time. See Part II, Item 8 of this Form 10-K in the "Consolidated Statements of Shareholders' Equity" and in the Notes to Consolidated Financial Statements in Note 17 for additional information.

**Approximate Number of Equity Security Holders.**

---

| | |
|:---|:---|
| **Title of Class** | **Number of shareholders of record as of February 20, 2026** |
| Common stock, par value 12 <sup>1</sup>/2¢ per share | 2766 |

---

**Issuer Purchases of Equity Securities.**

The following information summarizes information with respect to the Company's purchase of its common stock during the year ended December 31, 2025, reported on a settlement date basis.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Period** | **Total number of shares purchased** | **Average price paid per share** | **Total number of shares purchased as part of publicly announced plans or programs**<sup>(1)</sup> | **Approximate dollar value of shares that may yet be purchased under the plans or programs**<sup>(1)</sup><br>***(Dollars in Millions)*** |
| October 1-31, 2025 | 210002 | $62.83 | 210002 | $487 |
| November 1-30, 2025 | 174872 | 65.17 | 174872 | 475 |
| December 1-31, 2025 | 199041 | 66.29 | 199041 | 462 |
| Total | 583915 | $64.71 | 583915 | $462 |

---

(1)As announced on August 5, 2025, our Board of Directors authorized a repurchase plan of up to $500 million of common stock. The program began on October 1, 2025 and does not have a specified term of termination date. Subject to market conditions, we expect to repurchase all shares under this authorization, in open market or privately negotiated transactions, including pursuant to Rule 10b5-1 under the Exchange Act, and in block trades, or a combination of the foregoing.

**ITEM 6.&nbsp;&nbsp;&nbsp;&nbsp;[RESERVED]**

**ITEM 7.&nbsp;&nbsp;&nbsp;&nbsp;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.**

**(UNLESS INDICATED OTHERWISE, DOLLARS IN MILLIONS EXCEPT PER SHARE AMOUNTS)**

**OVERVIEW**

**Company Background**

In 2025, we were organized into five reportable operating segments: Taste, Food Ingredients, Health & Biosciences, Scent and, until its divestiture in May 2025, Pharma Solutions.

Our Taste segment consists of the development and production of a range of flavor compounds and natural taste solutions that are ultimately used by our customers in a diverse variety of products, including savory products (soups, sauces, meat, fish, poultry, snacks, etc.), beverages (juice drinks, carbonated or flavored beverages, spirits, etc.), sweets (bakery products, candy, cereal, chewing gum, etc.), and dairy products (yogurt, ice cream, cheese, etc.). Taste also includes value-added spices and seasoning ingredients for meat, food service, convenience, alternative protein and culinary products.

Our Food Ingredients segment consists of a diversified portfolio across natural, artificial and plant-based specialty food ingredients that provide functional properties solutions for food and beverage products, as well as specialty soy and pea protein with value-added formulations, emulsifiers and sweeteners. Natural food protection ingredients consist of natural antioxidants and anti-microbials used for natural food preservation and shelf-life extension for beverages, cosmetic and healthcare products, pet food and feed additives. Food Ingredients also includes savory solutions (such as spices, marinades, and mixtures) and inclusion products (such as products combining flavorings with fruit, vegetables and other natural ingredients).

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

Our Health & Biosciences segment consists of the development and production of an advanced biotechnology-derived portfolio of enzymes, food cultures, probiotics and specialty ingredients for food and non-food applications. Among many other applications, our portfolio includes cultures for use in fermented foods such as yogurt, cheese and fermented beverages, probiotic strains, household detergents, animal feed, ethanol production and brewing. Health & Biosciences is comprised of Health, Food Biosciences, Home & Personal Care, Animal Nutrition and Grain Processing.

Our Scent segment creates fragrance compounds and fragrance ingredients that are integral elements in the world's finest perfumes and best-known household and personal care products. Consumer insights, science and creativity are at the heart of our Scent business, along with our unique portfolio of natural and synthetic ingredients, global footprint, innovative technologies and know-how, and customer intimacy. The Scent segment is comprised of Fragrance Compounds and Fragrance Ingredients.

Our former Pharma Solutions segment produced, among other things, a vast portfolio of cellulosics and seaweed-based pharmaceutical excipients, used in prescription and over-the-counter pharmaceuticals and dietary supplements. We completed the divestiture of our Pharma Solutions disposal group, which included certain adjacent businesses, on May 1, 2025 and we divested our nitrocellulose business, which was within our Pharma Solutions segment, on May 9, 2025.

**2025 Segment Reorganization** 

Effective January 1, 2025, our former Nourish segment was restructured into two newly designated operating segments: Taste and Food Ingredients. With additional minor adjustments, our Flavors business, was renamed Taste, and our Ingredients business, was renamed Food Ingredients. Consequently, starting in the first quarter of 2025, our business segments were as follows: Taste, Food Ingredients, Health & Biosciences, Scent, and Pharma Solutions. We divested the Pharma Solutions segment in May 2025.

**Financial Measures — Comparable Currency Neutral**

Our financial results include the impact of foreign currency exchange rates and business divestitures. We provide currency neutral calculations in this report to remove the impact of foreign currency exchange rates fluctuations and business divestitures. We calculate comparable currency neutral numbers by translating current year transactions amounts at the exchange rates used for the corresponding prior year period and adjust prior year results to exclude businesses divested for the comparable period. We use comparable currency neutral results in our analysis of subsidiary and/or segment performance. We also use comparable currency neutral numbers when analyzing our performance against our competitors. See "Non-GAAP Financial Measures" for further discussion on the comparable currency neutral measure.

**Impairment of Goodwill**

As a result of the segment reorganization that occurred on January 1, 2025, goodwill related to the Nourish reporting unit was allocated between the Taste and Food Ingredients reporting units. In accordance with ASC 350, we performed a quantitative goodwill impairment test on the former Nourish reporting unit immediately prior to the change, and separately tested goodwill for the new Taste and Food Ingredients reporting units following the reorganization. Based on the results of the impairment testing, we determined that the carrying value of the Food Ingredients reporting unit exceeded its fair value and recorded an impairment charge of $1.153 billion. This charge is reflected in the Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) for the year ended December 31, 2025. See Note 12 to the Consolidated Financial Statements for additional information.

During 2024, we determined that the carrying value of the Pharma Solutions disposal group exceeded its fair value and recorded an impairment charge of $64 million in the Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) for the year ended December 31, 2024.

During 2023, we determined that the carrying value of the Nourish reporting unit exceeded its fair value and recorded an impairment charge of $2.623 billion in the Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) for the year ended December 31, 2023.

See "Critical Accounting Policies and Use of Estimates" and Note 12 to the Consolidated Financial Statements for additional information. For more detailed information about risks related to impairment of goodwill, refer to Item 1A, "Risk Factors" – *"Any impairment of our tangible or intangible long-lived assets, including goodwill, may adversely impact our profitability."*

**2025 Financial Performance Overview**

For a reconciliation between reported and adjusted figures, please refer to the "Non-GAAP Financial Measures" section.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

*Sales*

Sales in 2025 of $10.890 billion decreased 5% compared to sales of $11.484 billion in 2024. On a comparable currency neutral basis, sales in 2025 increased 2% compared to 2024. Exchange rates impact on sales was less than 1%. The effect of exchange rates can vary by business and region, depending upon the mix of sales priced in U.S. dollars as compared to other currencies. Comparable portfolio results exclude the impact of divestitures of the Flavors & Essences UK business ("F&E UK"), Rene Laurent business in France, Cosmetic Ingredients business, and the Pharma Solutions disposal group and Nitrocellulose business ("change in business portfolio mix due to divestitures"), which was approximately $757 million.

A key factor for commercial success is our inclusion on strategic customers' core supplier lists, which provides opportunities to expand and win new business. We are on the core supplier lists of a large majority of our global and strategic customers. Additionally, a significant portion of our sales comes from a relatively small number of large multinational customers. In 2025, our 25 largest customers, a majority of which were multinational consumer products companies, collectively accounted for approximately 32% of our sales. Beyond large multinational customers, our customer base continues to be diverse. Based on fiscal-year 2025 sales, we had approximately 20,000 customers. Approximately 69% of sales were from small and mid-sized companies. In 2025, no customer accounted for 10% or more of sales.

*Gross Profit*

Gross profit in 2025 decreased $186 million, or 5% on a reported basis, to $3.938 billion (36.2% of sales) from $4.124 billion (35.9% of sales) in the 2024 period. The decrease in gross profit was primarily driven by the impact of divestitures of $264 million and the effect of exchange rate variations, offset in part by volume increases and productivity gains.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

**RESULTS OF OPERATIONS**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Change** | **Change** | **Change** | **Change** |
| *<u>(DOLLARS IN MILLIONS EXCEPT PER SHARE AMOUNTS)</u>* | **2025** | **2024** | **2023** | **2025 vs. 2024** | **2025 vs. 2024** | **2024 vs. 2023** | **2024 vs. 2023** |
| Net sales | $10890 | $11484 | $11479 | (5) | % |  | % |
| Cost of sales | 6952 | 7360 | 7798 | (6) | % | (6) | % |
| Gross profit | 3938 | 4124 | 3681 | (5) | % | 12 | % |
| Research and development (R&D) expenses | 694 | 671 | 636 | 3 | % | 6 | % |
| Selling and administrative (S&A) expenses | 1834 | 1995 | 1787 | (8) | % | 12 | % |
| Restructuring and other charges | 70 | 29 | 68 | 141 | % | (57) | % |
| Amortization of acquisition-related intangibles | 568 | 610 | 680 | (7) | % | (10) | % |
| Impairment of goodwill | 1153 | 64 | 2623 | NMF | NMF | (98) | % |
| Losses (Gains) on sale of assets | 1 | (11) | (3) | (109) | % | 267 | % |
| Operating (loss) profit | (382) | 766 | (2110) | (150) | % | (136) | % |
| Interest expense | 229 | 305 | 380 | (25) | % | (20) | % |
| Gain on extinguishment of debt | (488) |  |  | NMF | NMF | NMF | NMF |
| Losses (Gains) on business disposals | 109 | (346) | 23 | (132) | % |  | % |
| Loss on assets classified as held for sale | 115 | 317 |  | NMF | NMF |  | % |
| Other expense, net | 65 | 182 | 5 | (64) | % | NMF | NMF |
| (Loss) income before taxes | (412) | 308 | (2518) | (234) | % | (112) | % |
| Provision for income taxes | (53) | 41 | 69 | (229) | % | (41) | % |
| Net (loss) income | (359) | 267 | (2587) | (234) | % | (110) | % |
| Net income attributable to non-controlling interest | 2 | 4 | 4 | (50) | % |  | % |
| Net (loss) income attributable to IFF shareholders | $(361) | $263 | $(2591) | (237) | % | (110) | % |
| Net income (loss) per share — basic and diluted | $(1.41) | $1.04 | $(10.14) | (236) | % | (110) | % |
| Gross margin | 36.2% | 35.9% | 32.1% | 30 | bps | NMF | NMF |
| R&D as a percentage of sales | 6.4% | 5.8% | 5.5% | 60 | bps | 30 | bps |
| S&A as a percentage of sales | 16.8% | 17.4% | 15.6% | (60) | bps | 180 | bps |
| Operating margin | (3.5)% | 6.7% | (18.4)% | NMF | NMF | NMF | NMF |
| Effective tax rate | 12.9% | 13.3% | (2.7)% | (40) | bps | NMF | NMF |
| <u>Segment net sales</u> |  |  |  |  |  |  |  |
| Taste | $2481 | $2428 | $2303 | 2 | % | 5 | % |
| Food Ingredients | 3278 | 3365 | 3692 | (3) | % | (9) | % |
| Health & Biosciences | 2283 | 2203 | 2071 | 4 | % | 6 | % |
| Scent | 2479 | 2439 | 2393 | 2 | % | 2 | % |
| Pharma Solutions | 369 | 1049 | 1020 | (65) | % | 3 | % |
| Consolidated | $10890 | $11484 | $11479 | (5) | % |  | % |

---

_______________________

NMF: Not meaningful

Cost of sales includes the cost of materials and manufacturing expenses. R&D expenses include expenses related to the development of new and improved products and technical product support. S&A expenses include expenses necessary to support our commercial activities and administrative expenses supporting our overall operating activities including compliance with governmental regulations.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

**<u>2025 IN COMPARISON TO 2024</u>**

Sales performance by segment was as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **% Change in Sales - 2025 vs. 2024** | **% Change in Sales - 2025 vs. 2024** | **% Change in Sales - 2025 vs. 2024** |
| | **Reported** | **Currency Neutral**<sup>(2)</sup> | **Comparable Currency Neutral**<sup>(1)(2)</sup> |
| **Taste** | **2%** | **3%** | **4%** |
| **Food Ingredients** | **-3%** | **-3%** | **-3%** |
| **Health & Biosciences** | **4%** | **3%** | **3%** |
| **Scent** | **2%** | **2%** | **3%** |
| **Pharma Solutions** | **-65%** | **-64%** | **12%** |
| &nbsp;&nbsp;&nbsp;&nbsp;***Total*** | ***-5*** *%*** | ***-5*** *%*** | ***2*** *%*** |

---

Comparable currency neutral reported performance by segment was as follows:

---

| | | |
|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** |
| **Net Sales** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Taste | $2508 | $2410 |
| &nbsp;&nbsp;&nbsp;&nbsp;Food Ingredients | 3279 | 3365 |
| &nbsp;&nbsp;&nbsp;&nbsp;Health & Biosciences | 2275 | 2203 |
| &nbsp;&nbsp;&nbsp;&nbsp;Scent | 2495 | 2412 |
| &nbsp;&nbsp;&nbsp;&nbsp;Pharma Solutions | 376 | 337 |
| &nbsp;&nbsp;&nbsp;&nbsp;Impact of Business Divestitures<sup>(1)</sup> |  | 757 |
| &nbsp;&nbsp;&nbsp;&nbsp;Impact of Currency Fluctuation<sup>(2)</sup> | (43) |  |
| Total | $10890 | $11484 |

---

_______________________

(1)Impact of business divestitures includes the results of the F&E UK business that was divested on September 1, 2024 (for January 1, 2024 to September 1, 2024), the Rene Laurent business that was divested on December 1, 2025 (for December 1, 2024 to December 31, 2024), the Cosmetic Ingredients business that was divested on April 2, 2024 (for January 1, 2024 to April 2, 2024), and the Pharma Solutions disposal group and Nitrocellulose business that were divested on May 1, 2025 and May 9, 2025, respectively (for May 1, 2024 to December 31, 2024 and May 9, 2024 to December 31, 2024, respectively).

(2)Currency neutral sales are calculated by translating current year invoiced sale amounts at the exchange rates for the corresponding prior year period.

*Taste*

Taste sales in 2025 increased $53 million, or 2% on a reported basis, to $2.481 billion compared to $2.428 billion in 2024. On a comparable currency neutral basis, Taste sales increased 4% in 2025 compared to the 2024 period, driven by volume increases across all business entities. Exchange rate variations had an unfavorable impact of 1%. Comparable portfolio results exclude the impact of the divestitures of the F&E UK business and Rene Laurent business of approximately $18 million.

*Food Ingredients*

Food Ingredients sales in 2025 decreased $87 million, or 3% on a reported basis, to $3.278 billion compared to $3.365 billion in 2024. On a comparable currency neutral basis, Food Ingredients sales decreased 3% in 2025 compared to the 2024 period, driven by volumes decreases in Protein Solutions offset by volume growth in Inclusions as well the proactive exit of low margin business over the course of 2025. Exchange rates impact on sales was less than 1%.

*Health & Biosciences*

Health & Biosciences sales in 2025 increased $80 million, or 4% on a reported basis, to $2.283 billion compared to $2.203 billion in 2024. On a comparable currency neutral basis, Health & Biosciences sales increased 3% in 2025 compared to the 2024 period driven by volume increases across various business units and price increases across Food Biosciences and Grain Processing business units. Exchange rate variations had a favorable impact of 1%.

*Scent*

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

Scent sales in 2025 increased $40 million, or 2% on a reported basis, to $2.479 billion compared to $2.439 billion in 2024. On a comparable currency neutral basis, Scent sales increased 3% in 2025 compared to the 2024 period driven by volume increases in Fragrance Compounds offset by decreases in Fragrance Ingredients. Exchange rates impact on sales was less than 1%. Comparable portfolio results exclude the impact of the divestiture of the Cosmetic Ingredients business, with an impact of approximately $27 million.

*Pharma Solutions*

Pharma Solutions sales in 2025 decreased $680 million, or 65% on a reported basis, to $369 million compared to $1.049 billion in 2024. On a comparable currency neutral basis, Pharma Solutions sales increased 12% in 2025 compared to the 2024 period driven by volume and price increases. The impact of exchange rate variations had an unfavorable impact of 1% and the divestitures of the Pharma Solutions disposal group and Nitrocellulose disposal group had a sales impact of approximately $712 million. This comparison reflects a full year of contributions from both businesses in 2024, whereas 2025 includes only four months of activity prior to the divestitures, contributing significantly to the year-over-year decline.

**Cost of Sales**

Cost of sales decreased $408 million to $6.952 billion (63.8% of sales) in 2025 compared to $7.360 billion (64.1% of sales) in 2024. The decrease in cost of sales was primarily driven by the divestitures the impact of which was approximately $493 million, lower raw material costs and lower unfavorable manufacturing absorption compared to the prior year period, increased productivity compared to the prior year period, offset in part by volume increases. With the decrease in cost of sales, gross margin increased, reflecting the benefit of lower costs and improved productivity.

**Research and Development ("R&D") Expenses**

R&D expenses increased $23 million to $694 million (6.4% of sales) in 2025 compared to $671 million (5.8% of sales) in 2024. The increase in R&D expenses was primarily driven by an increase in employee related costs and operating expenses for R&D related activities, offset in part by the impact of the divestitures and the effect of exchange rate variations.

**Selling and Administrative ("S&A") Expenses**

S&A expenses decreased $161 million to $1.834 billion (16.8% of sales) in 2025 compared to $1.995 billion (17.4% of sales) in 2024. The decrease in S&A expenses was primarily driven by a decrease in the incentive compensation expense and lower consulting fees incurred in relation to business divestitures.

**Restructuring and Other Charges**

Restructuring and other charges increased to $70 million in 2025 compared to $29 million in 2024. The increase was driven by higher severance costs incurred as part of the IFF Productivity Program. See Note 5 for additional information.

**Amortization of Acquisition-Related Intangibles**

Amortization expenses decreased to $568 million in 2025 compared to $610 million in 2024. The decrease in amortization expense was primarily driven by the intangible assets of the Pharma Solutions disposal group being classified as "held for sale," and therefore no longer recognizing amortization expense on those intangible assets. See Note 4 for additional information.

**Impairment of Goodwill**

The impairment of goodwill was $1.153 billion in 2025 compared to $64 million in 2024, which was related to the Food Ingredients reporting unit and the Pharma Solutions disposal group, respectively. See Note 1, Note 3, and Note 12 for additional information.

**Interest Expense**

Interest expense decreased $76 million to $229 million in 2025 compared to $305 million in 2024. The decrease in interest expense was due to lower debt outstanding. See Note 14 for additional information.

**Losses (Gains) on Business Disposals**

Losses (Gains) on business disposals was $109 million in 2025 compared to $(346) million in 2024. The net loss in 2025 was primarily driven by the Pharma Solutions disposal group and Nitrocellulose business divestitures, while the gain recognized in 2024 related to the Cosmetic Ingredients business divestiture, offset in part by the loss recognized on the sale of the F&E UK business. See Note 3 for additional information.

**Loss on Assets Classified as Held for Sale**

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

Loss on assets classified as held for sale was $115 million in 2025 and $317 million in 2024. The loss in 2025 related to assets classified as held for sale for the Soy Crush, Concentrates & Lecithin business. The loss in 2024 related to assets classified as held for sale for the Pharma Solutions disposal group and the portion of the Savory Solutions business in Turkey. See Note 4 for additional information.

**Other Expense, Net**

Other expense, net, decreased $117 million to $65 million in 2025 compared to $182 million in 2024. $130 million of the decrease was driven by a settlement loss that was recognized upon termination of the International Flavors & Fragrances Inc. Pension Plan in 2024. See Note 8 and Note 9 for additional information.

**Income Taxes**

The effective tax rate in 2025 was 12.9% compared to 13.3% in 2024. The year-over-year decrease was primarily driven by the tax benefit resulting from the entity realignment project, offset in part by the impact of business divestitures, tax effects of non-deductible goodwill impairment and changes in the mix of earnings post-divestitures. See Note 10 for additional information.

**Segment Adjusted Operating EBITDA Results**

We use Segment Adjusted Operating EBITDA for internal reporting and performance measurement purposes. Segment Adjusted Operating EBITDA is defined as (Loss) Income Before Taxes before depreciation and amortization expense, interest expense, restructuring and other charges and certain items that are not related to recurring operations. Our determination of reportable segments was made on the basis of our strategic priorities within each segment and corresponds to the manner in which our Chief Operating Decision Maker reviews and evaluates operating performance to make decisions about resources to be allocated to the segment. In addition to our strategic priorities, segment reporting is also based on differences in the products we sell.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

Adjusted Operating EBITDA performance by segment was as follows:

---

| | | |
|:---|:---|:---|
| | **% Change in Adjusted Operating EBITDA - 2025 vs. 2024** | **% Change in Adjusted Operating EBITDA - 2025 vs. 2024** |
| | **Reported**<sup>(1)</sup> | **Comparable Currency Neutral Adjusted** <sup>(1)(2)(3)</sup> |
| **Taste** | **4%** | **10%** |
| **Food Ingredients** | **4%** | **10%** |
| **Health & Biosciences** | **3%** | **7%** |
| **Scent** | **-6%** | **2%** |
| **Pharma Solutions** | **-65%** | **16%** |
| &nbsp;&nbsp;&nbsp;&nbsp;***Total*** | ***-5*** *%*** | ***7*** *%*** |

---

Comparable Currency Neutral Adjusted Operating EBITDA by segment was as follows:

---

| | | |
|:---|:---|:---|
| | **For the Year Ended<br>December 31,** | **For the Year Ended<br>December 31,** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **2025** | **2024** |
| **Segment Adjusted Operating EBITDA** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Taste | $490 | $446 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Food Ingredients | 439 | 399 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Health & Biosciences | 608 | 568 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Scent | 537 | 526 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pharma Solutions | 79 | 68 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impact of Currency Fluctuation<sup>(3)</sup> | (67) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impact of Business Divestitures<sup>(2)</sup> |  | 198 |
| Total | 2086 | 2205 |
| Depreciation & Amortization | (962) | (1015) |
| Interest Expense | (229) | (305) |
| Other (Expense) Income, net | (65) | (182) |
| Restructuring and Other Charges | (70) | (29) |
| Impairment of Goodwill | (1153) | (64) |
| (Losses) Gains on Business Disposals | (109) | 346 |
| Loss on Assets Classified as Held for Sale | (115) | (317) |
| Gain on Extinguishment of Debt | 488 |  |
| Acquisition, Divestiture and Integration Related Costs | (125) | (228) |
| Strategic Initiatives Costs | (35) | (33) |
| Regulatory Costs | (106) | (73) |
| Entity Realignment Costs | (8) | (6) |
| Other | (9) | 9 |
| (Loss) Income Before Taxes | $(412) | $308 |
| **Segment Adjusted Operating EBITDA margin:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Taste | 19.5% | 18.5% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Food Ingredients | 13.4% | 11.9% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Health & Biosciences | 26.7% | 25.8% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Scent | 21.5% | 21.8% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pharma Solutions | 21.0% | 20.2% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consolidated | 19.2% | 19.2% |

---

_______________________

(1)Refer to Note 7 for a reconciliation of Adjusted Operating EBITDA to Income (Loss) Before Taxes.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

(2)Comparable portfolio results for 2024 exclude the impact of divestitures. Impact of business divestitures includes the results of the F&E UK business that was divested on September 1, 2024 (for January 1, 2024 to September 1, 2024), the Rene Laurent business that was divested on December 1, 2025 (for December 1, 2024 to December 31, 2024), the Cosmetic Ingredients business that was divested on April 2, 2024 (for January 1, 2024 to April 2, 2024), and the Pharma Solutions disposal group and Nitrocellulose business that were divested on May 1, 2025 and May 9, 2025, respectively (for May 1, 2024 to December 31, 2024 and May 9, 2024 to December 31, 2024, respectively).

(3)Currency neutral amounts are calculated by translating current year transaction amounts at the exchange rates for the corresponding prior year period.

Following the completed divestitures of the Pharma Solutions disposal group on May 1, 2025 and the Nitrocellulose business on May 9, 2025, we retrospectively reallocated certain corporate costs previously attributed to the Pharma Solutions segment. These costs have been redistributed across the Taste, Food Ingredients, Health & Biosciences, and Scent segments for comparability purposes.

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31, 2024** | **For the Year Ended December 31, 2024** | **For the Year Ended December 31, 2024** |
| | Selling & Administrative Expenses | Research & Development Expenses | Total EBITDA Impact |
| Taste | $7 | $1 | $(8) |
| Food Ingredients | 9 |  | (9) |
| Health & Biosciences | 7 | 1 | (8) |
| Scent | 5 | 1 | (6) |
| Total | $28 | $3 | $(31) |

---

*Taste Segment Adjusted Operating EBITDA*

Taste Segment Adjusted Operating EBITDA increased $18 million, or 4% on a reported basis, to $478 million (19.3% of segment sales) in 2025 from $460 million (18.9% of segment sales) in 2024. On a comparable currency neutral basis, Taste Segment Adjusted Operating EBITDA increased 10% in 2025 compared to 2024 led by primarily favorable net pricing, volume increases and productivity gains. Comparable portfolio results exclude the impact of the divestitures of the F&E UK business with an impact of approximately $14 million.

*Food Ingredients Segment Adjusted Operating EBITDA*

Food Ingredients Segment Adjusted Operating EBITDA increased $15 million, or 4% on a reported basis, to $423 million (12.9% of segment sales) in 2025 from $408 million (12.1% of segment sales) in 2024. On a comparable currency neutral basis, Food Ingredients Segment Adjusted Operating EBITDA increased 10% in 2025 compared to 2024 led by primarily favorable net pricing and productivity gains.

*Health & Biosciences Segment Adjusted Operating EBITDA*

Health & Biosciences Segment Adjusted Operating EBITDA increased $17 million, or 3% on a reported basis, to $594 million (26.0% of segment sales) in 2025 from $577 million (26.2% of segment sales) in 2024. On a comparable currency neutral basis, Health & Biosciences Segment Adjusted Operating EBITDA increased 7% in 2025 compared to 2024 led by primarily favorable net pricing, volume increases, and productivity gains.

*Scent Segment Adjusted Operating EBITDA*

Scent Segment Adjusted Operating EBITDA decreased $30 million, or 6% on a reported basis, to $515 million (20.8% of segment sales) in 2025 from $545 million (22.3% of segment sales) in 2024. On a comparable currency neutral basis, Scent Segment Adjusted Operating EBITDA increased 2% in 2025 compared to 2024 led by primarily volume increases and productivity gains. Comparable portfolio results exclude the impact of the divestiture of the Cosmetic Ingredients business, with an impact of approximately $19 million.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

*Pharma Solutions Segment Adjusted Operating EBITDA*

Pharma Solutions Segment Adjusted Operating EBITDA decreased $139 million, or 65% on a reported basis, to $76 million (20.6% of segment sales) in 2025 from $215 million (20.5% of segment sales) in 2024. On a comparable currency neutral basis, Pharma Solutions Segment Adjusted Operating EBITDA increased 16% in 2025 compared to 2024 led by primarily favorable net pricing. The divestitures of the Pharma Solutions disposal group and Nitrocellulose business had an impact on Adjusted Operating EBITDA of approximately $147 million. This comparison reflects a full year of contributions from both businesses in 2024, whereas 2025 includes only four months of activity prior to the divestitures, contributing significantly to the year-over-year decline.

**<u>2024 IN COMPARISON TO 2023</u>**

Sales performance by segment was as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **% Change in Sales - 2024 vs. 2023** | **% Change in Sales - 2024 vs. 2023** | **% Change in Sales - 2024 vs. 2023** |
| | **Reported** | **Currency Neutral**<sup>(2)</sup> | **Comparable Currency Neutral**<sup>(1)(2)</sup> |
| **Taste** | **5%** | **11%** | **12%** |
| **Food Ingredients** | **-9%** | **-7%** | **-1%** |
| **Health & Biosciences** | **6%** | **8%** | **8%** |
| **Scent** | **2%** | **7%** | **12%** |
| **Pharma Solutions** | **3%** | **3%** | **3%** |
| &nbsp;&nbsp;&nbsp;&nbsp;***Total*** | ***—*** *%*** | ***3*** *%*** | ***6*** *%*** |

---

Comparable reported performance by segment was as follows:

---

| | | |
|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2024** | **2023** |
| **Net Sales** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Taste | $2428 | $2281 |
| &nbsp;&nbsp;&nbsp;&nbsp;Food Ingredients | 3365 | 3470 |
| &nbsp;&nbsp;&nbsp;&nbsp;Health & Biosciences | 2203 | 2071 |
| &nbsp;&nbsp;&nbsp;&nbsp;Scent | 2439 | 2277 |
| &nbsp;&nbsp;&nbsp;&nbsp;Pharma Solutions | 1049 | 1020 |
| &nbsp;&nbsp;&nbsp;&nbsp;Impact of Business Divestitures<sup>(1)</sup> |  | 360 |
| Total | $11484 | $11479 |

---

Comparable currency neutral reported performance by segment was as follows:

---

| | | |
|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2024** | **2023** |
| **Net Sales** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Taste | $2560 | $2281 |
| &nbsp;&nbsp;&nbsp;&nbsp;Food Ingredients | 3429 | 3470 |
| &nbsp;&nbsp;&nbsp;&nbsp;Health & Biosciences | 2244 | 2071 |
| &nbsp;&nbsp;&nbsp;&nbsp;Scent | 2554 | 2277 |
| &nbsp;&nbsp;&nbsp;&nbsp;Pharma Solutions | 1048 | 1020 |
| &nbsp;&nbsp;&nbsp;&nbsp;Impact of Business Divestitures<sup>(1)</sup> |  | 360 |
| &nbsp;&nbsp;&nbsp;&nbsp;Impact of Currency Fluctuation<sup>(2)</sup> | (351) |  |
| Total | $11484 | $11479 |

---

_______________________

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

(1)Comparable portfolio results for 2023 exclude the impact of divestitures. Impact of business divestitures include the results of a portion of the Savory Solutions business that was divested on May 31, 2023 (for January 1, 2023 to May 31, 2023), the Flavor Specialty Ingredients business that was divested on August 1, 2023 (for January 1, 2023 to August 1, 2023), the Sonarome business that was divested on December 1, 2023 (for January 1, 2023 to December 1, 2023), the Cosmetic Ingredients business that was divested on April 2, 2024 (for April 2, 2023 to December 31, 2023), and the Flavors & Essences UK business that was divested on September 1, 2024 (for September 1, 2023 to December 31, 2023).

(2)Currency neutral sales are calculated by translating current year invoiced sale amounts at the exchange rates for the corresponding prior year period.

*Taste*

Taste sales in 2024 increased $125 million, or 5% on a reported basis, to $2.428 billion compared to $2.303 billion in 2023. On a comparable currency neutral basis, Taste sales increased 12% in 2024 compared to the 2023 period, driven by volume increases. Exchange rate variations had an unfavorable impact of 6%. Comparable portfolio results exclude the impact of the divestitures of the Sonarome business and F&E UK business, with an impact of approximately $22 million.

*Food Ingredients*

Food Ingredients sales in 2024 decreased $327 million, or 9% on a reported basis, to $3.365 billion compared to $3.692 billion in 2023. On a comparable currency neutral basis, Food Ingredients sales decreased 1% in 2024 compared to the 2023 period, driven by volume decreases in Emulsifiers and Sweeteners offset by volumes increases across other business units. Exchange rate variations had an unfavorable impact of 2%. Comparable portfolio results exclude the impact of the divestiture of the portion of the Savory Solutions business with an impact of approximately $222 million.

*Health & Biosciences*

Health & Biosciences sales in 2024 increased $132 million, or 6% on a reported basis, to $2.203 billion compared to $2.071 billion in 2023. On a comparable currency neutral basis, Health & Biosciences sales increased 8% in 2024 compared to the 2023 period driven by volume increases across various business units and price increases across Food Biosciences and Grain Processing business units. Exchange rate variations had an unfavorable impact of 2%.

*Scent*

Scent sales in 2024 increased $46 million, or 2% on a reported basis, to $2.439 billion compared to $2.393 billion in 2023. On a comparable currency neutral basis, Scent sales increased 12% in 2024 compared to the 2023 period driven by price increases in the Fragrance Compounds business unit and volume increases across all business units. Exchange rate variations had an unfavorable impact of 5%. Comparable portfolio results exclude the impact of the divestitures of the Flavors Specialty Ingredients business and Cosmetic Ingredients business, with an impact of approximately $116 million.

*Pharma Solutions*

Pharma Solutions sales in 2024 increased $29 million, or 3% on a reported basis, to $1.049 billion compared to $1.020 billion in 2023. On a comparable currency neutral basis, Pharma Solutions sales also increased 3% in 2024 compared to the 2023 period driven by volume growth in industrial markets. Exchange rates impact on sales was less than 1%. Performance in the Pharma Solutions operating segment was driven by volume growth in industrial markets.

**Cost of Sales**

Cost of sales decreased $438 million to $7.360 billion (64.1% of sales) in 2024 compared to $7.798 billion (67.9% of sales) in 2023. The decrease in cost of sales was primarily driven by the change in business portfolio mix due to divestitures which was approximately $227 million, lower raw material costs and manufacturing expenses, lower unfavorable manufacturing absorption compared to the prior year period, increased productivity compared to the prior year period, offset in part by volume increases. With the decrease in cost of sales, gross margin increased, reflecting the benefit of lower costs and improved productivity.

**Research and Development ("R&D") Expenses**

R&D expenses increased $35 million to $671 million (5.8% of sales) in 2024 compared to $636 million (5.5% of sales) in 2023. The increase in R&D expenses was primarily driven by an increase in incentive compensation expense, offset in part by the net impact of the change in business portfolio mix due to divestitures and the effect of exchange rate variations.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

**Selling and Administrative ("S&A") Expenses**

S&A expenses increased $208 million to $1.995 billion (17.4% of sales) in 2024 compared to $1.787 billion (15.6% of sales) in 2023. The increase in S&A expenses was primarily driven by an increase in incentive compensation expense, professional fees, legal fees and provisions incurred for the ongoing investigations of the fragrance businesses, and divestiture related costs incurred in preparation for the sale of the Pharma Solutions disposal group, offset in part by the change in business portfolio mix due to divestitures.

**Restructuring and Other Charges**

Restructuring and other charges decreased to $29 million in 2024 compared to $68 million in 2023. The 2024 amounts represent costs primarily related to the IFF Productivity Program and the 2023 amounts represent severance costs primarily incurred as part of the 2023 Restructuring Program. See Note 5 for additional information.

**Amortization of Acquisition-Related Intangibles**

Amortization expenses decreased to $610 million in 2024 compared to $680 million in 2023. The decrease in amortization expense was primarily driven by the reduction in intangible assets as a result of the change in business portfolio mix due to divestitures and intangible assets of the Pharma Solutions disposal group being classified as "held for sale," and therefore no longer recognizing amortization expense on those intangible assets. See Note 4 for additional information.

**Impairment of Goodwill**

The impairment of goodwill was $64 million in 2024 compared to $2.623 billion in 2023, which was related to the Pharma Solutions disposal group and Nourish reporting units, respectively. See Note 1, Note 3, and Note 12 for additional information.

**Interest Expense**

Interest expense decreased $75 million to $305 million in 2024 compared to $380 million in 2023. The decrease in interest expense was due to lower debt outstanding. See Note 14 for additional information.

**Losses (Gains) on Business Disposals**

Losses (Gains) on business disposals increased to $(346) million in 2024 compared to $23 million in 2023. The net gain on business disposals in 2024 primarily relates to the gain recognized on the sale of the Cosmetic Ingredients business, offset in part by the loss recognized on the sale of the F&E UK business. The loss in 2023 primarily relates to the sale of the Flavors Specialty Ingredients business, the sale of a portion of the Savory Solutions business, and liquidation of a business in Russia for the sale of the portion of the Savory Solutions business. See Note 3 for additional information.

**Loss on Assets Classified as Held for Sale**

Loss on assets classified as held for sale was $317 million in 2024. This related to assets classified as held for sale for the Pharma Solutions disposal group and a portion of the Savory Solutions business in Turkey. See Note 4 for additional information.

**Other Expense, Net**

Other expense, net, increased $177 million to $182 million in 2024 compared to $5 million in 2023. $153 million of increased expense was driven by increased pension-related expense, $130 million of which was due to a settlement loss that was recognized upon termination of the International Flavors & Fragrances Inc. Pension Plan in 2024. See Note 8 and Note 9 for additional information.

**Income Taxes**

The effective tax rate in 2024 was 13.3% compared to (2.7)% in 2023. The year-over-year increase was primarily driven by an increase in pre-tax income, changes in the mix of earnings, the tax impact of business divestitures and certain non-recurring tax benefits. See Note 10 for additional information.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

**Segment Adjusted Operating EBITDA Results**

Adjusted Operating EBITDA performance by segment was as follows:

---

| | | |
|:---|:---|:---|
| | **% Change in Adjusted Operating EBITDA - 2024 vs. 2023** | **% Change in Adjusted Operating EBITDA - 2024 vs. 2023** |
| | **Reported**<sup>(1)</sup> | **Comparable Adjusted**<sup>(1)(2)</sup> |
| **Taste** | **18%** | **21%** |
| **Food Ingredients** | **11%** | **18%** |
| **Health & Biosciences** | **10%** | **10%** |
| **Scent** | **10%** | **21%** |
| **Pharma Solutions** | **7%** | **7%** |
| &nbsp;&nbsp;&nbsp;&nbsp;***Total*** | ***11*** *%*** | ***16*** *%*** |

---

Comparable Adjusted Operating EBITDA by segment was as follows:

---

| | | |
|:---|:---|:---|
| | **For the Year Ended<br>December 31,** | **For the Year Ended<br>December 31,** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **2024** | **2023** |
| **Segment Adjusted Operating EBITDA** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Taste | $460 | $381 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Food Ingredients | 408 | 346 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Health & Biosciences | 577 | 524 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Scent | 545 | 450 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pharma Solutions | 215 | 202 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impact of Business Divestitures<sup>(2)</sup> |  | 77 |
| Total | 2205 | 1980 |
| Depreciation & Amortization | (1015) | (1142) |
| Interest Expense | (305) | (380) |
| Other (Expense) Income, net | (182) | (5) |
| Restructuring and Other Charges | (29) | (68) |
| Impairment of Goodwill | (64) | (2623) |
| Gains (Losses) on Business Disposals | 346 | (23) |
| Loss on Assets Classified as Held for Sale | (317) |  |
| Acquisition, Divestiture and Integration Related Costs | (228) | (174) |
| Strategic Initiatives Costs | (33) | (31) |
| Regulatory Costs | (73) | (50) |
| Entity Realignment Costs | (6) | (2) |
| Other | 9 |  |
| Income (Loss) Before Taxes | $308 | $(2518) |
| **Segment Adjusted Operating EBITDA margin:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Taste | 18.9% | 16.7% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Food Ingredients | 12.1% | 10.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Health & Biosciences | 26.2% | 25.3% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Scent | 22.3% | 19.8% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pharma Solutions | 20.5% | 19.8% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consolidated | 19.2% | 17.2% |

---

_______________________

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

(1)Refer to Note 7 for a reconciliation of Adjusted Operating EBITDA to Income (Loss) Before Taxes.

(2)Comparable portfolio results for 2023 exclude the impact of divestitures. Impact of business divestitures include the results of a portion of the Savory Solutions business that was divested on May 31, 2023 (for January 1, 2023 to May 31, 2023), the Flavor Specialty Ingredients business that was divested on August 1, 2023 (for January 1, 2023 to August 1, 2023), the Sonarome business that was divested on December 1, 2023 (for January 1, 2023 to December 1, 2023), the Cosmetic Ingredients business that was divested on April 2, 2024 (for April 2, 2023 to December 31, 2023), and the Flavors & Essences UK business that was divested on September 1, 2024 (for September 1, 2023 to December 31, 2023).

*Taste Segment Adjusted Operating EBITDA*

Taste Segment Adjusted Operating EBITDA increased $71 million, or 18% on a reported basis, to $460 million (18.9% of segment sales) in 2024 from $389 million (16.9% of segment sales) in 2023. On a comparable basis, Taste Segment Adjusted Operating EBITDA increased 21% in 2024 compared to 2023 led by primarily volume increases and favorable net pricing. Comparable portfolio results exclude the impact of the divestitures of the Sonarome business and F&E UK business of approximately $9 million.

*Food Ingredients Segment Adjusted Operating EBITDA*

Food Ingredients Segment Adjusted Operating EBITDA increased $39 million, or 11% on a reported basis, to $408 million (12.1% of segment sales) in 2024 from $369 million (10.0% of segment sales) in 2023. On a comparable basis, Food Ingredients Segment Adjusted Operating EBITDA increased 18% in 2024 compared to 2023 led by primarily volume increases and favorable net pricing. Comparable portfolio results exclude the impact of the divestiture of a portion of the Savory Solutions business of approximately $23 million.

*Health & Biosciences Segment Adjusted Operating EBITDA*

Health & Biosciences Segment Adjusted Operating EBITDA increased $53 million, or 10% on a reported and comparable adjusted basis, to $577 million (26.2% of segment sales) in 2024 from $524 million (25.3% of segment sales) in 2023 led by primarily volume increases and productivity gains.

*Scent Segment Adjusted Operating EBITDA*

Scent Segment Adjusted Operating EBITDA increased $49 million, or 10% on a reported basis, to $545 million (22.3% of segment sales) in 2024 from $496 million (20.7% of segment sales) in 2023. On a comparable basis, Scent Segment Adjusted Operating EBITDA increased 21% in 2024 compared to 2023 led by primarily volume increases and productivity gains. Comparable portfolio results exclude the impact of the divestitures of the Flavors Specialty Ingredients business and Cosmetic Ingredients business of approximately $45 million.

*Pharma Solutions Segment Adjusted Operating EBITDA*

Pharma Solutions Segment Adjusted Operating EBITDA increased $13 million, or 6% on a reported and comparable adjusted basis, to $215 million (20.5% of segment sales) in 2024 from $202 million (19.8% of segment sales) in 2023 led by primarily volume increases and productivity gains.

**Liquidity and Capital Resources**

*Cash, Cash Equivalents and Restricted Cash*

We had cash, cash equivalents and restricted cash of approximately $590 million on the Consolidated Balance Sheets, at December 31, 2025 compared to $471 million, inclusive of $2 million in Assets held for sale on the Consolidated Balance Sheets, at December 31, 2024. The majority of this balance was held outside the United States. Cash balances held in foreign jurisdictions are, in most circumstances, available to be repatriated to the United States.

Effective utilization of the cash generated by our international operations is a critical component of our strategy. We regularly repatriate cash from our non-U.S. subsidiaries to fund financial obligations in the U.S. As we repatriate these funds to the U.S., we will be required to pay income taxes in certain U.S. states and applicable foreign withholding taxes during the period when such repatriation occurs. Accordingly, as of December 31, 2025, we had a deferred tax liability of approximately 155 million for the effect of repatriating the funds to the U.S., attributable to various non-U.S. subsidiaries. There is no deferred tax liability associated with non-U.S. subsidiaries where we intend to indefinitely reinvest the earnings to fund local operations and/or capital projects.

*Cash Flows Provided By Operating Activities*

Cash flows provided by operating activities in 2025 were $850 million, or 7.8% of sales, compared to $1.070 billion, or 9.3% of sales, in 2024. The decrease in cash flows from operating activities from 2024 to 2025 was primarily driven by an increase in working capital and a larger incentive compensation payout made in 2025 related to 2024 results, offset in part by an increase in accounts receivables in the prior year.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

*Cash Flows Provided By Investing Activities*

Cash flows provided by investing activities in 2025 were $2.269 billion compared to $326 million in 2024. The increase in cash flows from investing activities from 2024 to 2025 was primarily driven by higher net proceeds received from business divestitures, including the Pharma Solutions disposal group, the Nitrocellulose business, the Tobacco Flavoring business in North America, and the Rene Laurent business in France, compared to the net proceeds received during 2024 primarily from the divestiture of the Cosmetic Ingredients business. This increase was offset in part by higher spending on property, plant and equipment during 2025 compared to 2024.

We have evaluated and re-prioritized our capital projects and expect that capital spending in 2026 will be approximately 6% of sales.

*Cash Flows Used In Financing Activities*

Cash flows used in financing activities in 2025 were $3.091 billion compared to $1.606 billion in 2024. The increase in cash flows used in financing activities from 2024 to 2025 was primarily driven by our purchase with cash of certain of our outstanding series of Senior Notes for $2.0 billion, excluding accrued and unpaid interest. We also repaid the outstanding borrowings under both the 2026 Term Loan Facility and the 2025 Notes during the period. In addition, during 2025 we repurchased $38 million of common stock, as part of the share repurchase program that began on October 1, 2025. These outflows were partially offset by an increase in commercial paper borrowings during 2025.

We paid dividends totaling $409 million and $514 million in 2025 and 2024, respectively. The cash dividends declared was $1.60 per share in both 2025 and 2024.

Our capital allocation strategy seeks to maintain investment grade ratings while investing in the business, continuing to pay dividends, repurchasing shares outstanding and repaying debt. We do not have any rating downgrade triggers that would accelerate the maturity dates of our senior unsecured debt. However, any downgrade in our credit rating may, depending on the extent of such downgrade, negatively impact our ability to raise additional debt capital, our liquidity and capital position, and may increase our cost of borrowing for new capital raises. In addition, our existing Revolving Credit Facility has pricing grids that are based on credit rating, such that our cost of borrowing may increase if our credit rating decreases. We make capital investments in our businesses to support our operational needs and strategic long-term plans. We are committed to maintaining our history of paying a dividend to investors which is determined by our Board of Directors at its discretion based on various factors.

**Capital Resources**

Operating cash flow provides the primary source of funds for capital investment needs, dividends paid to shareholders, treasury share repurchases and debt service repayments. We anticipate that cash flows from operations, cash proceeds generated from planned business divestitures and availability under our existing credit facilities will be sufficient to meet our investing and financing needs, including our debt service requirements for the foreseeable future. We regularly assess our capital structure, including both current and long-term debt instruments, as compared to our cash generation and investment needs in order to provide ample flexibility and to optimize our leverage ratios. See Note 14 for additional information.

*Revolving Credit Facility*

Our Revolving credit agreement contains various covenants, limitations and events of default customary for similar facilities for similarly rated borrowers, including the requirement for us to maintain, at the end of each fiscal quarter, a ratio of net debt for borrowed money to credit adjusted EBITDA in respect of the previous 12-month period.

Our Revolving Credit Facility bears interest at a base rate or a rate equal to Secured Overnight Financing Rate ("Term SOFR"), or, in the case of euro-denominated loans, the Euro interbank offered rate, plus, in each case, an applicable margin based on our public debt rating. Loans may be prepaid without premium or penalty, subject to customary breakage costs.

On June 25, 2025, we entered into the Fourth Amended and Restated Credit Agreement ("Revolving Credit Agreement"), which amended and restated the most recent Amendment No. 4 to the Third Amended and Restated Credit Agreement dated September 19, 2023. This amendment and restatement, among other things, extended the termination date to June 25, 2030. The Revolving Credit Agreement states that from the effective date through September 30, 2025, our net debt to credit adjusted EBITDA ratio shall not exceed 4.00x, and shall not exceed 3.75x thereafter, with a temporary step-up to 4.25x permitted for three fiscal quarters following an acquisition exceeding $500 million in paid consideration. As of December 31, 2025, we were in compliance with all financial and other covenants.

As of December 31, 2025, we had no outstanding borrowings under our $2 billion Revolving Credit Facility or other lines of credit. The amount that we are able to draw down under the Revolving Credit Facility is limited by financial covenants as described in more detail below. As of December 31, 2025, our available capacity was $2 billion under the Revolving Credit Facility.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

See Note 14 to the Consolidated Financial Statements for additional information on our credit agreements.

*Credit Adjusted EBITDA*

At December 31, 2025, we were in compliance with all financial and other covenants under our credit agreements, including the net debt to credit adjusted EBITDA<sup>(1)</sup> ratio. At December 31, 2025, our net debt to credit adjusted EBITDA<sup>(1)</sup> ratio was 2.59 to 1.0 as defined by the credit facility agreements, which is below the relevant level provided by our financial covenants of existing outstanding debt.

_______________________

(1)Credit adjusted EBITDA and net debt, which are non-GAAP measures used for these covenants, are calculated in accordance with the definition in the debt agreements. In this context, these measures are used solely to provide information on the extent to which we are in compliance with debt covenants and may not be comparable to credit adjusted EBITDA and net debt used by other companies. Reconciliations of credit adjusted EBITDA to net income and net debt to total debt are as follows:

---

| | |
|:---|:---|
| *<u>(DOLLARS IN MILLIONS)</u>* | **Year Ended December 31, 2025** |
| Net income | $(359) |
| Interest expense | 229 |
| Income taxes | (53) |
| Depreciation and amortization | 962 |
| Specified items<sup>(1)</sup> | 1018 |
| Non-cash items<sup>(2)</sup> | 303 |
| **Credit Adjusted EBITDA** | $2100 |

---

_______________________

(1)Specified items consisted of restructuring and other charges, impairment of goodwill, acquisition, divestiture and integration costs, strategic initiatives costs, regulatory costs and other costs that are not related to recurring operations.

(2)Non-cash items consisted of losses (gains) on sale of assets, losses (gains) on business disposals, losses on assets classified as held for sale, pension settlement losses, and stock-based compensation.

---

| | |
|:---|:---|
| *<u>(DOLLARS IN MILLIONS)</u>* | **December 31, 2025** |
| Total debt<sup>(1)</sup> | $6026 |
| Adjustments: |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | 590 |
| Net debt | $5436 |

---

_______________________

(1)Total debt used for the calculation of net debt consisted of short-term debt, long-term debt, short-term finance lease obligations and long-term finance lease obligations.

*Senior Notes*

As of December 31, 2025, we had $5.637 billion aggregate principal amount outstanding in senior unsecured notes, with $940 million principal amount denominated in EUR and $4.697 billion principal amount denominated in USD. The notes bear effective interest rates ranging from 1.56% per year to 5.12% per year, with maturities from September 25, 2026 to December 1, 2050. See Note 14 to the Consolidated Financial Statements for additional information.

**Other Contingencies**

See Note 21 to the Consolidated Financial Statements for information related to Other Contingencies.

**Other Commitments**

Compliance with existing governmental requirements regulating the discharge of materials into the environment has not materially affected our operations, earnings or competitive position. In 2025 and 2024, we spent approximately $22 million and $32 million on capital projects and $119 million and $136 million in operating expenses and governmental charges, respectively, for the purpose of complying with such regulations. Expenditures for these purposes will continue for the foreseeable future. In addition, we are party to a number of proceedings brought under the Comprehensive Environmental Response, Compensation and Liability Act or similar state statutes. It is expected that the impact of any judgments in or voluntary settlements of such proceedings will not be material to our financial condition, results of operations or liquidity.

**Contractual Obligations**

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

We believe our balances of cash and cash equivalents, which totaled approximately $590 million as of December 31, 2025, along with cash generated by ongoing operations and access to the Revolving Credit Facility and unsecured short-term promissory notes ("Commercial Paper") as discussed in Note 14 to the Consolidated Financial Statements, will be sufficient to satisfy its cash requirements and capital return program over the next 12 months and beyond. Our material cash requirements include the following contractual and other obligations.

*Borrowings and Interest on Borrowings*

As of December 31, 2025, we had outstanding fixed rate notes with varying maturities for an aggregate principal amount of approximately $5.637 billion (collectively the "Notes"), with approximately $940 million payable within 12 months. Future interest payments associated with the Notes total approximately $2.268 billion, with approximately $165 million payable within 12 months.

We also issue Commercial Paper pursuant to a commercial paper program. As of December 31, 2025, we had $314 million of Commercial Paper outstanding.

As of December 31, 2025, we had no borrowings outstanding under the Revolving Credit Facility.

See Note 14 to the Consolidated Financial Statements for a further discussion of our various borrowing facilities.

*Leases*

We have lease arrangements for certain corporate offices, manufacturing facilities, research and development facilities, and certain transportation and office equipment. As of December 31, 2025, we had fixed lease payment obligations of approximately $811 million, with approximately $131 million payable within 12 months. See Note 15 to the Consolidated Financial Statements for a further discussion of our various lease arrangements.

*Pension and Other Postretirement Obligations*

As of December 31, 2025, we had pension funding obligations of approximately $521 million payable within 10 years, with approximately $46 million payable within 12 months. See Note 8 to the Consolidated Financial Statements for a further discussion of our retirement plans.

As of December 31, 2025, we had postretirement obligations of approximately $40 million payable within 10 years, with approximately $4 million payable within 12 months.

*Purchase Commitments*

We have various purchase commitments that include agreements for raw material procurement and contractual capital expenditures. As of December 31, 2025, we had purchase commitment obligations of approximately $415 million, with approximately $184 million payable within 12 months.

**Critical Accounting Policies and Use of Estimates**

Our significant accounting policies are more fully described in Note 1 to the Consolidated Financial Statements. As disclosed in Note 1, the preparation of financial statements in conformity with U.S. generally accepted accounting principles ("GAAP") requires management to make estimates and assumptions that affect reported amounts and accompanying disclosures. These estimates are based on management's best judgment of current events and actions that we may undertake in the future. Actual results may ultimately differ from these estimates.

Those areas requiring the greatest degree of management judgment or deemed most critical to our financial reporting involve:

*The Periodic Assessment of Potential Impairment of Goodwill*

Effective January 1, 2025, we reorganized the Nourish segment into two new reportable segments: Taste and Food Ingredients, to align with changes in our internal management reporting structure. As a result of this change, goodwill previously allocated to the Nourish reporting unit was reallocated between the new Taste and Food Ingredients reporting units. In accordance with ASC 350, we performed a quantitative goodwill impairment test on the former Nourish reporting unit immediately prior to the change, and separately tested goodwill for the new Taste and Food Ingredients reporting units following the reorganization. Based on the results of the impairment testing, we determined that the carrying amount of the Food Ingredients reporting unit exceeded its estimated fair value, and accordingly recognized a goodwill impairment charge of $1.153 billion. This charge is reflected in the Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) for the year ended December 31, 2025.

As of December 31, 2025, we have goodwill of approximately $8.269 billion. We test goodwill for impairment at the reporting unit level as of November 30 every year or more frequently if events or changes in circumstances indicate the

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

goodwill might be impaired. A reporting unit is an operating segment or one level below an operating segment (referred to as a component) to which goodwill is assigned when initially recorded.

We identify our reporting units by assessing whether the components of our operating segments constitute businesses for which discrete financial information is available and management of each operating segment regularly reviews the operating results of those components. Components within a segment that have similar economic characteristics have been aggregated as a single reporting unit. We determined that we have five reporting units under the Food Ingredients, Taste, Scent and Health & Biosciences segments: (1) Food Ingredients, (2) Taste, (3) Fragrance Compounds, (4) Fragrance Ingredients and (5) Health & Biosciences.

For the annual impairment test as of November 30, 2025, we performed quantitative impairment tests by comparing the fair value of the reporting units with their carrying amounts.

We assessed the fair value of the reporting units using an income approach. Under the income approach, we determined the fair value by using a discounted cash flow method at a rate of return that reflects the relative risk of the projected future cash flows of each reporting unit, as well as a terminal value. We used the most current actual and forecasted operating data available. Key estimates and assumptions used in these valuations include revenue growth rates, gross margins, adjusted operating EBITDA margins, terminal growth rates and discount rates.

In performing the quantitative impairment test, we determined that the fair value of the reporting units exceeded their carrying values and determined that there was no further impairment of goodwill in these reporting units as of November 30, 2025. Based on the quantitative impairment test performed, the Taste, Fragrance Compounds and Fragrance Ingredients reporting units had substantial headroom, as fair value exceeded carrying value by a wide margin, while the fair value of the Health & Biosciences reporting unit exceeded carrying value by 9%. There was no quantitative impairment test performed on the Food Ingredients reporting unit as there was no goodwill remaining in the reporting unit after the impairment charge of $1.153 billion was recorded as of January 1, 2025. While management believes that the assumptions used in the impairment test were reasonable, changes in key assumptions, including lower revenue growth, operating margin, terminal growth rates or increase in discount rates could result in a future impairment. Such impairment could have a material effect on our Consolidated Statements of Operations and Balance Sheets.

For the Health & Biosciences reporting unit, if all other assumptions were held constant and the weighted average cost of capital was increased by 50 basis points, the estimated fair value would decrease such that the fair value would be less than carrying value by 2% and result in an impairment charge. If all other assumptions were held constant and the long-term growth rate was decreased by 50 basis points, the estimated fair value would decrease such that the fair value would exceed carrying value by 1%.

During 2024, we recorded a goodwill impairment charge of $64 million related to the Pharma Solutions disposal group, which is presented in the Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) for the twelve months ended December 31, 2024.

During 2023, based on the quantitative impairment test using the income approach, we determined that the carrying value of the previous Nourish reporting unit exceeded its fair value and recorded a goodwill impairment charge of $2.623 billion in the Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) for the year ended December 31, 2023.

See Note 12 to the Consolidated Financial Statements for additional information.

*Valuation of Certain U.S. and Foreign Legal Entities Associated with the Legal Entity Realignment Project*

As described in Note 10 to the Consolidated Financial Statements, during the year ended December 31, 2025, we recorded an income tax benefit associated with the legal entity realignment project, which resulted in the recognition of a tax loss and related income tax benefit of $360 million in the Consolidated Statements of Income (Loss) and Comprehensive Income (Loss). The legal entity realignment project is a phased restructuring initiative involving certain of our U.S. and foreign legal entities. To determine the amount of the income tax benefit recorded, we first estimated the fair value of the relevant legal entities using the discounted cash flow method or the net asset value method and then analyzed the relevant tax laws and regulations in assessing the tax consequences of the steps within the realignment project, including obtaining opinions from third-party tax and legal advisors. Under the discounted cash flow method, we used a rate of return that reflects the relative risk of the projected future cash flows of each legal entity, as well as a terminal value. Estimates and assumptions include revenue growth rates, gross margins, adjusted operating EBIT margins, terminal growth rates, and discount rates.

**New Accounting Standards**

See Note 1 to the Consolidated Financial Statements for a discussion of recent accounting pronouncements.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

**Non-GAAP Financial Measures**

We use non-GAAP financial measures in this Form 10-K, including: (i) currency neutral metrics, (ii) comparable portfolio metrics and (iii) adjusted operating EBITDA and adjusted operating EBITDA margin. We also provide the non-GAAP measure net debt solely for the purpose of providing information on our compliance with debt covenants contained in its debt agreements. Our non-GAAP financial measures are defined below.

These non-GAAP financial measures are intended to provide additional information regarding our underlying operating results and comparable year-over-year performance. Such information is supplemental to information presented in accordance with GAAP and is not intended to represent a presentation in accordance with GAAP. In discussing our historical and expected future results and financial condition, we believe it is meaningful for investors to be made aware of and to be assisted in a better understanding of, on a period-to-period comparable basis, financial amounts both including and excluding these identified items, the impact of exchange rate fluctuations, as well as the impact of acquisitions and divestitures. These non-GAAP measures should not be considered in isolation or as substitutes for analysis of our results under GAAP and may not be comparable to other companies' calculation of such metrics.

Adjusted operating EBITDA and adjusted operating EBITDA margin exclude depreciation and amortization expense, interest expense, other (expense) income, net, restructuring and other charges and certain items unrelated to recurring operations such as impairment of goodwill, gains (losses) on business disposals, loss on assets classified as held for sale, acquisition, divestiture and integration costs, strategic initiatives costs, regulatory costs and other costs that are not related to recurring operations.

Net debt to credit adjusted EBITDA is the leverage ratio used in our credit agreement and defined as net debt divided by credit adjusted EBITDA. However, as credit adjusted EBITDA for these purposes was calculated in accordance with the provisions of the credit agreement, it may differ from the calculation used for adjusted operating EBITDA.

**Cautionary Statement Under the Private Securities Litigation Reform Act of 1995** 

This Form 10-K includes statements that are not historical facts and are "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on management's current assumptions, estimates and expectations, including with respect to our financial and operational outlook (sales, adjusted operating EBITDA and cash flow), portfolio optimization initiatives (including the ongoing sale process for our Food Ingredients division), pricing, productivity and cost-discipline actions, capital allocation, future operations, growth potential, strategic investments and the expected effects of foreign exchange. These statements reflect management's present views, are based on a series of expectations, assumptions estimates and projections about the Company, are subject to change, and involve uncertainties that could cause actual results to differ materially. Certain of such forward-looking information may be identified by such terms as "expect", "anticipate", "believe", "intend", "outlook", "may", "estimate", "should", "predict", "plan", "project", "could", and similar terms or variations thereof. These statements are not guarantees of future performance and are subject to risks and uncertainties that could lead to materially different outcomes. Such risks, uncertainties and other factors include, among others, the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• demand trends, competitive dynamics and customer concentration in our end markets;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• execution of our strategic transformation and other strategic transactions, divestitures, acquisitions, collaborations and joint ventures;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• working capital and inventory management;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• outcomes of legal claims, disputes, regulatory investigations and litigation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• tariffs and trade actions, supply chain disruptions and macro events, including geopolitical developments, climate events, natural disasters, public health crises; volatility in input costs (such as raw materials, transportation and energy);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• attraction, retention and turnover of key employees and executives; product innovation, time-to-market, product safety and quality;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• cybersecurity incidents, artificial intelligence related risks, data privacy and compliance with data protection laws;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• exposure to emerging markets, foreign currency fluctuations and international regulatory and political risks;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• capital allocation, dividend policy and potential impairments of tangible or intangible assets; our indebtedness, credit rating liquidity, and access to capital;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• pension and postretirement obligations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• compliance with federal, state, local and international rules and regulations, and regulatory, environmental, anti-corruption and sanctions laws and related ethical business practices;

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• protection and enforcement of intellectual property;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• changes in tax laws and policies, tax audits and outcomes, including potential tax liabilities related to prior transactions; and changes in federal, state, local and international rules and regulations.

The foregoing list of important factors does not include all such factors, nor necessarily present them in order of importance. Important factors are described under "Risk Factors" of this Form 10-K and in our subsequent filings with the SEC.

We intend our forward-looking statements to speak only as of the time of such statements and do not undertake or plan to update or revise them as more information becomes available or to reflect changes in expectations, assumptions or results, whether as a result of new information, future events or otherwise. We can give no assurance that such expectations or forward-looking statements will prove to be correct. An occurrence of, or any material adverse change in, one or more of the risk factors or risks and uncertainties referred to in this report or included in our other periodic reports filed with the SEC could materially and adversely impact our operations and our future financial results.

Any public statements or disclosures made by us following this report that modify or impact any of the forward-looking statements contained in or accompanying this report will be deemed to modify or supersede such outlook or other forward-looking statements in or accompanying this report.

**ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.**

We operate on a global basis and are exposed to currency fluctuation related to the manufacture and sale of our products in currencies other than the U.S. dollar. The major foreign currencies involve the markets in the European Union, Great Britain, Mexico, Brazil, China, India, Indonesia, Australia, Japan and Argentina, although all regions are subject to foreign currency fluctuations versus the U.S. dollar. We actively monitor our foreign currency exposures in all major markets in which we operate, and employ a variety of techniques to mitigate the impact of exchange rate fluctuations, including foreign currency hedging activities.

We have established a centralized reporting system to evaluate the effects of changes in interest rates, currency exchange rates and other relevant market risks. Our risk management procedures include the monitoring of interest rate and foreign exchange exposures and hedge positions utilizing statistical analyses of cash flows, market value and sensitivity analysis. However, the use of these techniques to quantify the market risk of such instruments should not be construed as an endorsement of their accuracy or the accuracy of the related assumptions. For the year ended December 31, 2025, our exposure to market risk was estimated using sensitivity analyses, which illustrate the change in the fair value of a derivative financial instrument assuming hypothetical changes in foreign exchange rates and interest rates.

We enter into foreign currency forward contracts with the objective of managing our exchange rate risk related to foreign currency denominated monetary assets and liabilities of our operations. These contracts, and the counterparties to which are major international financial institutions, generally involve the exchange of one currency for a second currency at a future date, have maturities not exceeding twelve months, and are marked-to-market with changes in fair value that are recorded to Other expense, net within our Consolidated Statements of Income (Loss) and Comprehensive Income (Loss). Based on a hypothetical decrease or increase of 10% in the applicable balance sheet exchange rates (primarily against the U.S. dollar), the estimated fair value of our foreign currency forward contracts would change by approximately $199 million as of December 31, 2025. However, any change in the value of the contracts, real or hypothetical, would be significantly offset by a corresponding change in the value of the underlying hedged items.

We use derivative instruments as part of our interest rate risk management strategy. We have entered into certain cross currency swap agreements in order to mitigate a portion of our net European investments from foreign currency risk. As of December 31, 2025, these swaps were in a net liability position with an aggregate fair value of $237 million. Based on a hypothetical decrease or increase of 10% in the value of the U.S. dollar against the Euro, the estimated fair value of our cross currency swaps would change by approximately $211 million.

At December 31, 2025, the fair value of our EUR fixed rate debt was $935 million. Based on a hypothetical decrease or increase of 10% in foreign exchange rates, the estimated fair value of our EUR fixed rate debt would change by approximately $94 million.

At December 31, 2025, the fair value of our USD fixed rate debt was $4.053 billion. Based on a hypothetical decrease or increase of 10% in interest rates, the estimated fair value of our U.S. fixed rate debt would change by approximately $405 million.

We purchase certain commodities, such as natural gas, electricity, petroleum-based products and certain crop related items. We generally purchase these commodities based upon market prices that are established with the vendor as part of the purchase process. In general, with the exception of soy and natural gas, we do not use commodity financial instruments to hedge commodity prices.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

**ITEM 8.&nbsp;&nbsp;&nbsp;&nbsp;FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.**

See index to Consolidated Financial Statements on page [45](#i5239245a6bb24ffbb6af4395e0b30886_97).

**ITEM 9.&nbsp;&nbsp;&nbsp;&nbsp;CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.**

None.

**ITEM 9A.&nbsp;&nbsp;&nbsp;&nbsp;CONTROLS AND PROCEDURES.**

***Evaluation of Disclosure Controls and Procedures and Changes in Internal Control over Financial Reporting.***

Our Chief Executive Officer and Chief Financial Officer, with the assistance of other members of our management, have evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Form 10-K. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures are effective as of the end of the period covered by this Form 10-K.

We have established controls and procedures designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Commission's rules and forms and is accumulated and communicated to management, including the principal executive officer and the principal financial officer, to allow timely decisions regarding required disclosure.

Our Chief Executive Officer and Chief Financial Officer have concluded that there have not been any changes in our internal control over financial reporting during the fourth quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

***Management's Report on Internal Control Over Financial Reporting.***

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Management assessed the effectiveness of our internal control over financial reporting as of December 31, 2025. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO") in its 2013 *Internal Control — Integrated Framework*.

Based on this assessment, management determined that, as of December 31, 2025, our internal control over financial reporting was effective.

PricewaterhouseCoopers LLP, our independent registered public accounting firm, has audited the effectiveness of our internal control over financial reporting as of December 31, 2025 as stated in their report which is included herein.

**ITEM 9B.&nbsp;&nbsp;&nbsp;&nbsp;OTHER INFORMATION.**

**Rule 10b5-1 Trading Plans**

During the year ended December 31, 2025, none of our directors or Section 16 officers adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) (a "10b5-1 trading arrangement") or any "non-Rule 10b5-1 trading arrangement" as defined in Item 408(c) of Regulation S-K. Non-Rule 10b-1 Plans are not permitted as per our Insider Trading Policy.

**Updates to Preliminary Financial Results**

On February 11, 2026, we issued a press release announcing unaudited financial results for the quarter and year ended December 31, 2025, which was furnished on a Current Report on Form 8-K on February 11, 2026, and we presented, via webcast, a supplemental earnings presentation setting forth such results, or collectively, the Earnings Materials. Subsequent to the date of presenting our Earnings Materials, we recorded immaterial adjustments to the fourth quarter and full year of 2025 results, primarily related to a correction of tax expense on business disposals during the second quarter of 2025. See Note 1 and Note 22 to the Consolidated Financial Statements within Item 8 of this Form 10-K for more information.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

**ITEM 9C.&nbsp;&nbsp;&nbsp;&nbsp;DISCLOSURES REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.**

None.

**PART III**

**ITEM 10.&nbsp;&nbsp;&nbsp;&nbsp;DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.**

The information relating to directors and nominees of the Company is set forth in the IFF 2026 Proxy Statement and is incorporated by reference herein. The information relating to Section 16(a) beneficial ownership reporting compliance that appears in the IFF 2026 Proxy Statement is also incorporated by reference herein. See Part I, Item 1 of this Form 10-K for information relating to the Company's Executive Officers.

We have adopted a Code of Conduct (the "Code of Conduct") that applies to all of our employees, including our chief executive officer and our chief financial officer. We have also adopted a Code of Conduct for Directors and a Code of Conduct for Executive Officers (together with the Code of Conduct, the "Codes"). The Codes are available through the Investors — Governance link on our website at *https://ir.iff.com/governance.*

Only the Board of Directors or the Audit Committee of the Board may grant a waiver from any provision of our Codes in favor of a director or executive officer, and any such waiver will be publicly disclosed. We will disclose substantive amendments to and any waivers from the Codes provided to our chief executive officer, principal financial officer or principal accounting officer, as well as any other executive officer or director, on the Company's website: *www.iff.com*.

The information regarding the Company's Audit Committee and its designated audit committee financial experts is set forth in the IFF 2026 Proxy Statement and such information is incorporated by reference herein.

The information concerning procedures by which shareholders may recommend director nominees is set forth in the IFF 2026 Proxy Statement and such information is incorporated by reference herein.

We have adopted an insider trading policy and procedures applicable to our directors', officers' and employees' purchase, sale or other disposition of our securities that we believe are reasonably designed to promote compliance with insider trading laws, rules and regulations and New York Stock Exchange listing standards. This policy and the procedures are set forth in our Insider Trading Policy included as Exhibit 19 to this report. It is the Company's policy to comply with all applicable securities and state laws (including appropriate approvals by the Company's board of directors or appropriate committee, if required) when engaging in transactions in the Company's securities.

**ITEM 11.&nbsp;&nbsp;&nbsp;&nbsp;EXECUTIVE COMPENSATION.**

The items required by Part III, Item 11 are incorporated herein by reference from the IFF 2026 Proxy Statement to be filed on or before April 30, 2026, except as to information required pursuant to Item 402(v) of Regulation S-K relating to pay versus performance.

**ITEM 12.&nbsp;&nbsp;&nbsp;&nbsp;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.**

The items required by Part III, Item 12 are incorporated herein by reference from the IFF 2026 Proxy Statement to be filed on or before April 30, 2026.

**ITEM 13.&nbsp;&nbsp;&nbsp;&nbsp;CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.**

The items required by Part III, Item 13 are incorporated herein by reference from the IFF 2026 Proxy Statement to be filed on or before April 30, 2026.

**ITEM 14.&nbsp;&nbsp;&nbsp;&nbsp;PRINCIPAL ACCOUNTANT FEES AND SERVICES.**

The items required by Part III, Item 14 are incorporated herein by reference from the IFF 2026 Proxy Statement to be filed on or before April 30, 2026.

**PART IV**

**ITEM 15.&nbsp;&nbsp;&nbsp;&nbsp;EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.**

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

---

| | |
|:---|:---|
| (a)(1) FINANCIAL STATEMENTS: The following consolidated financial statements, related notes, and independent registered public accounting firm's report are included in this Form 10-K: |  |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>[Report of Independent Registered Public Accounting Firm](#i5239245a6bb24ffbb6af4395e0b30886_103)</u> (PCAOB ID: 238) | <u>[47](#i5239245a6bb24ffbb6af4395e0b30886_103)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>[Consolidated Statements of Income (Loss) and Comprehensive](#i5239245a6bb24ffbb6af4395e0b30886_106)[Income (](#i5239245a6bb24ffbb6af4395e0b30886_106)[Loss](#i5239245a6bb24ffbb6af4395e0b30886_106)[)](#i5239245a6bb24ffbb6af4395e0b30886_106)[for the years ended December 31, 202](#i5239245a6bb24ffbb6af4395e0b30886_106)[5](#i5239245a6bb24ffbb6af4395e0b30886_106)[, 202](#i5239245a6bb24ffbb6af4395e0b30886_106)[4](#i5239245a6bb24ffbb6af4395e0b30886_106)[and 20](#i5239245a6bb24ffbb6af4395e0b30886_106)[23](#i5239245a6bb24ffbb6af4395e0b30886_106)</u> | <u>[50](#i5239245a6bb24ffbb6af4395e0b30886_106)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>[Consolidated Balance Sheets as of December 31, 202](#i5239245a6bb24ffbb6af4395e0b30886_109)[5](#i5239245a6bb24ffbb6af4395e0b30886_109)[and 20](#i5239245a6bb24ffbb6af4395e0b30886_109)[24](#i5239245a6bb24ffbb6af4395e0b30886_109)</u> | <u>[51](#i5239245a6bb24ffbb6af4395e0b30886_109)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>[Consolidated Statements of Shareholders' Equity for the years ended December 31, 202](#i5239245a6bb24ffbb6af4395e0b30886_112)[5](#i5239245a6bb24ffbb6af4395e0b30886_112)[, 202](#i5239245a6bb24ffbb6af4395e0b30886_112)[4](#i5239245a6bb24ffbb6af4395e0b30886_112)[and 20](#i5239245a6bb24ffbb6af4395e0b30886_112)[23](#i5239245a6bb24ffbb6af4395e0b30886_112)</u> | <u>[52](#i5239245a6bb24ffbb6af4395e0b30886_112)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>[Consolidated Statements of Cash Flows for the years ended December 31, 202](#i5239245a6bb24ffbb6af4395e0b30886_118)[5](#i5239245a6bb24ffbb6af4395e0b30886_118)[, 202](#i5239245a6bb24ffbb6af4395e0b30886_118)[4](#i5239245a6bb24ffbb6af4395e0b30886_118)[and 20](#i5239245a6bb24ffbb6af4395e0b30886_118)[23](#i5239245a6bb24ffbb6af4395e0b30886_118)</u> | <u>[53](#i5239245a6bb24ffbb6af4395e0b30886_118)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>[Notes to Consolidated Financial Statements](#i5239245a6bb24ffbb6af4395e0b30886_121)</u> | <u>[54](#i5239245a6bb24ffbb6af4395e0b30886_121)</u> |
| <u>[(a)(3) EXHIBITS](#i5239245a6bb24ffbb6af4395e0b30886_232)</u> | <u>[114](#i5239245a6bb24ffbb6af4395e0b30886_232)</u> |
| (a)(2) FINANCIAL STATEMENT SCHEDULES |  |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>[Schedule II — Valuation and Qualifying Accounts and Reserves for the years ended December 31, 202](#i5239245a6bb24ffbb6af4395e0b30886_241)[5](#i5239245a6bb24ffbb6af4395e0b30886_241)[, 202](#i5239245a6bb24ffbb6af4395e0b30886_241)[4](#i5239245a6bb24ffbb6af4395e0b30886_241)[and 20](#i5239245a6bb24ffbb6af4395e0b30886_241)[23](#i5239245a6bb24ffbb6af4395e0b30886_241)</u> | <u>[S-1](#i5239245a6bb24ffbb6af4395e0b30886_241)</u> |

---

All other schedules are omitted because they are not applicable or the required information is shown in the financial statements or notes thereto.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

**Report of Independent Registered Public Accounting Firm**

To the Board of Directors and Shareholders of International Flavors & Fragrances Inc.

***Opinions on the Financial Statements and Internal Control over Financial Reporting***

We have audited the accompanying consolidated balance sheets of International Flavors & Fragrances Inc. and its subsidiaries (the "Company") as of December 31, 2025 and 2024, and the related consolidated statements of income (loss) and comprehensive income (loss), of shareholders' equity and of cash flows for each of the three years in the period ended December 31, 2025, including the related notes and financial statement schedule listed in the index appearing under Item 15(a)(2) (collectively referred to as the "consolidated financial statements"). We also have audited the Company's internal control over financial reporting as of December 31, 2025, based on criteria established in *Internal Control - Integrated Framework* (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2025 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2025, based on criteria established in *Internal Control - Integrated Framework* (2013) issued by the COSO.

***Basis for Opinions***

The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management's Report on Internal Control Over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company's consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.

Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

***Definition and Limitations of Internal Control over Financial Reporting***

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

***Critical Audit Matters***

The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that (i) relate to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

*Interim Goodwill Impairment Assessments of the Taste and Food Ingredients Reporting Units and Annual Goodwill Impairment Assessment of the Health & Biosciences Reporting Unit*

As described in Notes 1 and 12 to the consolidated financial statements, the Company's goodwill balance was $8.269 billion as of December 31, 2025, and the goodwill related to the Taste, Food Ingredients, and Health & Biosciences reporting units was $2.296 billion, $0, and $4.465 billion, respectively. The Company has five reporting units, three of which are the Taste, Food Ingredients, and Health & Biosciences reporting units. Management tests goodwill for impairment at the reporting unit level as of November 30 every year or more frequently, if events or changes in circumstances indicate it might be impaired. If a reporting unit's carrying amount exceeds its fair value, the Company will record an impairment charge based on that difference. Effective January 1, 2025, the Nourish operating segment was reorganized into two new operating segments: Taste and Food Ingredients, which also represent reporting units. As a result of this change, goodwill related to the Nourish reporting unit was allocated between the two new reporting units and management performed interim quantitative goodwill impairment assessments. Management determined that the carrying amount of the Food Ingredients reporting unit exceeded its estimated fair value and recognized an impairment charge of $1.153 billion. For the annual impairment assessment as of November 30, 2025, management performed a quantitative impairment assessment of the Health & Biosciences reporting unit by comparing the fair value of the reporting unit with its carrying amount. Management determined the fair value of the reporting units by using a discounted cash flow method at a rate of return that reflects the relative risk of the projected future cash flows of each reporting unit, as well as a terminal value. Estimates and assumptions used in these valuations by management include revenue growth rates, gross margins, adjusted operating EBITDA margins, forecasted capital expenditures, terminal growth rates, and discount rates.

The principal considerations for our determination that performing procedures relating to the interim goodwill impairment assessments of the Taste and Food Ingredients reporting units and the annual goodwill impairment assessment of the Health & Biosciences reporting unit is a critical audit matter are (i) the significant judgment by management when developing the fair value estimate of the Taste, Food Ingredients, and Health & Biosciences reporting units; (ii) a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating management's significant assumptions related to revenue growth rates, gross margins, adjusted operating EBITDA margins, and forecasted capital expenditures for the Taste and Health & Biosciences reporting units and terminal growth rates and discount rates for the Taste, Food Ingredients, and Health & Biosciences reporting units; and (iii) the audit effort involved the use of professionals with specialized skill and knowledge.

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to management's goodwill impairment assessments, including controls over the valuation of the Taste, Food Ingredients, and Health & Biosciences reporting units. These procedures also included, among others (i) testing management's process for developing the fair value estimate of the Taste, Food Ingredients, and Health & Biosciences reporting units; (ii) evaluating the appropriateness of the discounted cash flow method used by management; (iii) testing the completeness and accuracy of underlying data used in the discounted cash flow method; and (iv) evaluating the reasonableness of the significant assumptions used by management related to revenue growth rates, gross margins, adjusted operating EBITDA margins, and forecasted capital expenditures for the Taste and Health & Biosciences reporting units and terminal growth rates and discount rates for the Taste, Food Ingredients, and Health & Biosciences reporting units. Evaluating management's assumptions related to revenue growth rates, gross margins, adjusted operating EBITDA margins, and forecasted capital expenditures involved evaluating whether the assumptions used by management were reasonable considering (i) the current and past performance of the Taste and Health & Biosciences reporting units; (ii) the consistency with external market and industry data; and (iii) whether the assumptions were consistent with evidence obtained in other areas of the audit. Professionals with specialized skill and knowledge were used to assist in evaluating (i) the appropriateness of the discounted cash flow method and (ii) the reasonableness of the terminal growth rate and discount rate assumptions.

*Valuation of Certain U.S. and Foreign Legal Entities and the Related Income Tax Benefit Associated with the Legal Entity Realignment Project*

As described in Note 10 to the consolidated financial statements, during the year ended December 31, 2025, the Company recorded an income tax benefit associated with the legal entity realignment project of $360 million. The legal entity realignment project is a phased restructuring initiative involving certain of the Company's U.S. and foreign legal entities. To determine the

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

amount of the income tax benefit recorded, first management estimated the fair value of the relevant legal entities using the discounted cash flow method or the net asset value method, and then analyzed the relevant tax laws and regulations in assessing the tax consequences of the steps within the realignment project, including obtaining opinions from third-party tax and legal advisors. Under the discounted cash flow method, management used a rate of return that reflects the relative risk of the projected future cash flows of each legal entity, as well as a terminal value. Estimates and assumptions include revenue growth rates, gross margins, adjusted operating EBIT margins, terminal growth rates, and discount rates.

The principal considerations for our determination that performing procedures relating to the valuation of the certain U.S. and foreign legal entities and the related income tax benefit associated with the legal entity realignment project is a critical audit matter are (i) the significant judgment by management when developing the fair value estimate of the certain U.S. and foreign legal entities and when determining and measuring the related income tax benefit associated with the legal entity realignment project; (ii) a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating management's significant assumptions related to certain revenue growth rates and terminal growth rates used in the valuation of the certain U.S. and foreign legal entities and in evaluating audit evidence related to management's determination and measurement of the related income tax benefit; and (iii) the audit effort involved the use of professionals with specialized skill and knowledge.

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to income taxes, including controls over the valuation of the certain U.S. and foreign legal entities and the determination and measurement of the related income tax benefit associated with the legal entity realignment project. These procedures also included, among others (i) reading the underlying agreements; (ii) testing management's process for developing the fair value estimate of the certain U.S. and foreign legal entities; (iii) evaluating the appropriateness of the discounted cash flow and net asset value methods used by management; (iv) testing the completeness and accuracy of certain underlying data used in the discounted cash flow and net asset value methods; (v) evaluating the reasonableness of significant assumptions used by management related to certain revenue growth rates and terminal growth rates; and (vi) testing the completeness and accuracy of certain underlying data used in the determination and measurement of the related income tax benefit associated with the legal entity realignment project. Evaluating management's assumption related to certain revenue growth rates involved evaluating whether the assumption used by management was reasonable considering (i) the current and past performance of the certain U.S. and foreign legal entities; (ii) the consistency with external market and industry data; and (iii) whether the assumption was consistent with evidence obtained in other areas of the audit. Professionals with specialized skill and knowledge were used to assist in evaluating (i) the appropriateness of the discounted cash flow and net asset value methods; (ii) the reasonableness of the assumption related to certain terminal growth rates; and (iii) management's assessment of the relevant tax laws and regulations in assessing the tax consequences of the steps within the realignment project.

/s/ PricewaterhouseCoopers LLP

New York, New York

February 27, 2026

We have served as the Company's auditor since 1957.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

**INTERNATIONAL FLAVORS & FRAGRANCES INC.**

**CONSOLIDATED STATEMENTS OF INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS)**

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| *<u>(AMOUNTS IN MILLIONS EXCEPT PER SHARE AMOUNTS)</u>* | **2025** | **2024** | **2023** |
| Net sales | $10890 | $11484 | $11479 |
| Cost of sales | 6952 | 7360 | 7798 |
| Gross profit | 3938 | 4124 | 3681 |
| Research and development expenses | 694 | 671 | 636 |
| Selling and administrative expenses | 1834 | 1995 | 1787 |
| Restructuring and other charges | 70 | 29 | 68 |
| Amortization of acquisition-related intangibles | 568 | 610 | 680 |
| Impairment of goodwill | 1153 | 64 | 2623 |
| Losses (Gains) on sale of assets | 1 | (11) | (3) |
| Operating (loss) profit | (382) | 766 | (2110) |
| Interest expense | 229 | 305 | 380 |
| Gain on extinguishment of debt | (488) |  |  |
| Losses (Gains) on business disposals | 109 | (346) | 23 |
| Loss on assets classified as held for sale | 115 | 317 |  |
| Other expense, net | 65 | 182 | 5 |
| (Loss) income before taxes | (412) | 308 | (2518) |
| (Benefit) Provision for income taxes | (53) | 41 | 69 |
| Net (loss) income | (359) | 267 | (2587) |
| Net income attributable to non-controlling interest | 2 | 4 | 4 |
| Net (loss) income attributable to IFF shareholders | $(361) | $263 | $(2591) |
| Net (loss) income per share — basic and diluted | $(1.41) | $1.04 | $(10.14) |
| Average number of shares outstanding — basic and diluted | 256 | 256 | 255 |
| Statements of Comprehensive Income (Loss) |  |  |  |
| Net (loss) income | $(359) | $267 | $(2587) |
| Other comprehensive income (loss), after tax: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation adjustments | 1153 | (774) | 414 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gains (losses) on derivatives qualifying as hedges | (2) | (3) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Pension and postretirement liability adjustment | (54) | 146 | (112) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income (loss) | 1097 | (631) | 302 |
| Comprehensive income (loss) | 738 | (364) | (2285) |
| Net income attributable to non-controlling interest | 2 | 4 | 4 |
| Comprehensive income (loss) attributable to IFF shareholders | $736 | $(368) | $(2289) |

---

See Notes to Consolidated Financial Statements

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

**INTERNATIONAL FLAVORS & FRAGRANCES INC.**

**CONSOLIDATED BALANCE SHEETS**

---

| | | |
|:---|:---|:---|
|  | **December 31,** | **December 31,** |
| *<u>(AMOUNTS IN MILLIONS EXCEPT PER SHARE AMOUNTS)</u>* | **2025** | **2024** |
| **ASSETS** |  |  |
| **Current Assets:** |  |  |
| Cash, cash equivalents, and restricted cash | $590 | $469 |
| Trade receivables (net of allowances of $27 and $26, respectively) | 1731 | 1624 |
| Inventories | 2245 | 2133 |
| Assets held for sale | 151 | 3056 |
| Prepaid expenses and other current assets | 877 | 686 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Current Assets | 5594 | 7968 |
| Property, plant and equipment, net | 4029 | 3739 |
| Goodwill | 8269 | 9075 |
| Other intangible assets, net | 6043 | 6445 |
| Operating lease right-of-use assets | 579 | 589 |
| Other assets | 1025 | 907 |
| Total Assets | $25539 | $28723 |
| **LIABILITIES AND SHAREHOLDERS' EQUITY** |  |  |
| **Current Liabilities:** |  |  |
| Short-term debt and current portion of long-term debt | $1254 | $1413 |
| Accounts payable | 1287 | 1283 |
| Accrued payroll and bonus | 327 | 420 |
| Dividends payable | 102 | 102 |
| Liabilities held for sale | 44 | 332 |
| Other current liabilities | 919 | 802 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Current Liabilities | 3933 | 4352 |
| **Other Liabilities:** |  |  |
| Long-term debt | 4740 | 7564 |
| Retirement liabilities | 186 | 167 |
| Deferred income taxes | 1379 | 1594 |
| Operating lease liabilities | 533 | 550 |
| Other liabilities | 582 | 627 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Other Liabilities | 7420 | 10502 |
| **Commitments and Contingencies (Note 21)** |  |  |
| **Shareholders' Equity:** |  |  |
| Common stock $0.125 par value; 500.0 shares authorized; 275.7 and 275.7 shares issued as of December 31, 2025 and December 31, 2024, respectively; and 255.7 and 255.7 shares outstanding as of December 31, 2025 and December 31, 2024, respectively | 35 | 35 |
| Capital in excess of par value | 19918 | 19917 |
| Accumulated deficit | (3417) | (2647) |
| Accumulated other comprehensive loss | (1430) | (2527) |
| Treasury stock, at cost (20.0 and 20.0 shares as of December 31, 2025 and December 31, 2024, respectively) | (952) | (944) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Shareholders' Equity | 14154 | 13834 |
| Non-controlling interest | 32 | 35 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Shareholders' Equity including non-controlling interest | 14186 | 13869 |
| Total Liabilities and Shareholders' Equity | $25539 | $28723 |

---

See Notes to Consolidated Financial Statements

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

**INTERNATIONAL FLAVORS & FRAGRANCES INC.**

**CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY**

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| *<u>(AMOUNTS IN MILLIONS EXCEPT PER SHARE AMOUNTS)</u>* | **Common<br>stock** | **Common<br>stock** | **Capital in<br>excess of<br>par value** | **Retained<br>earnings (accumulated deficit)** | **Accumulated other<br>comprehensive<br>loss** | **Treasury stock** | **Treasury stock** | **Non-controlling<br>interest** | **Total** |
| *<u>(AMOUNTS IN MILLIONS EXCEPT PER SHARE AMOUNTS)</u>* | **Shares** | **Cost** | **Capital in<br>excess of<br>par value** | **Retained<br>earnings (accumulated deficit)** | **Accumulated other<br>comprehensive<br>loss** | **Shares** | **Cost** | **Non-controlling<br>interest** | **Total** |
| Balance at December 31, 2022 | 275.7 | $35 | $19841 | $917 | $(2198) | (20.8) | $(978) | $30 | $17647 |
| Net income (loss) |  |  |  | (2591) |  |  |  | 4 | (2587) |
| Other Comprehensive (loss) income, after tax |  |  |  |  | 302 |  |  |  | 302 |
| Cash dividends declared<sup>(1)</sup> |  |  |  | (827) |  |  |  |  | (827) |
| Stock options/SSARs |  |  | (4) |  |  | 0.1 | 4 |  |  |
| Vested restricted stock units and awards |  |  | (22) |  |  | 0.3 | 11 |  | (11) |
| Stock-based compensation |  |  | 65 |  |  |  |  |  | 65 |
| Redeemable NCI |  |  | (6) |  |  |  |  |  | (6) |
| Dividends on non-controlling interest and other |  |  |  |  |  |  |  | (3) | (3) |
| Balance at December 31, 2023 | 275.7 | $35 | $19874 | $(2501) | $(1896) | (20.4) | $(963) | $31 | $14580 |
| Net income (loss) |  |  |  | 263 |  |  |  | 4 | 267 |
| Other Comprehensive (loss) income, after tax |  |  |  |  | (631) |  |  |  | (631) |
| Cash dividends declared<sup>(1)</sup> |  |  |  | (409) |  |  |  |  | (409) |
| Stock options/SSARs |  |  | (1) |  |  |  | 2 |  | 1 |
| Vested restricted stock units and awards |  |  | (33) |  |  | 0.4 | 17 |  | (16) |
| Stock-based compensation |  |  | 77 |  |  |  |  |  | 77 |
| Balance at December 31, 2024 | 275.7 | $35 | $19917 | $(2647) | $(2527) | (20.0) | $(944) | $35 | $13869 |
| Net income (loss) |  |  |  | (361) |  |  |  | 2 | (359) |
| Other Comprehensive (loss) income, after tax |  |  |  |  | 1097 |  |  |  | 1097 |
| Cash dividends declared<sup>(1)</sup> |  |  |  | (409) |  |  |  |  | (409) |
| Stock options/SSARs |  |  | (4) |  |  |  | 2 |  | (2) |
| Vested restricted stock units and awards |  |  | (113) |  |  | 0.6 | 28 |  | (85) |
| Stock-based compensation |  |  | 88 |  |  |  |  |  | 88 |
| Treasury share repurchases |  |  |  |  |  | (0.6) | (38) |  | (38) |
| Impact of Business Divestitures |  |  |  |  |  |  |  | (4) | (4) |
| Dividends on non-controlling interest and other |  |  | 30 |  |  |  |  | (1) | 29 |
| Balance at December 31, 2025 | 275.7 | $35 | $19918 | $(3417) | $(1430) | (20.0) | $(952) | $32 | $14186 |

---

_______________________

(1)Cash dividends declared per common share were $1.60, $1.60, and $3.24 for the twelve months ended December 31, 2025, 2024, and 2023, respectively.

See Notes to Consolidated Financial Statements

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

**INTERNATIONAL FLAVORS & FRAGRANCES INC.**

**CONSOLIDATED STATEMENTS OF CASH FLOWS**

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| *<u>(AMOUNTS IN MILLIONS)</u>* | **2025** | **2024** | **2023** |
| **Cash flows from operating activities:** |  |  |  |
| Net (loss) income | $(359) | $267 | $(2587) |
| Adjustments to reconcile to net cash provided by operating activities: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 962 | 1015 | 1142 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes | (270) | (323) | (371) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss on assets classified as held for sale | 115 | 317 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gains on sale of assets | 1 | (11) | (3) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Losses (Gains) on business disposals | 109 | (346) | 23 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | 88 | 77 | 65 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain on extinguishment of debt | (488) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pension contributions | (29) | (29) | (36) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pension-related (benefit) expense | (11) | 125 | (28) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impairment of goodwill | 1153 | 64 | 2623 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory write-down |  |  | 72 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes in assets and liabilities, net of acquisitions: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Trade receivables | (68) | (217) | 51 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories | (41) | (34) | 605 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | (57) | 40 | (39) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accruals for incentive compensation | (106) | 190 | (2) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other assets/liabilities, net | (149) | (65) | (60) |
| Net cash provided by operating activities | 850 | 1070 | 1455 |
| **Cash flows from investing activities:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additions to property, plant and equipment | (594) | (463) | (503) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additions to intangible assets | (2) | (5) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from disposal of assets | 21 | 21 | 27 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net proceeds received from business disposals | 2743 | 875 | 1050 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash received (paid) on foreign currency forward contracts | 105 | (102) | (16) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Joint venture capital contributions | (4) |  |  |
| Net cash provided by investing activities | 2269 | 326 | 558 |
| **Cash flows from financing activities:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash dividends paid to shareholders | (409) | (514) | (826) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dividends paid to redeemable non-controlling interests |  |  | (13) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Decrease in revolving credit facility and short term borrowings |  |  | (99) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net borrowings (repayments) of commercial paper (maturities less than three months) | 314 |  | (187) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Principal payments of debt | (2913) | (1030) | (655) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchases of redeemable non-controlling interests |  |  | (39) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred and contingent consideration paid |  | (36) | (6) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Withholding tax paid on stock-based compensation | (24) | (16) | (13) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other, net | (21) | (10) | (13) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchase of treasury stock | (38) |  |  |
| Net cash used in financing activities | (3091) | (1606) | (1851) |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 91 | (54) | 21 |
| **Net change in cash, cash equivalents and restricted cash** | 119 | (264) | 183 |
| Cash, cash equivalents and restricted cash at beginning of year | 471 | 735 | 552 |
| **Cash, cash equivalents and restricted cash at end of year** | $590 | $471 | $735 |
| **Supplemental Disclosures:** |  |  |  |
| Interest paid, net of amounts capitalized | $229 | $308 | $370 |
| Income taxes paid | 329 | 370 | 578 |
| Accrued capital expenditures | 176 | 158 | 109 |

---

See Notes to Consolidated Financial Statements

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

**INTERNATIONAL FLAVORS & FRAGRANCES INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**NOTE 1.&nbsp;&nbsp;&nbsp;&nbsp;NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

**Nature of Operations**

International Flavors & Fragrances Inc. and its subsidiaries (the "Registrant," "IFF," the "Company," "we," "us" and "our") is a leading creator and manufacturer of products for application in food, beverage, health & biosciences, scent (and pharmaceuticals, until the recent sale of our Pharma Solutions disposal group), as well as complementary adjacent products, including natural health ingredients, all of which are used in a wide variety of consumer and end-use products. Our products are sold principally to manufacturers of dairy, meat, beverages, snacks, savory, sweet, baked goods, grain processors and other foods, personal care products, soaps and detergents, cleaning products, perfumes, dietary supplements, food protection, infant, elderly and animal nutrition, functional food, bio-fuel, pharmaceutical and oral care products. As a result, we hold global leadership positions in the Food & Beverage, Home & Personal Care and Health & Wellness markets, and across key Tastes, Textures, Scents, Nutrition, Enzymes, Cultures, Soy Proteins, and Probiotics categories, among others.

**Fiscal Year End**

The Company uses a calendar year of the twelve-month period from January 1 to December 31.

**Use of Estimates**

The preparation of financial statements in conformity with U.S. generally accepted accounting principles ("U.S. GAAP") requires management to make estimates and judgments that affect the amounts reported in the Consolidated Financial Statements and accompanying notes. The inputs into the Company's judgments and estimates take into account ongoing global current events and adverse macroeconomic impacts on the critical and significant accounting estimates, including estimates associated with future cash flows that are used in assessing the risk of impairment of certain assets and in business combinations. Actual results could differ from those estimates.

**Principles of Consolidation**

The Consolidated Financial Statements include the accounts of International Flavors & Fragrances Inc. and those of its subsidiaries. Intercompany balances and transactions have been eliminated. To the extent a subsidiary is not wholly owned, any related non-controlling interests are included as a separate component of Shareholders' Equity.

**Revision of Previously Issued Financial Statements**

In preparing the Consolidated Financial Statements as of and for the three and nine months ended September 30, 2025, Management identified certain income tax-related adjustments that primarily relate to the understatement of income tax expense due to errors in the accounting for transfer pricing, the correction of deferred tax liabilities on goodwill recorded in purchase accounting, and other income tax entries that impacted prior interim and annual financial statements.

Management also identified certain other errors that were concluded to be immaterial, individually and in the aggregate, to the Company's consolidated financial statements as of and for the relevant periods. These include an adjustment to the Pharma Solutions disposal group loss on business disposal which should have been recognized upon the initial classification of the disposal group as held for sale, tax adjustments identified in prior periods primarily related to deferred taxes, balance sheet misclassifications to correct the netting of value added tax receivables and payables and uncertain tax provisions and benefits, an error in the classification of uncertain tax provisions recognized as deferred tax liabilities, an adjustment to record the right of use asset and lease liability related to a lease upon lease commencement that was incorrectly omitted, and a cash flow adjustment to correct the classification of cash paid/received on foreign currency forward contracts from operating activities to investing activities.

Management assessed the materiality of the errors on prior period interim and annual consolidated financial statements in accordance with the Securities and Exchange Commission ("SEC") Staff Accounting Bulletin No. 99, "Materiality," codified in ASC 250, Accounting Changes and Error Corrections ("ASC 250"). Based on this assessment, in consideration of both quantitative and qualitative factors, management determined that the related impacts of the errors were not material to any previously issued interim or annual financial statements. However, if the corrections were recorded in the three months ended September 30, 2025, they would be material to that period. As such, management revised the prior period amounts presented in these financial statements to correct the errors.

In preparing the Consolidated Financial Statements for the year ended December 31, 2025, management identified an additional error related to tax expense on business disposals that affects the interim condensed consolidated financial statements for the three months and six months ended June 30, 2025 and nine months ended September 30, 2025 reported within our Quarterly Report on Form 10-Q for the fiscal periods ended June 30, 2025 and September 30, 2025. Management revised the

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

prior interim periods to correct this error. The error had no impact to our Consolidated Financial Statements as of and for the year ended December 31, 2025.

The following tables include the revisions to previously filed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss), Consolidated Balance Sheets, Consolidated Statements of Shareholders' Equity, and Consolidated Statements of Cash Flows. A summary of the revisions to the previously issued interim financial information is included in Note 22 of the Consolidated Financial Statements, Revision of Quarterly Financial Information (Unaudited). The applicable notes to the accompanying financial statements have also been corrected to reflect the impact of the revisions of the previously filed consolidated interim financial statements and consolidated annual financial statements.

*Impacts to Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)*

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Year Ended December 31, 2024** | **Year Ended December 31, 2024** | **Year Ended December 31, 2024** | **Year Ended December 31, 2023** | **Year Ended December 31, 2023** | **Year Ended December 31, 2023** |
| *<u>(DOLLARS IN MILLIONS EXCEPT PER SHARE AMOUNTS)</u>* | **As Previously Reported** | **Adjustments** | **As Revised** | **As Previously Reported** | **Adjustments** | **As Revised** |
| Net sales | $11484 | $— | $11484 | $11479 | $— | $11479 |
| Gross profit | 4124 |  | 4124 | 3681 |  | 3681 |
| Loss on assets classified as held for sale | 347 | (30) | 317 |  |  |  |
| Income (loss) before income taxes | 278 | 30 | 308 | (2518) |  | (2518) |
| Provision for income taxes | 31 | 10 | 41 | 45 | 24 | 69 |
| Net income (loss) | 247 | 20 | 267 | (2563) | (24) | (2587) |
| Net income (loss) attributable to IFF shareholders | 243 | 20 | 263 | (2567) | (24) | (2591) |
| Net income (loss) per share – basic | $0.95 | $0.09 | $1.04 | $(10.05) | $(0.09) | $(10.14) |
| Net income (loss) per share – diluted | $0.95 | $0.09 | $1.04 | $(10.05) | $(0.09) | $(10.14) |
| Comprehensive income (loss) | (384) | 20 | (364) | (2261) | (24) | (2285) |
| Comprehensive income (loss) attributable to IFF shareholders | $(388) | $20 | $(368) | $(2265) | $(24) | $(2289) |

---

*Impacts to Consolidated Balance Sheet*

---

| | | | |
|:---|:---|:---|:---|
| | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **As Previously Reported** | **Adjustments** | **As Revised** |
| Assets held for sale | $3030 | $26 | $3056 |
| Prepaid expenses and other current assets | 737 | (51) | 686 |
| &nbsp;&nbsp;Total Current Assets | 7993 | (25) | 7968 |
| Goodwill | 9080 | (5) | 9075 |
| Operating lease right-of-use assets | 573 | 16 | 589 |
| Other Assets | 837 | 70 | 907 |
| Total Assets | 28667 | 56 | 28723 |
| Other current liabilities | 783 | 19 | 802 |
| &nbsp;&nbsp;Total Current Liabilities | 4333 | 19 | 4352 |
| Deferred income taxes | 1592 | 2 | 1594 |
| Operating lease liabilities | 534 | 16 | 550 |
| Other Liabilities | 566 | 61 | 627 |
| &nbsp;&nbsp;Total Other Liabilities | 10423 | 79 | 10502 |
| Accumulated deficit | (2605) | (42) | (2647) |
| &nbsp;&nbsp;Total Shareholders' Equity | 13876 | (42) | 13834 |
| Total Shareholders' Equity including Non-controlling interests | 13911 | (42) | 13869 |
| Total Liabilities and Shareholders' Equity | $28667 | $56 | $28723 |

---

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

*Impacts to Consolidated Statements of Shareholders' Equity*

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **As Previously Reported** | **As Previously Reported** | **Adjustments** | **As Revised** | **As Revised** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **Retained Earnings (Accumulated Deficit)** | **Total** | **Retained Earnings (Accumulated Deficit)** | **Retained Earnings (Accumulated Deficit)** | **Total** |
| Balance at January 1, 2023 | $955 | $17685 | $(38) | $917 | $17647 |
| Net income (loss) | (2567) | (2563) | (24) | (2591) | (2587) |
| Balance at December 31, 2023 | (2439) | 14642 | (62) | (2501) | 14580 |
| Balance at January 1, 2024 | (2439) | 14642 | (62) | (2501) | 14580 |
| Net income (loss) | 243 | 247 | 20 | 263 | 267 |
| Balance at December 31, 2024 | $(2605) | $13911 | $(42) | $(2647) | $13869 |

---

*Impacts to Consolidated Statements of Cash Flows*

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Year Ended December 31, 2024** | **Year Ended December 31, 2024** | **Year Ended December 31, 2024** | **Year Ended December 31, 2023** | **Year Ended December 31, 2023** | **Year Ended December 31, 2023** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **As Previously Reported** | **Adjustments** | **As Revised** | **As Previously Reported** | **Adjustments** | **As Revised** |
| Net Income (loss) | $247 | $20 | $267 | $(2563) | $(24) | $(2587) |
| &nbsp;&nbsp;Adjustments to reconcile to net cash provided by operating activities: |  |  |  |  |  |  |
| &nbsp;&nbsp;Deferred Income taxes | (304) | (19) | (323) | (369) | (2) | (371) |
| &nbsp;&nbsp;Loss on assets classified as held for sale | 347 | (30) | 317 |  |  |  |
| &nbsp;&nbsp;Changes in assets and liabilities, net of acquisitions: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Other assets/liabilities, net | (94) | 29 | (65) | (102) | 42 | (60) |
| Net cash provided by operating activities | 1070 |  | 1070 | 1439 | 16 | 1455 |
| &nbsp;&nbsp;Cash received (paid) on foreign currency forward contracts | (102) |  | (102) |  | (16) | (16) |
| Net cash provided by investing activities | $326 | $— | $326 | $574 | $(16) | $558 |

---

The Company also revised the Inventory and Property, plant, and equipment, net disclosures as of December 31, 2024 as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31, 2024**<sup>(1)</sup> | **Year Ended December 31, 2024**<sup>(1)</sup> | **Year Ended December 31, 2024**<sup>(1)</sup> |
| *<u>(DOLLARS IN MILLIONS EXCEPT PER SHARE AMOUNTS)</u>* | **As Previously Reported** | **Adjustments** | **As Revised** |
| Raw materials | $657 | $27 | $684 |
| Work in process | 368 | 75 | 443 |
| Finished goods | 1108 | (102) | 1006 |
| &nbsp;&nbsp;Total Inventory | 2133 |  | 2133 |
| Land | 136 | 1 | 137 |
| Building and improvements | 1688 | 7 | 1695 |
| Machinery and equipment | 3447 | 24 | 3471 |
| Information technology | 507 | 7 | 514 |
| Construction in process | 389 | (39) | 350 |
| &nbsp;&nbsp;Total Property, plant and equipment | $6167 | $— | $6167 |

---

_______________________

(1)The revision to the asset classes of Inventory was to correct certain classification errors. The revision to the asset classes of Property, plant and equipment, net was to correct the timing of transfer of completed Construction in process projects into service. As previously disclosed within our Quarterly Report on Form 10-Q for the fiscal period ended September 30, 2025, the Inventory, net disclosures as of December 31, 2024 reflected a $30 million reclassification from Raw materials to Finished goods. Those Inventory and Property, plant and equipment, net disclosures as of December 31, 2024 have since been updated to reflect additional corrections of the same nature.

**Reclassifications**

Certain amounts in the prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported consolidated Net (loss) income.

Effective January 1, 2025, the Company implemented a reorganization of its internal structure, which impacted the way the Chief Operating Decision Maker ("CODM"), the Chief Executive Officer, allocates resources and assesses financial

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

performance. As a result, the Company has updated its reportable segments beginning with the first quarter of 2025. The Company also adjusted its corporate cost allocations to align with the new organizational structure and updated operating model, consistent with how management assesses performance effective January 1, 2025. As a result, certain segment information for the twelve months ended December 31, 2024 and December 31, 2023 has been recast to reflect these changes in corporate allocations among the Company's reportable segments on a comparable basis. Please see Note 7 for more information.

**Revenue Recognition**

The Company recognizes revenue from contracts with customers when the contract or purchase order has received approval and commitment from both parties, has the rights of the parties and payment terms (which can vary by customer) identified, has commercial substance, collectability of consideration is probable, and control has transferred. The revenue recognized reflects the consideration the Company expects to be entitled to in exchange for those goods. Sales, value added, and other taxes the Company collects are excluded from revenues. The Company receives payment in accordance with standard customer terms.

Sales are reduced, at the time revenue is recognized, for applicable discounts, rebates, prebates, and sales allowances based on historical experience. Related accruals are included in Other current liabilities and Other assets in the accompanying Consolidated Balance Sheets. The Company considers shipping and handling activities undertaken after the customer has obtained control of the related goods as a fulfillment activity. Net sales include shipping and handling charges billed to customers. Cost of sales includes all costs incurred in connection with shipping and handling.

**Contract Assets and Liabilities**

With respect to a small number of contracts for the sale of compounds, the Company has an "enforceable right to payment for performance to date" and as the products do not have an alternative use, the Company recognizes revenue for these contracts over time and records a contract asset using the output method. The output method recognizes revenue on the basis of direct measurements of the value to the customer of the goods or services transferred to date relative to the remaining goods or services promised under the contract.

As of December 31, 2025 and 2024, the Company's gross accounts receivable was $1.758 billion and $1.650 billion, respectively. The Company's contract assets and contract liabilities as of December 31, 2025 and 2024 were not material.

**Foreign Currency Translation**

The Company translates the assets and liabilities of non-U.S. subsidiaries into U.S. dollars at year-end exchange rates. Income and expense items are translated at average exchange rates during the year. Foreign currency translation adjustments are shown as a component of Other comprehensive income (loss) on the Statements of Comprehensive Income (Loss) .

**Research and Development**

Research and development ("R&D") expenses relate to the development of new and improved products, technical product support and compliance with governmental regulation. All research and development costs are expensed as incurred.

**Cash, Cash Equivalents and Restricted Cash**

Cash and cash equivalents include highly liquid investments with maturities of three months or less at date of purchase. Restricted cash is comprised of cash or cash equivalents which have been placed into an account that is restricted for a specific use and from which the Company cannot withdraw the cash on demand.

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported on the Company's balance sheets as of December 31, 2025, 2024 and 2023 to the amounts reported on the Company's statement of cash flows periods ended December 31, 2025, 2024 and 2023.

---

| | | | |
|:---|:---|:---|:---|
| *<u>(DOLLARS IN MILLIONS)</u>* | **December 31, 2025** | **December 31, 2024** | **December 31, 2023** |
| Current assets |  |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $590 | $469 | $703 |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents included in Assets held for sale |  | 2 | 26 |
| &nbsp;&nbsp;&nbsp;Restricted cash |  |  | 6 |
| Cash, cash equivalents and restricted cash | $590 | $471 | $735 |

---

**Accounts Receivable**

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

The Company has various factoring agreements globally under which it can factor up to approximately $533 million of its trade receivables ("Company's own factoring agreements") at a point in time. In addition, the Company utilizes factoring agreements sponsored by certain customers. Under all of the arrangements, the Company sells the trade receivables on a non-recourse basis to unrelated financial institutions and accounts for the transactions as sales of receivables. The applicable receivables are removed from the Company's Consolidated Balance Sheets when the cash proceeds are received by the Company.

The Company sold approximately $1.873 billion, $1.732 billion and $1.752 billion of receivables in 2025, 2024 and 2023, respectively, under the Company's own factoring agreements and customer sponsored factoring agreements. The cost of participating in these programs was approximately $23 million, $27 million and $25 million, in 2025, 2024 and 2023, respectively, and is included as a component of interest expense. Under the Company's own factoring agreements for which the Company has continued responsibility to collect receivables and provide to its sponsor, it sold approximately $1.205 billion, $850 million and $843 million of receivables in 2025, 2024 and 2023, respectively. The outstanding principal amounts of receivables under the Company's own factoring agreements amounted to approximately $361 million and $189 million as of December 31, 2025 and 2024, respectively. The proceeds from the sales of receivables are included in net cash from operating activities in the Consolidated Statements of Cash Flows.

**Expected Credit Losses**

The Company is exposed to credit losses primarily through its sales of products. To determine the appropriate allowance for expected credit losses, the Company considers certain credit quality indicators, such as aging of customer receivable balances, loss history and creditworthiness of debtors. The Company also considers current and anticipated future conditions of the general economy in the determination of allowances, including significant aspects of a geographic location and the industries in which the Company operates. The Company's general allowance for credit losses is calculated using a loss rate model that is primarily based on historical write-off experiences and applied to trade receivables. As necessary, additional reserves are established based on other factors, such as aging of receivables, customer credit quality and account collectability and country risk. These allowances are reviewed and approved by the Regional and Global Credit committees.

As of December 31, 2025, the Company reported $1.731 billion of trade receivables, net of allowances of $27 million. Based on the aging analysis as of December 31, 2025, approximately 1% of the Company's accounts receivable were past due by over 365 days based on the payment terms of the invoice.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

The following is a roll forward of the Company's allowances for bad debts for the years ended December 31, 2023, 2024 and 2025:

---

| | |
|:---|:---|
| *<u>(DOLLARS IN MILLIONS)</u>* | **Allowance for Bad Debts** |
| Balance at January 1, 2023 | $53 |
| Bad debt expense (reversal) | 9 |
| Write-offs | (11) |
| Foreign exchange losses (gains) | 1 |
| Balance at January 1, 2024 | 52 |
| Bad debt expense (reversal) | (4) |
| Write-offs | (19) |
| Foreign exchange losses (gains) | (3) |
| Balance at January 1, 2025 | 26 |
| Bad debt expense (reversal) | 6 |
| Write-offs | (8) |
| Foreign exchange losses (gains) | 3 |
| Balance at December 31, 2025 | $27 |

---

**Inventories**

Inventories are stated at the lower of cost (on a weighted-average basis) or net realizable value. The Company's inventories consisted of the following:

---

| | | |
|:---|:---|:---|
| | **December 31,** | **December 31,** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **2025** | **2024** |
| Raw materials | $731 | $684 |
| Work in process | 454 | 443 |
| Finished goods | 1060 | 1006 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $2245 | $2133 |

---

**Leases**

The Company determines if an arrangement is a lease at contract inception. A lease exists when a contract conveys to the customer the right to control the use of identified property, plant or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: (1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment), and (2) the customer has the right to control the use of the identified asset.

When the Company determines the arrangement is a lease, or contains a lease, at inception, it then determines whether the lease is an operating lease or a finance lease at the commencement date.

The Company leases property and equipment principally under operating leases and records a right-of-use asset and related obligation at the present value of lease payments. Over the term of the lease, the Company depreciates the right-of-use asset and accretes the related obligation to future value. Some of the leases include rental escalation clauses, renewal options and/or termination options that are factored into the determination of lease payments when appropriate. The Company has elected not to separate non-lease components from lease components for all classes of leased assets.

When available, the Company uses the rate implicit in the lease to discount lease payments to present value, however, most of the Company's leases do not provide a readily determinable implicit rate and the Company calculates the applicable incremental borrowing rate to discount the lease payments based on the term of the lease at lease commencement. The incremental borrowing rate is determined based on the Company's credit rating, currency and lease terms.

**Long-Lived Assets**

*Property, Plant and Equipment*

Property, plant and equipment are recorded at cost. Depreciation is calculated on a straight-line basis, principally over the following estimated useful lives: buildings and improvements, 1 to 40 years; machinery and equipment, 1 to 20 years;

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

information technology hardware and software, 1 to 7 years; and leasehold improvements which are included in buildings and improvements, the estimated life of the improvements or the remaining term of the lease, whichever is shorter.

Interest incurred during the construction period of certain property, plant and equipment is capitalized until the underlying assets are placed in service, at which time straight-line amortization of the capitalized interest begins over the estimated useful lives of the related assets.

*Finite-Lived Intangible Assets*

Finite-lived intangible assets include customer relationships, patents, trade names, technological know-how and other intellectual property valued at acquisition and are amortized on a straight-line basis over the following estimated useful lives: customer relationships, 15 to 20 years; patents and trade names, 4 to 23 years; and technological know-how, 5 to 15 years.

The Company reviews long-lived assets for impairment when events or changes in business conditions indicate that their carrying value may not be recovered. An estimate of undiscounted future cash flows produced by an asset or group of assets is compared to the carrying value to determine whether impairment exists. If assets are determined to be impaired, the loss is measured based on an estimate of fair value using various valuation techniques, including a discounted estimate of future cash flows.

**Goodwill**

Goodwill represents the difference between the total purchase price and the fair value of identifiable assets and liabilities acquired in business acquisitions.

The Company tests goodwill for impairment at the reporting unit level as of November 30 every year or more frequently if events or changes in circumstances indicate that it might be impaired. A reporting unit is an operating segment or one level below an operating segment (referred to as a component) to which goodwill is assigned when initially recorded.

The Company identifies its reporting units by assessing whether the components of its reporting units constitute businesses for which discrete financial information is available and management of each reporting unit regularly reviews the operating results of those components. As of December 31, 2025, the Company has five reporting units under the Food Ingredients, Taste, Scent and Health & Biosciences segments: (1) Food Ingredients, (2) Taste, (3) Fragrance Compounds, (4) Fragrance Ingredients and (5) Health & Biosciences. As of December 31, 2024, the Company had five reporting units under the previous Nourish, Scent, Health & Biosciences and Pharma Solutions segments: (1) Nourish, (2) Fragrance Compounds, (3) Fragrance Ingredients, (4) Health & Biosciences and (5) Pharma Solutions. These reporting units were determined based on the level at which the performance is measured and reviewed by segment management. In cases where the components of an operating segment have similar economic characteristics, they are aggregated into a single reporting unit.

When testing goodwill for impairment, the Company has the option of first performing a qualitative assessment to determine whether it is more likely than not that the fair value of a reporting unit is less than the carrying amount. If the Company elects to bypass the qualitative assessment for any reporting units, or if a qualitative assessment indicates it is more likely than not that the estimated carrying value of a reporting unit exceeds its fair value, the Company performs a quantitative goodwill impairment test.

Under the quantitative goodwill impairment test, if a reporting unit's carrying amount exceeds its fair value, the Company will record an impairment charge based on that difference, and the impairment charge will be limited to the amount of goodwill allocated to that reporting unit.

**Income Taxes**

The Company accounts for taxes under the asset and liability method. Under this method, deferred income taxes are recognized for temporary differences between the financial statement and tax return bases of assets and liabilities, based on enacted tax rates and other provisions of the tax law. The effect of a change in tax laws or rates on deferred tax assets and liabilities is recognized as income in the period in which such change is enacted. Future tax benefits are recognized to the extent that the realization of such benefits is more likely than not, and a valuation allowance is established for any portion of a deferred tax asset that management believes may not be realized.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

The Company recognizes uncertain tax positions that it has taken or expects to take on a tax return. Pursuant to accounting requirements, the Company first determines whether it is "more likely than not" its tax position will be sustained if the relevant tax authority were to audit the position with full knowledge of all the relevant facts and other information. For those tax positions that meet this threshold, the Company measures the amount of tax benefit based on the largest amount of tax benefit that it has a greater than 50% chance of realizing in a final settlement with the relevant authority. Those tax positions failing to qualify for initial recognition are recognized in the first interim period in which they meet the more likely than not standard. The Company maintains a cumulative risk portfolio relating to all of its uncertainties in income taxes in order to perform this analysis, but the evaluation of its tax positions requires significant judgment and estimation in part because, in certain cases, tax law is subject to varied interpretation, and whether a tax position will ultimately be sustained may be uncertain.

Interest and penalties related to unrecognized tax benefits are recognized as a component of income tax expense.

**Retirement Benefits**

The vested benefit obligations for the Company's pension and postretirement plans are determined using the actuarial present value of benefits earned to date, reflecting the benefits employees are entitled to receive at their expected date of separation or retirement. The current service cost component of net periodic benefit cost is accrued and presented within either Cost of sales, Research and Development expenses or Selling and Administrative expenses on the Consolidated Statements of Income (Loss) and Comprehensive Income (Loss). The interest cost, expected return on plan assets, amortization of actuarial (gain)/loss, amortization of prior service credit and settlement and curtailment loss components of net periodic benefit cost are presented within Other expense, net, on the Consolidated Statements of Income (Loss) and Comprehensive Income (Loss).

Actuarial gains and losses in excess of 10% of the greater of the projected benefit obligation or the market-related value of plan assets are classified in Accumulated Other Comprehensive Income (Loss) along with the related tax impact, and recognized as a component of net periodic benefit cost over the average remaining service period of a plan's active employees for active defined benefit pension plans and over the average remaining life expectancy of a plan's active and inactive employees for frozen defined benefit pension plans. Prior service costs resulting from plan improvements are amortized over periods ranging from 7 to 25 years.

**Financial Instruments**

Derivative financial instruments are used to manage interest and foreign currency exposures. The gain or loss on the hedging instrument is recorded in earnings at the same time as the transaction being hedged is recorded in earnings. The associated asset or liability related to the open hedge instrument is recorded in Prepaid expenses and Other current assets or Other current liabilities, as applicable.

The Company records all derivative financial instruments on the balance sheet at fair value. Changes in a derivative's fair value are recognized in earnings unless specific hedge criteria are met. If the derivative is designated as a fair value hedge, the changes in the fair value of the derivative and of the hedged item attributable to the hedged risk are recognized in Net (loss) income. If the derivative is designated as a cash flow hedge, the effective portions of changes in the fair value of the derivative are recorded in Accumulated other comprehensive loss in the accompanying Consolidated Balance Sheets and are subsequently recognized in Net (loss) income when the hedged item affects earnings. Ineffective portions of changes in the fair value of cash flow hedges, if any, are recognized as a charge or credit to earnings.

**Software Costs**

The Company capitalizes direct internal and external development costs for certain significant projects associated with internal-use software and typically amortizes these costs over seven years. Neither preliminary evaluation costs nor costs associated with the software after implementation are capitalized. Costs related to projects that are not significant are expensed as incurred.

**Net (Loss) Income Per Share**

Under the two-class method, earnings are adjusted by accretion of amounts to redeemable non-controlling interests recorded at redemption value. The adjustments represent in-substance dividend distributions to the non-controlling interest holders as the holders have a contractual right to receive a specified amount upon redemption. As a result, earnings are adjusted to reflect this in-substance distribution that is different from other common shareholders. In addition, the Company has unvested share-based payment awards with a right to receive non-forfeitable dividends and thus are considered participating securities which are required to be included in the computation of basic and diluted earnings per share.

Basic income (loss) per share represents the amount of earnings available to each share of common stock outstanding during the period. Basic income (loss) per share includes the effect of issuing shares of common stock. Diluted (loss) income per share also includes the effect of issuing shares of common stock, assuming (i) stock options and warrants are exercised, and (ii) restricted stock units are fully vested under the treasury stock method. See Note 2 for additional information.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

**Stock-Based Compensation**

Compensation cost of all stock-based awards is measured at fair value on the date of grant and recognized over the service period for which awards are expected to vest. The cost of such stock-based awards is principally recognized on a straight-line attribution basis over their respective vesting periods, net of estimated forfeitures.

**Financing Costs**

Costs incurred in the issuance of debt are deferred and amortized as part of interest expense over the stated life of the applicable debt instrument. Unamortized deferred financing costs relating to debt are presented as a reduction in the amount of debt outstanding on the Consolidated Balance Sheets. Unamortized deferred financing costs relating to the revolving credit facility are recorded in Other assets on the Consolidated Balance Sheets.

**Held for Sale**

Assets and liabilities to be disposed of by sale ("disposal groups") are reclassified into assets and liabilities held for sale on the Company's Consolidated Balance Sheets. The reclassification occurs when management has committed to a plan to sell the assets within one year. Disposal groups are measured at the lower of carrying value or fair value less costs to sell and are not depreciated or amortized. When the net realizable value of a disposal group increases during a period, a gain can be recognized to the extent that it does not increase the value of the disposal group beyond its original carrying value when the disposal group was reclassified as held for sale. The fair value of a disposal group, less any costs to sell, is assessed each reporting period it remains classified as held for sale and any remeasurement to the lower of carrying value or fair value less costs to sell is reported as an adjustment to the carrying value of the disposal group. See Note 4 for additional information.

**Recent Accounting Pronouncements**

In December 2025, the FASB issued ASU 2025-12 "Codification Improvements" to address suggestions received from stakeholders on the Accounting Standards Codification and to make other incremental improvements to U.S. GAAP. The update represents changes to the Codification that (1) clarify, (2) correct errors, or (3) make minor improvements. The amendments make the Codification easier to understand and apply. The guidance is effective for fiscal years beginning after December 15, 2026, including interim periods within those fiscal years. The Company is currently evaluating the impact of this guidance on our Consolidated Financial Statements and related disclosures.

In December 2025, the FASB issued ASU 2025-11 to amend the guidance in "Interim Reporting" (Topic 270). The update provides clarifications intended to improve the consistency and usability of interim disclosure requirements, including a comprehensive listing of required interim disclosures and a new disclosure principle for reporting material events occurring after the most recent annual period. The amendments do not change the underlying objectives of interim reporting but are designed to enhance clarity in application. The guidance is effective for fiscal years beginning after December 15, 2027, including interim periods within those fiscal years. The Company does not expect any significant impact on its financial condition or results of operations upon adoption.

In December 2025, the FASB issued ASU 2025-10, "Government Grants (Topic 832)". The update provides recognition, measurement, presentation, and disclosure requirements for government grants, including guidance for grants related to an asset and grants related to income. The amendments introduce two permitted approaches for asset-related grants: a deferred income approach or a cost accumulation approach. The guidance is effective for fiscal years beginning after December 15, 2028, including interim periods within those fiscal years. The Company is currently evaluating the impact of this guidance on our Consolidated Financial Statements and related disclosures.

In November 2025, the FASB issued ASU 2025-09 to amend the guidance in "Derivatives and Hedging" (Topic 815). The update provides targeted improvements intended to enhance the application of hedge accounting, including expanded eligibility of forecasted transactions, additional flexibility in measuring hedge effectiveness, and clarifications related to hedging non-financial items. The guidance is effective for fiscal years beginning after December 15, 2026, including interim periods within those fiscal years. The Company is currently evaluating the impact of this guidance on our Consolidated Financial Statements and related disclosures.

In September 2025, the FASB issued ASU 2025-06, "Intangibles - Goodwill and Other - Internal use Software (Subtopic 350-40): Targeted improvements to the Accounting for Internal-use Software". The ASU was issued to modernize the accounting for internal-use software by eliminating the accounting consideration of software project development stages and clarifying the threshold applied to begin capitalizing costs. This guidance is effective for annual periods beginning after December 15, 2027, and interim reporting periods within those annual reporting periods, with early adoption permitted. Public business entities are permitted to adopt the ASU prospectively or retrospectively. The Company is currently evaluating the impact of this guidance on our Consolidated Financial Statements and related disclosures.

In July 2025, the FASB issued ASU 2025-05, "Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets", which provides a practical expedient to measure credit losses on

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

accounts receivable and contract assets. This guidance is effective for annual reporting periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods. The Company will adopt the ASU prospectively and has determined that there is no material impact of this guidance on our Consolidated Financial Statements and related disclosures.

In November 2024, the FASB issued ASU 2024-03, "Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses", and in January 2025, issued ASU 2025-01, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date ("ASU 2025-01"). The ASU was issued to improve the disclosures about a public business entity's expenses, primarily through disaggregation of certain expense captions into specified categories in disclosures within the footnotes to the financial statements. This guidance is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. Public business entities are permitted to adopt the ASU prospectively or retrospectively. The Company is currently evaluating the impact that this guidance will have on its Consolidated Financial Statements and related disclosures.

In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures." The ASU was issued to further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. This guidance was effective on a prospective basis for fiscal years beginning after December 15, 2024. The Company has adopted this guidance. See Note 10 for the updated disclosure.

**NOTE 2.&nbsp;&nbsp;&nbsp;&nbsp;NET (LOSS) INCOME PER SHARE**

A reconciliation of shares used in the computation of basic and diluted net (loss) income per share is as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **December 31,** | **December 31,** | **December 31,** |
| *<u>(AMOUNTS IN MILLIONS EXCEPT PER SHARE AMOUNTS)</u>* | **2025** | **2024** | **2023** |
| **Net (Loss) Income** |  |  |  |
| Net (loss) income attributable to IFF shareholders | $(361) | $263 | $(2591) |
| Adjustment related to decrease in redemption value of redeemable non-controlling interests in excess of earnings allocated |  |  | 2 |
| Net (loss) income available to IFF shareholders | $(361) | $263 | $(2589) |
| **Shares** |  |  |  |
| Weighted average common shares outstanding (basic and diluted) | 256 | 256 | 255 |
| **Net (Loss) Income per Share** |  |  |  |
| Net (loss) income per share – basic and diluted<sup>(1)</sup> | $(1.41) | $1.04 | $(10.14) |

---

_______________________

(1)For the years ended December 31, 2024 and 2023, the basic and diluted net (loss) income per share cannot be recalculated based on the information presented in the table above due to the effects of rounding.

There were approximately 1 million and 0.2 million potentially dilutive securities excluded from the computation of diluted net loss per share for the years ended December 31, 2025 and December 31, 2023, respectively, because there was a net loss attributable to IFF for the period and, as such, the inclusion of these securities would have been anti-dilutive.

In addition to the above, for the years ended December 31, 2025, 2024 and 2023, there were approximately 0.3 million, 0.3 million and 0.4 million of share equivalents, respectively, that had an anti-dilutive effect and therefore were excluded from the computation of diluted net (loss) income per share.

**NOTE 3. BUSINESS DIVESTITURES** 

**Divestiture of the Rene Laurent Business in France**

The Company completed the sale of its Rene Laurent business in France on December 1, 2025. The business was included within the Company's Taste reportable operating segment. The Company received gross cash proceeds of approximately $19.3 million. The sale consideration is subject to certain post-closing adjustments, which are primarily related to cash, working capital balances, and other adjustments per the sale and purchase agreement.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

As a result of the business divestiture, the Company recognized a pre-tax gain of approximately $2 million, subject to certain post-closing adjustments, presented in Losses (Gains) on business disposals on the Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) for the year ended December 31, 2025. The total income tax expense recognized was approximately $3 million for the year-ended December 31, 2025.

**Divestiture of the Pharma Solutions Disposal Group**

During March 2024, the Company announced it had entered into an agreement to sell its Pharma Solutions business that is primarily made up of most businesses within the Company's existing Pharma Solutions reportable operating segment (the "Pharma Solutions disposal group"). The Company completed the divestiture on May 1, 2025, and received gross cash proceeds of approximately $2.581 billion. The sale consideration is subject to certain post-closing adjustments, which are primarily related to cash, working capital balances, and other adjustments per the transaction agreement. There is significant uncertainty regarding the resolution of these post-closing adjustments, which can result in a significant increase or decrease in the total consideration received.

The following table summarizes the fair value of sale consideration received in connection with the business divestiture:

---

| | |
|:---|:---|
| *<u>(DOLLARS IN MILLIONS)</u>* |  |
| Cash proceeds from the buyer | $2581 |
| 2024 earnout receivable | 97 |
| Other post-closing adjustment and 2025 earnout, net | 42 |
| Indemnifications payable | (12) |
| Direct costs to sell | (30) |
| Fair value of sale consideration | $2678 |

---

The fair value of sale consideration includes a payout of $97 million related to an earnout on 2024 results, which was collected by the Company in January 2026. The Company can earn up to $150 million of additional proceeds based on the 2025 results of the Pharma Solutions disposal group. The Company engaged an independent third party to determine the fair value of the expected earnout consideration as of December 31, 2025, which was based on a Monte Carlo simulation. The fair value estimation uses Level 3 unobservable inputs as categorized within the ASC Topic 820 fair value hierarchy. This method considers the terms and conditions of the earnout as described in the relevant transaction agreements, our best estimates of forecasted EBITDA for the earnout periods as applicable, and assumptions such as risk-adjusted discount rate, EBITDA volatility, counterparty discount rate and risk-free rate. The simulation consists first in risk-adjusting the EBITDA projections using a risk-adjusted discount rate and then simulating a range of EBITDA over the applicable period using the estimate of EBITDA volatility. The fair value of the earnout is estimated as the present value of the potential range of payouts averaged across the range of simulated EBITDA using the counterparty discount rate. As the determination of performance of the subject business in 2024 has not been resolved and the actual performance for all of 2025 is not yet known, these estimations are subject to significant uncertainty. The Company is also in process of determining final closing price adjustments with the buyer. Based on the final calculation of 2025 results and post-closing adjustments, there could be a significant increase or decrease in the total sale consideration.

The net proceeds received from the business divestiture presented under Cash flows from investing activities represent the cash portion of the sale consideration, reduced by the cash transferred to the buyer as part of the transaction. Amounts paid for direct costs to sell are presented under Cash flows from operating activities.

The following table summarizes the different components of net proceeds received from the business divestiture presented under Cash flows from investing activities:

---

| | |
|:---|:---|
| *<u>(DOLLARS IN MILLIONS)</u>* |  |
| Cash proceeds from the buyer | $2581 |
| Cash transferred to the buyer | (29) |
| Net Cash flows from investing activities | $2552 |

---

The carrying value of net assets associated with the Pharma Solutions disposal group, adjusted for currency translation adjustment, NCI, and pension adjustments, amounted to approximately $2.799 billion. The major classes of assets and liabilities sold consisted of the following:

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

---

| | |
|:---|:---|
| *<u>(DOLLARS IN MILLIONS)</u>* | **May 1, 2025** |
| Assets |  |
| Cash and cash equivalents | $29 |
| Trade receivables, net | 218 |
| Inventories | 289 |
| Property, plant and equipment, net | 439 |
| Goodwill<sup>(1)</sup> | 1190 |
| Other intangible assets, net | 1093 |
| Operating lease right-of-use assets | 68 |
| Deferred tax assets | 17 |
| Other assets | 116 |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: Loss recognized on assets held-for-sale<sup>(2)</sup> | (307) |
| Total assets | 3152 |
| Liabilities |  |
| Accounts payable | $(131) |
| Deferred tax liability | (75) |
| Other liabilities | (166) |
| Total liabilities | (372) |
| Equity |  |
| Accumulated other comprehensive income - currency translation adjustment | 49 |
| Accumulated other comprehensive income - pension adjustment | (26) |
| Non-controlling Interests (NCI) | (4) |
| Total equity | 19 |
| Carrying value of net assets (adjusted for currency translation, pension, and NCI adjustments) | $2799 |

---

_______________________

<sup>(1)</sup> The goodwill balance presented here is net of the $64 million goodwill impairment charge.

<sup>(2)</sup> A loss was recorded on assets held-for-sale in the amount of $307 million through March 31, 2025.

As a result of the business divestiture, the Company recognized a pre-tax loss of approximately $121 million, subject to certain post-closing adjustments, presented in Losses (Gains) on business disposals on the Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) for the year ended December 31, 2025. This is in addition to the life-to-date loss on assets classified as held for sale of $307 million recognized through March 31, 2025. $274 million of the loss on assets classified as held for sale was recognized during the year ended December 31, 2024. The total income tax expense recognized was approximately $64 million, including approximately $70 million of income tax benefit that was recognized during the year ended December 31, 2024.

**Divestiture of the Nitrocellulose Business**

During October 2024, the Company entered into an agreement to sell its Nitrocellulose business (including the related industrial park in Germany), which was included within the Company's existing Pharma Solutions reportable operating segment. The Company completed the divestiture on May 9, 2025, and received cash proceeds of approximately $161 million. The sale consideration is subject to certain post-closing adjustments, which are primarily related to cash, working capital balances, and other adjustments per the transaction agreement.

The following table summarizes the fair value of sale consideration received in connection with the business divestiture:

---

| | |
|:---|:---|
| *<u>(DOLLARS IN MILLIONS)</u>* |  |
| Cash proceeds from the buyer | $161 |
| Direct costs to sell | (3) |
| &nbsp;&nbsp;&nbsp;&nbsp;Fair value of sale consideration | $158 |

---

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

The net proceeds received from the business divestiture presented under Cash flows from investing activities represent the cash portion of the sale consideration, which was determined as the fair value of sale consideration adjusted by the cash transferred to the buyer as part of the transaction. Amounts paid for direct costs to sell are presented under Cash flows from operating activities.

The following table summarizes the different components of net proceeds received from the business divestiture presented under Cash flows from investing activities:

---

| | |
|:---|:---|
| *<u>(DOLLARS IN MILLIONS)</u>* |  |
| Cash proceeds from the buyer | $161 |
| Cash transferred to the buyer | (9) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net Cash flows from investing activities | $152 |

---

The carrying amount of net assets associated with the Nitrocellulose business, adjusted for currency translation adjustment and pension adjustments, was approximately $148 million. The major classes of assets and liabilities sold consisted of the following:

---

| | |
|:---|:---|
| *<u>(DOLLARS IN MILLIONS)</u>* | **May 9, 2025** |
| **Assets** |  |
| Cash and cash equivalents | $9 |
| Trade receivables, net | 33 |
| Inventories | 15 |
| Property, plant and equipment, net | 60 |
| Goodwill | 77 |
| Other intangible assets, net | 19 |
| Other assets | 40 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total assets | 253 |
| **Liabilities** |  |
| Accounts payable | $(30) |
| Other liabilities | (50) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | (80) |
| **Equity** |  |
| Accumulated other comprehensive income - currency translation adjustment | (1) |
| Accumulated other comprehensive income - pension adjustment | (24) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total equity | (25) |
| Carrying value of net assets (adjusted for currency translation and pension adjustments) | $148 |

---

As a result of the business divestiture, the Company recognized a pre-tax gain of approximately $10 million, subject to certain post-closing adjustments, presented in Losses (Gains) on business disposals on the Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) for the year ended December 31, 2025. The total income tax benefit recognized was approximately $1 million for the year ended December 31, 2025.

**Divestiture of a Tobacco Flavoring Business in North America**

The Company completed the divestiture of the Tobacco Flavoring Business in North America on April 1, 2025, and received gross cash proceeds of approximately $20 million.

As a result of the divestiture, the Company recognized a pre-tax gain of less than $1 million presented in Losses (Gains) on business disposals on the Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) for the year ended December 31, 2025. The total income tax expense recognized was approximately $5 million for the year ended December 31, 2025.

**Divestiture of the Cosmetic Ingredients Business**

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

During the third quarter of 2023, the Company announced it had entered into an agreement to sell its Cosmetic Ingredients business, which was a part of the Scent segment. The Company completed the divestiture on April 2, 2024, and received cash proceeds of approximately $839 million, which includes a $2 million post-closing net working capital adjustment made in the fourth quarter of 2024.

The following table summarizes the fair value of sale consideration received in connection with the business divestiture:

---

| | |
|:---|:---|
| *<u>(DOLLARS IN MILLIONS)</u>* |  |
| Cash proceeds from the buyer | $839 |
| Direct costs to sell | (10) |
| &nbsp;&nbsp;&nbsp;&nbsp;Fair value of sale consideration | $829 |

---

The Net proceeds received from business disposals presented under Cash flows from investing activities represent the cash portion of the sale consideration, which was determined as the fair value of sale consideration adjusted by the cash transferred to the buyer as part of the transaction and the net cash settlement for post-closing adjustments. Amounts paid for direct costs to sell are presented under Cash flows from operating activities. The following table summarizes the different components of Net proceeds received from business disposals presented under Cash flows from investing activities:

---

| | |
|:---|:---|
| *<u>(DOLLARS IN MILLIONS)</u>* |  |
| Cash proceeds from the buyer | $839 |
| Cash transferred to the buyer | (32) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net Cash flows from investing activities | $807 |

---

The carrying amount of net assets associated with the business unit, adjusted for currency translation adjustment, was approximately $466 million. The major classes of assets and liabilities sold consisted of the following:

---

| | |
|:---|:---|
| *<u>(DOLLARS IN MILLIONS)</u>* | **April 2, 2024** |
| **Assets** |  |
| Cash and cash equivalents | $32 |
| Trade receivables, net | 18 |
| Inventories | 17 |
| Property, plant and equipment, net | 7 |
| Goodwill | 271 |
| Other intangible assets, net | 144 |
| Operating lease right-of-use assets | 10 |
| Other assets | 11 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total assets | 510 |
| **Liabilities** |  |
| Accounts payable | $(5) |
| Deferred tax liability | (25) |
| Other liabilities | (18) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | (48) |
| **Equity** |  |
| Accumulated other comprehensive income - currency translation adjustment | 4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total equity | 4 |
| Carrying value of net asset (adjusted for currency translation adjustment) | $466 |

---

As a result of the business divestiture, the Company recognized a pre-tax gain of approximately $363 million, presented in Losses (Gains) on business disposals on the Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) for the year ended December 31, 2024. The total income tax expense/(benefit) recognized was approximately $31 million, with approximately $(7) million that was recognized during the year ended December 31, 2023.

**Divestiture of the Flavors and Essences UK Business**

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

During the third quarter of 2024, the Company completed the divestiture of its Flavors and Essences UK ("F&E") business, which was a part of the former Nourish segment. The Company completed the divestiture on September 1, 2024, and received net cash proceeds of approximately $28 million. The carrying amount of net assets associated with the business unit, adjusted for currency translation adjustment, was approximately $48 million. The majority of net assets sold included intangible assets and goodwill attributable to the F&E business. As part of the business divestiture, the Company recognized a pre-tax loss of approximately $20 million presented in Losses (Gains) on business disposals and a tax benefit of approximately $1 million presented in Provision for income taxes on the Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) for the year ended December 31, 2024.

**Divestiture of the Flavor Specialty Ingredients Business**

The Company completed the divestiture of the Flavors Specialty Ingredients ("FSI") business on August 1, 2023, and received net cash proceeds of approximately $200 million.

As a result of the business divestiture, the Company recognized a pre-tax loss of approximately $10 million, presented in Losses (Gains) on business disposals on the Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) for the year ended December 31, 2023. There was a net working capital adjustment of $(3) million for the year ended December 31, 2024, resulting in a cumulative pre-tax loss of approximately $7 million.

**Divestiture of a Portion of the Savory Solutions Business**

The Company completed the divestiture of a portion of the Savory Solutions business on May 31, 2023, and received net cash proceeds of approximately $821 million. In addition, a receivable of approximately $37 million was recorded which reflected the remaining sale consideration that was received in January 2024.

As a result of the divestiture, the Company recognized a pre-tax loss of approximately $3 million presented in Losses (Gains) on business disposals on the Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) for the year ended December 31, 2023.

*Liquidation of a Business in Russia*

As part of the liquidation of a business in Russia for the sale of the portion of the Savory Solutions business, the Company recognized a pre-tax loss of approximately $10 million presented in the Losses (Gains) on business disposals, and tax benefits of approximately $2 million presented in Provision for income taxes on the Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) for the year ended December 31, 2023.

**NOTE 4. ASSETS AND LIABILITIES HELD FOR SALE**

**Assets and Liabilities Held for Sale**

***Sale of Soy Crush, Concentrates & Lecithin Business***

On August 5, 2025, the Company announced it had entered into a definitive agreement to divest its Soy Crush, Concentrates, and Lecithin business (the "SCL disposal group"), which is included in the Food Ingredients segment. This sale aligns with IFF's strategy to strengthen its portfolio and supports the ongoing evaluation of strategic alternatives for the Food Ingredients segment. The transaction is subject to customary closing conditions and is expected to close by the second quarter of 2026.

The sale does not constitute a strategic shift of the Company's operations and does not, and will not, have major effects on the Company's operations and financial results considering only the SCL disposal group and not any future divestitures which may be considered as part of the same disposal plan. Therefore, the transaction does not meet the discontinued operations criteria.

The Company determined that the assets and liabilities of the SCL disposal group met the criteria to be presented as "held for sale" during the third quarter of 2025. As a result, as of December 31, 2025, such assets and liabilities were classified as held for sale on the Consolidated Balance Sheets.

The Company determined that the fair value of $107 million (fair value of $109 million less estimated costs to sell of $2 million) of the disposal group was less than its book value. As such, the Company recorded a year-to-date impairment loss of $115 million to adjust the net book value of this business to its fair value less costs to sell. The Company recorded the loss on classification of held for sale as a valuation allowance on the group of assets held for sale, without allocation to the individual assets or major classes of assets within the group. Due to the nature of estimates, the carrying value is subject to change based on developments leading up to the closing date, and the actual amounts realized upon sale may be more than or less than the estimated carrying value of the disposal group. Any difference will be recognized as a gain or loss in future financial statements.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

For the year ended December 31, 2025, the Company recognized total income tax benefits of approximately $27 million related to loss on assets classified as held for sale for the SCL disposal group.

***Carrying Amount of Assets and Liabilities Held for Sale***

The Company's Consolidated Balance Sheet as of December 31, 2025 included the carrying amounts of the assets and liabilities of the SCL disposal group as held for sale.

The Company's Consolidated Balance Sheet as of December 31, 2024 included the carrying amounts of the assets and liabilities of the Pharma Solutions disposal group, Nitrocellulose disposal group, and a portion of the Savory Solutions business in Turkey as held for sale. The Company completed the sale of a portion of the Savory Solutions business in Turkey during the three months ended March 31, 2025, and the sale of the Pharma Solutions disposal group and Nitrocellulose disposal group during the three months ended June 30, 2025.

Included in the Company's Consolidated Balance Sheets as of December 31, 2025 and December 31, 2024 are the following carrying amounts of the assets and liabilities held for sale:

---

| | | |
|:---|:---|:---|
| *<u>(DOLLARS IN MILLIONS)</u>* | **December 31, 2025** | **December 31, 2024** |
| **Assets** |  |  |
| Cash and cash equivalents | $— | $2 |
| Trade receivables, net | 25 | 187 |
| Inventories | 37 | 274 |
| Property, plant and equipment, net | 98 | 451 |
| Goodwill<sup>(1)</sup> |  | 1216 |
| Other intangible assets, net | 89 | 1078 |
| Operating lease right-of-use assets | 7 | 57 |
| Other assets | 10 | 108 |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: Loss recognized on assets held-for-sale<sup>(2)</sup> | (115) | (317) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total assets held-for-sale | $151 | $3056 |
| **Liabilities** |  |  |
| Accounts payable | $34 | $90 |
| Deferred tax liability |  | 51 |
| Other liabilities | 10 | 191 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total liabilities held-for-sale | $44 | $332 |

---

_______________________

<sup>(1)</sup> The Company determined that the carrying value of the Pharma Solutions disposal group exceeded its fair value and recorded an impairment charge of $64 million in the Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) for the year ended December 31, 2024. The goodwill balance in assets held for sale for the Pharma Solutions disposal group as of December 31, 2024, is presented net of $64 million of goodwill impairment.

<sup>(2)</sup> The balance as of December 31, 2024 includes the impact of $131 million, primarily related to losses on foreign currency translation, which was reclassified out of accumulated other comprehensive loss upon close of the sales.

**NOTE 5.&nbsp;&nbsp;&nbsp;&nbsp;RESTRUCTURING AND OTHER CHARGES**

Restructuring and other charges primarily consist of separation costs for employees including severance, outplacement and other employee benefit costs ("Severance"), charges related to the write-down of fixed assets of plants to be closed ("Fixed asset write-down") and all other related restructuring ("Other") costs. All restructuring and other charges are separately stated on the Consolidated Statements of Income (Loss) and Comprehensive Income (Loss).

**N&B Merger Restructuring Liability**

During 2024, the Company incurred approximately $2 million of charges related to a lease impairment and no charges related to severance. During 2023, the Company incurred approximately $2 million of lease termination costs and lease impairment charges. From the inception of the program in 2021 to its completion, there were a total of 215 headcount reductions and the Company expensed a total of $49 million, of which $35 million related to severance and $14 million related to lease termination, lease impairment, and other costs. As of December 31, 2024, the program was completed.

**2023 Restructuring Program**

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

In December 2022, the Company announced a restructuring program mainly related to headcount reduction to improve its organizational and operating structure, drive efficiencies and achieve cost savings. From the inception of the restructuring program, there were a total of 670 actual headcount reductions. During 2024 and 2023, the Company incurred approximately $4 million and $70 million of charges related to severance, respectively. As of December 31, 2024, the program was completed.

**IFF Productivity Program**

Beginning in 2024, the Company began undertaking a productivity enhancement program aimed at improving productivity and optimizing its organizational footprint to align with business needs. This program will involve a series of actions, including ceasing operations in select manufacturing plants, consolidating leased and owned real estate space, and reducing employee headcount. The Company aims to substantially complete this productivity program by December 31, 2026.

The estimated total cost of the program initiatives ranges from $110 million to $130 million. The anticipated cash charges include employee-related costs such as severance, contract terminations, and dismantling costs. Additionally, non-cash charges related to assets, such as fixed asset write downs, are expected.

Since the inception of the program, the Company has recognized $79 million in severance costs and $14 million in fixed asset write-downs and related expense. During 2025, the Company recognized $76 million in severance costs and $(6) million in fixed asset write-downs and site closure expenses, net of the gain on sale of fixed assets previously written down. During 2024, the Company incurred initial costs in connection with the program, recognizing $20 million in fixed asset write-downs and $3 million in severance costs.

**Changes in Restructuring Liability**

Changes in restructuring liabilities during 2023, 2024 and 2025 were as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| *<u>(DOLLARS IN MILLIONS)</u>* | **Balance at January 1, 2023** | **Additional Charges (Reversals), Net** | **Non-Cash Charges** | **Cash Payments** | **Balance at December 31, 2023** |
| <u>Frutarom Integration Initiative</u> |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Severance | $4 | $(3) | $— | $(1) | $— |
| <u>Other Restructuring Charges</u> |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Severance | 1 | (1) |  |  |  |
| <u>N&B Merger Restructuring Liability</u> |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Severance | 9 |  |  | (9) |  |
| &nbsp;&nbsp;Other<sup>(1)</sup> | 1 | 2 | (2) | (1) |  |
| <u>2023 Restructuring Program</u> |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Severance |  | 70 |  | (56) | 14 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Restructuring and other charges | $15 | $68 | $(2) | $(67) | $14 |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| *<u>(DOLLARS IN MILLIONS)</u>* | **Balance at January 1, 2024** | **Additional Charges (Reversals), Net** | **Non-Cash Charges** | **Cash Payments** | **Balance at December 31, 2024** |
| <u>N&B Merger Restructuring Liability</u> |  |  |  |  |  |
| &nbsp;&nbsp;Other<sup>(1)</sup> | $— | $2 | $(2) | $— | $— |
| <u>2023 Restructuring Program</u> |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Severance | 14 | 4 |  | (18) |  |
| <u>IFF Productivity Program</u> |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Severance |  | 3 |  |  | 3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Fixed asset write-downs |  | 20 | (20) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Restructuring and other charges | $14 | $29 | $(22) | $(18) | $3 |

---

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| *<u>(DOLLARS IN MILLIONS)</u>* | **Balance at January 1, 2025** | **Additional Charges (Reversals), Net** | **Non-Cash Charges** | **Cash Payments** | **Balance at December 31, 2025** |
| <u>IFF Productivity Program</u> |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Severance | $3 | $76 | $— | $(43) | $36 |
| &nbsp;&nbsp;&nbsp;&nbsp;Fixed asset write-downs & related expense<sup>(2)</sup> |  | (6) | 7 | (1) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Restructuring and other charges | $3 | $70 | $7 | $(44) | $36 |

---

_______________________

(1)Includes lease impairment charges and losses incurred from restructuring activities related to the merger with N&B.

(2)Represents additional fixed asset write-downs and site closure expenses, net of the gain on sale of fixed assets previously written down..

**Charges by Segment**

The following table summarizes the total amount of costs incurred in connection with these restructuring programs and activities by segment:

---

| | | | |
|:---|:---|:---|:---|
| | **December 31,** | **December 31,** | **December 31,** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **2025** | **2024** | **2023** |
| Taste | $20 | $11 | $14 |
| Food Ingredients | 10 | 15 | 23 |
| Health & Biosciences | 19 | 1 | 13 |
| Scent | 21 | 1 | 15 |
| Pharma Solutions |  | 1 | 3 |
| Total Restructuring and other charges | $70 | $29 | $68 |

---

**NOTE 6.&nbsp;&nbsp;&nbsp;&nbsp;STOCK COMPENSATION PLANS**

The Company has various equity plans under which its officers, senior management, other key employees and Board of Directors may be granted options to purchase IFF common stock or other forms of stock-based awards.

The cost of all employee stock-based awards is principally recognized on a straight-line attribution basis over their respective vesting periods, net of estimated forfeitures. Total stock-based compensation expense included in the Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) was as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **December 31,** | **December 31,** | **December 31,** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **2025** | **2024** | **2023** |
| Equity-based awards | $88 | $77 | $65 |
| Liability-based awards | 1 | 2 | 2 |
| &nbsp;&nbsp;&nbsp;Total stock-based compensation | 89 | 79 | 67 |
| Less: Tax benefit | (18) | (15) | (11) |
| &nbsp;&nbsp;&nbsp;Total stock-based compensation, net of tax | $71 | $64 | $56 |

---

The shareholders of the Company approved the Company's Amended and Restated 2021 Stock Award and Incentive Plan on May 1, 2024 (the "2021 A&R SAIP"). The shareholders of the Company approved the Company's 2021 Stock Award and Incentive Plan (the "2021 Plan") on May 5, 2021. The 2021 Plan replaced the Company's 2015 Stock Award and Incentive Plan (the "2015 Plan") and the Company's 2010 Stock Award and Incentive Plan (the "2010 Plan"), and provides the source for future deferrals of cash into deferred stock under the Company's Deferred Compensation Plan (with the Deferred Compensation Plan being deemed a subplan under the 2010 Plan for the sole purpose of funding deferrals under the IFF Share Fund).

Under the 2021 A&R SAIP, an additional 6,900,000 shares were authorized for issuance, bringing the total number of shares authorized for issuance to 9,190,000. Under the 2021 Plan, a total of 2,290,000 shares were authorized for issuance. As of December 31, 2025, 2,275,605 shares were subject to outstanding awards and 5,627,390 shares remained available for future awards under all of the Company's equity award plans (excluding shares not yet issued under open cycles of the Company's Long-Term Incentive Plan).

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

The Company offers a Long-Term Incentive Plan ("LTIP") for senior management. Beginning 2023, the targeted payout for all new cycles is 100% IFF common stock at the end of the three-year cycle.

For the 2023-2025 cycle, the LTIP awards are earned based on the achievement of: (i) 3-year cumulative Return on Invested Capital ("ROIC") (representing one-half of the award value) and (ii) Relative Total Shareholder Return ("TSR") targets (representing one-half of the award value).

The ROIC measures adjusted net operating profit after tax against average invested capital. When the award is granted, 50% of the target dollar value of the award is converted to a number of "notional" shares based on the closing price at the beginning of the cycle. For those shares whose payout is based on Relative TSR, compensation expense is recognized using a graded-vesting attribution method, while compensation expense for the remainder of the performance shares (ROIC targets for the applicable cycle) is recognized on a straight-line basis over the vesting period based on the probable outcome of the performance condition.

For the 2024-2026 cycle, the LTIP awards are earned based on the achievement of: (i) the Company's stock price appreciation based on the average of the highest 20 consecutive trading days over the 3-year cumulative period ("Stock Price Appreciation") (representing 40% of the award value) (ii) Measurable savings related to organizational optimization programs & productivity programs ("Productivity Savings") (representing 40% of the award value), and (iii) overall annual employee engagement survey results ("Employee Engagement") (representing 20% of the award value). In addition, at the conclusion of the 3-year cycle, the final payout will be adjusted in accordance with a Performance Modifier based on the Company's Relative TSR. If the Company's Relative TSR for the 3-year cumulative period is at or above the 75th percentile or at or below the 25th percentile of the S&P 500 companies, the number of shares earned according to the performance metrics will be multiplied by 1.2x or 0.75x, respectively, for a maximum potential payout of 200% of target shares. If the Company's relative TSR is between the 25th and 75th percentiles of the S&P 500 Companies, the Performance Modifier shall be determined on a straight-line interpolation basis.

For the 2024-2026 cycle, when the award is granted, the target dollar value of the award is converted to a number of "notional" shares based on the 20-day trailing average closing price at the beginning of the cycle. For those shares whose payout is based on a performance metric (Productivity Savings and Employee Engagement targets), compensation expense is recognized on a straight-line basis over the vesting period based on the probable outcome of the performance condition. For those shares whose payout is based on Stock Price Appreciation, compensation expense is recognized using a graded-vesting attribution method.

For the 2025–2027 Performance Cycle, LTIP awards are earned based on the achievement of the following performance metrics: (i) Adjusted EBITDA Margin, which measures basis-point improvement versus the comparable 2024 year-end adjusted operating EBITDA margin as of December 31, 2027 (representing 40% of the award value); (ii) Relative Total Shareholder Return ("Relative TSR"), measured against the S&P 500 Chemicals companies over the Performance Cycle, calculated using (1) the average closing stock price over the 20 consecutive trading days preceding January 1, 2025 and (2) the average closing stock price over the 20 consecutive trading days preceding December 31, 2027 (representing 40% of the award value); and (iii) Employee Engagement, which reflects the average employee engagement survey results over the three-year period (representing 20% of the award value).

For the 2025–2027 cycle, when the award is granted, the target dollar value of the LTIP award is converted into a number of "notional" shares based on the closing price on the day of the grant. The valuation of the long-term incentive plan awards was determined using a Monte Carlo valuation approach. For those shares whose payout is tied to the achievement of performance metrics (Adjusted EBITDA Margin and Employee Engagement), compensation expense is recognized on a straight-line basis over the vesting period based on the probable outcome of each performance condition. For those shares whose payout is based on Relative Total Shareholder Return, compensation expense is recognized using a graded-vesting attribution method.

The 2021-2023 cycle concluded at the end of 2023 and 5,333 shares of common stock were issued in March 2024. The 2022-2024 cycle concluded at the end of 2024 and no shares of common stock were issued in March 2025. The 2023-2025 cycle concluded at the end of 2025 and no shares of common stock will be issued in March 2026.

**SSARs and Options**

Stock-Settled Appreciation Rights ("SSARs") are a contractual right to receive the value, in shares of Company stock, of the appreciation in our stock price from the grant date to the date the SSARs are exercised by the participant. SSARs granted become exercisable on the third anniversary of the grant date and have a maximum term of seven years. SSARs do not require a financial investment by the SSARs grantee. Stock options require the participant to pay the exercise price at the time they exercise their stock options. No SSARs or stock options were granted in 2025, 2024 or 2023.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

SSARs and options activity was as follows:

---

| | | | |
|:---|:---|:---|:---|
| *<u>(SHARE AMOUNTS IN THOUSANDS)</u>* | **Shares Subject to<br>SSARs/Options** | **Weighted<br>Average Exercise<br>Price** | **SSARs/<br>Options<br>Exercisable** |
| December 31, 2024 | 288 | $116.45 | 197 |
| &nbsp;&nbsp;&nbsp;&nbsp;Granted |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Exercised |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Canceled | (11) | 131.30 |  |
| December 31, 2025 | 277 | $115.87 | 277 |
| Expected to Vest at December 31, 2025 |  | $— |  |

---

The weighted average exercise price of SSARs and options exercisable at December 31, 2025, 2024 and 2023 were $115.87, $111.70 and $109.59, respectively.

All outstanding SSARs and options are exercisable. SSARs and options outstanding and exercisable at December 31, 2025 was as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **<u>Price Range</u>** | **Number<br>Outstanding and Exercisable<br>(in thousands)** | **Weighted Average<br>Remaining<br>Contractual Life<br>(in years)** | **Weighted<br>Average<br>Exercise Price** | **Aggregate<br>Intrinsic Value<br>(in millions)** |
| Over $65 | 277 | 2.78 | $115.87 | $— |

---

The total intrinsic value of options/SSARs exercised was $0 in 2025 and was less than $1 million in each of 2024 and 2023.

**Restricted Stock Units**

The Company has granted Restricted Stock Units ("RSUs") to eligible employees and members of the Board of Directors. The Company has granted both time-based RSUs, which contain no performance criteria provisions, and performance-based RSUs. Such RSUs are subject to forfeitures or adjustments if certain conditions are not met, including service period or pre-established cumulative performance targets. RSUs principally vest 100% at the end of three years. An RSU's fair value is calculated based on the market price of the Company's stock at date of grant, with an adjustment to reflect the fact that such awards do not participate in dividend rights. The aggregate fair value is amortized to expense ratably over the vesting period.

RSU activity was as follows:

---

| | | |
|:---|:---|:---|
| *<u>(SHARE AMOUNTS IN THOUSANDS)</u>* | **Number of Shares** | **Weighted Average<br>Grant Date Fair<br>Value Per Share** |
| December 31, 2024 | 1785 | $87.75 |
| &nbsp;&nbsp;&nbsp;&nbsp;Granted | 1021 | 73.84 |
| &nbsp;&nbsp;&nbsp;&nbsp;Vested | (868) | 94.34 |
| &nbsp;&nbsp;&nbsp;&nbsp;Forfeited | (137) | 80.08 |
| &nbsp;&nbsp;&nbsp;&nbsp;Change due to performance conditions, net | (4) | 125.82 |
| December 31, 2025 | 1797 | $77.36 |

---

The total fair value of RSUs that vested during the year ended December 31, 2025 was approximately $82 million.

As of December 31, 2025, there was approximately $71 million of total unrecognized compensation cost related to non-vested RSUs granted under the equity incentive plans; such cost is expected to be recognized over a weighted average period of approximately 1.79 years.

**Liability Awards**

The Company has granted cash-settled RSUs ("Cash RSUs") to eligible employees that are paid out 100% in cash upon vesting. Such RSUs are subject to forfeiture if certain conditions are not met. Cash RSUs principally vest 100% at the end of three years and contain no performance criteria provisions. A Cash RSU's fair value is calculated based on the market price of the Company's stock at the date of the closing period and is accounted for as a liability award. The aggregate fair value is amortized to expense ratably over the vesting period.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

Cash RSU activity was as follows:

---

| | | |
|:---|:---|:---|
| *<u>(SHARE AMOUNTS IN THOUSANDS)</u>* | **Cash RSUs** | **Weighted Average <br>Fair<br>Value Per Share** |
| December 31, 2024 | 57 | $84.55 |
| &nbsp;&nbsp;&nbsp;&nbsp;Granted | 34 | 67.39 |
| &nbsp;&nbsp;&nbsp;&nbsp;Vested | (45) | 76.95 |
| &nbsp;&nbsp;&nbsp;&nbsp;Forfeited | (1) | 67.56 |
| December 31, 2025 | 45 | $67.39 |

---

The total fair value of Cash RSUs that vested during the year ended December 31, 2025 was approximately $3 million.

As of December 31, 2025, there was approximately $1 million of total unrecognized compensation cost related to non-vested Cash RSUs granted under the equity incentive plans; such cost is expected to be recognized over a weighted average period of approximately 2.07 years. The aggregate compensation cost will be adjusted based on changes in the Company's stock price.

**NOTE 7.&nbsp;&nbsp;&nbsp;&nbsp;SEGMENT INFORMATION**

Effective January 1, 2025, the Company implemented a reorganization of its internal structure, which impacted the way the CODM, the Chief Executive Officer, allocates resources and assesses financial performance. As a result, the Company updated its reportable segments beginning with the first quarter of 2025.

Specifically, the former Nourish segment has been separated into two new reportable segments: Taste and Food Ingredients. The Taste segment (formerly the Flavors business within Nourish) includes flavor compounds and natural taste solutions used in food and beverage applications. The Food Ingredients segment (formerly the Ingredients business within Nourish) includes a broad portfolio of natural and plant-based specialty ingredients that provide texturizing and food protection capabilities, as well as soy and pea protein solutions, emulsifiers, and sweeteners.

In addition, immaterial business transfers occurred between Food Ingredients and Pharma Solutions, and between Health & Biosciences and Taste. Accordingly, the Company's reportable segments as of January 1, 2025 are: Taste, Food Ingredients, Health & Biosciences, Scent, and Pharma Solutions.

The Company also adjusted its corporate cost allocations to align with the new organizational structure and updated operating model, consistent with how management assesses performance effective January 1, 2025.

Segment information for the year ended December 31, 2024 and 2023 has been recast to reflect the updated segment structure and changes in corporate allocations among the Company's reportable segments on a comparable basis.

Taste is comprised of a range of flavor compounds and natural taste solutions that are ultimately used by IFF's customers in a diverse variety of products, including savory products (soups, sauces, meat, fish, poultry, snacks, etc.), beverages (juice drinks, carbonated or flavored beverages, spirits, etc.), sweets (bakery products, candy, cereal, chewing gum, etc.), and dairy products (yogurt, ice cream, cheese, etc.). Taste also include value-added spices and seasoning ingredients for meat, food service, convenience, alternative protein and culinary products.

Food Ingredients is comprised of a diversified portfolio across natural, artificial, and plant-based specialty food ingredients that provide functional properties solutions for food and beverage products, as well as specialty soy and pea protein with value-added formulations, emulsifiers and sweeteners. Natural food protection ingredients consist of natural antioxidants and anti-microbials used for natural food preservation and shelf-life extension for beverages, cosmetic and healthcare products, pet food and feed additives. Food Ingredients also includes savory solutions (such as spices, marinades, mixtures) and inclusion products (such as products combining flavorings with fruit, vegetables and other natural ingredients).

Health & Biosciences is comprised of Health, Food Biosciences, Home & Personal Care, Animal Nutrition and Grain Processing, with a biotechnology-derived portfolio of enzymes, food cultures, probiotics and specialty ingredients for non-food applications. Health provides ingredients for dietary supplements, food and beverage, specialized nutrition and pharma. Food Biosciences provides products that aim to serve the global demand for healthy, natural, clean label and fermented food for fresh dairy, cheese, bakery and brewing products. Such products contribute to extended shelf life, stability, taste, and texture, helping IFF's customers to improve their product offerings. The business's enzyme solutions also allow IFF's customers to provide low sugar, high fiber and lactose-free dairy products. Home & Personal Care produces enzymes for detergents, cleaning and textiles to help enhance the product and process performance of products in the fabric and home care, textiles and industrials and personal care markets. The business also produces patented enzymatic polymers that are renewable, biodegradable alternatives to functional ingredients used in home cleaning and beauty care products. Animal Nutrition produces feed enzymes and animal

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

health solutions that help to improve nutrition, welfare, performance and sustainability of livestock animal farming. Grain Processing produces yeast and enzymes for biofuel production and carbohydrate processing.

Scent is comprised of (1) Fragrance Compounds, which are ultimately used by IFF's customers in two broad categories: Fine Fragrances, including perfumes and colognes, and Consumer Fragrances, including fragrance compounds for personal care (e.g., soaps), household products (e.g., detergents and cleaning agents) and beauty care, including toiletries; and (2) Fragrance Ingredients, which consists of natural and synthetic, and active and functional ingredients that are used internally and sold to third parties, including competitors, for use in the preparation of compounds. While the principal role of IFF's fragrance ingredients facilities is to support the fragrance compounds business, the Company utilizes excess manufacturing capacity to manufacture and sell certain fragrance ingredients to third parties, enabling the Company to leverage fixed costs while maintaining the security of supply for perfumers and ultimately IFF's customers.

The former Pharma Solutions segment produced, among other things, a vast portfolio of cellulosics and seaweed-based pharmaceutical excipients, used in prescription and over-the-counter pharmaceuticals and dietary supplements. IFF completed the divestiture of the Pharma Solutions disposal group, which included certain adjacent businesses, on May 1, 2025 and divested the nitrocellulose business, which was within the Pharma Solutions segment, on May 9, 2025.

The Company's CODM evaluates the performance of these reportable segments based on its Adjusted Operating EBITDA, which is defined as (Loss) Income Before Taxes before depreciation and amortization expense, interest expense, restructuring and other charges and certain items that are not related to recurring operations.

The Company's CODM uses Adjusted Operating EBITDA to evaluate segment performance in deciding whether to reinvest resources into the respective segment or into other parts of the entity. Budget versus actual results of Adjusted Operating EBITDA is used in assessing performance of the segment and in establishing certain compensation payouts. The Company's CODM also uses Adjusted Operating EBITDA in competitive analysis by benchmarking to the Company's competitors.

The Company's CODM does not use assets by segment to evaluate segment performance or allocate resources and thus, total assets by segment are not disclosed.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

The following tables show the Company's reportable segment information for the years ended December 31, 2025, 2024 and 2023:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** |
| | **Taste** | **Food Ingredients** | **H&B** | **Scent** | **Pharma** | **Total** |
| Net sales | $2481 | $3278 | $2283 | $2479 | $369 | $10890 |
| Cost of sales | (1500) | (2531) | (1246) | (1424) | (248) |  |
| Research & development expenses | (172) | (54) | (219) | (241) | (8) |  |
| Selling & administrative expenses | (396) | (400) | (348) | (366) | (42) |  |
| Depreciation expense add-back (a) | 65 | 130 | 124 | 67 | 5 |  |
| **Adjusted Operating EBITDA** | $478 | $423 | $594 | $515 | $76 | $2086 |

---

---

| | |
|:---|:---|
| **Reconciliation of Adjusted Operating EBITDA:** | |
| Total Adjusted Operating EBITDA | $2086 |
| Depreciation & Amortization | (962) |
| Interest Expense | (229) |
| Other (Expense), net (b) | (65) |
| Restructuring and Other Charges (c) | (70) |
| Impairment of Goodwill (d) | (1153) |
| (Losses) on Business Disposals (e) | (109) |
| Loss on Assets Classified as Held for Sale (f) | (115) |
| Gain on Extinguishment of Debt (g) | 488 |
| Acquisition, Divestiture and Integration Related Costs (h) | (125) |
| Strategic Initiatives Costs (i) | (35) |
| Regulatory Costs (j) | (106) |
| Entity Realignment Costs (k) | (8) |
| Other (l) | (9) |
| (Loss) Before Taxes | $(412) |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** |
| | **Taste** | **Food Ingredients** | **H&B** | **Scent** | **Pharma** | **Total** |
| Net sales | $2428 | $3365 | $2203 | $2439 | $1049 | $11484 |
| Cost of sales | (1470) | (2626) | (1183) | (1361) | (719) |  |
| Research & development expenses | (160) | (71) | (190) | (225) | (25) |  |
| Selling & administrative expenses | (403) | (391) | (368) | (376) | (115) |  |
| Depreciation expense add-back (a) | 65 | 131 | 115 | 68 | 25 |  |
| **Adjusted Operating EBITDA** | $460 | $408 | $577 | $545 | $215 | $2205 |

---

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

---

| | |
|:---|:---|
| **Reconciliation of Adjusted Operating EBITDA:** | |
| Total Adjusted Operating EBITDA | $2205 |
| Depreciation & Amortization | (1015) |
| Interest Expense | (305) |
| Other (Expense), net (b) | (182) |
| Restructuring and Other Charges (c) | (29) |
| Impairment of Goodwill (d) | (64) |
| Gains on Business Disposals (e) | 346 |
| Loss on Assets Classified as Held for Sale (f) | (317) |
| Acquisition, Divestiture and Integration Related Costs (h) | (228) |
| Strategic Initiatives Costs (i) | (33) |
| Regulatory Costs (j) | (73) |
| Entity Realignment Costs (k) | (6) |
| Other (l) | 9 |
| Income Before Taxes | $308 |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **December 31, 2023** | **December 31, 2023** | **December 31, 2023** | **December 31, 2023** | **December 31, 2023** | **December 31, 2023** |
| | **Taste** | **Food Ingredients** | **H&B** | **Scent** | **Pharma** | **Total** |
| Net sales | $2303 | $3692 | $2071 | $2393 | $1020 | $11479 |
| Cost of sales | (1449) | (3028) | (1168) | (1401) | (752) |  |
| Research & development expenses | (154) | (70) | (172) | (213) | (26) |  |
| Selling & administrative expenses | (379) | (385) | (320) | (343) | (99) |  |
| Depreciation expense add-back (a) | 68 | 160 | 113 | 60 | 59 |  |
| **Adjusted Operating EBITDA** | $389 | $369 | $524 | $496 | $202 | $1980 |

---

---

| | |
|:---|:---|
| **Reconciliation of Adjusted Operating EBITDA:** | |
| Total Adjusted Operating EBITDA | $1980 |
| Depreciation & Amortization | (1142) |
| Interest Expense | (380) |
| Other (Expense), net (b) | (5) |
| Restructuring and Other Charges (c) | (68) |
| Impairment of Goodwill (d) | (2623) |
| (Losses) on Business Disposals (e) | (23) |
| Acquisition, Divestiture and Integration Related Costs (h) | (174) |
| Strategic Initiatives Costs (i) | (31) |
| Regulatory Costs (j) | (50) |
| Entity Realignment Costs (k) | (2) |
| (Loss) Before Taxes | $(2518) |

---

&nbsp;&nbsp;&nbsp;&nbsp;

_______________________

(a) There is depreciation recorded within Cost of sales, Research & development, and Selling & administrative expenses, so there is an add-back of depreciation to calculate segment Adjusted Operating EBITDA. This reflects how the CODM reviews Segment results.

(b) For 2024, the amount includes a settlement loss of $130 million that was recognized as a result of the termination of the International Flavors & Fragrances Inc. Pension Plan. During 2025, a reduction of the previous settlement loss was recognized. See Note 8 for additional information on the net settlement loss and Note 9 for additional information on Other expense, net.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

(c) For 2025, represents costs related to the IFF Productivity Program including severance, fixed asset write-downs and site closure expenses, net of the gain on sale of fixed assets previously written down. For 2024, represents initial costs in connection with the IFF Productivity Program, primarily related to fixed asset write-downs. For 2023, represents costs primarily related to severance as part of the Company's 2023 Restructuring Program.

(d) For 2025, represents the impairment of goodwill related to the Food Ingredients reporting unit. For 2024, represents the impairment of goodwill related to the Pharma Solutions disposal group. For 2023, represents the impairment of goodwill in the Nourish reporting unit.

(e) For 2025, primarily represents losses recognized as part of the sale of the Pharma Solutions disposal group, offset in part by gains recognized as part of the sale of the Nitrocellulose business and sale of the Rene Laurent business in France. For 2024, primarily represents gains recognized as part of the sale of the Cosmetic Ingredients business and losses recognized as part of the sale of the F&E UK business. For 2023, primarily represents losses recognized as part of the sale of the Flavors Specialty Ingredients business, the sale of a portion of the Savory Solutions business, and liquidation of a business in Russia for the sale of the portion of the Savory Solutions business.

(f) For 2025, represents the loss recognized on assets classified as held for sale of the Soy Crush, Concentrates & Lecithin business. For 2024, represents the losses recognized on assets classified as held for sale of the Pharma Solutions disposal group and portion of the Savory Solutions business in Turkey.

(g) For 2025, represents the gain recognized on extinguishment of debt in connection with the completion of tender offers.

(h) For 2025, 2024 and 2023, primarily represents costs related to the Company's actual and planned acquisitions, divestitures and integration related activities primarily for N&B. These costs primarily consisted of external consulting fees, professional and legal fees and salaries of individuals who are fully dedicated to such efforts. For 2023, acquisition costs primarily relate to earn-out adjustments. For 2025, business divestiture costs were approximately $125 million. For 2024, business divestiture and integration costs were approximately $223 million and $5 million, respectively. For 2023, business divestiture, integration and acquisition related costs were approximately $108 million, $59 million, and $7 million, respectively.

(i) Represents costs related to the Company's strategic assessment and business portfolio optimization efforts and reorganizing the Global Shared Services Centers, primarily consulting fees, and strategic initiatives related to the Company's business unit re-organization efforts.

(j) Represents costs primarily related to legal fees incurred and provisions recognized for the ongoing investigations of the fragrance businesses.

(k) Represents costs related to a phased restructuring initiative aimed at optimizing its legal entity framework.

(l) For 2025, primarily represents the net impact of costs related to severance, including accelerated stock compensation expense, for certain executives who have separated from the Company. For 2025, also represents the impact of legislation changes in India related to the Wage Code. For 2024, primarily relates to gains on sales of assets.

Long-lived assets, net, by geographic area, consisted as follows:

---

| | | |
|:---|:---|:---|
| | **December 31,** | **December 31,** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **2025** | **2024**<sup>(1)</sup> |
| United States | $1620 | $1610 |
| Foreign Countries | 2409 | 2129 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consolidated | $4029 | $3739 |

---

_______________________

(1)The Long-lived assets, net for both the United States and Foreign Countries as of December 31, 2024 were revised from $1.326 billion to $1.610 billion and from $2.413 billion to $2.129 billion, respectively, to correct for certain assets incorrectly allocated by geographic area. These revisions did not impact the total Long-lived assets, net.

Segment capital expenditures consisted as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **Capital Expenditures** | **Capital Expenditures** | **Capital Expenditures** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **2025** | **2024** | **2023** |
| Taste | $99 | $69 | $75 |
| Food Ingredients | 223 | 166 | 177 |
| Health & Biosciences | 145 | 73 | 85 |
| Scent | 89 | 70 | 62 |
| Pharma Solutions | 38 | 85 | 104 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consolidated | $594 | $463 | $503 |

---

Net sales are attributed to individual regions based upon the destination of product delivery and are as follows:

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

---

| | | | |
|:---|:---|:---|:---|
| | **Net Sales by Geographic Area** | **Net Sales by Geographic Area** | **Net Sales by Geographic Area** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **2025** | **2024** | **2023** |
| Europe, Africa and Middle East | $3727 | $3840 | $3834 |
| Greater Asia | 2546 | 2731 | 2677 |
| North America | 3195 | 3440 | 3477 |
| Latin America | 1422 | 1473 | 1491 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consolidated | $10890 | $11484 | $11479 |

---

---

| | | | |
|:---|:---|:---|:---|
| | **Net Sales by Geographic Area** | **Net Sales by Geographic Area** | **Net Sales by Geographic Area** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **2025** | **2024** | **2023** |
| Net sales related to the U.S. | $3075 | $3219 | $3185 |
| Net sales attributed to all foreign countries | 7815 | 8265 | 8294 |

---

The Company had no customers that accounted for greater than 10% of consolidated net sales in 2025, 2024 and 2023.

No country other than the U.S. had net sales greater than 10% of total consolidated net sales for 2025, 2024 and 2023.

**NOTE 8.&nbsp;&nbsp;&nbsp;&nbsp;EMPLOYEE BENEFITS**

The Company has pension and/or other retirement benefit plans covering approximately 20% of active employees. In 2007, the Company amended its U.S. qualified and non-qualified pension plans under which accrual of future benefits was suspended for all participants that did not meet the rule of 70 (age plus years of service equal to at least 70 as of December 31, 2007). Pension benefits are generally based on years of service and compensation during the final years of employment. Plan assets consist primarily of equity securities and corporate and government fixed income securities. Substantially all pension benefit costs are funded as accrued; such funding is limited, where applicable, to amounts deductible for income tax purposes. Certain other retirement benefits are provided by general corporate assets.

The Company sponsors a qualified defined contribution plan covering substantially all U.S. employees. Under this plan, effective January 1, 2023, the Company matches 100% of the first 6% of participants' contributions.

In addition to pension benefits, certain health care and life insurance benefits are provided to qualifying U.S. employees upon retirement from IFF. Such coverage is provided through insurance plans with premiums based on benefits paid. The Company does not generally provide health care or life insurance coverage for retired employees of foreign subsidiaries; such benefits are provided in most foreign countries by government-sponsored plans, and the cost of these programs is not material.

The Company offers a non-qualified Deferred Compensation Plan ("DCP") for certain key employees and non-employee directors. Eligible employees and non-employee directors may elect to defer receipt of salary, incentive payments and Board of Directors' fees into participant-directed investments which are generally invested by the Company in individual variable life insurance contracts it owns that are designed to informally fund savings plans of this nature. The cash surrender value of life insurance is based on the net asset values of the underlying funds available to plan participants. At December 31, 2025 and December 31, 2024, the Consolidated Balance Sheets reflect liabilities of approximately $63 million and $57 million, respectively, related to the DCP in Other liabilities and approximately $9 million and $15 million, respectively, included in Capital in excess of par value related to the portion of the DCP that will be paid out in IFF shares.

The total cash surrender value of life insurance contracts the Company owns in relation to the DCP and post-retirement life insurance benefits amounted to $57 million and $52 million at December 31, 2025 and 2024, respectively, and are recorded in Other assets in the Consolidated Balance Sheets.

**International Flavors & Fragrances Inc. Pension Plan Termination**

On August 18, 2023, the Human Capital and Compensation Committee approved the termination of the International Flavors & Fragrances Inc. Pension Plan (the "Plan"). The Plan was formally terminated on April 1, 2024. The settlements of the terminated plan primarily occurred during November 2024, in which lump sum settlements in the amount of approximately $73 million were paid to eligible plan participants who elected such payments, and the purchase of annuity contracts in the amount of approximately $360 million were made to the remaining participants.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

Upon settlement of the terminated plan, a settlement loss of $130 million was recognized and is presented in Other expense, net on the Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) for the twelve months ended December 31, 2024. The settlement loss primarily relates to the recognition of actuarial losses upon termination of the Plan. During 2025, a final true-up of the settlement was performed and the Company recognized a reduction of the previously recognized settlement loss of approximately $6 million, which is presented in Other expense, net on the Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) for the twelve months ended December 31, 2025. The total life to date tax benefit recognized upon termination of the Plan was $45 million, with $46 million recognized in 2024.

Upon completion of the Plan termination and settlement processes, the Company had a remaining pension surplus balance of $42 million as of December 31, 2025. In 2025, the pension surplus was transferred to the Company's defined contribution plan trust covering substantially all U.S. employees. The majority of the surplus is presented in Other assets on the Consolidated Balance Sheets at December 31, 2025. Approximately $6 million of this balance, which was paid to U.S. employees in 2026, is presented in Prepaid expenses and other current assets on the Consolidated Balance Sheets at December 31, 2025.

**Defined Benefit Pension Plans**

The plan assets and benefit obligations of the defined benefit pension plans are measured at December 31 of each year.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **U.S. Plans** | **U.S. Plans** | **U.S. Plans** | **Non-U.S. Plans** | **Non-U.S. Plans** | **Non-U.S. Plans** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **2025** | **2024** | **2023** | **2025** | **2024** | **2023** |
| **Components of net periodic benefit cost** |  |  |  |  |  |  |
| &nbsp;&nbsp;Service cost for benefits earned<sup>(1)</sup> | $— | $— | $— | $20 | $23 | $21 |
| &nbsp;&nbsp;Interest cost on projected benefit obligation<sup>(2)</sup> | 3 | 23 | 25 | 35 | 36 | 36 |
| &nbsp;&nbsp;Expected return on plan assets<sup>(2)</sup> |  | (23) | (31) | (48) | (50) | (47) |
| &nbsp;&nbsp;Net amortization of deferrals<sup>(2)</sup> | 1 | 4 | 2 | 6 | 7 | (1) |
| &nbsp;&nbsp;Settlements and curtailments<sup>(2)</sup> |  | 130 |  |  | (1) | (8) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net periodic benefit (income) cost | 4 | 134 | (4) | 13 | 15 | 1 |
| &nbsp;&nbsp;&nbsp;Defined contribution and other retirement plans | 31 | 31 | 30 | 49 | 46 | 51 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total expense | $35 | $165 | $26 | $62 | $61 | $52 |
| **Changes in plan assets and benefit obligations recognized in OCI** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net actuarial loss (gain) | $4 | $(2) |  | $11 | $(59) |  |
| &nbsp;&nbsp;&nbsp;Recognized actuarial (loss) gain | (1) | (135) |  | (6) | (6) |  |
| &nbsp;&nbsp;&nbsp;Business Divestitures |  |  |  | 71 |  |  |
| &nbsp;&nbsp;&nbsp;Recognized prior service credit |  |  |  | 1 |  |  |
| &nbsp;&nbsp;&nbsp;Currency translation adjustment |  |  |  | 9 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total loss (gain) recognized in OCI (before tax effects) | $3 | $(137) |  | $86 | $(65) |  |

---

_______________________

(1)Included as a component of Operating (loss) profit.

(2)Included as a component of Other expense, net.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

---

| | | | |
|:---|:---|:---|:---|
| | **Postretirement Benefits** | **Postretirement Benefits** | **Postretirement Benefits** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **2025** | **2024** | **2023** |
| **Components of net periodic benefit cost** |  |  |  |
| &nbsp;&nbsp;&nbsp;Interest cost on projected benefit obligation | $3 | $3 | $3 |
| &nbsp;&nbsp;&nbsp;Net amortization and deferrals | (2) | (2) | (6) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total cost (income) | $1 | $1 | $(3) |
| **Changes in plan assets and benefit obligations recognized in OCI** |  |  |  |
| &nbsp;&nbsp;&nbsp;Net actuarial loss | $— | $4 |  |
| &nbsp;&nbsp;&nbsp;Recognized actuarial loss |  | (1) |  |
| &nbsp;&nbsp;&nbsp;Recognized prior service credit | 1 | 2 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total recognized in OCI (before tax effects) | $1 | $5 |  |

---

The weighted-average actuarial assumptions used to determine expense at December 31 of each year are:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **U.S. Plans** | **U.S. Plans** | **U.S. Plans** | **Non-U.S. Plans** | **Non-U.S. Plans** | **Non-U.S. Plans** |
| | **2025** | **2024** | **2023** | **2025** | **2024** | **2023** |
| Discount rate | 5.52% | 4.47% | 5.42% | 4.02% | 3.60% | 3.98% |
| Expected return on plan assets | 5.20% | 4.93% | 6.00% | 4.87% | 4.95% | 4.92% |
| Rate of compensation increase | N/A | 3.75% | 3.75% | 3.14% | 3.06% | 3.01% |

---

Changes in the postretirement benefit obligation and plan assets, as applicable, are detailed in the following table:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **U.S. Plans** | **U.S. Plans** | **Non-U.S. Plans** | **Non-U.S. Plans** | **Postretirement Benefits** | **Postretirement Benefits** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **2025** | **2024** | **2025** | **2024** | **2025** | **2024** |
| Benefit obligation at beginning of year | $55 | $524 | $852 | $1056 | $56 | $52 |
| Service cost for benefits earned |  |  | 20 | 23 |  |  |
| Interest cost on projected benefit obligation | 3 | 23 | 35 | 36 | 3 | 3 |
| Actuarial loss (gain) | 4 | (14) | (30) | (75) |  | 4 |
| Adjustments for expense/tax contained in service cost |  |  | (3) | (3) |  |  |
| Plan participants' contributions |  |  | 4 | 4 |  |  |
| Benefits paid | (6) | (40) | (37) | (35) | (2) | (4) |
| Curtailments/settlements |  | (439) | (3) | (13) |  |  |
| Translation adjustments |  |  | 105 | (51) |  |  |
| Transferred to Liabilities held for sale |  |  | (11) | (89) |  |  |
| Other | (1) | 1 | 6 | (1) |  | 1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Benefit obligation at end of year | $55 | $55 | $938 | $852 | $57 | $56 |
| Fair value of plan assets at beginning of year | $9 | $505 | $920 | $1000 |  |  |
| Actual return on plan assets | 1 | 13 | 3 | 30 |  |  |
| Employer contributions | 5 | 6 | 24 | 23 |  |  |
| Plan participants' contributions |  |  | 4 | 4 |  |  |
| Benefits paid | (6) | (40) | (37) | (35) |  |  |
| Settlements |  | (439) | (3) | (13) |  |  |
| Translation adjustments |  |  | 112 | (51) |  |  |
| Transferred to Assets held for sale |  |  | (4) | (39) |  |  |
| Other<sup>(1)</sup> |  | (36) |  | 1 |  |  |
| &nbsp;&nbsp;&nbsp;Fair value of plan assets at end of year | $9 | $9 | $1019 | $920 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Funded status at end of year | $(46) | $(46) | $81 | $68 |  |  |

---

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

_______________________

(1)2024 amount represents remaining pension surplus balance as a result of the Plan termination, that is presented in Other assets on the Consolidated Balance Sheets at December 31, 2024. As of December 31, 2025, the pension surplus balance has increased to $42 million.

The Company maintains defined benefit pension plans for certain employees in the United Kingdom (U.K.). In July 2024, the U.K. Court of Appeal upheld a ruling in the matter of Virgin Media Limited v NTL Pension Trustees II Limited, a decision that the Company was not a party to or involved in, that certain historical amendments for contracted out defined benefit schemes were invalid if they were not accompanied by the correct actuarial confirmation. In 2025, the U.K. Government has announced proposals to legislate in response to this case. The Company and its pension scheme trustees in the U.K. will continue to review this development and consider whether this decision has any implications for its U.K. defined benefit schemes.

The plan assets and benefit obligations of the defined benefit pension plans and postretirement benefits recognized in the balance sheet are detailed in the following table:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **U.S. Plans** | **U.S. Plans** | **Non-U.S. Plans** | **Non-U.S. Plans** | **Postretirement Benefits** | **Postretirement Benefits** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **2025** | **2024** | **2025** | **2024** | **2025** | **2024** |
| &nbsp;&nbsp;&nbsp;Other assets | $— | $1 | $177 | $143 | $— | $— |
| &nbsp;&nbsp;&nbsp;Other current liabilities | (5) | (5) | (4) | (3) | (4) | (4) |
| &nbsp;&nbsp;&nbsp;Retirement liabilities | (41) | (42) | (92) | (72) | (53) | (52) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net amount recognized | $(46) | $(46) | $81 | $68 | $(57) | $(56) |

---

The amounts recognized in AOCI are detailed in the following table:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **U.S. Plans** | **U.S. Plans** | **Non-U.S. Plans** | **Non-U.S. Plans** | **Postretirement Benefits** | **Postretirement Benefits** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **2025** | **2024** | **2025** | **2024** | **2025** | **2024** |
| &nbsp;&nbsp;&nbsp;Net actuarial loss | $20 | $18 | $203 | $134 | $3 | $4 |
| &nbsp;&nbsp;&nbsp;Prior service credit |  |  |  | (1) |  | (2) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total AOCI (before tax effects) | $20 | $18 | $203 | $133 | $3 | $2 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **U.S. Plans** | **U.S. Plans** | **Non-U.S. Plans** | **Non-U.S. Plans** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **2025** | **2024** | **2025** | **2024** |
| Accumulated Benefit Obligation — end of year | $55 | $54 | $876 | $800 |
| Information for Pension Plans with an Accumulated Benefit Obligation ("ABO") in excess of Plan Assets: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Accumulated benefit obligation | $55 | $45 | $99 | $83 |
| &nbsp;&nbsp;&nbsp;Fair value of plan assets | 9 |  | 37 | 32 |
| Information for Pension Plans with a Projected Benefit Obligation ("PBO") in excess of Plan Assets: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Projected benefit obligation | $55 | $45 | $119 | $99 |
| &nbsp;&nbsp;&nbsp;Fair value of plan assets | 9 |  | 37 | 35 |
| Weighted-average assumptions used to determine obligations at December 31 |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Discount rate | 5.19% | 5.52% | 4.41% | 4.06% |
| &nbsp;&nbsp;&nbsp;Rate of compensation increase | N/A | N/A | 3.42% | 3.18% |

---

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

---

| | | | |
|:---|:---|:---|:---|
| *<u>(DOLLARS IN MILLIONS)</u>* | **U.S. Plans** | **Non-U.S. Plans** | **Postretirement<br>Benefits** |
| **Estimated Future Benefit Payments** |  |  |  |
| &nbsp;&nbsp;&nbsp;2026 | $6 | $40 | $4 |
| &nbsp;&nbsp;&nbsp;2027 | 6 | 40 | 4 |
| &nbsp;&nbsp;&nbsp;2028 | 5 | 44 | 4 |
| &nbsp;&nbsp;&nbsp;2029 | 5 | 43 | 4 |
| &nbsp;&nbsp;&nbsp;2030 | 5 | 48 | 4 |
| &nbsp;&nbsp;&nbsp;2031 – 2035 | 22 | 257 | 20 |
| **Contributions** |  |  |  |
| &nbsp;&nbsp;Required Company Contributions in the Following Year (2026) | $5 | $17 | $— |

---

The Company considers a number of factors in determining and selecting assumptions for the overall expected long-term rate of return on plan assets. The Company considers the historical long-term return experience of its assets, the current and expected allocation of its plan assets and expected long-term rates of return. The Company derives these expected long-term rates of return with the assistance of its investment advisors. The Company bases its expected allocation of plan assets on a diversified portfolio consisting of domestic and international equity securities, fixed income, property and alternative asset classes. The asset allocation is monitored on an ongoing basis.

The Company considers a variety of factors in determining and selecting its assumptions for the discount rate at December 31. For the Non-U.S. Plans, the discount rates were determined by region and are based on high quality long-term corporate bonds. Consideration has been given to the duration of the liabilities in each plan when selecting the bonds to be used in determining the discount rate. The rate of compensation increase for all plans are based on plan experience.

The percentage of assets in the Company's pension plans, by type, is as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **U.S. Plans** | **U.S. Plans** | **Non-U.S. Plans** | **Non-U.S. Plans** |
| | **2025** | **2024** | **2025** | **2024** |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | —% | —% | 1% | 1% |
| &nbsp;&nbsp;&nbsp;Equities | 20% | 19% | 21% | 17% |
| &nbsp;&nbsp;&nbsp;Fixed income | 80% | 81% | 42% | 41% |
| &nbsp;&nbsp;&nbsp;Property | —% | —% | 8% | 8% |
| &nbsp;&nbsp;&nbsp;Alternative and other investments | —% | —% | 28% | 33% |

---

The expected annual rate of return for the non-U.S. plans employs a similar set of criteria adapted for local investments, inflation rates and in certain cases specific government requirements. Each plan has its own target asset allocation, which is reviewed periodically and rebalanced when necessary.

The following tables present the Company's plan assets for the U.S. and non-U.S. plans using the fair value hierarchy as of December 31, 2025 and 2024. The plans' assets were accounted for at fair value and are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company's assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of fair value assets and their placement within the fair value hierarchy levels. For more information on a description of the fair value hierarchy, see Note 16.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **U.S. Plans for the Year Ended** | **U.S. Plans for the Year Ended** | **U.S. Plans for the Year Ended** | **U.S. Plans for the Year Ended** |
| | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **Level 1** | **Level 2** | **Level 3** | **Total** |
| ***Assets Measured at Net Asset Value***<sup>(1)</sup> |  |  |  |  |
| &nbsp;&nbsp;&nbsp;U.S. Equities |  |  |  | $2 |
| &nbsp;&nbsp;&nbsp;U.S. Fixed Income |  |  |  | 7 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total Assets Measured at Net Asset Value** | $— | $— | $— | $9 |

---

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **U.S. Plans for the Year Ended** | **U.S. Plans for the Year Ended** | **U.S. Plans for the Year Ended** | **U.S. Plans for the Year Ended** |
| | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **Level 1** | **Level 2** | **Level 3** | **Total** |
| ***Assets Measured at Net Asset Value***<sup>(1)</sup> |  |  |  |  |
| &nbsp;&nbsp;&nbsp;U.S. Equities |  |  |  | $2 |
| &nbsp;&nbsp;&nbsp;U.S. Fixed Income |  |  |  | 7 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total Assets Measured at Net Asset Value** | $— | $— | $— | $9 |

---

_______________________

(1)Investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. The fair value amounts presented in the table above are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the Consolidated Balance Sheets.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Non-U.S. Plans for the Year Ended** | **Non-U.S. Plans for the Year Ended** | **Non-U.S. Plans for the Year Ended** | **Non-U.S. Plans for the Year Ended** |
| | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **Level 1** | **Level 2** | **Level 3** | **Total** |
| ***Cash*** | $7 | $— | $— | $7 |
| ***Equity Securities*** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;U.S. Large Cap | 153 |  |  | 153 |
| &nbsp;&nbsp;&nbsp;Non-U.S. Large Cap | 48 |  |  | 48 |
| &nbsp;&nbsp;&nbsp;Emerging Markets | 11 |  |  | 11 |
| ***Fixed Income Securities*** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;U.S. Corporate Bonds | 42 |  |  | 42 |
| &nbsp;&nbsp;&nbsp;Non-U.S. Treasuries/Government Bonds | 118 |  |  | 118 |
| &nbsp;&nbsp;&nbsp;Non-U.S. Corporate Bonds | 63 | 82 |  | 145 |
| &nbsp;&nbsp;&nbsp;Non-U.S. Other Fixed Income |  | 50 |  | 50 |
| ***Alternative Types of Investments*** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Insurance Contracts |  |  | 285 | 285 |
| &nbsp;&nbsp;&nbsp;Absolute Return Funds | 1 |  |  | 1 |
| ***Property*** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Non-U.S. Property |  |  | 2 | 2 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total Assets Measured at Fair Value** | $443 | $132 | $287 | $862 |
| ***Assets Measured at Net Asset Value***<sup>(1)</sup> |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Non-U.S. Fixed Income |  |  |  | $72 |
| &nbsp;&nbsp;&nbsp;Non-U.S. Property |  |  |  | 85 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total Assets Measured at Net Asset Value** |  |  |  | 157 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Non-U.S. Plan Assets** |  |  |  | $1019 |

---

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Non-U.S. Plans for the Year Ended** | **Non-U.S. Plans for the Year Ended** | **Non-U.S. Plans for the Year Ended** | **Non-U.S. Plans for the Year Ended** |
| | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **Level 1** | **Level 2** | **Level 3** | **Total** |
| ***Cash*** | $11 | $— | $— | $11 |
| ***Equity Securities*** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;U.S. Large Cap | 101 |  |  | 101 |
| &nbsp;&nbsp;&nbsp;U.S. Mid Cap | 8 |  |  | 8 |
| &nbsp;&nbsp;&nbsp;Non-U.S. Large Cap | 43 |  |  | 43 |
| &nbsp;&nbsp;&nbsp;Non-U.S. Mid Cap | 3 |  |  | 3 |
| &nbsp;&nbsp;&nbsp;Non-U.S. Small Cap | 1 |  |  | 1 |
| &nbsp;&nbsp;&nbsp;Emerging Markets | 9 |  |  | 9 |
| ***Fixed Income Securities*** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;U.S. Corporate Bonds | 42 |  |  | 42 |
| &nbsp;&nbsp;&nbsp;Non-U.S. Treasuries/Government Bonds | 165 |  |  | 165 |
| &nbsp;&nbsp;&nbsp;Non-U.S. Corporate Bonds | 50 | 66 |  | 116 |
| &nbsp;&nbsp;&nbsp;Non-U.S. Other Fixed Income |  | 10 |  | 10 |
| ***Alternative Types of Investments*** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Insurance Contracts |  |  | 270 | 270 |
| &nbsp;&nbsp;&nbsp;Absolute Return Funds | 1 |  |  | 1 |
| ***Property*** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Non-U.S. Property | 7 |  | 2 | 9 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total Assets Measured at Fair Value** | $441 | $76 | $272 | $789 |
| ***Assets Measured at Net Asset Value***<sup>(1)</sup> |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Non-U.S. Fixed Income |  |  |  | $60 |
| &nbsp;&nbsp;&nbsp;Non-U.S. Property |  |  |  | 71 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total Assets Measured at Net Asset Value** |  |  |  | 131 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Non-U.S. Plan Assets** |  |  |  | $920 |

---

_______________________

(1)As of December 31, 2024, the Company revised the total non-U.S. Plan assets measured at fair value from $920 million to $789 million. $131 million of assets were corrected to be presented at net asset value, with $60 million and $71 million of assets previously presented as Level 2 and Level 3 investments in the fair value hierarchy, respectively. These revisions did not impact the total non-U.S. Plan Assets. Investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. The fair value amounts presented in the table above are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the Consolidated Balance Sheets.

Cash and cash equivalents are primarily held in registered money market funds which are valued using a market approach based on the quoted market prices of identical instruments. Other cash and cash equivalents are valued daily by the fund using a market approach with inputs that include quoted market prices for similar instruments.

Equity securities are primarily valued using a market approach based on the quoted market prices of identical instruments. Pooled funds are typically common or collective trusts valued at their net asset values (NAVs).

Fixed income securities are primarily valued using a market approach with inputs that include broker quotes and benchmark yields.

Derivative instruments are valued by the custodian using closing market swap curves and market derived inputs.

Property values are primarily based on valuation of the underlying investments, which include inputs such as cost, discounted future cash flows, independent appraisals and market comparable data.

Hedge funds are valued based on valuation of the underlying securities and instruments within the funds. Quoted market prices are used when available and NAVs are used for unquoted securities within the funds.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

The following table presents a reconciliation of Level 3 non-U.S. plan assets held during the year ended December 31, 2025:

---

| | | | |
|:---|:---|:---|:---|
| | **Non-U.S. Plans** | **Non-U.S. Plans** | **Non-U.S. Plans** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **Property** | **Insurance Contracts** | **Total** |
| Ending balance as of December 31, 2024 | $2 | $270 | $272 |
| &nbsp;&nbsp;&nbsp;Actual return on plan assets |  | 15 | 15 |
| Ending balance as of December 31, 2025 | $2 | $285 | $287 |

---

The following weighted average assumptions were used to determine the postretirement benefit expense and obligation for the years ended December 31:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Expense** | **Expense** | **Liability** | **Liability** |
| | **2025** | **2024** | **2025** | **2024** |
| Discount rate | 5.70% | 5.10% | 5.50% | 5.70% |
| Current medical cost trend rate | 7.00% | 7.25% | 9.25% | 7.00% |
| Ultimate medical cost trend rate | 4.75% | 4.75% | 4.75% | 4.75% |
| Medical cost trend rate decreases to ultimate rate in year | 2034 | 2034 | 2035 | 2034 |

---

The Company contributed $24 million to its non-U.S. pension plans in 2025. $5 million of contributions were made to the Company's non-qualified U.S. pension plans in 2025. In addition, $2 million of payments were made with respect to the Company's other postretirement plans.

**NOTE 9. OTHER EXPENSE, NET**

Other expense, net consisted of the following:

---

| | | | |
|:---|:---|:---|:---|
| | **December 31,** | **December 31,** | **December 31,** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **2025** | **2024** | **2023** |
| Foreign exchange losses | $(92) | $(91) | $(77) |
| Interest income | 19 | 15 | 5 |
| Gain on China facility relocation |  |  | 22 |
| Pension-related benefit (expense)<sup>(1)</sup> | 11 | (125) | 28 |
| Other | (3) | 19 | 17 |
| &nbsp;&nbsp;&nbsp;Other expense, net | $(65) | $(182) | $(5) |

---

_______________________

(1)2025 and 2024 amounts include a reduction of the previously recognized settlement loss of $6 million and a settlement loss of $130 million, respectively, that were recognized as a result of the termination of the International Flavors & Fragrances Inc. Pension Plan. Refer to Note 8 for further information.

**NOTE 10.&nbsp;&nbsp;&nbsp;&nbsp;INCOME TAXES**

Earnings before income taxes consisted of the following:

---

| | | | |
|:---|:---|:---|:---|
| | **December 31,** | **December 31,** | **December 31,** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **2025** | **2024** | **2023** |
| U.S. income (loss) before taxes | $(1421) | $(810) | $(1777) |
| Foreign income (loss) before taxes | 1009 | 1118 | (741) |
| Total income (loss) before taxes | $(412) | $308 | $(2518) |

---

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

The income tax provision consisted of the following:

---

| | | | |
|:---|:---|:---|:---|
| | **December 31,** | **December 31,** | **December 31,** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **2025** | **2024** | **2023** |
| Current tax provision |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Federal | $(178) | $(44) | $47 |
| &nbsp;&nbsp;&nbsp;&nbsp;State and local | 4 | 9 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign | 391 | 399 | 393 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current tax provision | 217 | 364 | 440 |
| Deferred tax provision |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Federal | (144) | (203) | (161) |
| &nbsp;&nbsp;&nbsp;&nbsp;State and local | (16) | (28) | 32 |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign | (110) | (92) | (242) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total deferred tax benefit | (270) | (323) | (371) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total (benefit) provision for income taxes | $(53) | $41 | $69 |

---

**Effective Tax Rate Reconciliation**

As further described in Note 1, Summary of Significant Accounting Policies, the Company has adopted the guidance in ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Taxes Disclosures, or ASU 2023-09. The following table is a reconciliation of the U.S. federal statutory tax rate of 21% to the Company's effective tax rate for the year ended December 31, 2025 in accordance with the guidance in ASU 2023-09:

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

---

| | | |
|:---|:---|:---|
| | **Year Ended December 31, 2025** | **Year Ended December 31, 2025** |
| | **Total** | **%** |
| Earnings from continuing operations, before income tax expense | $(412) |  |
| U.S. Federal Statutory Tax Rate | (87) | 21.1% |
| &nbsp;&nbsp;**United States** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;State and Local Income Taxes <sup>(a)</sup> | (13) | 3.2% |
| &nbsp;&nbsp;**Federal** |  |  |
| &nbsp;&nbsp;**Effect of Cross-Border Tax Laws** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Global intangible low taxed income | 36 | (8.7)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | (3) | 0.7% |
| &nbsp;&nbsp;**Tax Credits** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development credit | (20) | 4.8% |
| &nbsp;&nbsp;**Changes in Valuation Allowances** | 22 | (5.3)% |
| &nbsp;&nbsp;**Nontaxable or Nondeductible Items** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-taxable income | 28 | (6.8)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tax effects of non-deductible goodwill impairment | 236 | (57.3)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tax impact on gain on business divestitures | 115 | (27.9)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | 4 | (1.0)% |
| &nbsp;&nbsp;**Other Adjustments** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Entity Realignment - One-time impact | (348) | 84.4% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | (11) | 2.7% |
| **Foreign Tax Effects** |  |  |
| &nbsp;&nbsp;**Brazil** | 10 | (2.4)% |
| &nbsp;&nbsp;**China** | 22 | (5.3)% |
| &nbsp;&nbsp;**Cyprus** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effect of rates different than statutory | (13) | 3.2% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Enactment of new tax laws | (28) | 6.8% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notional interest deduction | (12) | 2.9% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | (1) | 0.2% |
| &nbsp;&nbsp;**Denmark** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-taxable income | (28) | 6.8% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | 15 | (3.6)% |
| &nbsp;&nbsp;**Germany** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Goodwill and intangibles | (16) | 3.9% |
| &nbsp;&nbsp;**Luxembourg** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes in valuation allowances | (27) | 6.5% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | 28 | (6.8)% |
| &nbsp;&nbsp;**Netherlands** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tax benefit from supply chain optimization | (13) | 3.2% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | 10 | (2.4)% |
| &nbsp;&nbsp;**Singapore** | (11) | 2.6% |
| **Other Foreign Jurisdictions** | 63 | (15.3)% |
| **Changes in Unrecognized Tax Benefits** | (11) | 2.7% |
| Income Tax Expense | $(53) | 12.9% |

---

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

<sup>(a)</sup>State taxes in Illinois, Minnesota and Michigan made up the majority of the tax effect of this category.

The Company has elected to treat global intangible low-taxed income ("GILTI") as a current period cost if and when incurred. This tax position resulted in a net income tax expense of approximately $215 million for the year ended December 31, 2025, offset in part by foreign tax credits of approximately $178 million.

The following table is a reconciliation between the U.S. federal statutory income tax rate of 21% to the Company's effective tax rate for the years ended December 31, 2024 and 2023 in accordance with the guidance prior to the adoption of 2023-09.

---

| | | |
|:---|:---|:---|
| | **December 31,** | **December 31,** |
| | **2024** | **2023** |
| Statutory tax rate | 21.0% | 21.0% |
| &nbsp;&nbsp;&nbsp;Tax effect of non-deductible goodwill impairment |  | (20.4) |
| &nbsp;&nbsp;&nbsp;Difference in effective tax rate on foreign earnings and remittances | 34.7 | (1.1) |
| &nbsp;&nbsp;&nbsp;Tax benefit from supply chain optimization | (4.4) | 0.5 |
| &nbsp;&nbsp;&nbsp;Unrecognized tax benefit, net of reversals | 6.5 | (0.8) |
| &nbsp;&nbsp;Tax impact on gain on business disposals<sup>(1)</sup> | (21.0) | (3.7) |
| &nbsp;&nbsp;Deferred taxes on deemed repatriation<sup>(2)</sup> | 0.3 | 0.5 |
| &nbsp;&nbsp;&nbsp;Global intangible low-taxed income | 10.8 | (0.4) |
| &nbsp;&nbsp;&nbsp;U.S. foreign tax credit - general limitation | (8.7) | 0.2 |
| &nbsp;&nbsp;&nbsp;Research and development credit | (7.3) | 0.5 |
| &nbsp;&nbsp;State and local taxes including rate changes<sup>(3)</sup> | (6.4) | (1.7) |
| &nbsp;&nbsp;&nbsp;Tax impact on internal asset transfer | (9.5) | 5.3 |
| &nbsp;&nbsp;&nbsp;Other, net | (2.7) | (2.6) |
| Effective tax rate | 13.3% | (2.7)% |

---

_______________________

(1)For 2024 the effective tax rate reflects the recording of the tax effects of the divestiture of the Cosmetic Ingredients business.

(2)For 2023 and 2024 the rate includes the establishment of the held for sale deferred tax liabilities due to a change in assertion.

(3)For 2023 and 2024 the rate includes rate change impacts related to the remeasurement of the state tax rate on deferred taxes.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

**Deferred Taxes**

The deferred tax assets and liabilities, shown before jurisdictional netting, consisted of the following amounts:

---

| | | |
|:---|:---|:---|
| | **December 31,** | **December 31,** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **2025** | **2024** |
| Employee and retiree benefits | $62 | $90 |
| Credit and net operating loss carryforwards | 359 | 294 |
| Amortizable research and development expenses | 167 | 154 |
| Interest limitation | 205 | 226 |
| Inventory | 33 | 29 |
| Lease obligations | 146 | 143 |
| Other, net | 125 | 101 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross deferred tax assets | 1097 | 1037 |
| Property, plant and equipment, net | (203) | (195) |
| Intangible assets<sup>(1)</sup> | (1241) | (1529) |
| Right-of-use assets | (138) | (132) |
| Deferred taxes on deemed repatriation | (155) | (154) |
| Other, net |  | (5) |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross deferred tax liabilities | (1737) | (2015) |
| &nbsp;&nbsp;&nbsp;&nbsp;Valuation allowance | (454) | (376) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total net deferred tax liabilities | $(1094) | $(1354) |

---

_______________________

(1)Includes deferred taxes on intangible assets owned by a fully consolidated partnership.

Net operating loss carryforwards were approximately $334 million and $267 million as of December 31, 2025 and 2024, respectively. If unused, approximately $103 million will expire between 2026 and 2045. The remainder, totaling approximately $231 million, may be carried forward indefinitely. Tax credit carryforwards were approximately $21 million as of both December 31, 2025 and 2024. If unused, the $21 million will expire between 2026 and 2045.

Of the deferred tax assets at December 31, 2025, the Company considers it unlikely that a portion of the tax benefit will be realized. Accordingly, a valuation allowance of approximately $454 million has been established against these deferred tax assets.

**Uncertain Tax Positions**

A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **December 31,** | **December 31,** | **December 31,** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **2025** | **2024** | **2023** |
| Balance of unrecognized tax benefits at beginning of year | $270 | $215 | $144 |
| Gross amount of increases in unrecognized tax benefits as a result of positions taken during a prior year | 41 | 65 | 61 |
| Gross amount of decreases in unrecognized tax benefits as a result of positions taken during a prior year | (21) | (12) |  |
| Gross amount of increases in unrecognized tax benefits as a result of positions taken during the current year | 9 | 15 | 19 |
| The amounts of decreases in unrecognized benefits relating to settlements with taxing authorities | (117) | (5) | (3) |
| Reduction in unrecognized tax benefits due to the lapse of applicable statute of limitation | (12) | (8) | (6) |
| Balance of unrecognized tax benefits at end of year | $170 | $270 | $215 |

---

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

As of December 31, 2025, 2024 and 2023, there were approximately $151 million, $270 million and $215 million, respectively, of unrecognized tax benefits recorded to Other liabilities. As of December 31, 2025, there were approximately $19 million recorded to Other current liabilities. There were no amounts recorded to Other current liabilities for 2024 and 2023. If these unrecognized tax benefits were recognized, all the benefits and related interest and penalties would be recorded as a benefit to income tax expense.

The Company decreased its liabilities for interest and penalties by approximately $26 million, net, for the year ended December 31, 2025. The Company increased its liabilities for interest and penalties by approximately $16 million, net, and increased its liabilities for interest and penalties by approximately $14 million, net, for the years ended December 31, 2024 and 2023, respectively. As of December 31, 2025, 2024 and 2023, the Company had accrued approximately $33 million, $63 million and $49 million respectively, of interest and penalties classified as Other liabilities. As of December 31, 2025, the Company has accrued approximately $4 million of interest and penalties classified as other current liabilities.

As of December 31, 2025, the Company's aggregate provision for unrecognized tax benefits, including interest and penalties, was approximately $208 million associated with various tax positions principally asserted in foreign jurisdictions.

The following table is a reconciliation of the Company's tax payments and refunds for the year ended December 31, 2025:

---

| | |
|:---|:---|
| | **December 31,** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **2025** |
| Federal | $27 |
| State and local | 10 |
| Foreign | 292 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $329 |

---

Income taxes paid (net of refunds) exceeded 5 percent of total income taxes paid (net of refunds) in the following jurisdictions:

---

| | |
|:---|:---|
| | **December 31,** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **2025** |
| Brazil | $18 |
| China | 27 |
| France | 33 |
| Germany | 20 |
| Mexico | 19 |
| Netherlands | 54 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $171 |

---

*Other*

During the year ended December 31, 2025, the Company recorded an income tax benefit associated with the legal entity realignment project of $360 million. The legal entity realignment project is a phased restructuring initiative involving certain of the Company's U.S. and foreign legal entities. To determine the amount of the income tax benefit recorded, first management estimated the fair value of the relevant legal entities using the discounted cash flow method or the net asset value method and then analyzed the relevant tax laws and regulations in assessing the tax consequences of the steps within the realignment project, including obtaining opinions from third-party tax and legal advisors. Under the discounted cash flow method, management used a rate of return that reflects the relative risk of the projected future cash flows of each legal entity, as well as a terminal value. Estimates and assumptions include revenue growth rates, gross margins, adjusted operating EBIT margins, terminal growth rates, and discount rates.

Tax benefits credited to Shareholders' equity were not material for the years ended December 31, 2025, 2024 and 2023 associated with stock option exercises and purchased restricted stock unit dividends.

The Company regularly repatriates earnings from non-U.S. subsidiaries. As the Company repatriates these funds to the U.S., there will be required income taxes payable in certain U.S. states and applicable foreign withholding taxes during the period when such repatriation occurs. Accordingly, as of December 31, 2025, the Company had a deferred tax liability of approximately $155 million for the effect of repatriating the funds to the U.S., attributable to various non-U.S. subsidiaries.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

There is no deferred tax liability associated with non-U.S. subsidiaries where the Company intends to indefinitely reinvest the earnings to fund local operations and/or capital projects.

The Company has ongoing income tax audits and legal proceedings which are at various stages of administrative or judicial review. In addition, the Company has other ongoing tax audits and legal proceedings that relate to indirect taxes, such as value-added taxes, capital tax, sales and use and property taxes, which are discussed in Note 21.

The Company also has several other tax audits in process and has open tax years with various taxing jurisdictions that range primarily from 2011 to 2024.

**NOTE 11.&nbsp;&nbsp;&nbsp;&nbsp;PROPERTY, PLANT AND EQUIPMENT, NET**

Property, plant and equipment, net consisted of the following amounts:

---

| | | |
|:---|:---|:---|
| *<u>(DOLLARS IN MILLIONS)</u>* | **December 31,** | **December 31,** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **2025** | **2024** |
| &nbsp;&nbsp;&nbsp;Land | $135 | $137 |
| &nbsp;&nbsp;&nbsp;Buildings and improvements | 1798 | 1695 |
| &nbsp;&nbsp;&nbsp;Machinery and equipment | 3761 | 3471 |
| &nbsp;&nbsp;&nbsp;Information technology | 627 | 514 |
| &nbsp;&nbsp;&nbsp;Construction in process | 504 | 350 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Property, plant and equipment | 6825 | 6167 |
| Accumulated depreciation | (2796) | (2428) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Property, plant and equipment, net | $4029 | $3739 |

---

**Depreciation**

Depreciation expense was $394 million, $405 million and $462 million for the years ended December 31, 2025, 2024 and 2023, respectively.

**Capitalized Interest**

Capitalized interest was approximately $12 million, $14 million and $17 million for the years ended December 31, 2025, 2024 and 2023, respectively.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

**NOTE 12. &nbsp;&nbsp;&nbsp;&nbsp;GOODWILL AND OTHER INTANGIBLE ASSETS, NET**

**Goodwill**

Movements in goodwill attributable to each reportable segment during the years ended December 31, 2024 and 2025 were as follows:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| *<u>(DOLLARS IN MILLIONS)</u>* | **Nourish** | **Taste** | **Food Ingredients** | **Scent** | **Health & Biosciences** | **Pharma Solutions** | **Total** |
| Balance at December 31, 2023 | $3489 | $— | $— | $1490 | $4391 | $1265 | $10635 |
| Transferred to assets held for sale<sup>(1)</sup> | (55) |  |  |  |  | (1248) | (1303) |
| Reduction from business divestitures<sup>(2)</sup> | (10) |  |  |  |  |  | (10) |
| Foreign Exchange | (104) |  |  | (25) | (96) | (17) | (242) |
| Other | (5) |  |  |  |  |  | (5) |
| Balance at December 31, 2024 | 3315 |  |  | 1465 | 4295 |  | 9075 |
| Reallocation of goodwill in segment reorganization | (3315) | 2176 | 1153 |  | (14) |  |  |
| Transferred to assets held for sale<sup>(1)</sup> |  | (6) |  |  |  |  | (6) |
| Reduction from business divestitures<sup>(2)</sup> |  | (8) |  |  |  |  | (8) |
| Impairment |  |  | (1153) |  |  |  | (1153) |
| Foreign exchange |  | 134 |  | 43 | 184 |  | 361 |
| Balance at December 31, 2025 | $— | $2296 | $— | $1508 | $4465 | $— | $8269 |

---

_______________________

(1)For 2025, related to the Tobacco Flavoring business. For 2024, related to the Pharma Solutions disposal group and the Nitrocellulose business. The Company recognized $64 million of impairment related to the Pharma Solutions disposal group classified as held for sale as of December 31, 2024. See Note 3 for additional information.

(2)For 2025, relates to the divestiture of the Rene Laurent business. For 2024, relates to the divestiture of the Flavors & Essences UK business. See Note 3 for additional information.

The goodwill balance at December 31, 2025 was net of accumulated goodwill impairment charges of $6.026 billion, which included $1.153 billion related to the Food Ingredients reporting unit, $2.623 billion related to the previous Nourish reporting unit, and $2.250 billion related to the Health & Biosciences reporting unit.

The goodwill balance at December 31, 2024 and December 31, 2023 was net of accumulated goodwill impairment charges of $4.873 billion, which included $2.623 billion related to the previous Nourish reporting unit and $2.250 billion related to the Health & Biosciences reporting unit.

For the interim and annual impairment assessments, the Company performed quantitative impairment assessments by comparing the fair value of the reporting units with their carrying amounts.

The Company assessed the fair value of the reporting units using an income approach for all impairment assessments performed. Under the income approach, the Company determined the fair value of the reporting units by using a discounted cash flow method at a rate of return that reflects the relative risk of the projected future cash flows of each reporting unit, as well as a terminal value. The Company used the most current actual and forecasted operating data available. Key estimates and assumptions used in these valuations include revenue growth rates, gross margins, adjusted operating EBITDA margins, forecasted capital expenditures, terminal growth rates and discount rates.

In performing the quantitative impairment assessment, the Company determined that the fair value of the reporting units exceeded their carrying values and determined that there was no impairment of goodwill in these reporting units as of November 30, 2025. Based on the quantitative impairment assessment performed, the Taste, Fragrance Compounds and Fragrance Ingredients reporting units had substantial headroom, as fair value exceeded carrying value by a wide margin, while the fair value of the Health & Biosciences reporting unit exceeded carrying value by 9%. While management believes that the assumptions used in the impairment assessment were reasonable, changes in key assumptions, including lower revenue growth,

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

operating margin, terminal growth rates or increase in discount rates could result in a future impairment. Such impairment could have a material effect on our Consolidated Statements of Operations and Balance Sheets.

Effective January 1, 2025, the Nourish operating segment was reorganized into two new operating segments: Taste and Food Ingredients, which also represent reporting units. As a result of this change in management reporting, goodwill related to the Nourish reporting unit was allocated between the two new reporting units and interim quantitative goodwill impairment assessments were performed both prior to and subsequent to the change. As a result, the Company determined that the carrying amount of the Food Ingredients reporting unit exceeded its estimated fair value and recognized an impairment charge of $1.153 billion, which is reflected in the Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) during the year ended December 31, 2025.

During 2024, the Company determined that goodwill impairment triggering events occurred for its Pharma Solutions disposal group. The Company determined that the carrying value of the disposal group exceeded its fair value and recorded an impairment charge of $64 million in the Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) for the year ended December 31, 2024.

During 2023, the Company determined that goodwill impairment triggering events occurred for its Nourish reporting unit. The Company determined that the carrying value of the Nourish reporting unit exceeded its fair value and recorded an impairment charge of $2.623 billion in the Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) for the year ended December 31, 2023. The primary drivers of the impairment charge were a decrease in fair value due to declines in projections of the reporting unit, impacts of continued inflation and increases in interest rates.

**Other Intangible Assets**

Other intangible assets, net consisted of the following amounts:

---

| | | |
|:---|:---|:---|
| | **December 31,** | **December 31,** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **2025** | **2024** |
| **Asset Type** |  |  |
| &nbsp;&nbsp;&nbsp;Customer relationships | $7200 | $7004 |
| &nbsp;&nbsp;&nbsp;Technological know-how | 1999 | 1937 |
| &nbsp;&nbsp;&nbsp;Trade names & patents | 285 | 268 |
| &nbsp;&nbsp;&nbsp;Other | 24 | 25 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total carrying value | 9508 | 9234 |
| **Accumulated Amortization** |  |  |
| &nbsp;&nbsp;&nbsp;Customer relationships | (2198) | (1765) |
| &nbsp;&nbsp;&nbsp;Technological know-how | (1087) | (875) |
| &nbsp;&nbsp;&nbsp;Trade names & patents | (159) | (128) |
| &nbsp;&nbsp;&nbsp;Other | (21) | (21) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total accumulated amortization | (3465) | (2789) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other intangible assets, net | $6043 | $6445 |

---

**Amortization**

Amortization expense was $568 million for the year ended December 31, 2025, $610 million for the year ended December 31, 2024 and $680 million for the year ended December 31, 2023. Amortization expense for the next five years is expected to be as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **December 31,** | **December 31,** | **December 31,** | **December 31,** | **December 31,** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **2026** | **2027** | **2028** | **2029** | **2030** |
| Estimated future intangible amortization expense | $582 | $494 | $481 | $444 | $440 |

---

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

**NOTE 13.&nbsp;&nbsp;&nbsp;&nbsp;OTHER CURRENT ASSETS AND LIABILITIES, AND OTHER ASSETS**

Prepaid expenses and other current assets consisted of the following amounts:

---

| | | |
|:---|:---|:---|
| | **December 31,** | **December 31,** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **2025** | **2024** |
| Value-added tax receivable | $131 | $118 |
| Prepaid income taxes | 212 | 177 |
| Packaging materials and supplies | 119 | 123 |
| Prepaid expenses | 170 | 159 |
| Earnout receivable | 139 |  |
| Other | 106 | 109 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $877 | $686 |

---

Other assets consisted of the following amounts:

---

| | | |
|:---|:---|:---|
| | **December 31,** | **December 31,** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **2025** | **2024** |
| Finance lease right-of-use assets | $32 | $27 |
| Deferred income taxes | 285 | 240 |
| Overfunded pension plans | 177 | 144 |
| Cash surrender value of life insurance contracts | 57 | 52 |
| Equity method investments | 15 | 10 |
| Other<sup>(1)</sup> | 459 | 434 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $1025 | $907 |

---

_______________________

(1)Primarily relates to long-term tax receivables due to an operating loss carryback, long-term uncertain tax benefits, receivables from certain government authorities which the Company has corresponding payables to DuPont in relation to the N&B merger in 2021, and land usage rights in China.

Other current liabilities consisted of the following amounts:

---

| | | |
|:---|:---|:---|
| | **December 31,** | **December 31,** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **2025** | **2024** |
| Rebates and incentives payable | $103 | $111 |
| Value-added tax payable | 30 | 24 |
| Interest payable | 27 | 42 |
| Current pension and other postretirement benefit obligation | 13 | 12 |
| Accrued restructuring | 36 | 3 |
| Current operating lease obligation | 92 | 82 |
| Accrued income taxes | 180 | 129 |
| Accrued expenses payable | 283 | 203 |
| Other | 155 | 196 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $919 | $802 |

---

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

**NOTE 14.&nbsp;&nbsp;&nbsp;&nbsp;DEBT**

Debt consisted of the following at December 31:

---

| | | | |
|:---|:---|:---|:---|
| *<u>(DOLLARS IN MILLIONS)</u>* | **Effective Interest Rate** | **2025** | **2024** |
| 2025 Notes<sup>(1)(2)</sup> | 1.22% |  | 1000 |
| 2026 Euro Notes<sup>(1)</sup> | 1.93% | 940 | 827 |
| 2027 Notes<sup>(1)(2)</sup> | 1.56% | 804 | 1209 |
| 2028 Notes<sup>(1)</sup> | 4.57% | 399 | 398 |
| 2030 Notes<sup>(1)(2)</sup> | 2.21% | 1238 | 1507 |
| 2040 Notes<sup>(1)(2)</sup> | 3.04% | 341 | 771 |
| 2047 Notes<sup>(1)(2)</sup> | 4.44% | 392 | 495 |
| 2048 Notes<sup>(1)(2)</sup> | 5.12% | 674 | 787 |
| 2050 Notes<sup>(1)(2)</sup> | 3.21% | 888 | 1568 |
| 2026 Term Loan Facility<sup>(1)</sup> | 4.88% |  | 413 |
| Revolving Credit Facility<sup>(3)</sup> |  |  |  |
| Commercial Paper<sup>(4)</sup> |  | 314 |  |
| Bank overdrafts and other |  | 4 | 2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total debt |  | $5994 | $8977 |
| Less: Short term borrowings |  | (1254) | (1413) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Long-term debt |  | $4740 | $7564 |

---

_______________________

(1)Amount is net of unamortized discount and debt issuance costs.

(2)Included in the tender offers described below.

(3)Borrowings under the Revolving Credit Facility are subject to interest at varying spreads above quoted market rates and a commitment fee is paid on the total unused borrowings.

(4)The effective interest rate of commercial paper issuances fluctuates as short-term interest rates and demand fluctuate, and deferred debt issuance costs are immaterial. Refer to "Commercial Paper" below.

**Tender Offers**

On May 20, 2025, the Company completed tender offers to purchase for cash certain of its outstanding series of Senior Notes for an aggregate purchase price, excluding accrued and unpaid interest, of $2.0 billion. The carrying value of this series of Senior Notes purchased as a result of these tender offers was $2.5 billion. The Company also incurred approximately $6 million of banking and legal costs. In connection with the completion of these tender offers, the Company recognized a gain on debt extinguishment of $488 million within the Consolidated Statements of Income (Loss) and Comprehensive Income (Loss). The tender offers were primarily funded through the proceeds received from the divestiture of the Pharma Solutions disposal group.

**Term Loan Facility and Senior Notes**

Following the business combination (the "Merger") of IFF and the nutrition and biosciences business (the "N&B Business") of DuPont de Nemours, Inc ("DuPont"), the Company assumed the indebtedness incurred by N&B in the debt financings completed prior to the Merger. This indebtedness includes (i) a Term Loan Facility of $1.250 billion pursuant to the term loan credit agreement (the "N&B Term Loan Facility") and (ii) a series of Senior Notes in the aggregate amount of $6.250 billion with maturities ranging from 2 to 30 years as further described below.

*N&B Term Loan Facility*

The N&B Term Loan Facility was funded on February 1, 2021, and provided for a senior unsecured term loan credit facility in an aggregate principal amount of $1.250 billion, comprised of a $625 million three-year tranche ("2024 Term Loan Facility") and a $625 million five-year tranche ("2026 Term Loan Facility"). Interest for each tranche equaled, at the Company's option, a per annum rate equal to either (x) an adjusted LIBOR rate plus an applicable margin varying from 0.750% to 2.000% for the three-year tranche and from 1.125% to 2.375% for the five-year tranche or (y) a base rate plus an applicable margin varying from zero to 1.000% for the three-year tranche and from 0.125% to 1.375% for the five-year tranche, in each case depending on the class of IFF's non-credit-enhanced, senior unsecured long-term debt credit rating.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

The 2024 Term Loan Facility and 2026 Term Loan Facility were subject to customary affirmative and negative covenants and events of default after the closing of the Merger. On and after the closing of the Merger transaction, the 2024 Term Loan Facility and 2026 Term Loan Facility were also subject to financial covenant maintenance requirements.

During 2023, the Company made voluntary debt repayments of $355 million related to the 2024 Term Loan Facility. During 2024, the Company made a $270 million debt repayment at maturity related to the 2024 Term Loan Facility. The Company also made quarterly debt repayments totaling approximately $63 million related to the 2026 Term Loan Facility in accordance with the terms of the debt agreement, and voluntary repayments of $150 million related to the 2026 Term Loan Facility. During 2025, the Company made debt repayments totaling approximately $413 million on the remaining balance of the 2026 Term Loan Facility. This was done using a portion of the cash proceeds from the divestiture of the Pharma Solutions disposal group in accordance with the terms of the Term Loan Facility agreement.

*N&B Senior Notes*

On September 16, 2020, N&B issued $6.250 billion in aggregate principal amount of senior unsecured notes consisting of: (i) $300 million senior unsecured notes which matured on September 15, 2022 (the "2022 Notes"); (ii) $1.000 billion senior unsecured notes which matured on October 1, 2025 (the "2025 Notes"), bearing interest at a rate of 1.230% per year, payable semi-annually on April 1 and October 1 of each year, beginning April 1, 2021; (iii) $1.200 billion senior unsecured notes maturing on October 15, 2027 (the "2027 Notes"), bearing interest at a rate of 1.832% per year, payable semi-annually on April 15 and October 15 of each year, beginning April 15, 2021; (iv) $1.500 billion senior unsecured notes maturing on November 1, 2030 (the "2030 Notes"), bearing interest at a rate of 2.300% per year, payable semi-annually on May 1 and November 1 of each year, beginning May 1, 2021; (v) $750 million senior unsecured notes maturing on November 15, 2040 (the "2040 Notes"), bearing interest at a rate of 3.268% per year, payable semi-annually on May 15 and November 15 of each year, beginning May 15, 2021, and; (vi) $1.500 billion senior unsecured notes maturing on December 1, 2050 (the "2050 Notes"), bearing interest at a rate of 3.468% per year, payable semi-annually on June 1 and December 1 of each year, beginning June 1, 2021.

Interest on each series of notes began accruing from September 16, 2020 payable semi-annually in arrears as described above. Interest is computed on the basis of a 360-day year comprised of twelve 30-day months.

The 2025, 2027, 2030, 2040, and 2050 Notes outstanding as of May 20, 2025 were subject to the tender offers as described above.

On September 30, 2025, the Company made a $500 million debt repayment related to the 2025 Notes, which was primarily funded from commercial paper issuances.

**Revolving Credit Facility**

The Revolving Credit Facility is available for general corporate purposes of each borrower and its subsidiaries. The obligations under the Revolving Credit Facility are unsecured and the Company has guaranteed the obligations of each other borrower under the Revolving Credit Facility. The Company pays a commitment fee on the aggregate unused commitments; such fee is not material. The Revolving Credit Facility contains various covenants, limitations and events of default customary for similar facilities for similarly rated borrowers, including a maximum permitted ratio of Net Debt to Consolidated EBITDA. In connection with the initial issuance of the Revolving Credit Facility, the Company incurred $1 million of debt issuance costs.

On June 25, 2025, the Company, with its lenders, entered into the Fourth Amended and Restated Credit Agreement ("Revolving Credit Agreement"), which amended and restated the most recent Amendment No. 4 to the Third Amended and Restated Credit Agreement dated September 19, 2023. This amendment and restatement, among other things, extended the termination date to June 25, 2030. The Revolving Credit Agreement states that from the effective date through September 30, 2025, our net debt to credit adjusted EBITDA ratio shall not exceed 4.00x, and shall not exceed 3.75x thereafter, with a temporary step-up to 4.25x permitted for three fiscal quarters following an acquisition exceeding $500 million in paid consideration. As of December 31, 2025, the Company was in compliance with all financial and other covenants.

As of December 31, 2025, total capacity under the Revolving Credit Facility was $2.000 billion, with no outstanding borrowings. The Revolving Credit Facility matures on June 25, 2030 and, at the option of the Company, may be increased to $2.500 billion subject to certain conditions.

During 2025, the Company had no drawdowns or repayments under the Revolving Credit Facility. During 2024, the Company had drawdowns of $250 million and repayments of $250 million under the Revolving Credit Facility. During 2023, the Company had drawdowns of $800 million and repayments of $900 million under the Revolving Credit Facility.

**2018 Senior Unsecured Notes**

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

On September 25, 2018, the Company issued €800 million aggregate principal amount of senior unsecured notes that mature on September 25, 2026 (the "2026 Euro Notes"). The 2026 Euro Notes bear interest at a rate of 1.8% per year, payable annually on September 25 of each year, beginning September 25, 2019. Total proceeds from the issuance of the 2026 Notes, net of underwriting discounts and offering costs, were €794 million ($932 million in USD).

On September 26, 2018, the Company issued $400 million aggregate principal amount of senior unsecured notes that mature on September 26, 2028 (the "2028 Notes"). The 2028 Notes bear interest at a rate of 4.45% per year, payable semi-annually on March 26 and September 26 of each year, beginning March 26, 2019. Total proceeds from the issuance of the 2028 Notes, net of underwriting discounts and offering costs, were $397 million.

On September 26, 2018, the Company issued $800 million aggregate principal amount of senior unsecured notes that mature on September 26, 2048 (the "2048 Notes" and collectively with the 2026 Euro Notes, 2020 Notes, 2028 Notes, the "2018 Senior Unsecured Notes"). The 2048 Notes bear interest at a rate of 5.0% per year, payable semi-annually on March 26 and September 26 of each year, beginning March 26, 2019. Total proceeds from the issuance of the 2048 Notes, net of underwriting discounts and offering costs, were $787 million.

As discussed in Note 16, the 2026 Euro Notes have been designated as a hedge of the Company's net investment in certain subsidiaries.

**2024 Euro Notes**

On March 14, 2016, the Company issued €500 million aggregate principal amount of senior unsecured notes that matured on March 14, 2024 ("2024 Euro Notes"). The 2024 Euro Notes bore interest at a rate of 1.75% per year, paid annually on March 14 of each year, beginning March 14, 2017. Total proceeds from the issuance of the 2024 Euro Notes, net of underwriting discounts and offering costs, were €496 million. In connection with the debt issuance, the Company entered into pre-issuance hedging transactions that were settled upon issuance of the debt and resulted in a loss of approximately $3 million. The discount, deferred financing costs and pre-issuance hedge loss were amortized as interest expense over the eight year term of the debt.

As discussed in Note 16, the 2024 Euro Notes were designated as a hedge of the Company's net investment in certain subsidiaries.

For the year ended December 31, 2024, the Company made a €500 million (approximately $547 million) debt repayment at maturity related to the 2024 Euro Notes.

**2047 Notes**

On May 18, 2017, the Company issued $500 million aggregate principal amount of senior unsecured notes that mature on June 1, 2047 ("2047 Notes"). The 2047 Notes bear interest at a rate of 4.375% per year, payable semi-annually on June 1 and December 1 of each year, beginning December 1, 2017. Total proceeds from the issuance of the 2047 Notes, net of underwriting discounts and offering costs, were $494 million. In addition, the Company incurred $1 million in legal and professional costs associated with the issuance and such costs were recorded as deferred financing costs. In connection with the debt issuance, the Company entered into pre-issuance hedging transactions that were settled upon issuance of the debt and resulted in a loss of approximately $5 million. The discount, deferred financing costs and pre-issuance hedge loss are being amortized as interest expense over the 30-year term of the debt.

The 2047 Notes outstanding as of May 20, 2025 were subject to the tender offers as described above.

**Commercial Paper**

As of December 31, 2025, the amount of commercial paper outstanding was $314 million with a weighted average interest rate of 4.21% and a weighted average maturity of 35 days. As of December 31, 2024, there was no commercial paper outstanding.

During 2025, the Company had gross issuances of $5.146 billion and repayments of $4.832 billion under the commercial paper program. The commercial paper issued had original maturities of less than 90 days. During 2024, the Company had gross issuances of $4.083 billion and repayments of $4.083 billion under the commercial paper program.

The Commercial Paper Program is backed by the borrowing capacity available under the Revolving Credit Facility. The effective interest rate of commercial paper issuances does not materially differ from short-term interest rates, which fluctuate due to market conditions and as a result may impact our interest expense.

**Lines of Credit** 

The Company has various lines of credit which are available to support its ongoing business operations. As of December 31, 2025, the Company has a total capacity of approximately $1.733 billion of lines of credit with various institutions, of which $1.731 billion is available as of December 31, 2025.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

**Redemption Provisions**

The 2026 Euro Notes, 2028 Notes, 2047 Notes, and 2048 Notes (collectively, the "Notes") share the same redemption provisions. Upon 30 days' notice to holders of the Notes, the Company may redeem the Notes at any time at the greater of 100% or the discounted present value of the remaining scheduled payments of principal and interest from the redemption date to the maturity date at the Treasury Rate or the Comparable Government Bond Rate (as defined in the applicable agreements) plus (i) 25 basis points in the case of the 2026 Euro Notes, (ii) 25 basis points in the case of the 2028 Notes, (iii) 25 basis points in the case of the 2047 Notes and (iv) 30 basis points in the case of the 2048 Notes. The redemption dates of each of the Notes are provided in the below table:

---

| | |
|:---|:---|
| **Note** | **Redemption Date** |
| 2026 Euro Notes | June 25, 2026 |
| 2028 Notes | June 26, 2028 |
| 2047 Notes | December 1, 2046 |
| 2048 Notes | March 26, 2048 |

---

The 2027 Notes, 2030 Notes, 2040 Notes and 2050 Notes (collectively, the "N&B Senior Notes") were assumed as a result of the N&B Merger and share the same redemption provisions. Upon 15 days' notice to holders of the N&B Senior Notes, the Company may redeem the N&B Senior Notes at any time at the greater of 100% or the discounted present value of the remaining scheduled payments of principal and interest from the redemption date to the maturity date at the Treasury Rate (as defined in the applicable agreements) plus (i) 25 basis points in the case of the 2027 Notes, (ii) 25 basis points in the case of the 2030 Notes, (iii) 30 basis points in the case of the 2040 Notes and (iv) 30 basis points in the case of the 2050 Notes. The redemption dates of each of the N&B Senior Notes are provided in the table below:

---

| | |
|:---|:---|
| **Note** | **Redemption Date** |
| 2027 Notes | August 15, 2027 |
| 2030 Notes | August 1, 2030 |
| 2040 Notes | May 15, 2040 |
| 2050 Notes | June 1, 2050 |

---

On or after the applicable redemption dates, each series of the Notes and N&B Senior Notes (collectively, the "IFF Notes") may be redeemed by the issuer at a redemption price equal to 100% of the principal amount of the IFF Notes to be redeemed, plus accrued and unpaid interest on the notes to be redeemed to, but excluding, the redemption date.

The indenture of the IFF Notes provides for customary events of default and contains certain negative covenants that limit the ability of the Company and its subsidiaries to grant liens on assets, or to enter into sale-leaseback transactions. In addition, subject to certain limitations, in the event of the occurrence of both (1) a change of control of the Company and (2) ratings of the IFF Notes is under publicly announced consideration or is downgraded below investment grade by either Moody's Investors Services, Inc. or Standard & Poor's Ratings Services within a specified time period, the Company will be required to make an offer to repurchase the IFF Notes at a price equal to 101% of the principal amount of the IFF Notes, plus accrued and unpaid interest to the date of repurchase.

**Outstanding Borrowings**

The following table shows the contractual maturities of the Company's long-term debt as of December 31, 2025.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Payments Due by Period** | **Payments Due by Period** | **Payments Due by Period** | **Payments Due by Period** | **Payments Due by Period** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **Total** | **Less than 1 Year** | **1-3 Years** | **3-5 Years** | **More than<br>5 Years** |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Outstanding Borrowings<sup>(1)</sup> | $5637 | $940 | $1200 | $1233 | $2264 |

---

_______________________

(1)The difference between the payments due by period and the carrying value of debt is due to purchase accounting adjustments, debt issuance costs, and deferred financing fees.

**NOTE 15.&nbsp;&nbsp;&nbsp;&nbsp;LEASES**

The Company has leases for corporate offices, manufacturing facilities, research and development facilities and certain transportation and office equipment, the majority of which are operating leases. The Company's leases have remaining lease terms of up to 50 years, some of which include options to extend the leases for up to 15 years.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

The components of lease expense were as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **December 31,** | **December 31,** | **December 31,** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **2025** | **2024** | **2023** |
| Operating leases |  |  |  |
| &nbsp;&nbsp;&nbsp;Operating lease cost | $123 | $126 | $137 |
| &nbsp;&nbsp;&nbsp;Variable lease cost | 68 | 58 | 56 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating lease cost | $191 | $184 | $193 |
| Finance leases |  |  |  |
| &nbsp;&nbsp;&nbsp;Finance lease cost | $14 | $12 | $10 |

---

Supplemental cash flow information related to leases was as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **December 31,** | **December 31,** | **December 31,** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **2025** | **2024** | **2023** |
| Cash paid for amounts included in the measurement of lease liabilities |  |  |  |
| &nbsp;&nbsp;&nbsp;Operating cash flows for operating leases | $131 | $122 | $122 |
| &nbsp;&nbsp;&nbsp;Operating cash flows for finance leases | 2 | 1 | 1 |
| &nbsp;&nbsp;&nbsp;Financing cash flows for finance leases | 12 | 10 | 8 |
| Right-of-use assets obtained in exchange for lease obligations |  |  |  |
| &nbsp;&nbsp;&nbsp;Operating leases | 77 | 69 | 49 |
| &nbsp;&nbsp;&nbsp;Finance leases | 20 | 16 | 22 |

---

Supplemental balance sheet information related to leases was as follows:

---

| | | |
|:---|:---|:---|
| | **December 31,** | **December 31,** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **2025** | **2024** |
| **Operating Leases** |  |  |
| &nbsp;&nbsp;&nbsp;Operating lease right-of-use assets | $579 | $589 |
| &nbsp;&nbsp;Current operating lease obligations<sup>(2)</sup> | 92 | 82 |
| &nbsp;&nbsp;&nbsp;Operating lease liabilities | 533 | 550 |
| Total operating lease liabilities | $625 | $632 |
| **Finance Leases** |  |  |
| &nbsp;&nbsp;Finance lease right-of-use assets<sup>(1)</sup> | $32 | $27 |
| &nbsp;&nbsp;Current finance lease obligations<sup>(2)</sup> | 12 | 10 |
| &nbsp;&nbsp;Finance lease liabilities<sup>(3)</sup> | 20 | 18 |
| Total finance lease liabilities | $32 | $28 |

---

_______________________

(1)Presented in Other assets on the Consolidated Balance Sheets.

(2)Presented in Other current liabilities on the Consolidated Balance Sheets.

(3)Presented in Other liabilities on the Consolidated Balance Sheets.

Weighted average remaining lease term and discount rate were as follows:

---

| | | |
|:---|:---|:---|
| | **December 31,** | **December 31,** |
| | **2025** | **2024** |
| **Weighted average remaining lease term in years** |  |  |
| &nbsp;&nbsp;&nbsp;Operating leases | 9.3 | 9.7 |
| &nbsp;&nbsp;&nbsp;Finance leases | 4.4 | 3.1 |
| **Weighted average discount rate** |  |  |
| &nbsp;&nbsp;&nbsp;Operating leases | 4.07% | 4.39% |
| &nbsp;&nbsp;&nbsp;Finance leases | 4.70% | 4.63% |

---

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

Maturities of lease liabilities as of December 31, 2025 were as follows:

---

| | | | |
|:---|:---|:---|:---|
| *<u>(DOLLARS IN MILLIONS)</u>* | **Operating Leases** | **Finance Leases** | **Total** |
| 2026 | $117 | $14 | $131 |
| 2027 | 102 | 10 | 112 |
| 2028 | 88 | 5 | 93 |
| 2029 | 76 | 2 | 78 |
| 2030 | 70 | 1 | 71 |
| Thereafter | 322 | 4 | 326 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total undiscounted liabilities | 775 | 36 | 811 |
| Less: Imputed interest | (150) | (4) | (154) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total lease liabilities | $625 | $32 | $657 |

---

**NOTE 16.&nbsp;&nbsp;&nbsp;&nbsp;FINANCIAL INSTRUMENTS**

**Fair Value**

Accounting guidance on fair value measurements specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the Company's market assumptions. These two types of inputs create the following fair value hierarchy:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Level 1 — Quoted prices for *identical* instruments in active markets.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Level 2 — Quoted prices for *similar* instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Level 3 — Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable*.*

This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. The Company also considers counterparty credit risk in its assessment of fair value. The Company determines the fair value of structured liabilities (where performance is linked to structured interest rates, inflation or currency risks) using the Secured Overnight Financing Rate ("Term SOFR") swap curve and forward interest and exchange rates at period end. Such instruments are classified as Level 2 based on the observability of significant inputs to the model. Instruments classified as Level 3 include the earnout receivable as discussed in Note 3, as well as instruments held in pension asset trusts as discussed in Note 8. These valuations take into consideration the Company's credit risk and its counterparties' credit risk.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

The carrying value and the estimated fair values of financial instruments at December 31 consisted of the following:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **2025** | **2025** | **2024** | **2024** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **Carrying Value** | **Fair<br>Value** | **Carrying Value** | **Fair<br>Value** |
| **LEVEL 1** |  |  |  |  |
| Cash and cash equivalents<sup>(1)</sup> | $590 | $590 | $469 | $469 |
| **LEVEL 2** |  |  |  |  |
| Bank overdrafts and other<sup>(2)</sup> | 4 | 4 | 2 | 2 |
| Derivatives |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Derivative assets<sup>(3)</sup> | 18 | 18 | 9 | 9 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Derivative liabilities<sup>(3)</sup> | 242 | 242 | 129 | 129 |
| Long-term debt: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2025 Notes<sup>(4)</sup> |  |  | 1000 | 972 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2026 Euro Notes<sup>(4)</sup> | 940 | 935 | 827 | 813 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2027 Notes<sup>(4)</sup> | 804 | 768 | 1209 | 1102 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2028 Notes<sup>(4)</sup> | 399 | 403 | 398 | 391 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2030 Notes<sup>(4)</sup> | 1238 | 1113 | 1507 | 1274 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2040 Notes<sup>(4)</sup> | 341 | 255 | 771 | 536 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2047 Notes<sup>(4)</sup> | 392 | 322 | 495 | 392 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2048 Notes<sup>(4)</sup> | 674 | 607 | 787 | 686 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2050 Notes<sup>(4)</sup> | 888 | 585 | 1568 | 985 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2026 Term Loan Facility<sup>(5)</sup> |  |  | 413 | 413 |

---

_______________________

(1)The carrying amount of cash and cash equivalents approximates fair value due to the short maturity of those instruments.

(2)The carrying amount approximates fair value as the interest rate is reset frequently based on current market rates as well as the short maturity of those instruments.

(3)The carrying amount approximates fair value as the instruments are marked-to-market and held at fair value on the Consolidated Balance Sheets.

(4)The fair value of the Note is obtained from pricing services engaged by the Company, and the Company receives one price for each security. The fair value provided by the pricing services are estimated using pricing models, where the inputs to those models are based on observable market inputs or recent trades of similar securities. The inputs to the valuation techniques applied by the pricing services are typically benchmark yields, benchmark security prices, credit spreads, reported trades and broker-dealer quotes, all with reasonable levels of transparency.

(5)The carrying amount approximates fair value as the interest rate is reset frequently based on current market rates.

**Derivatives and Other Hedging Activities**

*Foreign Currency Forward Contracts*

The Company periodically enters into foreign currency forward contracts with the objective of managing our exchange rate risk related to foreign currency denominated monetary assets and liabilities of our operations. These contracts generally involve the exchange of one currency for a second currency at a future date, have maturities not exceeding twelve months and are with counterparties which are major international financial institutions.

*Commodity Contracts*

The Company utilizes options that are not designated as hedging instruments to reduce exposure to commodity price fluctuations on purchases of inventory such as soybeans.

The Company also utilizes swaps that are designated as hedging instruments to reduce exposure to commodity price fluctuations on purchases of natural gas used in our manufacturing process.

*Hedges Related to Issuances of Debt*

Subsequent to the issuance of the 2026 Euro Notes during the third quarter of 2018, the Company designated the debt as a hedge of a portion of its net European investments. Accordingly, the change in the value of the debt that is attributable to

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

foreign exchange movements is recorded in Other comprehensive income ("OCI") as a component of foreign currency translation adjustments in the accompanying Consolidated Statements of Income (Loss) and Comprehensive Income (Loss).

Subsequent to the issuance of the 2024 Euro Notes during the first quarter of 2016, the Company designated the debt as a hedge of a portion of its net European investments. Accordingly, the change in the value of the debt that is attributable to foreign exchange movements is recorded in OCI as a component of foreign currency translation adjustments in the accompanying Consolidated Statements of Income (Loss) and Comprehensive Income (Loss).

During the first quarter of 2016, the Company entered into and settled two Euro interest rate swap agreements to hedge the anticipated issuance of fixed-rate debt. These swaps were designated as cash flow hedges. The effective portions of cash flow hedges are recorded in OCI as a component of Losses on derivatives qualifying as hedges in the accompanying Consolidated Statements of Income (Loss) and Comprehensive Income (Loss). The Company incurred a loss of €3 million ($3 million) due to the termination of these swaps. The loss was amortized as interest expense over the life of the 2024 Euro Notes as discussed in Note 14.

During the fourth quarter of 2016 and the first quarter of 2017, the Company entered into interest rate swap agreements to hedge the anticipated issuance of fixed-rate debt, which are designated as cash flow hedges. The various hedge instruments were settled upon issuance of the debt on May 18, 2017 and resulted in a loss of approximately $5 million. As discussed in Note 14, the loss is being amortized as interest expense over the life of the 2047 Notes.

*Cross Currency Swaps*

The Company has seventeen EUR/USD cross currency swaps, with a notional value of $1.900 billion that mature through November 2030. The swaps all qualified as net investment hedges in order to mitigate a portion of the Company's net European investments from foreign currency risk. As of December 31, 2025, the seventeen swaps were in a net liability position with an aggregate fair value of $237 million which were classified as Other liabilities on the Consolidated Balance Sheets. Changes in fair value related to cross currency swaps are recorded in OCI.

The following table shows the notional amount of the Company's derivative instruments outstanding as of December 31, 2025 and December 31, 2024:

---

| | | |
|:---|:---|:---|
| | **December 31,** | **December 31,** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **2025** | **2024** |
| Foreign currency forward contracts<sup>(1)</sup> | $(1840) | $(1512) |
| Commodity contracts<sup>(1)</sup> | 11 | 7 |
| Cross currency swaps | 1900 | 1400 |

---

______________________

(1)Foreign currency forward contracts and commodity contracts are presented net of contracts bought and sold.

The following tables show the Company's derivative instruments measured at fair value (Level 2 of the fair value hierarchy) as reflected in the Consolidated Balance Sheets as of December 31, 2025 and December 31, 2024:

---

| | | | |
|:---|:---|:---|:---|
| | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **Fair Value of Derivatives<br>Designated as Hedging<br>Instruments** | **Fair Value of Derivatives Not Designated as Hedging Instruments** | **Total Fair Value** |
| Derivative assets<sup>(1)</sup> |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency forward contracts | $— | $17 | $17 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cross currency swaps | 1 |  | 1 |
| &nbsp;&nbsp;&nbsp;Total derivative assets | $1 | $17 | $18 |
| Derivative liabilities<sup>(2)</sup> |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency forward contracts | $— | $3 | $3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cross currency swaps | 238 |  | 238 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commodity contracts | 1 |  | 1 |
| &nbsp;&nbsp;&nbsp;Total derivative liabilities | $239 | $3 | $242 |

---

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

---

| | | | |
|:---|:---|:---|:---|
| | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **Fair Value of Derivatives Designated as Hedging Instruments** | **Fair Value of Derivatives Not Designated as Hedging Instruments** | **Total Fair Value** |
| Derivative assets<sup>(1)</sup> |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency forward contracts | $— | $8 | $8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commodity contracts | 1 |  | 1 |
| &nbsp;&nbsp;&nbsp;Total derivative assets | $1 | $8 | $9 |
| Derivative liabilities<sup>(2)</sup> |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency forward contracts | $— | $39 | $39 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cross currency swaps | 90 |  | 90 |
| &nbsp;&nbsp;&nbsp;Total derivative liabilities | $90 | $39 | $129 |

---

_______________________

(1)Derivative assets are recorded to Prepaid expenses and other current assets on the Consolidated Balance Sheets.

(2)Derivative liabilities are recorded to Other current liabilities and Other liabilities on the Consolidated Balance Sheets.

The following table shows the effect of the Company's derivative instruments which were not designated as hedging instruments in the Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) for the years ended December 31, 2025, 2024, and 2023:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| *<u>(DOLLARS IN MILLIONS)</u>* | **Amount of Gain or (Loss)<br>Recognized in Income on <br>Derivative Settlements <br>December 31,** | **Amount of Gain or (Loss)<br>Recognized in Income on <br>Derivative Settlements <br>December 31,** | **Amount of Gain or (Loss)<br>Recognized in Income on <br>Derivative Settlements <br>December 31,** | **Amount of Gain (Loss) Recognized in Income on Changes in Fair Value<br>December 31,** | **Amount of Gain (Loss) Recognized in Income on Changes in Fair Value<br>December 31,** | **Amount of Gain (Loss) Recognized in Income on Changes in Fair Value<br>December 31,** | **Location of Gain (Loss)<br>Recognized in<br>Income on Derivative** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **2025** | **2024** | **2023** | **2025** | **2024** | **2023** | **Location of Gain (Loss)<br>Recognized in<br>Income on Derivative** |
| Foreign currency forward contracts<sup>(1)</sup> | $105 | $(102) | $(16) | $46 | $(68) | $37 | Other expense, net |
| Commodity contracts |  | (1) | 2 | 1 |  |  | Cost of sales |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $105 | $(103) | $(14) | $47 | $(68) | $37 |  |

---

_______________________

(1)The foreign currency forward contract net gains (losses) offset any recognized gains (losses) arising from the revaluation of the related intercompany loans during the same respective periods.

The following table shows the effect of the Company's derivative and non-derivative instruments designated as cash flow and net investment hedging instruments, net of tax, in the Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) for the years ended December 31, 2025, 2024, and 2023:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Amount of Gain (Loss)<br>Recognized in OCI on Derivative and Non-Derivative<br>(Effective Portion)** | **Amount of Gain (Loss)<br>Recognized in OCI on Derivative and Non-Derivative<br>(Effective Portion)** | **Amount of Gain (Loss)<br>Recognized in OCI on Derivative and Non-Derivative<br>(Effective Portion)** | **Location of Gain<br>(Loss) Reclassified<br>from AOCI into Income<br>(Effective Portion)** |
| | **For the years ended<br>December 31,** | **For the years ended<br>December 31,** | **For the years ended<br>December 31,** | **Location of Gain<br>(Loss) Reclassified<br>from AOCI into Income<br>(Effective Portion)** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **2025** | **2024** | **2023** | **Location of Gain<br>(Loss) Reclassified<br>from AOCI into Income<br>(Effective Portion)** |
| Derivatives in Cash Flow Hedging Relationships: |  |  |  |  |
| &nbsp;&nbsp;Foreign currency forward contracts | $— | $(7) | $— | N/A |
| &nbsp;&nbsp;&nbsp;Commodity contracts | (2) | 3 |  | Cost of sales |
| Derivatives in Net Investment Hedging Relationships: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Cross currency swaps | $(112) | $55 | $(67) | N/A |
| Non-Derivatives in Net Investment Hedging Relationships: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;2024 Euro Notes |  | 3 | (16) | N/A |
| &nbsp;&nbsp;&nbsp;2026 Euro Notes | (85) | 42 | (26) | N/A |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $(199) | $96 | $(109) |  |

---

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

---

| | | | |
|:---|:---|:---|:---|
| | **Amount of Gain (Loss) Reclassified from AOCI<br>into Income<br>(Effective Portion)** | **Amount of Gain (Loss) Reclassified from AOCI<br>into Income<br>(Effective Portion)** | **Amount of Gain (Loss) Reclassified from AOCI<br>into Income<br>(Effective Portion)** |
| | **For the year ended December 31,** | **For the year ended December 31,** | **For the year ended December 31,** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **2025** | **2024** | **2023** |
| Derivatives in Cash Flow Hedging Relationships: |  |  |  |
| &nbsp;&nbsp;Interest rate swaps<sup>(1)</sup> | $(1) | $— | $— |
| &nbsp;&nbsp;&nbsp;Commodity contracts | 1 | (1) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $— | $(1) | $— |

---

_______________________

(1) &nbsp;&nbsp;&nbsp;&nbsp;Interest rate swaps were entered into as pre-issuance hedges for the Company's bond offerings.

The ineffective portion of the above noted net investment hedges was approximately $15 million for each of the three years ended December 31, 2025, 2024, and 2023, and was recorded as a reduction to interest expense on the Consolidated Statements of Income (Loss) and Comprehensive Income (Loss).

At December 31, 2025, based on current market rates, the Company does not expect any derivative losses (net of tax), included in AOCI, to be reclassified into earnings within the next 12 months.

**Subsequent Event**

On February 18, 2026, the Company entered into agreements with various banks to expand its cross currency swap capacity by $500 million, bringing the total notional value of swaps to $2.4 billion. The swaps mature in February 2033 and February 2036 and qualify as net investment hedges in order to mitigate a portion of the Company's net European investments from foreign currency risk.

**NOTE 17.&nbsp;&nbsp;&nbsp;&nbsp;SHAREHOLDERS' EQUITY** 

**Dividends**

Cash dividends declared per share were $1.60, $1.60 and $3.24 for the years ended December 31, 2025, 2024 and 2023, respectively. The Consolidated Balance Sheets reflect $102 million of dividends payable at December 31, 2025. This amount relates to a cash dividend of $0.40 per share declared in December 2025 and paid in January 2026. Dividends declared, but not paid as of December 31, 2024 and December 31, 2023 were $102 million ($0.40 per share) and $207 million ($0.81 per share), respectively.

**Share Repurchase Program**

On August 5, 2025, the Company announced that its Board of Directors has authorized a new share repurchase program with a total value of $500 million. The program began on October 1, 2025 and does not have a specified term or termination date. Under the program, the Company is authorized to repurchase shares of common stock in privately negotiated transactions, and/or open market transactions, including under plans complying with Rule 10b5-1 under the Exchange Act, and in block trades, or a combination of the foregoing. The Board will review the share repurchase program periodically and may authorize adjustment of its term and size. The Company plans to fund repurchases from available cash and cash provided by operating activities.

During 2025, the Company repurchased approximately 584,000 shares of common stock at a cost of approximately $38 million.

**NOTE 18.&nbsp;&nbsp;&nbsp;&nbsp;ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)**

The following tables present changes in the accumulated balances for each component of other comprehensive income (loss), including current period other comprehensive income (loss) and reclassifications out of accumulated other comprehensive income (loss):

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

---

| | | | | |
|:---|:---|:---|:---|:---|
| *<u>(DOLLARS IN MILLIONS)</u>* | **Foreign<br>Currency<br>Translation<br>Adjustments** | **Gains (Losses) on Derivatives<br>Qualifying as<br>Hedges** | **Pension and<br>Postretirement<br>Liability<br>Adjustment** | **Total** |
| Accumulated other comprehensive (loss) income, net of tax, as of January 1, 2025 | $(2426) | $(2) | $(99) | $(2527) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;OCI before reclassifications | 1105 | (2) | (8) | 1095 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reclassifications due to business divestitures | 48 |  | (50) | (2) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amounts reclassified from AOCI |  |  | 4 | 4 |
| Net current period other comprehensive income (loss) | 1153 | (2) | (54) | 1097 |
| Accumulated other comprehensive (loss) income, net of tax, as of December 31, 2025 | $(1273) | $(4) | $(153) | $(1430) |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| *<u>(DOLLARS IN MILLIONS)</u>* | **Foreign<br>Currency<br>Translation<br>Adjustments** | **Gains (Losses) on Derivatives<br>Qualifying as<br>Hedges** | **Pension and<br>Postretirement<br>Liability<br>Adjustment** | **Total** |
| Accumulated other comprehensive (loss) income, net of tax, as of January 1, 2024 | $(1652) | $1 | $(245) | $(1896) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;OCI before reclassifications | (778) | (4) | 53 | (729) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reclassifications due to business divestitures | 4 |  |  | 4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amounts reclassified from AOCI |  | 1 | 93 | 94 |
| Net current period other comprehensive income (loss) | (774) | (3) | 146 | (631) |
| Accumulated other comprehensive (loss) income, net of tax, as of December 31, 2024 | $(2426) | $(2) | $(99) | $(2527) |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| *<u>(DOLLARS IN MILLIONS)</u>* | **Foreign<br>Currency<br>Translation<br>Adjustments** | **Gains (Losses) on Derivatives<br>Qualifying as<br>Hedges** | **Pension and<br>Postretirement<br>Liability<br>Adjustment** | **Total** |
| Accumulated other comprehensive (loss) income, net of tax, as of January 1, 2023 | $(2066) | $1 | $(133) | $(2198) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;OCI before reclassifications | 367 |  | (100) | 267 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reclassifications due to business divestitures | 47 |  | (1) | 46 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amounts reclassified from AOCI |  |  | (11) | (11) |
| Net current period other comprehensive income (loss) | 414 |  | (112) | 302 |
| Accumulated other comprehensive (loss) income, net of tax, as of December 31, 2023 | $(1652) | $1 | $(245) | $(1896) |

---

The following table provides details about reclassifications out of Accumulated other comprehensive loss including business divestitures to the Consolidated Statements of Income (Loss) and Comprehensive Income (Loss):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | |
| *<u>(DOLLARS IN MILLIONS)</u>* | **2025** | **2024** | **2023** | **Affected Line Item in the Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)** |
| Gains (losses) on pension and postretirement liability adjustments |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior service cost | $2 | $2 | $6 | <sup>(1)</sup> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Actuarial gains (losses) | (7) | (142) | 8 | <sup>(1)</sup> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Business divestitures | 50 |  |  | <sup>(2)</sup> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tax | 1 | 47 | (3) | Provision for income taxes |
| &nbsp;&nbsp;&nbsp;Total | $46 | $(93) | $11 | Total, net of income taxes |

---

_______________________

(1)The amortization of prior service cost and actuarial loss is included in the computation of net periodic benefit cost. See Note 8 for additional information regarding net periodic benefit cost.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

(2)The pension and postretirement liability adjustments related to business divestitures is included in the computation of Losses (Gains) on business disposals. See Note 3 for additional information regarding the pension adjustments recognized for the divestitures of the Pharma Solutions disposal group and Nitrocellulose business.

**NOTE 19. REDEEMABLE NON-CONTROLLING INTERESTS**

Through certain subsidiaries of the Company's Frutarom acquisition, there were certain non-controlling interests that carried redemption features. The non-controlling interest holders had the right, over a stipulated period of time, to sell their respective interests to Frutarom, and Frutarom had the option to purchase these interests (subject to the same timing). In most cases, these options carried similar price and conditions of exercise, and were settled on a pre-agreed formula based on a multiple of the average EBITDA of consecutive quarters to be achieved during the period ending prior to the exercise date.

The following table sets forth the details of the Company's redeemable non-controlling interests:

---

| | |
|:---|:---|
| *<u>(DOLLARS IN MILLIONS)</u>* | **Redeemable <br>Non-controlling Interests** |
| Balance at December 31, 2022 | $59 |
| &nbsp;&nbsp;&nbsp;Impact of foreign exchange translation | (8) |
| &nbsp;&nbsp;&nbsp;Redemption value adjustment for the current period | (2) |
| &nbsp;&nbsp;&nbsp;Dividends paid | (13) |
| &nbsp;&nbsp;&nbsp;Exercises of redeemable non-controlling interests | (25) |
| &nbsp;&nbsp;Disposal of redeemable non-controlling interests<sup>(1)</sup> | (11) |
| Balance at December 31, 2023 | $— |
| Balance at December 31, 2024 | $— |
| Balance at December 31, 2025 | $— |

---

_______________________

(1)The disposal of redeemable non-controlling interests was related to the sale of the Company's investment in the Sonarome business.

**NOTE 20.&nbsp;&nbsp;&nbsp;&nbsp;CONCENTRATIONS OF CREDIT RISK**

The Company does not have significant concentrations of risk in financial instruments. Temporary investments are made in a well-diversified portfolio of high-quality, liquid obligations of government, corporate and financial institutions.

A significant portion of our sales comes from a relatively small number of large multinational customers. In 2025, our 25 largest customers, a majority of which were multinational consumer products companies, collectively accounted for approximately 32% of our sales. Multinational customers have been facing their own competitive challenges, such as pressures by new smaller companies and specialty players that cater to or are more adept at adjusting to the latest consumer trends, including towards natural products and clean labels, changes in the retail landscape (including e-commerce and consolidation), and increased competition from private labels, which have resulted and may continue to result in decreased demand for our products. Multinational and increasingly middle market customers also rely on "core lists" of suppliers, requiring more favorable terms for inclusion, such as rebates, which could adversely affect our margins. If we fail to secure or maintain such "core list" status, our sales and margins could be adversely affected. Beyond large multinational customers, our customer base continues to be diverse. Based on fiscal year 2025 sales, we had approximately 20,000 customers. Approximately 69% of sales were from small and mid-sized companies. The Company had no customer that accounted for more than 10% of its consolidated net sales for the years ended 2025, 2024 and 2023. Given the large number of customers, including multinational customers, who are spread across many industries and geographic regions, there are limited concentrations of credit risk with respect to trade receivables.

**NOTE 21.&nbsp;&nbsp;&nbsp;&nbsp;COMMITMENTS AND CONTINGENCIES**

**Guarantees and Letters of Credit**

The Company has various bank guarantees, letters of credit and surety bonds which are used to support its ongoing business operations, satisfy governmental requirements associated with pending litigation in various jurisdictions and the payment of customs duties.

As of December 31, 2025, the Company had a total capacity of approximately $209 million of bank guarantees, commercial guarantees, standby letters of credit and surety bonds with various financial institutions. Included in the above aggregate amount was a total of approximately $11 million for other assessments in Brazil for various income tax and indirect tax disputes related to fiscal years 1998-2011. There was a total of approximately $50 million outstanding under the bank guarantees, standby letters of credit and commercial guarantees as of December 31, 2025.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

In order to challenge the assessments in these cases in Brazil, the Company has been required to, and has separately pledged assets, principally property, plant and equipment, to cover assessments in the amount of approximately $7 million as of December 31, 2025.

**Litigation**

The Company assesses contingencies related to litigation and/or other matters to determine the degree of probability and range of possible loss if reasonably estimable. A loss contingency is accrued in the Company's Consolidated Financial Statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because litigation is inherently unpredictable and unfavorable resolutions could occur, assessing contingencies is highly sensitive and requires judgments about future events and any assessments or the related decisions on accruals could be inaccurate. On at least a quarterly basis, the Company reviews contingencies related to litigation to determine the adequacy of accruals. The amount of ultimate loss may substantially differ from these estimates and the amounts accrued, and further events may require the Company to increase or decrease the amounts it has accrued on any matter.

Periodically, the Company assesses its insurance coverage for all known claims, where applicable, taking into account aggregate coverage by occurrence, limits of coverage, self-insured retentions and deductibles, historical claims experience and claims experience with its insurance carriers. The probable liabilities are recorded at management's best estimate of the probable outcome of the lawsuits and claims where reasonably estimable, taking into consideration the facts and circumstances of the individual matters as well as past experience on similar matters. At each balance sheet date, management assesses whether it is probable that a loss as to asserted or unasserted claims has been incurred and if so, whether the amount of loss can be reasonably estimated. The Company records the expected liability with respect to claims in Other current liabilities or Other liabilities and expected recoveries from its insurance carriers in Other current assets or Other assets. The Company recognizes a receivable when it believes that realization of the insurance receivable is probable under the terms of the insurance policies and its payment experience to date.

*Litigation Matters* 

A motion to approve a securities class action was filed in the Tel Aviv District Court, Israel, in August 2019, alleging, among other things, false and misleading statements largely in connection with IFF's acquisition of Frutarom and improper payments made by Frutarom businesses operating principally in Russia and Ukraine to representatives of customers. The motion ("Oman") (following an initial amendment) asserted claims under the Israeli Securities Act-1968 against IFF, its former Chairman and CEO, and its former CFO, and against Frutarom and certain former Frutarom officers and directors, as well as claims under the Israeli Companies Act-1999 against certain former Frutarom officers and directors. On July 14, 2022, the court approved the parties' motion to mediate the dispute, which postponed all case deadlines until after the mediation. The parties held mediation meetings on September 13, 2022, November 22, 2022, March 1, 2023, November 2023, March 3, 2024 and April 1, 2024. In November 2024, the court granted extensions to the parties' joint filings of the responses to the Oman motion and for the evidential hearings, for the parties to exhaust the mediation proceeding. In the second quarter of 2025, the parties finalized a settlement agreement and submitted it to the court for approval. The settlement, approved by the court in November 2025, resolves all claims against Frutarom and its former officers and directors, and was made to avoid the cost, distraction and uncertainty of prolonged litigation. The settlement agreement states the settlement payment, fees and expenses totaling 24 million New Israel Shekel (approximately $7 million) will be paid by the respondents' insurers.

On October 29, 2019, IFF and Frutarom filed a claim in the Tel Aviv District Court, Israel, against Ori Yehudai, the former President and CEO of Frutarom, and against certain former directors of Frutarom, challenging the bonus of $20 million granted to Yehudai in 2018. IFF and Frutarom allege, among other things, that Yehudai was not entitled to receive the bonus because he breached his fiduciary duty by, among other things, knowing of the above-mentioned improper payments and failing to prevent them from being made. The parties agreed, pursuant to the court's recommendation, to attempt to resolve the dispute through mediation, and a court decision is pending with regard to the order in which this claim and the class action described below will be heard.

On March 11, 2020, an IFF shareholder filed a motion to approve a class action in Israel against, among others, Frutarom, Yehudai, and Frutarom's former board of directors, alleging that former minority shareholders of Frutarom were harmed as a result of the US $20 million bonus paid to Yehudai. The court held an evidentiary hearing on the motion to approve a class action in March 2024. In September 2025, the court issued a decision granting the motion to certify a class action. In December 2025, Frutarom submitted its motion for rehearing of that decision.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

Since March 2023, various putative class action lawsuits have been filed against IFF, Firmenich International SA, Givaudan SA, and Symrise AG and/or certain affiliates thereof in the Quebec Superior Court, the Federal Court of Canada, Ontario Superior Court, the Supreme Court of British Columbia and, in several cases, the United States District Court for the District of New Jersey. These actions allege violations of the Canadian Competition Act and the Sherman Act, as applicable, and other related claims, and seek damages and other relief. IFF announced on October 17, 2025, that it entered into a settlement agreement which will be a full settlement of the multiple civil class actions brought by direct purchasers of fragrance products in the United States. On November 17, 2025, the Court granted the motion for preliminary approval of this settlement and IFF then contributed $26 million to a settlement fund to resolve all class claims related to this direct purchaser class. The parties expect to resolve the class actions brought by indirect purchasers and end-user plaintiffs in the United States in the near future. During the twelve months ended December 31, 2025, the Company recognized a total provision of $43 million within "Selling and Administrative Expenses" in connection with the U.S. class action lawsuits, based on estimated potential settlement amount inclusive of the $26 million noted above related to settlement with direct purchasers. This provision does not include any potential liabilities that may arise from other civil proceedings not encompassed by the U.S. class action lawsuits. On January 27, 2026, an additional class action complaint was filed in the District of New Jersey on behalf of a class of purchasers in the United States of consumer goods containing fragrance products that were purchased outside the United States. IFF may face additional civil suits, in the United States, Canada, United Kingdom, European Union or in other countries, relating to such alleged conduct. At this time, IFF is unable to predict the potential outcome of these lawsuits or any potential effect they may have on the Company's results of operations, liquidity or financial condition. The resolution of any of these items could have a material adverse effect on IFF's results of operation, financial condition, and overall business.

*Investigations*

On June 3, 2020, the Israel Police's National Fraud Investigation Unit and the Israeli Securities Authority commenced an investigation into Frutarom and certain of its former executives, based on suspected bribery of foreign officials, money laundering, and violations of the Israeli Securities Act-1968. On February 26, 2024, the Israeli authorities informed Frutarom that the authorities decided to close the criminal investigation.

On March 7, 2023, the European Commission ("EC") and the United Kingdom Competition and Markets Authority ("CMA") carried out unannounced inspections of certain of IFF's facilities. IFF understands the EC, CMA and the Swiss Competition Commission are investigating potential anticompetitive conduct as it relates to IFF's fragrance businesses. On the same day, IFF was served with a grand jury subpoena by the Antitrust Division of the U.S. Department of Justice ("DOJ"). The Mexican Competition Commission has also announced that it is investigating potential anticompetitive conduct in the fragrance and fragrance ingredients industries. On February 5, 2026, IFF received a letter from DOJ confirming the closing of its investigation (such decision is independent of the other related civil or regulatory matters). The Company has applied for leniency in a number of jurisdictions. Leniency, if obtained in a jurisdiction, would generally carry significant benefits by, for example, reducing or eliminating monetary liability in that jurisdiction. Since March 7, 2023, other investigations have been underway or threatened in other jurisdictions related to claimed anti-competitive conduct. While these investigations are confidential, the Company is cooperating and/or seeking leniency in those jurisdictions, as well. IFF has been and intends to continue actively cooperating with these investigations, as well as any other present or future inquiries from governmental authorities. During the first three months of 2024, IFF recognized a provision of €16 million (approximately $18 million) in connection with a settlement with the EC, which was paid during the third quarter of 2024. This settlement pertains to a charge related to the deletion of messages relevant to the investigation by a former Scent employee. This settlement does not conclude the ongoing antitrust investigation. IFF is currently unable, however, to predict or determine the duration or outcome of the investigations, or whether the outcome of the investigations will materially impact the Company's results of operations, liquidity or financial condition. However, an adverse judgment or other outcome or settlement with respect to any proceedings discussed above could result in significant fines or payments by IFF. The resolution of any of these items could have a material adverse effect on IFF's results of operations, financial condition, and overall business.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

**Environmental Proceedings**

Effective March 22, 2024, the Solae, LLC Memphis site ("Solae") signed an Administrative Order on Consent (the "Consent Order") resolving violations and penalties pertaining to the Administrative Order and Assessment received from the City of Memphis on May 27, 2022 related to alleged wastewater discharge violations. In view of the Consent Order, Solae withdrew its previously filed appeal. Pursuant to the Consent Order, Solae is completing its capital project efforts in accordance with the agreed schedule for attaining compliance with current wastewater permit requirements. This matter is not expected to have a material adverse effect on the Company's financial position, cash flows or results of operations.

**Other Commitments**

The Company has contingencies involving third parties (such as labor, contract, technology or product-related claims or litigation) as well as government-related items in various jurisdictions in which it operates pertaining to such items as value-added taxes, other indirect taxes, customs and duties and sales and use taxes. It is possible that cash flows or results of operations, in any period, could be materially affected by the unfavorable resolution of one or more of these contingencies.

The most significant government-related contingencies exist in Brazil. With regard to the Brazilian matters, the Company believes it has valid defenses for the underlying positions under dispute; however, in order to pursue these defenses, the Company is required to, and has provided, bank guarantees and pledged assets in the aggregate amount of approximately $18 million. The Brazilian matters take an extended period of time to proceed through the judicial process and there are a limited number of rulings to date.

*Other*

The Company is subject to various legal proceedings and claims that have arisen in the ordinary course of business and have not been fully resolved. Due to the inherent subjectivity and unpredictability of outcomes of legal proceedings, the Company is unable to determine, with certainty, the probability of the outcome of these matters or the range of reasonably possible losses, if any.

**NOTE 22. REVISION OF QUARTERLY FINANCIAL INFORMATION (UNAUDITED)**

As discussed in Note 1, in preparing the Consolidated Financial Statements as of and for the three and nine months ended September 30, 2025 and for the year ended December 31, 2025, Management identified certain income tax-related errors. As a result of these errors, Management has revised the financial information for each of the periods ended March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024, June 30, 2025, and September 30, 2025. There is no impact to our Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) for the quarterly period ended March 31, 2025 or the quarterly period ended September 30, 2025. The Company has reflected the revisions for the periods ended September 30, 2024 in a previous Quarterly Report filed on Form 10-Q. The Company will revise its Consolidated Financial Statements for the three and six months ended June 30, 2025 and for the nine months ended September 30, 2025 to correct the errors when the financial statements for these periods are presented as comparative periods to the second and third quarter 2026 interim financial statements to be filed on Form 10-Q.

The following tables reflect the impact of the revision on the Company's results of operations.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

**Impacts to Interim Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)**

---

| | | | |
|:---|:---|:---|:---|
| | **Nine Months Ended September 30, 2025** | **Nine Months Ended September 30, 2025** | **Nine Months Ended September 30, 2025** |
| *<u>(DOLLARS IN MILLIONS EXCEPT PER SHARE AMOUNTS)</u>* | **As Previously Reported** | **Adjustments** | **As Revised** |
| Net sales | $8301 | $— | $8301 |
| Gross profit | 3048 |  | 3048 |
| Income (loss) before income taxes | (434) |  | (434) |
| (Benefit) for income taxes | (44) | (13) | (57) |
| Net income (loss) | (390) | 13 | (377) |
| Net income (loss) attributable to IFF shareholders | (392) | 13 | (379) |
| Net income (loss) per share – basic | $(1.53) | $0.05 | $(1.48) |
| Net income (loss) per share – diluted | $(1.53) | $0.05 | $(1.48) |
| Comprehensive income (loss) | 674 | 13 | 687 |
| Comprehensive income (loss) attributable to IFF shareholders | $672 | $13 | $685 |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Six Months Ended June 30, 2025**<sup>(1)</sup> | **Six Months Ended June 30, 2025**<sup>(1)</sup> | **Six Months Ended June 30, 2025**<sup>(1)</sup> | **Three Months Ended June 30, 2025**<sup>(1)</sup> | **Three Months Ended June 30, 2025**<sup>(1)</sup> | **Three Months Ended June 30, 2025**<sup>(1)</sup> |
| *<u>(DOLLARS IN MILLIONS EXCEPT PER SHARE AMOUNTS)</u>* | **As Previously Reported** | **Adjustments** | **As Revised** | **As Previously Reported** | **Adjustments** | **As Revised** |
| Net sales | $5607 | $— | $5607 | $2764 | $— | $2764 |
| Gross profit | 2065 |  | 2065 | 1030 |  | 1030 |
| Loss on business disposals | 81 | 30 | 111 | 81 | 30 | 111 |
| Income (loss) before income taxes | (460) | (30) | (490) | 534 | (30) | 504 |
| (Benefit) for income taxes | (55) | (17) | (72) | (78) | (17) | (95) |
| Net income (loss) | (405) | (13) | (418) | 612 | (13) | 599 |
| Net income (loss) attributable to IFF shareholders | (406) | (13) | (419) | 612 | (13) | 599 |
| Net income (loss) per share – basic | $(1.59) | $(0.05) | $(1.64) | $2.39 | $(0.05) | $2.34 |
| Net income (loss) per share – diluted | $(1.59) | $(0.05) | $(1.64) | $2.38 | $(0.05) | $2.33 |
| Comprehensive income (loss) | 707 | (13) | 694 | 1320 | (13) | 1307 |
| Comprehensive income (loss) attributable to IFF shareholders | $706 | $(13) | $693 | $1320 | $(13) | $1307 |

---

______________________

(1)The previous revision to the Interim Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) for the three and six months ended June 30, 2025 as reported within our Quarterly Report on Form 10-Q for the fiscal period ended September 30, 2025, has been updated to reflect an additional correction of a $13 million reduction to tax expense on business disposals which has been reflected in (Benefit) for income taxes.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** | **Three Months Ended December 31, 2024** | **Nine Months Ended September 30, 2024** | **Nine Months Ended September 30, 2024** | **Nine Months Ended September 30, 2024** |
| *<u>(DOLLARS IN MILLIONS EXCEPT PER SHARE AMOUNTS)</u>* | **As Previously Reported** | **Adjustments** | **As Revised** | **As Previously Reported** | **Adjustments** | **As Revised** |
| Net sales | $2771 | $— | $2771 | $8713 | $— | $8713 |
| Gross profit | 980 |  | 980 | 3144 |  | 3144 |
| Loss on assets classified as held for sale | 33 |  | 33 | 314 | (30) | 284 |
| Income (loss) before income taxes | (115) |  | (115) | 393 | 30 | 423 |
| Provision (benefit) for income taxes | (69) | 14 | (55) | 100 | (4) | 96 |
| Net income (loss) | (46) | (14) | (60) | 293 | 34 | 327 |
| Net income (loss) attributable to IFF shareholders | (46) | (14) | (60) | 289 | 34 | 323 |
| Net income (loss) per share – basic | $(0.18) | $(0.05) | $(0.23) | $1.13 | $0.14 | $1.27 |
| Net income (loss) per share – diluted | $(0.18) | $(0.05) | $(0.23) | $1.13 | $0.14 | $1.27 |
| Comprehensive income (loss) | (813) | (14) | (827) | 429 | 34 | 463 |
| Comprehensive income (loss) attributable to IFF shareholders | $(813) | $(14) | $(827) | $425 | $34 | $459 |

---

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30, 2024** | **Three Months Ended September 30, 2024** | **Three Months Ended September 30, 2024** | **Six Months Ended June 30, 2024** | **Six Months Ended June 30, 2024** | **Six Months Ended June 30, 2024** |
| *<u>(DOLLARS IN MILLIONS EXCEPT PER SHARE AMOUNTS)</u>* | **As Previously Reported** | **Adjustments** | **As Revised** | **As Previously Reported** | **Adjustments** | **As Revised** |
| Net sales | $2925 | $— | $2925 | $5788 | $— | $5788 |
| Gross profit | 1052 |  | 1052 | 2092 |  | 2092 |
| Loss on assets classified as held for sale | 32 |  | 32 | 282 | (30) | 252 |
| Income (loss) before income taxes | 95 |  | 95 | 298 | 30 | 328 |
| Provision (benefit) for income taxes | 35 | 1 | 36 | 65 | (5) | 60 |
| Net income (loss) | 60 | (1) | 59 | 233 | 35 | 268 |
| Net income (loss) attributable to IFF shareholders | 59 | (1) | 58 | 230 | 35 | 265 |
| Net income (loss) per share – basic | $0.23 | $— | $0.23 | $0.90 | $0.14 | $1.04 |
| Net income (loss) per share – diluted | $0.23 | $— | $0.23 | $0.90 | $0.14 | $1.04 |
| Comprehensive income (loss) | 615 | (1) | 614 | (186) | 35 | (151) |
| Comprehensive income (loss) attributable to IFF shareholders | $614 | $(1) | $613 | $(189) | $35 | $(154) |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended June 30, 2024** | **Three Months Ended June 30, 2024** | **Three Months Ended June 30, 2024** | **Three Months Ended March 31, 2024** | **Three Months Ended March 31, 2024** | **Three Months Ended March 31, 2024** |
| *<u>(DOLLARS IN MILLIONS EXCEPT PER SHARE AMOUNTS)</u>* | **As Previously Reported** | **Adjustments** | **As Revised** | **As Previously Reported** | **Adjustments** | **As Revised** |
| Net sales | $2889 | $— | $2889 | $2899 | $— | $2899 |
| Gross profit | 1068 |  | 1068 | 1024 |  | 1024 |
| Loss on assets classified as held for sale | 282 | (30) | 252 |  |  |  |
| Income (loss) before income taxes | 183 | 30 | 213 | 115 |  | 115 |
| Provision (benefit) for income taxes | 11 | 6 | 17 | 54 | (11) | 43 |
| Net income (loss) | 172 | 24 | 196 | 61 | 11 | 72 |
| Net income (loss) attributable to IFF shareholders | 170 | 24 | 194 | 60 | 11 | 71 |
| Net income (loss) per share – basic | $0.67 | $0.09 | $0.76 | $0.23 | $0.05 | $0.28 |
| Net income (loss) per share – diluted | $0.66 | $0.10 | $0.76 | $0.23 | $0.05 | $0.28 |
| Comprehensive income (loss) | 48 | 24 | 72 | (234) | 11 | (223) |
| Comprehensive income (loss) attributable to IFF shareholders | $46 | $24 | $70 | $(235) | $11 | $(224) |

---

**Impacts to Interim Consolidated Statements of Cash Flows**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Nine Months Ended September 30, 2025** | **Nine Months Ended September 30, 2025** | **Nine Months Ended September 30, 2025** | **Six Months Ended June 30, 2025**<sup>(1)</sup> | **Six Months Ended June 30, 2025**<sup>(1)</sup> | **Six Months Ended June 30, 2025**<sup>(1)</sup> |
| *<u>(DOLLARS IN MILLIONS)</u>* | **As Previously Reported** | **Adjustments** | **As Revised** | **As Previously Reported** | **Adjustments** | **As Revised** |
| Net (loss) Income | $(390) | $13 | $(377) | $(405) | $(13) | $(418) |
| &nbsp;&nbsp;Adjustments to reconcile to net cash provided by operating activities: |  |  |  |  |  |  |
| &nbsp;&nbsp;Deferred income taxes | (213) | (13) | (226) | (163) | (14) | (177) |
| &nbsp;&nbsp;Loss on business disposals | 111 |  | 111 | 81 | 30 | 111 |
| &nbsp;&nbsp;Changes in assets and liabilities, net of acquisitions: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Other assets/liabilities, net | (77) |  | (77) | 26 | (3) | 23 |
| Net cash provided by operating activities | $532 | $— | $532 | $368 | $— | $368 |

---

______________________

(1)The previous revision to the Interim Consolidated Statement of Cash Flows for the six months ended June 30, 2025 as reported within our Quarterly Report on Form 10-Q for the fiscal period ended September 30, 2025, has been updated to reflect an additional correction of a $13 million reduction to tax expense on business disposals which has been reflected in Net (loss) Income and Deferred income taxes.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

---

| | | | |
|:---|:---|:---|:---|
| | **Nine Months Ended September 30, 2024** | **Nine Months Ended September 30, 2024** | **Nine Months Ended September 30, 2024** |
| *<u>(DOLLARS IN MILLIONS)</u>* | **As Previously Reported** | **Adjustments** | **As Revised** |
| Net (loss) Income | $293 | $34 | $327 |
| &nbsp;&nbsp;Adjustments to reconcile to net cash provided by operating activities: |  |  |  |
| &nbsp;&nbsp;Deferred Income taxes | (128) | (15) | (143) |
| &nbsp;&nbsp;Loss on assets classified as held for sale | 314 | (30) | 284 |
| &nbsp;&nbsp;Changes in assets and liabilities, net of acquisitions: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Other assets/liabilities, net | (102) | (10) | (112) |
| Net cash provided by operating activities | $702 | $(21) | $681 |
| &nbsp;&nbsp;Cash received on foreign currency forward contracts |  | 21 | 21 |
| Net cash provided by investing activities | $586 | $21 | $607 |

---

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

(a)(3) EXHIBITS

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| 2.1 | <u>[Agreement and Plan of Merger, dated May 7, 2018, by and among the Registrant, Frutarom Industries Ltd. and Icon Newco Ltd., incorporated by reference to Exhibit 2.1 to the Registrant's Current Report on Form 8-K filed on May 9, 2018.](https://www.sec.gov/Archives/edgar/data/51253/000119312518157733/d541104dex21.htm)</u> |
| 2.2 | <u>[Amendment No. 1 to Agreement and Plan of Merger, dated August 25, 2018, by and among](https://www.sec.gov/Archives/edgar/data/51253/000119312518258153/d474311dex21.htm)[the Registrant](https://www.sec.gov/Archives/edgar/data/51253/000119312518258153/d474311dex21.htm)[, Frutarom Industries Ltd. and Icon Newco Ltd. incorporated by reference to Exhibit 2.1 to the Registrant's Current Report on Form 8-K filed on August 27, 2018.](https://www.sec.gov/Archives/edgar/data/51253/000119312518258153/d474311dex21.htm)</u> |
| 2.3 | <u>[Agreement and Plan of Merger, dated December 15, 2019, by and among DuPont de Nemours Inc., Nutrition & Biosciences, Inc.,](https://www.sec.gov/Archives/edgar/data/51253/000119312519316726/d851060dex21.htm)[the Registra](https://www.sec.gov/Archives/edgar/data/51253/000119312519316726/d851060dex21.htm)[nt](https://www.sec.gov/Archives/edgar/data/51253/000119312519316726/d851060dex21.htm)[and Neptune Merger Sub I Inc., incorporated by reference to Exhibit 2.1 to the Registrant's Current Report on Form 8-K filed on December 18, 2019.](https://www.sec.gov/Archives/edgar/data/51253/000119312519316726/d851060dex21.htm)</u> |
| 2.4 | <u>[Separation and Distribution Agreement, dated as of December 15, 2019, by and among DuPont de Nemours Inc., Nutrition & Biosciences, Inc. and](https://www.sec.gov/Archives/edgar/data/51253/000119312519316726/d851060dex22.htm)[the Registrant](https://www.sec.gov/Archives/edgar/data/51253/000119312519316726/d851060dex22.htm)[, incorporated by reference to Exhibit 2.2 to the Registrant's Current Report on Form 8-K filed on December 18, 2019.](https://www.sec.gov/Archives/edgar/data/51253/000119312519316726/d851060dex22.htm)</u> |
| 2.4(i) | <u>[Amendment No. 1 to the Separation and Distribution Agreement, dated January 22, 2021, by and among DuPont de Nemours, Inc., Nutrition & Biosciences, Inc.,](https://www.sec.gov/Archives/edgar/data/0000051253/000119312521015368/d112975dex21.htm)[the Re](https://www.sec.gov/Archives/edgar/data/0000051253/000119312521015368/d112975dex21.htm)[gistrant](https://www.sec.gov/Archives/edgar/data/0000051253/000119312521015368/d112975dex21.htm)[and Neptune Merger Sub II LLC, incorporated by reference to Exhibit 2.1 to the Registrant's Current Report on Form 8-K filed on January 25, 2021.](https://www.sec.gov/Archives/edgar/data/0000051253/000119312521015368/d112975dex21.htm)</u> |
| 2.4(ii) | <u>[Amendment No. 2 to the Separation and Distribution Agreement, dated February 1, 2021, by and among DuPont de Nemours, Inc., Nutrition & Biosciences, Inc.,](https://www.sec.gov/Archives/edgar/data/0000051253/000119312521027533/d70626dex24.htm)[the Registrant](https://www.sec.gov/Archives/edgar/data/0000051253/000119312521027533/d70626dex24.htm)[and Neptune Merger Sub II LLC, incorporated by reference to Exhibit 2.4 to the Registrant's Current Report on Form 8-K filed on February 3, 2021.](https://www.sec.gov/Archives/edgar/data/0000051253/000119312521027533/d70626dex24.htm)</u> |
| 3.1 | <u>[Restated Certificate of Incorporation of the Registrant, incorporated by reference to Exhibit 10(g) to the Registrant's Quarterly Report on Form 10-Q filed on August 12, 2002.](https://www.sec.gov/Archives/edgar/data/51253/000095013602002297/file007.txt)</u> |
| 3.2 | <u>[By-Laws of International Flavors & Fragrances Inc., effective as of November 1, 2023, incorporated by reference to Exhibit 3.1 to the Registrant](https://www.sec.gov/Archives/edgar/data/51253/000119312523272442/d582222dex31.htm)['](http://www.sec.gov/Archives/edgar/data/51253/000119312513142141/d516642dex41.htm)[s Current Report on Form 8-K filed on November 7, 2023.](https://www.sec.gov/Archives/edgar/data/51253/000119312523272442/d582222dex31.htm)</u> |
| 3.3 | <u>[Amended and Restated By-Laws of International Flavors & Fragrances Inc., effective as of October 29, 2025, incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K filed on November 4, 2025.](https://www.sec.gov/Archives/edgar/data/51253/000114036125040332/ef20058220_ex3-1.htm)</u> |
| 4.1 | <u>[Indenture, dated as of March 2, 2016,](https://www.sec.gov/Archives/edgar/data/51253/000119312516490137/d136061dex41.htm)[by](https://www.sec.gov/Archives/edgar/data/51253/000119312516490137/d136061dex41.htm)[and](https://www.sec.gov/Archives/edgar/data/51253/000119312516490137/d136061dex41.htm)[between the Registrant and U.S. Bank National Association, as Trustee (including the form of Debt Security), incorporated by reference to Exhibit 4.1 to the Registrant's Registration Statement on Form S-3 (Registration No. 333-209889) filed on March 2, 2016.](https://www.sec.gov/Archives/edgar/data/51253/000119312516490137/d136061dex41.htm)</u> |
| 4.1(i) | <u>[Second Supplemental Indenture, dated as of May 18, 2017,](https://www.sec.gov/Archives/edgar/data/51253/000119312517175295/d392732dex47.htm)[by](https://www.sec.gov/Archives/edgar/data/51253/000119312517175295/d392732dex47.htm)[and](https://www.sec.gov/Archives/edgar/data/51253/000119312517175295/d392732dex47.htm)[between the Registrant and U.S. Bank National Association, as Trustee (including the form of Notes), incorporated by reference to Exhibit 4.7 to the Registrant's Current Report on Form 8-K filed on May 18, 2017.](https://www.sec.gov/Archives/edgar/data/51253/000119312517175295/d392732dex47.htm)</u> |
| 4.1(ii) | <u>[Fourth Supplemental Indenture, dated as of September 25, 2018,](https://www.sec.gov/Archives/edgar/data/51253/000119312518282495/d614128dex42.htm)[by and](https://www.sec.gov/Archives/edgar/data/51253/000119312518282495/d614128dex42.htm)[between](https://www.sec.gov/Archives/edgar/data/51253/000119312518282495/d614128dex42.htm)[the Registrant](https://www.sec.gov/Archives/edgar/data/51253/000119312518282495/d614128dex42.htm)[and U.S. Bank National Association, as trustee, incorporated by reference to Exhibit 4.2 to the Registrant's Current Report on Form 8-K filed on September 25, 2018.](https://www.sec.gov/Archives/edgar/data/51253/000119312518282495/d614128dex42.htm)</u> |
| 4.1(iii) | <u>[Fifth Supplemental Indenture, dated as of September 26, 2018,](https://www.sec.gov/Archives/edgar/data/51253/000119312518283834/d625848dex42.htm)[by and](https://www.sec.gov/Archives/edgar/data/51253/000119312518283834/d625848dex42.htm)[between](https://www.sec.gov/Archives/edgar/data/51253/000119312518283834/d625848dex42.htm)[the Registrant](https://www.sec.gov/Archives/edgar/data/51253/000119312518283834/d625848dex42.htm)[and U.S. Bank National Association, as trustee, incorporated by reference to Exhibit 4.2 to the Registrant's Current Report on Form 8-K filed on September 26, 2018.](https://www.sec.gov/Archives/edgar/data/51253/000119312518283834/d625848dex42.htm)</u> |
| 4.2 | <u>[Form of Global Note for the 2026 Notes, incorporated by reference to Exhibit 4.2 to the Registrant's Current Report on Form 8-K filed on September 25, 2018.](https://www.sec.gov/Archives/edgar/data/51253/000119312518282495/d614128dex42.htm)</u> |
| 4.3 | <u>[Form of Global Note for the 2028 Notes, incorporated by reference to Exhibit 4.2 to the Registrant's Current Report on Form 8-K filed on September 26, 2018.](https://www.sec.gov/Archives/edgar/data/51253/000119312518283834/d625848dex42.htm)</u> |
| 4.4 | <u>[Form of Global Notes for the 2048 Notes, incorporated by reference to Exhibit 4.2 to the Registrant's Current Report on Form 8-K filed on September 26, 2018.](https://www.sec.gov/Archives/edgar/data/51253/000119312518283834/d625848dex42.htm)</u> |
| 4.5 | <u>[Indenture, dated as of September 16, 2020,](https://www.sec.gov/Archives/edgar/data/51253/000119312520263904/d792766dex9916.htm)[by and](https://www.sec.gov/Archives/edgar/data/51253/000119312520263904/d792766dex9916.htm)[between the N&B and U.S. Bank National Association, as Trustee (including the form of Notes), incorporated by reference to Exhibit 99.16 to the Registrant's Registration Statement on Form S-4 (Registration No. 333-238072) filed on October 5, 2020.](https://www.sec.gov/Archives/edgar/data/51253/000119312520263904/d792766dex9916.htm)</u> |
| 4.5(i) | <u>[First Supplemental Indenture, dated as of February 1, 2021,](https://www.sec.gov/Archives/edgar/data/51253/000119312521027533/d70626dex42.htm)[by and](https://www.sec.gov/Archives/edgar/data/51253/000119312521027533/d70626dex42.htm)[among Nutrition & Biosciences, Inc.,](https://www.sec.gov/Archives/edgar/data/51253/000119312521027533/d70626dex42.htm)[the Registrant](https://www.sec.gov/Archives/edgar/data/51253/000119312521027533/d70626dex42.htm)[and U.S. Bank National Association, as Trustee. Incorporated by reference to Exhibit 4.2 to the Registrant's Current Report on Form 8-K filed on February 4, 2021.](https://www.sec.gov/Archives/edgar/data/51253/000119312521027533/d70626dex42.htm)</u> |
| 4.5(ii) | <u>[Second Supplemental Indenture, dated as of March 4, 2021,](https://www.sec.gov/Archives/edgar/data/51253/000119312521069776/d11494dex41.htm)[by and](https://www.sec.gov/Archives/edgar/data/51253/000119312521069776/d11494dex41.htm)[among Nutrition & Biosciences, Inc.,](https://www.sec.gov/Archives/edgar/data/51253/000119312521069776/d11494dex41.htm)[the Registrant](https://www.sec.gov/Archives/edgar/data/51253/000119312521069776/d11494dex41.htm)[and U.S. Bank National Association, as trustee, incorporated by reference to Exhibit 4.1 to the Registrant's Current Report on Form 8-K filed on March 4, 2021.](https://www.sec.gov/Archives/edgar/data/51253/000119312521069776/d11494dex41.htm)</u> |
| 4.6 | <u>[Description of Securities, incorporated by reference to Exhibit 4.17 to the Registrant's Annual Report on Form 10-K filed on March 3, 2020.](https://www.sec.gov/Archives/edgar/data/51253/000005125320000007/iff10k2019exhibit417.htm)</u> |

---

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| &nbsp;&nbsp;\*10.1 | <u>[Supplemental Retirement Plan, incorporated by reference to Exhibit 10.5 to the Registrant's Annual Report on Form 10-K filed on February 27, 2008.](https://www.sec.gov/Archives/edgar/data/51253/000095013608000919/file2.htm)</u> |
| \*10.2 | <u>[2021 Stock Award and Incentive Plan, incorporated by reference to Annex 1 to the Registrant's Proxy Statement filed with the Commission on March 23, 2021.](https://www.sec.gov/Archives/edgar/data/51253/000119312521091238/d87231ddef14a.htm#rom87231_65)</u> |
| \*10.3 | <u>[Form of Restricted Stock Units Agreement – Non-Employee Director under the 2021 Stock Award and Incentive Plan, incorporated by reference to Exhibit 10.5 to the Registrant's Annual Report on Form 10-K, filed on February 28, 2022.](https://www.sec.gov/Archives/edgar/data/51253/000005125322000007/iff10k2021exhibit105.htm)</u> |
| \*10.4 | <u>[Form of Restricted Stock Units Award Agreement under the 2021 Stock Award and Incentive Plan, incorporated by reference to Exhibit 10.6 to the Registrant's Annual Report on Form 10-K, filed on February 28, 2022.](https://www.sec.gov/Archives/edgar/data/51253/000005125322000007/iff10k2021exhibit106.htm)</u> |
| \*10.5 | <u>[Form of Equity Choice Program Award Agreement under the 2021 Stock Award and Incentive Plan, incorporated by reference to Exhibit 10.7 to the Registrant's Annual Report on Form 10-K, filed on February 28, 2022.](https://www.sec.gov/Archives/edgar/data/51253/000005125322000007/iff10k2021exhibit107.htm)</u> |
| \*10.6 | <u>[Form of Performance-Based Restricted Stock Units Award Agreement under the 2021 Stock Award and Incentive Plan, incorporated by reference to Exhibit 10.8 to the Registrant's Annual Report on Form 10-K, filed on February 28, 2022.](https://www.sec.gov/Archives/edgar/data/51253/000005125322000007/iff10k2021exhibit108.htm)</u> |
| \*10.7 | <u>[2015 Stock Award and Incentive Plan, as amended and restated February 7, 2017, incorporated by reference to Exhibit 10.13 to the Registrant's Annual Report on Form 10-K filed on February 28, 2017.](https://www.sec.gov/Archives/edgar/data/51253/000005125317000004/iff10k2016exhibit1013.htm)</u> |
| \*10.8 | <u>[Form of Annual Incentive Plan Award Agreement under the 2015 Stock Award and Incentive Plan, incorporated by reference to Exhibit 10.3 to the Registrant's Quarterly Report on Form 10-Q filed on May 12, 2015.](https://www.sec.gov/Archives/edgar/data/51253/000005125315000008/iff33115exhibit103.htm)</u> |
| \*10.9 | <u>[Form of Long-Term Incentive Plan Award Agreement under the 2015 Stock Award and Incentive Plan, incorporated by reference to Exhibit 10.4 to the Registrant's Quarterly Report on Form 10-Q filed on May 12, 2015.](https://www.sec.gov/Archives/edgar/data/51253/000005125315000008/iff33115exhibit104.htm)</u> |
| \*10.10 | <u>[Form of Equity Choice Program Award Agreement under the 2015 Stock Award and Incentive Plan, incorporated by reference to Exhibit 10.5 to the Registrant's Quarterly Report on Form 10-Q filed on May 12, 2015.](https://www.sec.gov/Archives/edgar/data/51253/000005125315000008/iff33115exhibit105.htm)</u> |
| \*10.11 | <u>[Form of Non-Employee Director Restricted Stock Units Award Agreement under the 2015 Stock Award and Incentive Plan, incorporated by reference to Exhibit 10.7 to the Registrant's Quarterly Report on Form 10-Q filed on May 12, 2015.](https://www.sec.gov/Archives/edgar/data/51253/000005125315000008/iff33115exhibit107.htm)</u> |
| \*10.12 | <u>[Form of Long-Term Incentive Plan Award Agreement under the 2015 Stock Award and Incentive Plan, incorporated by reference to Exhibit 10.25 to the Registrant's Annual Report on Form 10-K filed on March 1, 2016.](https://www.sec.gov/Archives/edgar/data/51253/000005125316000026/iff10k2015exhibit1025.htm)</u> |
| \*10.13 | <u>[Amended and Restated Executive Severance Policy, as amended through and including November 1, 2017, incorporated by reference to Exhibit 10.17 to the Registrant's Annual Report on Form 10-K filed on February 27, 2018 (the "Executive Severance Policy").](https://www.sec.gov/Archives/edgar/data/51253/000005125318000005/iff10k2017exhibit1017.htm)</u> |
| \*10.14 | <u>[Amendment to the Executive Severance Policy dated November 3, 2020, incorporated by reference to Exhibit 10.18 to the Registrant's Annual Report on Form 10-K filed on February 22, 2021.](https://www.sec.gov/Archives/edgar/data/51253/000005125321000011/iff10k2020exhibit1018.htm)</u> |
| \*10.15 | <u>[Amended and Restated Executive Severance Policy, as amended and restated on February 1, 2023 (the "Executive Severance Policy"), incorporated by reference to Exhibit 10.6 to the Registrant's Quarterly Report on Form 10-Q filed on May 10, 2023.](https://www.sec.gov/Archives/edgar/data/51253/000005125323000019/iff033123exhibit106.htm)</u> |
| \*10.16 | <u>[Form of Director/Officer Indemnification Agreement, incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed on July 28, 2008.](https://www.sec.gov/Archives/edgar/data/51253/000116923208002739/d74603_ex10-1.htm)</u> |
| \*10.17 | <u>[Form of Executive Death Benefit Program - Plan Agreement, incorporated by reference to Exhibit 10.27 to the Registrant's Annual Report on Form 10-K filed on February 28, 2012.](https://www.sec.gov/Archives/edgar/data/51253/000119312512084851/d280956dex1027.htm)</u> |
| \*10.18 | <u>[Deferred Compensation Plan (the "2023 Deferred Compensation Plan"), incorporated by reference to Exhibit 4.3 to the Registrant](https://www.sec.gov/Archives/edgar/data/51253/000119312522294271/d419757dex43.htm)['](http://www.sec.gov/Archives/edgar/data/51253/000005125315000008/iff33115exhibit107.htm)[s Registration Statement on Form S-8 filed on November 29, 2022.](http://www.sec.gov/Archives/edgar/data/51253/000119312522294271/d419757dex43.htm)</u> |
| 10.19 | <u>[Fourth Amended and Restated Credit Agreement, dated as of June 25, 2025, by and among the Registrant](https://www.sec.gov/Archives/edgar/data/821130/000082113025000039/usm2025fourthamendedtermlo.htm)[,](https://www.sec.gov/Archives/edgar/data/821130/000082113025000039/usm2025fourthamendedtermlo.htm)[as borrower](https://www.sec.gov/Archives/edgar/data/821130/000082113025000039/usm2025fourthamendedtermlo.htm)[,](https://www.sec.gov/Archives/edgar/data/821130/000082113025000039/usm2025fourthamendedtermlo.htm)[the lenders signatory thereto](https://www.sec.gov/Archives/edgar/data/821130/000082113025000039/usm2025fourthamendedtermlo.htm)[,](https://www.sec.gov/Archives/edgar/data/821130/000082113025000039/usm2025fourthamendedtermlo.htm)[and Citibank, N.A., as administrative agent.](https://www.sec.gov/Archives/edgar/data/821130/000082113025000039/usm2025fourthamendedtermlo.htm)</u> |
| 10.20 | <u>[Employee Matters Agreement, dated as of December 15, 2019, by and among](https://www.sec.gov/Archives/edgar/data/51253/000119312519316726/d851060dex101.htm)[the Registrant,](https://www.sec.gov/Archives/edgar/data/51253/000119312519316726/d851060dex101.htm)[DuPont de Nemours Inc.,](https://www.sec.gov/Archives/edgar/data/51253/000119312519316726/d851060dex101.htm)[and](https://www.sec.gov/Archives/edgar/data/51253/000119312519316726/d851060dex101.htm)[Nutrition & Biosciences, Inc](https://www.sec.gov/Archives/edgar/data/51253/000119312519316726/d851060dex101.htm)[,](https://www.sec.gov/Archives/edgar/data/51253/000119312519316726/d851060dex101.htm)[incorporated by reference to Exhibit 10.1 to the Registrant](https://www.sec.gov/Archives/edgar/data/51253/000119312519316726/d851060dex101.htm)['](http://www.sec.gov/Archives/edgar/data/51253/000119312520234877/d32016dex102.htm)[s Current Report on Form 8-K filed on December 18, 2019.](https://www.sec.gov/Archives/edgar/data/51253/000119312519316726/d851060dex101.htm)</u> |
| 10.20(i) | <u>[Amendment to the Employee Matters Agreement, dated January 22, 2021, by and among](https://www.sec.gov/Archives/edgar/data/0000051253/000119312521015368/d112975dex101.htm)[the Registrant](https://www.sec.gov/Archives/edgar/data/0000051253/000119312521015368/d112975dex101.htm)[, DuPont de Nemours, Inc. and Nutrition & Biosciences, Inc., incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed on January 25, 2021.](https://www.sec.gov/Archives/edgar/data/0000051253/000119312521015368/d112975dex101.htm)</u> |

---

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| 10.21 | <u>[Cooperation Agreement, dated as of February 1, 2023, by and](https://www.sec.gov/Archives/edgar/data/51253/000119312523022096/d452488dex101.htm)[between the Re](https://www.sec.gov/Archives/edgar/data/51253/000119312523022096/d452488dex101.htm)[gistrant,](https://www.sec.gov/Archives/edgar/data/51253/000119312523022096/d452488dex101.htm)[and Icahn Group, incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed on February 2, 2023.](https://www.sec.gov/Archives/edgar/data/51253/000119312523022096/d452488dex101.htm)</u> |
| 10.22 | <u>[Tax Matters Agreement, dated as of February 1, 2021, by and among DuPont de Nemours, Inc., Nutrition & Biosciences, Inc. and](https://www.sec.gov/Archives/edgar/data/51253/000119312521027533/d70626dex101.htm)[the Registrant,](https://www.sec.gov/Archives/edgar/data/51253/000119312521027533/d70626dex101.htm)[incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed on February 4, 2021.](https://www.sec.gov/Archives/edgar/data/51253/000119312521027533/d70626dex101.htm)</u> |
| 10.23 | <u>[Intellectual Property Cross-License Agreement, dated as of February 1, 2021, by and between Nutrition & Biosciences, Inc. and DuPont de Nemours, Inc., incorporated by reference to Exhibit 10.2 to the Registrant's Current Report on Form 8-K filed on February 4, 2021.](https://www.sec.gov/Archives/edgar/data/51253/000119312521027533/d70626dex102.htm)</u> |
| \*10.24 | <u>[Letter Agreement](https://www.sec.gov/Archives/edgar/data/51253/000119312524006619/d712376dex102.htm)[, effective January 11, 2024, by a](https://www.sec.gov/Archives/edgar/data/51253/000119312524006619/d712376dex102.htm)[nd](https://www.sec.gov/Archives/edgar/data/51253/000119312524006619/d712376dex102.htm)[between](https://www.sec.gov/Archives/edgar/data/51253/000119312524006619/d712376dex102.htm)[the Registrant](https://www.sec.gov/Archives/edgar/data/51253/000119312524006619/d712376dex102.htm)[and J. Erik Fyrwald,](https://www.sec.gov/Archives/edgar/data/51253/000119312524006619/d712376dex102.htm)[incorporated by reference to Exhibit 10.2 to the Registrant's Current Report on Form 8-K filed on January 11, 2024.](https://www.sec.gov/Archives/edgar/data/51253/000119312524006619/d712376dex102.htm)</u> |
| \*10.25 | <u>[International Flavors & Fragrances Inc. Executive Severance Policy.](iff10-k2025exhibit1031.htm)</u> |
| 19 | <u>[International Flavors & Fragrances Inc. Insider Trading Policy.](iff10-k2025exhibit19.htm)</u> |
| 21 | <u>[List of Subsidiaries of International Flavors & Fragrances Inc.](iff10-k2025exhibit21.htm)</u> |
| 23 | <u>[Consent of PricewaterhouseCoopers LLP.](iff10-k2025exhibit23.htm)</u> |
| 31.1 | <u>[Certification of J. Erik Fyrwald pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](iff10-k2025exhibit311.htm)</u> |
| 31.2 | <u>[Certification of Michael DeVeau pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](iff10-k2025exhibit312.htm)</u> |
| 32 | <u>[Certification of J. Erik Fyrwald and Michael DeVeau pursuant to 18 U.S.C. Section 1350 as adopted pursuant to the Sarbanes-Oxley Act of 2002.](iff10-k2025exhibit32.htm)</u> |
| 97 | <u>[International Flavors & Fragrances Inc. Policy for the Recovery of Erroneously Awarded Compensation](iff10-k2025exhibit97.htm)</u> |
| 101.INS | XBRL Instance Document |
| 101.SCH | XBRL Taxonomy Extensions Schema |
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase |
| 101.LAB | XBRL Taxonomy Extension Label Linkbase |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase |

---

**____________________**

\*Management contract or compensatory plan or arrangement

**ITEM 16.&nbsp;&nbsp;&nbsp;&nbsp;FORM 10-K SUMMARY.**

&nbsp;&nbsp;&nbsp;&nbsp;None.

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

**SIGNATURES**

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| **INTERNATIONAL FLAVORS & FRAGRANCES INC.** | **INTERNATIONAL FLAVORS & FRAGRANCES INC.** |
| By: | /s/ Michael DeVeau |
| Name: | **Michael DeVeau** |
| Title: | *Executive Vice President, Chief Financial Officer* |

---

Dated: February 27, 2026

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:

---

| | | |
|:---|:---|:---|
| **<u>Signature</u>** | **<u>Title</u>** | **<u>Date</u>** |
| /s/ J. Erik Fyrwald | Chief Executive Officer and Director (Principal Executive Officer) | February 27, 2026 |
| **J. Erik Fyrwald** |  |  |
| /s/ Michael DeVeau | Executive Vice President, Chief Financial Officer (Principal Financial Officer) | February 27, 2026 |
| **Michael DeVeau** |  |  |
| /s/ Marc Birenkrant | Controller & Chief Accounting Officer (Principal Accounting Officer) | February 27, 2026 |
| **Marc Birenkrant** |  |  |
| /s/ Kevin O'Byrne | Chair of the Board, Director | February 27, 2026 |
| **Kevin O'Byrne** |  |  |
| /s/ Kathryn J. Boor | Director | February 27, 2026 |
| **Kathryn J. Boor** |  |  |
| /s/ Mark J. Costa | Director | February 27, 2026 |
| **Mark J. Costa** |  |  |
| /s/ Virginia C. Drosos | Director | February 27, 2026 |
| **Virginia C. Drosos** |  |  |
| /s/ John F. Ferraro | Director | February 27, 2026 |
| **John F. Ferraro** |  |  |
| /s/ Paul J. Fribourg | Director | February 27, 2026 |
| **Paul J. Fribourg** |  |  |
| /s/ Brett Icahn | Director | February 27, 2026 |
| **Brett Icahn** |  |  |
| /s/ Cynthia T. Jamison | Director | February 27, 2026 |
| **Cynthia T. Jamison** |  |  |
| /s/ Mehmood Khan | Director | February 27, 2026 |
| **Mehmood Khan** |  |  |
| /s/ Jesus B. Mantas | Director | February 27, 2026 |
| **Jesus B. Mantas** |  |  |
| /s/ Richard Mulligan | Director | February 27, 2026 |
| **Richard Mulligan** |  |  |
| /s/ Dawn C. Willoughby | Director | February 27, 2026 |
| **Dawn C. Willoughby** |  |  |

---

------

<u>[**Table of Contents**](#i5239245a6bb24ffbb6af4395e0b30886_7)</u> 

**INTERNATIONAL FLAVORS & FRAGRANCES INC. AND SUBSIDIARIES**

**SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS AND RESERVES**

**(IN MILLIONS)**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **For the Year Ended December 31, 2025** | **For the Year Ended December 31, 2025** | **For the Year Ended December 31, 2025** | **For the Year Ended December 31, 2025** | **For the Year Ended December 31, 2025** | **For the Year Ended December 31, 2025** |
| | **Balance at<br>beginning<br>of period** | **Additions (deductions) charged to costs and expenses** | **Acquisitions** | **Translation<br>adjustments** | **Other** | **Balance at end of period** |
| Valuation allowance on credit and operating loss carryforwards and other net deferred tax assets | $376 | $57 | $— | $21 | $— | $454 |
|  | **For the Year Ended December 31, 2024** | **For the Year Ended December 31, 2024** | **For the Year Ended December 31, 2024** | **For the Year Ended December 31, 2024** | **For the Year Ended December 31, 2024** | **For the Year Ended December 31, 2024** |
|  | **Balance at<br>beginning<br>of period** | **Additions charged to costs and expenses** | **Acquisitions** | **Translation<br>adjustments** | **Other** | **Balance at<br>end of<br>period** |
| Valuation allowance on credit and operating loss carryforwards and other net deferred tax assets | $324 | $72 | $— | $(20) | $— | $376 |
|  | **For the Year Ended December 31, 2023** | **For the Year Ended December 31, 2023** | **For the Year Ended December 31, 2023** | **For the Year Ended December 31, 2023** | **For the Year Ended December 31, 2023** | **For the Year Ended December 31, 2023** |
|  | **Balance at<br>beginning<br>of period** | **Additions charged to costs and expenses** | **Acquisitions** | **Translation<br>adjustments** | **Other** | **Balance at<br>end of<br>period** |
| Valuation allowance on credit and operating loss carryforwards and other net deferred tax assets | $262 | $76 | $— | $(23) | $9 | $324 |

---

_______________________

## Exhibit 10.31

Exhibit 10.31

**INTERNATIONAL FLAVORS & FRAGRANCES INC.**

Amended and Restated <br>Executive Severance Policy<br>(As amended and restated on April 1, 2024)

------

**INTERNATIONAL FLAVORS & FRAGRANCES INC.**

Executive Severance Policy

**<u>Page</u>**

<u>2.</u>&nbsp;&nbsp;&nbsp;&nbsp;<u>Definitions</u>&nbsp;&nbsp;&nbsp;&nbsp;2

<u>3.</u>&nbsp;&nbsp;&nbsp;&nbsp;<u>Eligibility</u>&nbsp;&nbsp;&nbsp;&nbsp;8

<u>4.</u>&nbsp;&nbsp;&nbsp;&nbsp;<u>Administration</u>&nbsp;&nbsp;&nbsp;&nbsp;9

<u>5.</u>&nbsp;&nbsp;&nbsp;&nbsp;<u>Termination of Employment for any Reason</u>&nbsp;&nbsp;&nbsp;&nbsp;9

<u>6.</u>&nbsp;&nbsp;&nbsp;&nbsp;<u>Termination of Employment Prior to or More than Two Years After a Change in Control by (i) the Company either Without Cause or (ii) a Tier I Employee for Good Reason</u>&nbsp;&nbsp;&nbsp;&nbsp;10

<u>7.</u>&nbsp;&nbsp;&nbsp;&nbsp;<u>Termination Within Two Years After a Change in Control by (i) the Company either Without Cause or (ii) Employee for Good Reason</u>&nbsp;&nbsp;&nbsp;&nbsp;11

<u>8.</u>&nbsp;&nbsp;&nbsp;&nbsp;<u>Effect of Federal Excise Tax</u>&nbsp;&nbsp;&nbsp;&nbsp;12

<u>9.</u>&nbsp;&nbsp;&nbsp;&nbsp;<u>Conditions to Receipt of Severance Payments and Benefits: Forfeiture and Repayment Obligations</u>&nbsp;&nbsp;&nbsp;&nbsp;14

<u>10.</u>&nbsp;&nbsp;&nbsp;&nbsp;<u>Other Provisions Applicable to Severance Payments and Benefits</u>&nbsp;&nbsp;&nbsp;&nbsp;18

<u>11.</u>&nbsp;&nbsp;&nbsp;&nbsp;<u>Other Plans and Policies; Non-Duplication of Payments or Benefits</u>&nbsp;&nbsp;&nbsp;&nbsp;19

<u>12.</u>&nbsp;&nbsp;&nbsp;&nbsp;<u>Special Rules for Compliance with Code Section 409A</u>&nbsp;&nbsp;&nbsp;&nbsp;20

<u>13.</u>&nbsp;&nbsp;&nbsp;&nbsp;<u>Miscellaneous</u>&nbsp;&nbsp;&nbsp;&nbsp;21

-i-

------

**INTERNATIONAL FLAVORS & FRAGRANCES INC.**

Amended and Restated Executive Severance Policy

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.<u>Purpose</u>. The purpose of this International Flavors & Fragrances Inc. Amended and Restated Executive Severance Policy (this "<u>Policy</u>") is to provide certain Severance Payments and Benefits (as defined below) to designated key executives and employees of the Company in the event of a termination of their employment in certain specified circumstances. This Policy does not create any contract of employment or right to employment for any period of time. Employment with the Company is at-will, unless otherwise specified in an effective employment agreement between the Company and the Employee and may be terminated by either the Company or the Employee at any time for any reason consistent with the terms and conditions set forth herein and in any other applicable agreement. This Policy has been adopted in the form set forth herein effective as of April 1, 2024 (the "<u>Effective Date</u>"). This Policy is an amendment and restatement of the International Flavors & Fragrances Inc. Executive Severance Policy, which was adopted on November 1, 2017, and amended and restated effective as of February 7, 2017 and further amended on November 3, 2020, December 13, 2022, and February 1, 2023.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.<u>Definitions</u>. The following definitions are applicable for purposes of this Policy (including in any Annex hereto), in addition to terms defined in Section 1 above:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)"2015 SAIP" means the Company's 2015 Stock Award and Incentive Plan, as it may be amended and/or restated from time to time.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)"2021 SAIP" means the Company's 2021 Stock Award and Incentive Plan, as it may be amended and/or restated from time to time.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)"Accounting Forfeiture Event" has the meaning specified in Section 9(b)(ii).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)"Accrued Obligations" means (i) the Employee's base salary otherwise payable through the Date of Termination, (ii) any incentive compensation and benefits which have become vested or payable prior to the Date of Termination in accordance with the terms of the applicable Company incentive compensation and benefit plans and applicable Award Agreements (as defined below) but which have not yet been paid to the Employee, and (iii) unreimbursed business expenses reimbursable under Company policies then in effect; provided, however, that in each of (i), (ii) and (iii), to the extent permissible under applicable law, the Company may offset such amounts against any obligations and liabilities of the Employee to the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)"Affected Employee" has the meaning specified in Section 8(a).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)"Affiliate" means with respect to a specified Person, a Person that directly, or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with, the specified Person.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)"AIP" means, for each Employee, the plan or arrangement of the Company providing cash-denominated bonuses for annual Company and/or business unit performance in which such Employee participates.

-ii-

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)"Award" shall mean any stock-based award or cash award permitted to be granted to an Employee under a SAIP or an AIP.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)"Award Agreement" means an agreement (whether in written or electronic form) evidencing an Award granted under a SAIP or an AIP.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)"Beneficiary" means a person or entity that an Employee designates in writing to the Company to receive payments or benefits hereunder in the event of the Employee's death. If no such person or entity is named or there is no surviving designated Beneficiary, such Employee's Beneficiary shall be the Employee's estate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)"Benefit Continuation" shall mean, subject to the continued co-payment of premiums by the Employee, the continued participation for the Employee and his or her eligible dependents in the Company's Benefit Plans, upon the same terms and conditions in effect from time to time for active employees of the Company, as determined in good faith by the Committee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l)"Benefit Continuation Period" has the meaning specified in Section 6(c).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m)"Benefit Plans" shall mean all medical and dental benefit plans of the Company and any group life insurance plans of the Company, in each case, as may be in effect from time to time. For the avoidance of doubt, Benefit Plans shall not include the Company's group accident insurance and group disability insurance.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n)"Benefits Period" means, unless otherwise provided in the Employee's effective employment agreement with the Company as of the Date of Termination, the maximum period of a number of months following the Date of Termination for each Employee during which Benefit Continuation may be provided pursuant to this Policy, as set forth in Annex I hereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o)"Board" means the Board of Directors of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(p)"Cause" means, with respect to an Employee, the definition as such term is defined in any effective employment agreement with such Employee as of the Employee's Date of Termination, otherwise Cause means (i) the Employee's failure to perform his or her material duties in any material respect (other than as a result of physical or mental incapacity), which if such failure is reasonably susceptible to cure as reasonably determined in the sole discretion of the Committee, has continued after the Company has provided written notice of such failure and the Employee has not cured such failure within ten (10) days of receipt by the Employee of such written notice, (ii) willful misconduct or gross negligence by the Employee that has caused or is reasonably expected to result in material injury to the Company's business, reputation or prospects, (iii) the engagement by the Employee in illegal conduct or in any act of serious dishonesty which could reasonably be expected to result in material injury to the Company's business or reputation or which adversely affects the Employee's ability to perform his or her duties, (iv) the Employee being indicted or convicted of (or having pled guilty or nolo contendere to) a felony or any crime involving moral turpitude, dishonesty, fraud, theft or financial impropriety, or (v) a material and willful violation by the Employee of the Company's rules, policies or procedures. Notwithstanding the foregoing, a Tier I Employee shall not be deemed to have been terminated for Cause unless and until there shall have been delivered to the Employee a copy of the resolution duly adopted by the affirmative vote of the majority of the membership of the Board of Directors of the Company so finding.

-iii-

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(q)A "Change in Control" shall have the meaning set forth in the 2021 SAIP (or any successor plans to the 2021 SAIP).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(r)"CIC Benefit Continuation Period" has the meaning specified in Section 7(e).<sup>1</sup>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(s)"CIC Severance Factor" means, unless otherwise provided in the Employee's effective employment agreement with the Company as of the Date of Termination, the multiple for each Employee as set forth in Annex I hereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(t)"COBRA" means the continuation coverage requirements for "group health plans" under Title X of the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended, and as codified in Code Section 4980B and Sections 601 through 608 of the Employment Retirement Income Security Act of 1974, each as amended from time to time, including rules thereunder and successor provisions and rules thereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(u)"Code" means the Internal Revenue Code of 1986, as amended from time to time, and all regulations, interpretations, and administrative guidance issued thereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)"Code Section 409A" means Section 409A of the United States Internal Revenue Code of 1986, as amended from time to time, and the Treasury Regulations promulgated thereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(w)"Committee" means the Human Capital and Compensation Committee of the Board or such other committee as the Board may designate to perform administrative functions under this Policy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x)"Company" means International Flavors & Fragrances Inc., a New York corporation, and all of its Affiliates, collectively, (and any successors or assigns thereto).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(y)"Confidential Information" has the meaning specified in Section 9(a)(iii).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(z)"Covenant Forfeiture Event" has the meaning specified in Section 9(b)(i).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(aa)"Date of Termination" means, unless otherwise agreed by the Company, (i) if the Employee's employment is terminated by the Company for Cause, or by the Employee for Good Reason (where applicable) and there is an ability to cure, the date that is one day after the last day of any applicable cure period, (ii) if the Employee's employment is terminated by reason of death, the date of death of the Employee, (iii) if the Employee's employment is terminated by reason of disability then the date upon which the Employee becomes Disabled or (iv) if the Employee's employment is terminated for any other reason, the date on which a notice of termination is given or the date set forth in such notice, which, in the event of a termination by the Employee without Good Reason, shall not be less than 60 days after such notice, subject to the discretion of the Committee to accelerate the termination date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ab)"Delay Period" has the meaning specified in Section 12(c).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ac)"Disabled" or "Disability" means, unless otherwise set forth in the Employee's employment agreement with the Company, a condition that entitles an

-iv-

------

Employee to long term disability benefits under any applicable Company disability plan, any successor plan, or as defined under any applicable local laws, rules, or regulations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ad)"Effective Date" has the meaning specified in Section 1.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ae)"Employee" has the meaning specified in Section 3.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(af)"Entity" has the meaning specified in Section 10(a).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ag)"Equity Choice Award" means an equity choice program award under a SAIP.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ah)"Excess Benefit Plan" means the Company's Supplemental Retirement Plan and any other supplemental pension plans sponsored or maintained by the Company as may be in effect from time to time.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ai)"Excess Compensation" has the meaning specified in Section 9(b)(ii)(A).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(aj)"Exchange Act" means the Securities Exchange Act of 1934, as amended.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ak)"Excise Tax" has the meaning specified in Section 8.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(al)"Forfeiture Event" has the meaning specified in Section 9(b)(ii).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(am)"Good Reason" means, with respect to an Employee, where applicable, the definition as such term is defined in any effective employment agreement with such Employee as of the Employee's Date of Termination, otherwise Good Reason means the occurrence of any of the following events, unless the Employee has consented in writing thereto:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)a material decrease in the Employee's base salary or target bonus opportunity under an AIP, other than as part of an across-the-board reduction applicable to all similarly situated employees of the Employee's employer;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)a material diminution in the Employee's authority, duties or responsibilities (other than as a result of physical or mental incapacity);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)a relocation of the Employee's primary work location more than 50 miles from the Employee's primary work location at the time of such requested relocation, which also results in a material increase to the Employee's commute time;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)the failure of the Company to obtain the binding agreement of any successor to the Company expressly to assume and agree to fully perform the Company's obligations under this Policy, as contemplated in the last sentence of Section 13(a) hereof;

provided, that within 90 days after the initial occurrence of any of the events or the initial existence of any of the conditions set forth in (i) through (iv) above the Employee delivers written notice to the Company of his or her intention to terminate his or her employment for Good Reason which specifies in reasonable detail the circumstances claimed to give rise to the Employee's right to terminate employment for Good Reason, and the Company fails to correct such conduct or condition after a period of 30 days

-v-

------

following receipt of such notice. For purposes of this Policy, "Good Reason" is (i) intended to constitute an "involuntary separation" within the meaning of Treasury Regulation § 1.409A-1(n)(2), and (ii) applies to Tier II Employees only within two (2) years after a Change in Control as set forth in Section 7.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(an)"Independent Advisors" has the meaning specified in Section 8(c)(i).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ao)"Initial Payment Period" has the meaning specified in Section 12(c).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ap)"Legal Fees" has the meaning specified in Section 13(d).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(aq)"Limit" has the meaning specified in Section 12(c).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ar)"LTIP" means a long-term performance incentive plan of the Company under a SAIP.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(as)"Person" means an individual, corporation, partnership, limited liability company, association, trust, other entity, group or organization including a governmental authority.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(at)"Policy" has the meaning specified in Section 1.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(au)"PPACA" means the Patient Protection and Affordable Care Act of 2010 and the related regulations and guidance promulgated thereunder, or such other legislation that may be adopted to replace PPACA.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(av)"Reduced Amount" has the meaning specified in Section 8(a).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(aw)"Release" has the meaning specified in Section 9(c)(i).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ax)"Release Period" has the meaning specified in Section 9(c)(i).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ay)"Restatement Clawback Period" has the meaning specified in Section 9(b)(ii).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(az)"SAIP" shall mean each plan, policy, program or arrangement maintained by the Company pursuant to which equity-based awards or cash awards may be granted to Employees, as may be amended and/or restated from time to time. This shall include the 2015 SAIP and the 2021 SAIP. For all purposes hereunder, references to SAIP shall exclude AIP.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ba)"Severance Factor" means, unless otherwise provided in the Employee's effective employment agreement with the Company as of the Date of Termination, the multiple for each Employee as set forth in Annex I hereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(bb)"Severance Payments and Benefits" means all benefits provided or payments made by the Company to or for the benefit of an Employee under this Policy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(bc)"Supplemental Retirement Plan" means the International Flavors & Fragrances Inc. Supplemental Retirement Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.<u>Eligibility</u>. Each key executive or employee of the Company who has been designated in writing by the Committee (each an "<u>Employee</u>") shall be eligible for the Severance

-vi-

------

Payments and Benefits and other provisions of this Policy if his or her termination of employment qualifies hereunder. Each Employee shall be designated in writing by the Committee as either (i) the Chief Executive Officer, (ii) a Tier I Employee or (iii) a Tier II Employee. Employees shall include persons employed outside the United States, if designated by the Committee and subject to Section 13(h) of this Policy. Unless expressly indicated in this Policy, the Chief Executive Officer shall be a Tier I Employee for all purposes under this Policy. For the avoidance of doubt, for purposes of Section 7 herein, an "Employee" shall be each key executive or employee of the Company who has been designated in writing as a Tier I Employee (including the Chief Executive Officer) or Tier II Employee by the Committee as of the date of a Change in Control.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.<u>Administration</u>. Subject to Section 13(e) hereof, this Policy shall be interpreted, administered and operated by the Committee, which shall have complete authority, subject to the express provisions of this Policy, to interpret this Policy, to prescribe, amend and rescind rules and regulations relating to this Policy, and to make all other determinations necessary or advisable for the administration of this Policy. The Committee may delegate any of its duties hereunder to a subcommittee, or to such person or persons from time to time as it may designate. All decisions, interpretations and other actions of the Committee shall be final, conclusive and binding on all parties who have an interest in this Policy. No member of the Committee, nor any Person acting pursuant to authority delegated by the Committee, shall be liable for any action, omission, or determination relating to this Policy, and the Company shall, to the fullest extent permitted by law, indemnify and hold harmless each member of the Committee and each Person to whom any duty or power relating to the administration or interpretation of this Policy has been delegated, against any cost or liability arising out of any action, omission or determination relating to this Policy, unless, in either case, such action, omission, or determination was taken or made by such member or other Person acting pursuant to authority delegated by the Committee in bad faith and without reasonable belief that it was in the best interests of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.<u>Termination of Employment for any Reason</u>. Subject to the terms and conditions contained herein, in the event of any termination of an Employee's employment with the Company for any reason:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)The Company shall pay the Employee the Accrued Obligations, payable on the dates such amounts would have been payable under the Company's policies if the Employee's employment had not terminated, but in no event more than 60 days after Employee's Date of Termination, or sooner if required by applicable law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Except as expressly provided in Section 6 or Section 7 (in the event that either section is applicable), any outstanding Awards (including, for the avoidance of doubt, any AIP, LTIP, restricted stock unit, stock appreciation right, restricted stock and Equity Choice Awards) held by the Employee as of the Date of Termination shall be governed by the terms and conditions of the applicable Award Agreements, SAIP and AIP.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Except as expressly provided in Section 7 (in the event such section is applicable), the Employee's benefits and rights under any of the Company's Benefit Plans, tax-qualified retirement or pension plans and any Excess Benefit Plan shall be determined in accordance with the applicable provisions of such plans, as may be in effect at the Employee's Date of Termination.

In the event of a termination of employment by the Company for Cause, a termination of employment as a result of the Employee's death, Disability or retirement, or the voluntary resignation by Employee other than for Good Reason (where applicable), Employee shall not be

-vii-

------

entitled to receive any compensation, payments or benefits except as specified in Section 5(a)-(c).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.<u>Termination of Employment Prior to or More than Two Years After a Change in Control Either by (i) the Company Without Cause or (ii) a Tier I Employee for Good Reason</u>. In addition to the payments and benefits set forth in Section 5, in the event the Employee's employment with the Company is terminated prior to a Change in Control or more than two (2) years after a Change in Control either (i) by the Company without Cause or (ii) by a Tier I Employee for Good Reason, the Employee shall also be entitled to receive the following payments and benefits, subject to the terms and conditions contained herein including without limitation Sections 9 and 10:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)An amount equal to the product of the Employee's Severance Factor times the sum of (i) the Employee's annual base salary as of the Date of Termination and (ii) the Employee's target annual incentive under the AIP for the year in which the Date of Termination occurs, payable in a lump sum within sixty days (60) days following the Employee's Date of Termination.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)A cash payment equal to the Employee's annual incentive Award under the AIP for the year in which the Date of Termination occurs, based on actual performance, prorated based on the number of the Employee's active days of employment with the Company during the performance period in which the Employee's Date of Termination occurs, payable at the time provided by the AIP and the applicable Award Agreement and such payment shall be in full settlement of the Employee's rights under the AIP for the year in which the Date of Termination occurs.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)For a period commencing on the Employee's Date of Termination until the earlier of (i) the expiration of the Employee's Benefits Period, (ii) the date of the Employee's commencement of eligibility for benefits under a new employer's welfare benefit plans, and (iii) the Employee attaining age 65 (such period, the "<u>Benefit</u> <u>Continuation Period</u>"), the Employee shall be eligible for Benefit Continuation. Benefit Continuation shall be provided to U.S. Employees concurrently with any health care benefit required under COBRA. Notwithstanding the foregoing, if the Company's providing Benefit Continuation to U.S. Employees under this Section 6(b) would violate the nondiscrimination rules applicable to non-grandfathered plans, or would result in the imposition of penalties under the PPACA, the Committee shall have the right to amend this Section 6(b) in a manner it determines, in its sole discretion, to comply with the PPACA. In the case of non-U.S. Employees, Benefits Continuation only applies with respect to Benefit Plans offered to the Employees in their respective jurisdictions. For the avoidance of doubt, in no event shall an Employee's employment be deemed to have been terminated without Cause or for Good Reason as a result of the Employee's death, Disability or retirement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Any outstanding Awards under a SAIP (including, for the avoidance of doubt, any restricted stock unit, stock appreciation right, restricted stock, performance stock units, and Equity Choice Awards) held by the Employee as of the Date of Termination shall be governed by the terms and conditions of the applicable SAIP and award agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.<u>Termination Within Two Years After a Change in Control Either by (i) the Company Without Cause or (ii) Employee for Good Reason</u>. In addition to the payments and benefits set forth in Section 5, in the event the Employee's employment with the Company is terminated within two (2) years after a Change in Control either (i) by the Company without

-viii-

------

Cause or (ii) by the Employee for Good Reason, the Employee shall also be entitled to receive the following payments and benefits, subject to the terms and conditions contained herein including without limitation Sections 9 and 10:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)An amount equal to the product of the Employee's CIC Severance Factor times the sum of (i) the Employee's annual base salary as of the Date of Termination and (ii) the Employee's target annual incentive opportunity under the AIP for the year in which the Date of Termination occurs, payable in a lump sum within 60 days following the Employee's Date of Termination.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)A cash payment equal to the Employee's annual incentive Award under the AIP for the year in which the Date of Termination occurs, based on actual performance, with such Award prorated based on the number of the Employee's active days of employment with the Company during the performance period in which the Employee's Date of Termination occurs, payable at the time provided by the AIP Award Agreement and such payment shall be in full settlement of the Employee's rights under the AIP Award for the year in which the Date of Termination occurs.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)With respect only to LTIP Awards outstanding as of the Effective Date, unless otherwise provided in the applicable Award Agreement, with respect to each LTIP Award outstanding as of the Employee's Date of Termination, the Employee shall receive an LTIP Award payment equal to the product of (x) the LTIP Award payment, if any, the Employee would have been entitled to receive had the Employee's employment with the Company not been terminated, determined in accordance with the LTIP Award and the applicable Award Agreement and (y) a fraction, the numerator of which is the number of days during such performance segment preceding the Employee's Date of Termination and the denominator of which is the total number of days in such performance segment, paid on the date on which the Employee would have otherwise been entitled to receive payment in respect of such LTIP Award had the Employee's employment with the Company not been terminated.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Unless otherwise provided in Section 7(c) herein, any outstanding Awards under any SAIP (including, for the avoidance of doubt, any restricted stock unit, stock appreciation right, restricted stock, performance stock units, LTIP Awards granted after the Effective Date, Equity Choice Awards, and all other Awards under any SAIP) held by the Employee as of the Date of Termination shall be governed by the terms and conditions of the applicable SAIP, it being understood that with respect (i) with respect to Awards granted pursuant to the 2015 SAIP, this shall be Section 11(a) of the 2015 SAIP and (ii) with respect to Awards granted pursuant to the 2021 SAIP, this shall be Section 11(a) of the 2021 SAIP.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)The Employee will be deemed to be fully vested in any benefits he or she has accrued, if any, under the Supplemental Retirement Plan, with the time or times at which benefits are payable under the Supplemental Retirement Plan unchanged; provided, however, that with respect to any "grandfathered" accrued obligations or to the extent permitted under Code Section 409A, the Company may elect to satisfy all obligations to the Employee and his beneficiaries under the Supplemental Retirement Plan by a lump sum payment of the present value of the accrued benefit under the Supplemental Retirement Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)For a period commencing on the Employee's Date of Termination until the earlier of (i) the expiration of the Employee's Benefits Period, (ii) the date of the Employee's commencement of eligibility for benefits under a new employer's welfare benefit plans, and (iii) the Employee attaining age 65 (such period, the "<u>CIC</u> <u>Benefit</u> 

-ix-

------

<u>Continuation Period</u>"), the Employee shall be eligible for Benefit Continuation. Benefit Continuation shall be provided to U.S. Employees concurrently with any health care benefit required under COBRA. Notwithstanding the foregoing, if the Company's providing Benefit Continuation to U.S. Employees under this Section 7(e) would violate the nondiscrimination rules applicable to non-grandfathered plans, or would result in the imposition of penalties under the PPACA, the Committee shall have the right to amend this Section 7(e) in a manner it determines, in its sole discretion, to comply with the PPACA. In the case of non-U.S. Employees, Benefits Continuation only applies with respect to Benefit Plans offered to the Employees in their respective jurisdictions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.<u>Effect of Federal Excise Tax</u>. This Section 8 specifies certain adjustments to the Severance Payments and Benefits an Employee may receive under this Policy if the Company determines that any Severance Payment or Benefit would subject such Employee to an obligation to pay an excise tax imposed by Section 4999 of the Internal Revenue Code of 1986, as amended (or any similar tax that may be imposed) or any interest or penalties related to such excise tax (such excise tax, together with any such interest and penalties, are hereinafter collectively referred to as the "<u>Excise Tax</u>").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)*<u>Cut-Back to Maximize Retained After-Tax Amounts</u>*. In the event the Company determines that any Severance Payment or Benefits would, in whole or part when aggregated with any other right, payment or benefit to or for the Employee (such Employee, the "<u>Affected Employee</u>") under all other agreements, arrangements or plans of the Company, cause any Severance Payment and Benefit or any other payments or benefits to be subject to the Excise Tax, then the Severance Payments and Benefits and all such rights, payments and benefits shall, at the Company's discretion, either (i) be paid in full or (ii) be reduced (or appropriately adjusted) to an amount that is one dollar less than the smallest amount that would give rise to the Excise Tax (the "<u>Reduced</u> <u>Amount</u>"), but only if such Reduced Amount would be greater than the net after-tax proceeds (taking into account the Excise Tax) of the unreduced Severance Payments and Benefits and all such other rights, payments and benefits.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)*<u>Implementation Rules</u>*. If the Severance Payments and Benefits must be reduced as provided in Section 8(a), any reduction in payments and/or benefits required by this provision will occur in the following order: (1) reduction of cash payments; (2) reduction of vesting acceleration of equity awards; and (3) reduction of other benefits paid or provided. In the event that acceleration of vesting of equity awards is to be reduced, such acceleration of vesting will be cancelled in the reverse order of the date of grant for the equity awards. If two or more equity awards are granted on the same date, each award will be reduced on a pro-rata basis. The Employee shall be advised of the determination as to which compensation will be reduced and the reasons therefor, and the Employee and his or her advisors will be entitled to present information that may be relevant to this determination. In no event shall such reduction be effected through a delay in the timing of any Severance Payment and Benefit that is subject to Code Section 409A (or that would become subject to Code Section 409A as a result of such delay).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)For purposes of determining whether any of the Severance Payments or Benefits will be subject to the Excise Tax and the amount of such Excise Tax:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)All Severance Payments and Benefits shall be treated as "parachute payments" within the meaning of Section 280G(b)(2) of the Code, and all "excess parachute payments" within the meaning of Section 280G(b)(1) of the Code shall be treated as subject to the Excise Tax, unless, and except to the extent that, in the written opinion of independent compensation consultants, counsel or auditors of nationally recognized standing ("<u>Independent Advisors</u>") selected by the

-x-

------

Company, the Severance Payments and Benefits (in whole or in part) do not constitute parachute payments, or such excess parachute payments (in whole or in part) represent reasonable compensation for services actually rendered within the meaning of Section 280G(b)(4) of the Code in excess of the base amount within the meaning of Section 280G(b)(3) of the Code or are otherwise not subject to the Excise Tax.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)The value of any non-cash benefits or any deferred payment or benefit shall be determined by the Independent Advisors in accordance with the principles of Sections 280G(d)(3) and (4) of the Code.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)For purposes of determining the amount of the reductions in Severance Payments and Benefits pursuant to Section 8(b), the Affected Employee shall be deemed (i) to pay federal income taxes at the applicable rates of federal income taxation for the calendar year in which the compensation would be payable; and (ii) to pay any applicable state and local income taxes at the applicable rates of taxation for the calendar year in which the compensation would be payable, taking into account any effect on federal income taxes from payment of state and local income taxes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.<u>Conditions to Receipt of Severance Payments and Benefits: Forfeiture and Repayment Obligations</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)<u>Conditions to Receipt of Payments; Employee Obligations</u>. The following requirements must be met by the Employee as a condition to the right to receive, continue to receive, or retain any Severance Payments or Benefits under this Policy:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)The Employee, acting directly or indirectly, shall not, during the period of the Employee's employment and the twelve month period following the Employee's Date of Termination, become employed by, render services for, serve as an agent or consultant to, or become a partner, member, principal, shareholder or other owner of any Competing Business (as defined in Annex II-A for Tier I Participants, and Annex II-B for Tier II Participants). The foregoing notwithstanding, in the event that the provisions set forth in this Section 9(a)(i) conflict with the terms in any effective Employment Agreement or Security Agreement to which the applicable Employee is a party, the terms of such Employment Agreement and/or Security Agreement, as applicable, shall control and shall be incorporated into this Section 9(a)(i) as if set forth herein with regard to such Employee. In addition, the restriction in this Section 9(a)(i) shall not apply to an Employee to the extent it violates applicable law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)The Employee, acting directly or indirectly, shall not, during the Employee's period of employment and the twenty-four month period following the Employee's Date of Termination, (1) solicit, induce, divert, employ or retain, or interfere with or attempt to influence the relationship of the Company, with any Person or entity that is or was, during the last twelve (12) months of the Employee's employment with the Company, (i) an employee of the Company or (ii) a Person engaged to provide services to the Company; or (2) interfere with or attempt to influence the relationship of the Company with any customer, supplier or other Person with whom the Company does business. The foregoing notwithstanding, in the event that the provisions set forth in this Section 9(a)(ii) conflict with the terms in any effective Employment Agreement or Security Agreement to which the applicable Employee is a party, the terms of such Employment Agreement and/or Security Agreement, as applicable, shall control and shall be incorporated into this Section 9(a)(ii) as if set forth herein with regard

-xi-

------

to such Employee. In addition, the restriction in this Section 9(a)(ii) shall not apply to an Employee to the extent it violates applicable law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)The Employee shall not, at any time, directly or indirectly (a) disclose any Confidential Information (as defined below) to any Person (other than, only with respect to the period that the Employee is employed by the Company, to an employee or outside advisor of the Company who requires such information to perform his or her duties for the Company) or (b) use, sell or otherwise transfer, any Confidential Information for Employee's own benefit or the benefit of any third party. "<u>Confidential Information</u>" shall mean (without limiting any definition of the term "confidential information" set forth in any effective Employment Agreement or Security Agreement), confidential, proprietary or commercially sensitive information relating to the Company or its employees, board members, customers, vendors, or other business partners and its businesses, operations, or affairs, including, without limitation, information relating to products, formulations, protocols, processes, designs, formulae, ideas, know-how, test methods, evaluation techniques, patents, trade secrets, scientific or technical data, regardless of the form in which it is maintained or provided, orally or in writing, whether prepared by the Company, a third party or Employee, together with all analyses, compilations, notes and other documents relating thereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)The Employee shall cooperate with the Company by making himself or herself available to testify on behalf of the Company in any action, suit, or proceeding, whether civil, criminal, administrative, or investigative, and shall not otherwise fail to assist the Company in any such action, suit, or proceeding by providing information and meeting and consulting with members of management of, other representatives of, or counsel to, the Company, as reasonably requested.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)The Employee shall not have, during the period of employment, engaged in willful misconduct or violation of a Company policy that is materially detrimental to the Company or in any action or inaction that would constitute grounds for being terminated for Cause, as determined by the Committee in its sole discretion.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)The Employee shall, upon termination of employment with the Company, execute any documentation reasonably requested by the Company and return to the Company all property of the Company, its customers and vendors in Employee's possession or control including, without limitation, all materials, work product or documents containing or pertaining to Confidential Information, and including without limitation, any Company car, all computers (including laptops), cell phones, keys, PDAs, Blackberries, iPhones, Androids, iPads, credit cards, printers, facsimile machines, televisions, card access to any Company building, customer lists, reports, files, e-mails, work papers, memoranda, notes, formulae, tapes, programs, records and software, computer access codes or disks, instructional manuals, and other similar materials or documents used, received or prepared or supervised by Employee in connection with Employee's work for the Company. Employee shall not retain any copies, duplicates, reproductions or excerpts of any of the aforementioned materials or documents and shall not at any time use, recreate or reproduce any said materials or documents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)<u>Forfeiture and Repayment Obligations</u>.

-xii-

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)<u>Due to Employee Failure to Comply with Obligations</u>. If an Employee fails to comply with any of the obligations set forth in Section 9(a) (a "<u>Covenant Forfeiture Event</u>"), the Employee will forfeit or repay to the Company, as the case may be, all Severance Payments and Benefits, whether vested or unvested, paid or unpaid, in each case, that were settled, paid or provided to the Employee under this Policy, and the Company shall have no further obligation to pay, grant, settle, make, provide or continue to make or provide any Severance Payments and Benefits to the Employee under this Policy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)<u>Due to an Accounting Restatement or Misstatement</u>. If the Company is required to prepare an accounting restatement, or if the Company determines that it has misstated its financial results, whether or not as a result of misconduct on the part of the Employee (an "<u>Accounting Forfeiture Event</u>" and, together with a Covenant Forfeiture Event, a "<u>Forfeiture Event</u>"), then, the Employee shall forfeit or repay the Excess Compensation (as defined below) in respect of Severance Payments and Benefits, whether vested or unvested, paid or unpaid, that was granted, settled, provided or paid during the period commencing on the first day of the 12-month period covered by such misstated financial statement through the later of (x) the date of the filing of a restatement where an accounting restatement is required to be filed; (y) the date of the discovery of the misstated financials where any accounting restatement is not required to be filed; or (z) any later date as may be required by applicable law, (the "<u>Restatement</u> <u>Clawback Period</u>").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)For purposes of this Section 9(b)(ii), the term "<u>Excess</u> <u>Compensation</u>" means, the difference between (x) the fair market value of the cash or stock paid to or received by the Employee as part of its Severance Payments and Benefits less (y) the fair market value of the cash or stock that would have been paid to or received by the Employee had the financial statements requiring the misstatement or restatement been properly stated, in all cases as determined by the Committee in its sole discretion.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)For the avoidance of doubt, Severance Payments and Benefits subject to the forfeiture and repayment obligations under this Section 9 shall include any unvested Award, and any amounts paid to Employee on settlement or vesting of an Award but shall not include (A) any earned and unpaid base salary payable through the Employee's Date of Termination, (B) any unreimbursed business expenses reimbursable under Company policies then in effect, and (C) any amount paid by Employee to the Company as a condition of or in connection with settlement of a forfeited Award.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)Any policy of the Company providing for forfeiture or recoupment of compensation, including Section 32 of the 2015 SAIP, Section 32 of the 2021 SAIP and the Company's Policy for the Recovery of Erroneously Awarded Compensation, shall apply by its terms and shall not be deemed limited in any way by this Section 9 or any other provision of this Policy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)Any clawback or recoupment provisions required by law, including under the Dodd-Frank Wall Street Reform and Consumer Protection Act or any rules or regulations thereunder, shall apply to the Severance Payments and Benefits paid or payable under this Policy.

-xiii-

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)Any Severance Payments and Benefits (A) subject to repayment or reimbursement by the Employee under this Section 9 must be repaid or reimbursed to the Company, in the manner and on such terms and conditions as shall be required by the Company by written notice to the Employee, and (B) subject to forfeiture will be forfeited immediately upon written notice to Employee from the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii)For the avoidance of doubt, nothing in any agreement with the Company, or in any Company policy, including this Policy, shall be deemed to prohibit or restrict an Employee from lawfully communicating truthful information, or cooperating with, or otherwise assisting in an investigation by any governmental agency or self-regulatory organization regarding a possible violation of law or responding to any inquiry from any such organization, and an Employee's doing so shall not constitute a Forfeiture Event. If an Employee communicates any Confidential Information to a governmental agency or self- regulatory agency pursuant to this Section, Employee shall notify the agency of the confidentiality of such Confidential Information and ask the agency to also protect the confidentiality of such Confidential Information.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii)In accordance with the Defend Trade Secrets Act of 2016, an Employee will not be held criminally or civilly liable under any federal or state trade secret law for disclosure of a trade secret that: (A) is made (1) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, and (2) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document that is filed under seal in a lawsuit or other proceeding. If an Employee files a lawsuit for retaliation by the Company for reporting a suspected violation of law, the Employee may disclose the Company's trade secrets to his or her attorney and use the trade secret information in the court proceeding if the Employee (a) files any document containing the trade secret under seal, and (b) does not disclose the trade secret, except pursuant to court order.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)<u>Employee Obligation to Execute Release and Termination Agreement</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)The Company's obligations under this Policy to make and provide any Severance Payments and Benefits is also conditioned upon the Employee signing the Exiting Employee Acknowledgement/Certification, any other documentation reasonably requested by the Company, and a release and termination agreement (the "<u>Release</u>"), in a form acceptable to, and to be provided by the Company, and such Release becoming effective, enforceable and irrevocable within 60 days following the Employee's Date of Termination or such earlier date as may be set forth in the Release (such period, the "<u>Release Period</u>").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)Any Severance Payment or Benefit that is subject to Code Section 409A that would otherwise have been made to an Employee but that is conditioned upon the execution and effectiveness of the Release shall be paid or provided on the first business day following the Release Period subject to the execution and effectiveness of the Release; provided that any in-kind benefits provided pursuant to this Policy shall continue in effect after the Date of Termination pending the execution and delivery of the Release; provided that if the Release is not executed and delivered within the Release Period, the Employee shall reimburse the Company for the full cost of providing such in-kind benefits during the Release Period.

-xiv-

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)<u>Agreement Does Not Prohibit Competition or Certain Other Activities</u>. An Employee is not prohibited from engaging in an activity identified in Section 9(a)(i) solely as a result of such provision. Rather, the non-occurrence of the Forfeiture Events set forth in Section 9(a)(i) is a condition to the Employee's right to realize and retain value from his or her Severance Payments and Benefits, and the consequence under this Policy if the Employee engages in an activity giving rise to any such Forfeiture Event are the forfeitures specified herein. The Company and the Employee shall not be precluded by this provision or otherwise from entering into other agreements concerning the subject matter of Section 9.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)<u>No Limitation of Rights</u>. Any forfeiture or repayment under this Section 9 is in addition to, and not in lieu of, any other remedies or rights that may be available to the Company under applicable law, including, without limitation, the right to (i) terminate the Employee, (ii) adjust the future compensation of the Employee, or (iii) take such other action to enforce the Employee's obligations to Company as the Company may deem appropriate in view of the facts and circumstances surrounding the particular situation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)<u>Committee Discretion</u>. The Committee shall have the authority, in its sole discretion, to interpret and construe the provisions of this Section 9 and to make all determinations with respect hereto, including the determination of whether a Forfeiture Event has occurred, the timing of such Forfeiture Event and the amount and form of any forfeiture or reimbursement to be made to the Company by an Employee. The Committee may consider such factors as it deems relevant in making such determinations, including the factors contributing to the Forfeiture Event, harm or potential harm to the Company, the nature and severity of an Employee's behavior or conduct, legal and tax considerations and other facts and circumstances relating to a particular situation. All interpretations, constructions and determinations made by the Committee hereunder shall be final and binding on the Company and the Employee and the determinations of the Committee need not be uniform with respect to all Employees or situations. The Committee may waive in whole or in part the Company's right of recapture or impose additional conditions on any Severance Payment or Benefit granted, settled, paid or provided to an Employee under this Policy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.<u>Other Provisions Applicable to Severance Payments and Benefits</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)*<u>Limitation of Benefits In Case of Certain Business Dispositions</u>*. Notwithstanding anything in this Policy to the contrary, unless the Committee in its sole discretion provides otherwise, an Employee shall not be entitled to any Severance Payments or Benefits upon a termination of employment prior to or more than two years after a Change in Control under Section 6, in the event such termination of employment results from the sale or spin-off of an Affiliate, the sale of a division, other business unit or facility (each an "<u>Entity</u>") in which the Employee was employed immediately prior to such sale, and the Employee has been offered employment with the purchaser of such Entity on substantially the same terms and conditions, as determined by the Committee in its sole discretion, under which the Employee worked prior to the sale, whether or not such Employee accepts or rejects such offer of employment. Such terms and conditions shall include an agreement or plan binding on such purchaser or Entity providing that, upon any termination of the Employee's employment with the purchaser or spun-off Entity of the kinds described in Sections 6 and 7, within two years following such sale or spin-off, the purchaser or spun-off entity shall pay and provide to such Employee payments and benefits comparable to those the Employee would have received under the applicable provisions of Sections 6 and 7 if the Employee had been terminated in like circumstances at the time of such sale and provided Severance Payments and Benefits.

-xv-

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)*<u>Deferrals Included in Salary and Bonus</u>*. All references in this Policy to salary and annual incentive amounts mean those amounts before reduction pursuant to any deferred compensation plan or agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)*<u>Payments and Benefits to Beneficiary Upon Employee's Death</u>*. In the event of the death of an Employee, all payments and benefits hereunder due to such Employee shall be paid or provided to his or her Beneficiary.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)*<u>Transfers of Employment</u>*. Anything in this Policy to the contrary notwithstanding, a transfer of employment from the Company to an Affiliate or vice versa shall not be considered a termination of employment for purposes of this Policy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)*<u>Right of Setoff</u>.* The Company may, to the extent permitted by applicable law, deduct from and set off against any amounts the Company may owe to the Employee from time to time, including amounts payable in connection with any Severance Payment or Benefit, amounts payable in connection with any Award, owed as wages, fringe benefits, or other compensation owed to the Employee, such amounts as may be owed by the Employee to the Company, including but not limited to amounts owed under Section 9, although the Employee shall remain liable for any part of the Employee's payment obligation not satisfied through such deduction and setoff. By accepting the Severance Payments and Benefits under this Policy, the Employee agrees to any deduction or setoff under this Section 10(e).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.<u>Other Plans and Policies; Non-Duplication of Payments or Benefits</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)*<u>Superseded Agreements and Rights</u>*. This Policy constitutes the entire understanding between the Company and the Employee relating to Severance Payments and Benefits to be paid or provided to the Employee by the Company, and supersedes and cancels all prior agreements and understandings with respect to the subject matter of this Policy, other than (i) as expressly set forth in this Policy, (ii) as determined in writing by the Committee, or (iii) as expressly provided in a plan, program or arrangement of the Company which is established following April 1, 2024 and in which the Employee is a participant.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)*<u>Non-Duplication of Payments and Benefits</u>*. The Employee shall not be entitled to any Severance Payment or Benefit under this Policy which duplicates a payment or benefit received or receivable by the Employee under any employment or severance agreement, notice or garden leave provision, or any other plan, program or arrangement of the Company or any severance, notice or garden leave, or similar payment required by applicable law, regulation, sound business practices and customs; provided, however, that with respect to a benefit or payment that is expressly required to be provided by applicable law, regulation, sound business practices and customs, to the extent permissible under applicable law, the Company may offset the amount of any such benefits or payments against the Severance Payments or Benefits due under this Policy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.<u>Special Rules for Compliance with Code Section 409A</u>. This Section 12 serves to ensure compliance with applicable requirements of Code Section 409A. If the terms of this Section 12 conflict with other terms of this Policy, the terms of this Section 12 shall control.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)<u>Termination of Employment Defined</u>. For purposes of this Policy, a "termination of employment" means a separation from service within the meaning of Treasury Regulation § 1.409A-1(h), except for a termination of employment providing for payments or benefits that are "grandfathered" or excluded from being a deferral of compensation under Code Section 409A.

-xvi-

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)<u>Separate Payments</u>. Any payment of Severance Payments and Benefits shall be deemed a separate payment for all purposes, including for purposes of Code Section 409A.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)<u>Six-Month Delay Rule</u>. In the event that any Severance Payments or Benefits constitute "nonqualified deferred compensation" within the meaning of Code Section 409A and as of the date of the Employee's "separation from service," Employee is a "specified employee" (within the meaning of that term under Code Section 409A(a)(2)(B), or any successor provision thereto), then, if the amount of any Severance Payments and Benefits, or any other payments and benefits due pursuant to any other agreement with or plan, program, payroll practice of the Company to be paid within the first six months following the date of such separation from service (the "<u>Initial Payment</u> <u>Period</u>") exceed the amount referenced in Treas. Regs. Section 1.409A-1(b)(9)(iii)(A) (the "<u>Limit</u>"), then: (i) any portion of the Severance Payments and Benefits that is payable or can be provided during the Initial Payment Period that does not exceed the Limit shall be paid or provided at the times set forth in this Policy; (ii) any portion of the Severance Payments and Benefits that is a "short-term deferral" within the meaning of Treas. Regs. Section 1.409A-1(b)(4)(i) shall be paid or provided at the times set forth in in this Policy; and (iii) any portion of the Severance Payments and Benefits that exceeds the Limit and is not a "short-term deferral" (and would have been payable during the Initial Payment Period but for the Limit) shall not be paid or provided, to the extent making or providing such payment or benefit during the Initial Payment Period would result in additional taxes or interest under Code Section 409A of the Code, until the date which is the earlier of (i) the expiration of the six (6)-month period measured from the date of such "separation from service," and (ii) the date of Employee's death (the "<u>Delay</u> <u>Period</u>") and this Policy shall hereby be deemed amended accordingly. Upon the expiration of the Delay Period, all payments and benefits delayed pursuant to this section (whether they would have otherwise been payable in a single sum or in installments in the absence of such delay) shall be paid or reimbursed to Employee in a lump sum, and any remaining payments and benefits due under this Policy shall be paid or provided in accordance with the normal payment dates specified for them herein.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)<u>Continued Benefits</u>. To the extent required by Code Section 409A, any reimbursement or in-kind benefit provided under this Policy shall be provided in accordance with the following: (i) the amount of expenses eligible for reimbursement, or in-kind benefits provided during each calendar year cannot affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other calendar year; (ii) any payments in lieu of the benefits shall be paid no later than the end of Employee's taxable year next following Employee's taxable year in which the benefit or expense was due to be paid; and (iii) any right to reimbursements or in-kind benefits under this Plan shall not be subject to liquidation or exchange for another benefit.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)<u>No Acceleration</u>. The timing of payments and benefits under this Policy may not be accelerated to occur before the time specified for payment hereunder, except to the extent permitted under Treasury Regulation § 1.409A-3(j)(4) or as otherwise permitted under Code Section 409A without the Employee incurring a tax penalty.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)<u>Limitation on Offsets</u>. If the Company has a right of offset that could apply to a payment that constitutes a deferral of compensation under Code Section 409A, such right may only be exercised at the time the payment would have been made to the Employee and may be exercised only as an offset against an obligation that arose within 30 days before and within the same year as the payment date if application of such offset right against an earlier obligation would not be permitted under Code Section 409A.

-xvii-

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)<u>General Compliance</u>. In addition to the foregoing provisions, the terms of this Policy, including any authority of the Company and rights of the Employee which constitute a deferral of compensation subject to Code Section 409A (and which is not grandfathered or excluded from being deemed such a deferral), shall be limited to those terms permitted under Code Section 409A without resulting in a tax penalty to Employee, and any terms not so permitted under Code Section 409A shall be modified and limited to the extent necessary to conform with Code Section 409A but only to the extent that such modification or limitation is permitted under Code Section 409A and the regulations and guidance issued thereunder. The Company and its employees and agents make no representation and are providing no advice regarding the taxation of the payments and benefits under this Policy, including with respect to taxes, interest and penalties under Code Section 409A and similar liabilities under state and local tax laws. No indemnification or gross-up is payable under this Policy with respect to any such tax, interest, or penalty under Code Section 409A or similar liability under state or local tax laws applicable to any Employee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.<u>Miscellaneous</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)<u>Assignment; Non-transferability</u>. No right of an Employee to any payment or benefit under this Policy shall be subject to assignment, anticipation, alienation, sale, transfer, assignment, pledge, encumbrance, attachment, or garnishment by creditors of the Employee or of any beneficiary of the Employee. The terms and conditions of this Policy shall be binding on the successors and assigns of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)<u>Withholding</u>. The Company shall have the right to deduct from all payments hereunder any taxes required by law to be withheld therefrom.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)<u>No Right to Employment</u>. Nothing in this Policy shall be construed as giving any person the right to be retained in the employment of the Company, nor shall it affect the right of the Company to dismiss an Employee without any liability except as provided in this Policy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)<u>Legal Fees</u>. The Employee shall pay all legal fees and related expenses incurred by such Employee in seeking to obtain or enforce any payment, benefit or right provided by this Policy; provided, however, that if the Employee prevails on at least one material claim that forms part of a dispute with the Company regarding the enforceability of any provision of the Policy, the Company shall reimburse the Employee for all reasonable attorneys' fees and related expenses ("Legal Fees") incurred by the Employee in connection with such dispute, provided that the Employee shall have submitted an invoice for such Legal Fees at least 10 days before the end of the calendar year next following the calendar year in which an award to Employee on at least one material claim is rendered. In no event shall the payments by the Company of Legal Fees be made later than the end of the calendar year next following the calendar year in which such Legal Fees were incurred. The amount of such Legal Fees that the Company is obligated to pay in any given calendar year shall not affect the Legal Fees that the Company is obligated to pay in any other calendar year, and an Employee's right to have the Company pay such Legal Fees may not be liquidated or exchanged for any other benefit.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)<u>Amendment and Termination</u>. The Board may amend or terminate this Policy at any time; provided, however, (i) during the two years following a Change in Control, this Policy may not be amended or terminated in any manner materially adverse to an Employee without the written consent of such Employee, and (ii) at any other time, this Policy may not be amended or terminated in any manner materially adverse to an Employee except with 60 days' notice to the affected Employee (immediately after which

-xviii-

------

such amendment or termination becomes effective as to all affected Employees), and no such amendment or termination shall be effective to limit any right or benefit relating to a termination during the two years after a Change in Control under Section 7 if a Change in Control has occurred prior to the lapse of such 60-day notice period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)<u>Governing Law; Arbitration</u>. THE VALIDITY, CONSTRUCTION, AND EFFECT OF THIS POLICY AND ANY RULES AND REGULATIONS RELATING TO THIS POLICY SHALL BE DETERMINED IN ACCORDANCE WITH THE LAWS (INCLUDING THOSE GOVERNING CONTRACTS) OF THE STATE OF NEW YORK, WITHOUT GIVING EFFECT TO PRINCIPLES OF CONFLICTS OF LAWS, AND APPLICABLE FEDERAL LAW. If any provision hereof shall be held by a court or arbitrator of competent jurisdiction to be invalid and unenforceable, the remaining provisions shall continue to be fully effective. Any dispute or controversy arising under or in connection with this Policy shall be settled exclusively by arbitration in New York, New York by one arbitrator in accordance with the rules of the American Arbitration Association in effect at the time of submission to arbitration. Judgment may be entered on the arbitrator's award in any court having jurisdiction. For purposes of settling any dispute or controversy arising hereunder or for the purpose of entering any judgment upon an award rendered by the arbitrator, the Company and the Employee hereby consent to the jurisdiction of any or all of the following courts: (i) the United States District Court for the Southern District of New York, or (ii) any of the courts of the State of New York located in New York County. The Company and the Employee hereby waive, to the fullest extent permitted by applicable law, any objection which it may now or hereafter have to such jurisdiction and any defense of inconvenient forum. The Company and the Employee hereby agree that a judgment upon an award rendered by the arbitrator may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)<u>No Duty to Mitigate</u>. No employee shall be required to mitigate, by seeking employment or otherwise, the amount of any payment that the Company becomes obligated to make under this Policy, and, except as expressly provided in this Policy, any Severance Payment or Benefit to be paid or provided to an Employee pursuant to this Policy shall not be reduced by reason of the Employee's obtaining other employment or receiving similar payments or benefits from another employer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)<u>Awards to Employees Outside the United States</u>. The Committee may modify the terms and conditions of participation of any Employee who is then resident or primarily employed outside the United States or is subject to taxation by a non-U.S. jurisdiction in any manner deemed by the Committee to be necessary or appropriate in its sole discretion in order that such terms and conditions shall conform to the laws, regulations, sound business practices or customs of the country in which the Employee is then resident or primarily employed.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)<u>Notices</u>. All notices shall be in writing and shall be deemed duly given (a) on the date of delivery if delivered personally, (b) on the date sent by electronic mail or other electronic means, (c) on the date of delivery via a recognized overnight courier service (delivery receipt requested), or (d) on the fifth business day following the date of mailing, if mailed by first class mail and registered or certified mail, return receipt requested, postage prepaid to the party to receive such notice (irrespective of whether such registered or certified mail is signed for by the receiving party), at the business address in the case of the Company, and at the address on file with the Company, in the case of the Employee.

-xix-

------

**<u>Annex I</u>**

---

| | | | |
|:---|:---|:---|:---|
| **Title** | **Severance Factor** | **Benefits Period** | **CIC Severance Factor** |
| Tier I Employees | | | |
| • Chief Executive Officer | 2 | 24 months | 3 |
| • All Other Tier I Employees | 1.5 | 18 months | 2 |
| Tier II Employees | 1 | 12 months | 1.5 |

---

-xx-

------

**<u>ANNEX II-A</u>**

For purposes of the Policy, a "Competing Business" shall mean any individual or entity that develops, manufactures, sells, and/or distributes a product or service that competes directly or indirectly with those products or services offered by the Company during the last two (2) years of the applicable Employee's employment with the Company.

-xxi-

------

**<u>ANNEX II-B</u>**

For purposes of the Policy, a "Competing Business" shall mean any individual or entity that develops, manufactures, sells, and/or distributes a product or service that competes directly or indirectly with those products or services offered by the Company during the last two (2) years of the applicable Employee's employment with the Company, and: (i) which the Employee had responsibility for or worked on in the last two (2) years of employment with the Company, or (ii) where the Employee would be performing the same or similar duties that the Employee performed for the Company during the last two (2) years of employment with the Company.

In recognition of the international nature of the Company's business, which includes the sale of its products and services globally, this restriction shall apply to each state or territory of the United States of America, and each country of the world outside of the United States of America, in which the applicable Employee was employed or had responsibility within the last two (2) years of employment with the Company.

-xxii-

## Ex-19

Exhibit 19

![image_0.jpg](image_0.jpg)

**<u>INTERNATIONAL FLAVORS & FRAGRANCES INC. INSIDER TRADING POLICY</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**I.SUMMARY**

This Insider Trading Policy (the "Policy") is intended to assist Insiders (as defined below) in their compliance with laws that prohibit certain persons who are aware of "material non-public information" (as described below) from (i) trading in securities on the basis of such material non-public information or (ii) providing material non-public information to other persons who may trade securities on the basis of that information.

This Policy complements the Company's Window Period Policy attached hereto as Exhibit I and the Company's Confidential & Proprietary Information Policy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**II.APPLICABILITY & SCOPE**

This Policy applies to every employee, officer, member of the Board of Directors of the Company and their "Related Persons" (as defined below), as well as independent contractors or consultants who have access to material non-public information (each, an "Insider"). For purposes of this Policy, a "Related Person" includes a person's spouse, children and anyone else living in the person's household and other entities controlled by the person.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**III.OVERVIEW** 

U.S. securities laws regulate the sale and purchase of securities in the interest of protecting the investing public. It is a violation of U.S. securities laws for any person to buy or sell securities if he or she is in possession of material non-public information.

**What is Material Non-Public Information?**

Information is "material" if there's a substantial likelihood that a reasonable investor would consider it important in making a decision to buy, sell or hold securities. Information is "non-public" if it has not been publicly disclosed. Information is considered to have been publicly disclosed only after it has been released to the public through appropriate channels (typically, by means of a widely-disseminated press release, such as through the Dow Jones "broad tape" or newswire services, or in a filing with the Securities and Exchange Commission (the "SEC")), and only after enough time has elapsed to permit the investment community to absorb and evaluate the information.

The following are examples of non-public information that, if material, could qualify as material non-public information:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• unpublished operating or financial results;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• projections of future earnings or losses, or other earnings guidance, or changes to previously announced earnings guidance;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• a change in business plans, outlook or strategies;

------

Exhibit 19

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• a pending or proposed merger, acquisition, tender offer, exchange offer, divestiture or joint venture;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• a pending or proposed restructuring, such as the closure of a significant facility;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• a material sale or disposition of assets if not in the ordinary course of business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• a financing transaction or bank borrowing out of the ordinary course of business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• a change in dividend policy, the declaration of a stock split, an offering of securities or the establishment of a stock repurchase program;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• a change in senior management;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• a pending or threatened litigation or regulatory action, or the resolution of a litigation or regulatory action;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the introduction of a significant new product, process or service, including significant research and development discoveries; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• a change to the Company's pricing structure, the gain or loss of a significant customer, distributor, agent or supplier, the entry into a new line of business or product, or a significant new "win" or "loss".

The above is a representative list of material non-public information and is not the only information that could be considered as such.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**IV.GENERAL RULES**

**Non-Disclosure** 

Material non-public information must not be disclosed to anyone, including a fellow employee, family member, friend or other third party, who does not need to know such information for IFF business purposes. Each Insider has an obligation to maintain the confidentiality of such information. These obligations apply irrespective of whether such information is obtained from a director, officer, employee, independent contractor, consultant, customer, vendor or other business partner or otherwise, and they continue following the termination of an Insider's relationship with IFF.

**Trading in IFF Securities**

No Insider may purchase or sell, or place a purchase or sale order, or recommend that another person purchase or sell, or place a purchase or sale order, for Company securities when such person or entity has knowledge of material non-public information concerning IFF. This includes purchases and sales of stock, cashless exercises of stock options or stock-settled appreciation rights ("SSARs") and discretionary transactions (such as an election to increase or decrease periodic contributions in the IFF stock fund of IFF's Retirement Investment Fund Plan(s) (401(k)).

**Trading in Other IFF Securities**

No Insider should place a purchase or sale order, or purchase or sell, or recommend that another person purchase or sell, the securities of another company if the Insider learns, in the course of his or her employment or otherwise, material non-public information about the other company that is likely to affect the value of those securities. This applies even to companies located outside the United States.

------

Exhibit 19

**Tipping**

All Insiders are prohibited from providing any third party with information or from recommending that such third party buy or sell securities when that Insider is aware of material non-public information. This is called "tipping". Both the Insider and the third party receiving the tip could be held liable.

**Short Sales**

All Insiders are prohibited from effecting "short sales" of Company securities, in which the seller borrows the shares from his or her broker (who usually in turn has borrowed the shares from some other investor) and then sells them. "Sales against the box", which involve a sale of Company securities that are owned but are not delivered after the sale, are also prohibited.

**Margin Accounts and Pledging**

All Insiders are prohibited from purchasing Company securities on margin, holding Company securities in a margin account or pledging Company securities as collateral for a loan.

**Hedging and Monetization Transaction**

Certain forms of hedging or monetization transactions, such as zero-cost collars and forward sale contracts, allow an individual to lock in much of the value of his or her stock holdings, often in exchange for all or part of the potential for upside appreciation in the stock. These transactions allow the individual to continue to own the covered securities, but without the full risks and rewards of ownership. When that occurs, the individual may no longer have the same objectives as IFF's other shareholders. Therefore, Insiders may not engage in any such transactions in connection with IFF securities.

**Trading in Derivatives**

All Insiders are prohibited from trading in derivatives of IFF securities, such as put and call options.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**V. SPECIFIC PROHIBITIONS AND REQUIREMENTS**

**IFF Stock Options, SSARs, Restricted Stock and Restricted Stock Units**

The exercise of employee stock options or SSARs (other than a "cashless" exercise as described below) and vesting of restricted stock or restricted stock units ("RSU's") are not subject to this Policy. However, except for shares of stock withheld by IFF to pay taxes, stock that was acquired upon exercise of a stock option or SSAR, or upon vesting of restricted stock or RSU's, will be treated like any other stock, and may not be sold by an employee who possesses material non-public information.

**Cashless Exercise of Stock Options or SSARs**

Shares sold in a "cashless" exercise of stock options or SSARs (i.e., the simultaneous exercise of options or SSARs and sale of the underlying shares on the open market) are treated like any other sale of IFF's shares. Consequently, no Insider may transact a "cashless" exercise under IFF's equity award program while in possession of material nonpublic information.

**IFF Stock Fund under the IFF Retirement Investment Fund Plan(s) (401(k))**

Automatic acquisitions of IFF stock in IFF stock fund under IFF's 401(k) plan(s) or Deferred Compensation Plan ("DCP") based on an investment election made at a time that an Insider is not in possession of material non-public information are not subject to this Policy or, in the case of DCP, based on an investment election made during a routine annual election cycle. However,

------

Exhibit 19

no Insider may transfer funds in or out of the IFF stock fund or modify the Insider's investment elections relating to the IFF stock fund while in possession of material non-public information relating to IFF.

**Dividend Reinvestment**

Purchases of IFF securities under IFF's reinvestment plan resulting from reinvestment of dividends paid on IFF securities are not subject to this Policy. However, no Insider may make voluntary purchases of IFF securities resulting from additional contributions in IFF's dividend reinvestment plan while in possession of material non-public information relating to IFF.

**Restrictions on "Window Policy Persons"**

In accordance with IFF's Window Period Policy, "Window Policy Persons" consist of IFF's senior officers, employees regularly exposed to material non-public information, members of IFF's Board of Directors and their Related Persons. Window Policy Persons are subject to additional restrictions on trading in IFF securities as set forth in the IFF's Window Period Policy.

**Section 16 Filer Reporting Obligations**

"Section 16 Filers" have additional obligations to report all transactions relating to Company securities to the SEC on a Form 4 which must be filed no later than two (2) business days after the transaction is consummated. They also must disgorge "short- swing profits" earned from trading in such securities. In addition to obtaining the required pre-approval for trading in IFF securities under IFF's Window Period Policy, Section 16 Filers must report each transaction in IFF securities to the General Counsel, except that the General Counsel shall report each transaction in IFF securities to the Chief Executive Officer, in accordance with that policy.

**Rule 10b5-1 Trading Plans**

A Rule 10b5-1 trading plan is a written plan that (i) is a binding agreement to buy or sell IFF securities and (ii) instructs a third person to buy or sell a specific amount of IFF securities at specific price(s) and on specific dates or a period of time. Subject to IFF's Window Period Policy; and the 10b5-1 Trading Plan Guidelines in Exhibit A, Insiders may enter into a 10b5-1 trading plan if they are not aware of any material non-public information at the time of entering into such plan. Non-Rule 10b5-1 plans are not permitted, and any trading plan should be entered into pursuant to the guidelines in Exhibit A.

**Individual Responsibility**

Each Insider is responsible for making sure that he or she complies with this Policy and the Insider is responsible for complying with all applicable laws on this topic. The responsibility for determining whether an individual possesses material non-public information rests with that individual. Any action on the part of IFF under this Policy does not in any way constitute legal advice or otherwise insulate an individual from liability under applicable securities laws. A breach of insider trading laws could expose an Insider to criminal fines, imprisonment and civil penalties. Violations of this Policy may constitute grounds for disciplinary action, including dismissal. Employees are required to report possible violations of this Policy to IFF's General Counsel.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**VI.QUESTIONS**

While IFF personnel are not expected to be experts on the subject of this Policy, they must be aware of and comply with the restrictions contained in this Policy. If you have any questions regarding this Policy, please contact an attorney in the Legal Department.

------

Exhibit 19

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**VII.WHERE TO GO FOR HELP**

If you have questions about this Policy, contact Legal at <u>law.department@iff.com</u>.

If you believe that someone may have violated this Policy, please contact IFF's Global Ethics & Compliance team at <u>compliance@iff.com</u>. You may also report a concern or violation at <u>iff.com/speakup</u>.

IFF strictly forbids reprisal, retaliation, or subsequent discrimination against any person who in good faith raises a concern or reports possible misconduct.

IFF will investigate alleged misconduct in relation to this Policy in accordance with internal procedures on investigations. Any IFF Personnel who violates this Policy may be subject to disciplinary measures, up to and including termination of employment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**VIII.REFERENCE DOCUMENTS**

The following policies and procedures provide additional guidance and direction:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• IFF Code of Conduct

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• IFF Window Period Policy

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• IFF Confidential Information & Trade Secret Policy

All IFF policies, procedures, and guidelines can be found in the Policies & Procedures section of IFF Connect.

------

Exhibit 19

**Exhibit A** 

**<u>Rule 10b5-1 Trading Plan Guidelines February 2026</u>**

All sales or purchases of International Flavors & Fragrances Inc. (the "Company") securities made pursuant to a trading plan by Company Insiders (as defined below) must be made pursuant to a plan that complies with Rule 10b5-1 under the Securities and Exchange Act of 1934 and the Company guidelines included in the enclosed Annexes. "Company Insiders" refers to the members of the Board of Directors (the "Directors"), Section 16 Officers of the Company, other executives and Window Policy Persons as defined in the Company's Window Period Policy.

Entering into 10b5-1 trading plans reduces (i) the risk that members of senior management or company insiders may inadvertently violate insider trading laws; and (ii) the adverse publicity associated with transactions in Company securities by senior executives made outside of 10b5-1 plans. A 10b5-1 trading plan is a written plan that instructs a broker to buy or sell a specific amount of Company securities at specified times, at specific price(s) (e.g. limit or "not less than price" or market price) or when a combination of the two occur. Rule 10b5-1 trading plans can provide an affirmative defense to insider trading liability for trades executed as a part of the plan. Specifically, trades pursuant to the plan will not be viewed as being based on material nonpublic information if the trading plan is established in accordance with the appropriate protocol.

Attached in <u>Annex 1</u> is a set of frequently asked questions and in <u>Annex 2</u> a summary of restrictions regarding Rule 10b5-1 trading plans.

If you have any questions or are interested in entering into a 10b5-1 trading plan, please contact the Company's General Counsel.

------

Exhibit 19

**Annex 1** 

**<u>Rule 10b5-1 Trading Plans - Frequently Asked Questions</u>**

Rule 10b5-1 (the "Rule") Trading Plans provide a mechanism for Company Insiders to trade Company securities even while aware of material, nonpublic information. A trading plan, properly designed to comply with requirements of the Rule, will permit insiders to trade securities in many situations where they previously might not have been able to, thereby allowing them more opportunities to trade Company securities to meet their particular investment objectives.

The following Q&A describes the requirements of a Rule 10b5-1 Trading Plan, the advantages and disadvantages of such plans and the process for establishing, modifying and terminating such plans.

*Q: What is a Rule 10b5-1 Trading Plan?* 

A: &nbsp;&nbsp;&nbsp;&nbsp;A Rule 10b5-1 Trading Plan is a binding contract, instruction or written plan that specifies the amount, price and dates on which insiders may trade securities and complies with Rule 10b5-1 under the Securities and Exchange Act of 1934. A plan may include a formula for determining the amount, price and dates of trades, and Company Insiders cannot influence the purchase or sale of Company securities under a plan. A third-party broker would be responsible for executing trades. Trading plans which do not meet the requirements for a Rule 10b5-1 Trading Plan, referred to as non-Rule 10b5-1 Trading Plans, are not permitted for Company Insiders.

Company Insiders may enter into a plan only during an open Window Period and when they are not aware of any material nonpublic information. Although these plans act as an affirmative defense to insider trading liability with respect to trades pursuant to the plan, they do not prohibit or prevent derivative lawsuits from disgruntled investors. Instead, Company Insiders trading under a plan would demonstrate that their trades were made pursuant to the terms of their plan, not on inside information.

*Q: What is the advantage of these plans?* 

A: &nbsp;&nbsp;&nbsp;&nbsp;They can provide an affirmative defense to insider trading liability with respect to trades pursuant to the plan. Specifically, Company Insiders who trade pursuant to the plan will not be viewed as having traded based on material nonpublic information if they demonstrate that the transactions in question were done according to a written trading plan established in accordance with the requirements of the Rule before they became aware of the information. In addition, Company Insiders will not need to determine whether or not information they have about the Company would be deemed material non-public information. This is often a complicated determination. Further, a Rule 10b5- 1 Trading Plan can expand significantly the time period in which Company Insiders may execute transactions in Company securities.

*Q: Are there any drawbacks?* 

A: &nbsp;&nbsp;&nbsp;&nbsp;While Rule 10b5-1 Trading Plans provide some additional protection to Company Insiders from insider trading liability, there are some drawbacks. Company Insiders who enter into prearranged trading programs will lose some degree of investment control over their trading activity. Moreover, as stated above, trading under a pre-arranged trading program does not eliminate the possibility that a lawsuit could be filed alleging insider trading, nor does it prevent the media from reporting on the trading activity in question. All trades made under the plan still require public filings if you are otherwise required to make public filings of your trades.

*Q: Who should I contact if I want to set up a Rule 10b5-1 Trading Plan?*

A: You should contact your personal broker and the Company's General Counsel.

If you hold physical securities, you will need to provide the stock certificates and legal transfer documentation. As a Section 16 Officer or a Director or if you otherwise hold

------

Exhibit 19

restricted securities, you also must comply with Rule 144, and a timely Form 144 filing would be required.

*Q: Does the Company require me to use a specific document as my Rule10b5-1 Trading Plan?*

A: &nbsp;&nbsp;&nbsp;&nbsp;The Company has a preferred form of trading plan that you can use, but your broker may have its own form. If you would like a copy of our preferred form or if your broker requires use of its form, please contact the Company's General Counsel. We will need to approve changes to our form or the terms of your broker's form.

*Q: What details should I include in my plan?*

A: &nbsp;&nbsp;&nbsp;&nbsp;You must specify an amount, a price and a date for all transactions executed in your plan. The amount can be either a number of shares or a specific dollar value of securities. The price can be the market price on a particular date or a limit price. The date can be either a specific day of the year on which a market order is to be executed or a day or days of the year on which a limit order is in effect. The length of the plan should be no less than 9 months to one year in duration. Longer plans may be permissible. Once these parameters are set, your broker will have the authority to trade within these parameters without further consultation.

*Q: Do I need to obtain pre-clearance from the Company before adopting, modifying or terminating a plan?*

A: &nbsp;&nbsp;&nbsp;&nbsp;Any entry into, modification or termination of an existing plan by a Section 16 Officer or a Director must be pre-cleared by the Company's General Counsel and, in the case of the Company's General Counsel, the pre-clearance is required by the Chief Executive Officer. In addition, Company Insiders must include a representation certifying, at the time of adoption or modification of such plan, that: (1) such Company Insider is not aware of material nonpublic information about the Company or its securities; and (2) such Company Insider is adopting the plan in good faith and not as part of a plan or scheme to evade the prohibitions of the Rule.

*Q:&nbsp;&nbsp;&nbsp;&nbsp;What else do I need to consider when setting up a plan?*

A:&nbsp;&nbsp;&nbsp;&nbsp;We encourage you to consult your own legal counsel, investment advisor and tax advisor about the legal, investment and tax implications of your plan.

*Q: When can I start trading under a plan?*

A: &nbsp;&nbsp;&nbsp;&nbsp;There is a minimum waiting period between the date a Rule 10b5-1 trading plan is adopted or modified and when trading under the trading plan may commence. Trading may not commence:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• for Directors and Section 16 Officers, until the later of (1) 90 days following adoption or modification of such plan or (2) two business days following disclosure of the Company's financial results in a Form 10-Q or 10-K for the fiscal quarter in which the plan was adopted or modified (but not to exceed 120 days following plan adoption or modification); or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• for all other employees of the Company, until 30 days following adoption or modification of such plan.

*Q: What is the Good Faith requirement?*

A: You must "have acted in good faith with respect to" the contract, instruction or plan. For example, an employee would not be operating a Rule 10b5-1 plan in good faith, notwithstanding that the employee entered the plan in good faith, if the employee, while aware of material nonpublic information, directly or indirectly induces the issuer to publicly disclose that information in a manner that makes their trades under a Rule 10b5-1 plan more profitable.

------

Exhibit 19

*Q: Can I amend and/or terminate the plan?*

A: As noted above, any entry into, modification or termination of an existing plan by a Section 16 Officer or a Director must be pre-cleared by the Company's General Counsel and, in the case of the Company's General Counsel by the Company's Chief Executive Officer. You should also ask your broker about the implications of amending or terminating your plan. Subject to IFF internal approvals, as applicable, and as a general matter, you may terminate or amend a plan at any time by writing to your broker. However, terminating or amending a plan prior to its expiration under the provisions of the plan could call into question the good-faith nature of the plan (the premise that it is not part of a scheme to evade the prohibitions of Rule 10b5-1) and thus cause prior trades to lose the benefit of the affirmative defense. Therefore, to the extent possible, it is best to avoid making changes to the trading program. Most amendments will be treated as a termination of the original plan and the creation of a new one. Moreover, please note that any modifications to the amount, price or timing of the purchase or sale of securities under a trading plan will trigger a new waiting period, as discussed above. If not modified or terminated, your plan will expire on its own, based on a termination date, the number of shares bought or sold, the dollar amount or other reasons specified in the plan agreement.

*Q: Under what circumstances would my plan be suspended?*

A: A plan may be suspended if you or the Company notifies your broker of a restriction that would prevent transactions in your account, such as a tender offer for the Company's securities or a qualifying security offering by the Company. Your broker also may suspend your plan if it becomes aware of material nonpublic information concerning the Company or its securities or if market conditions prohibit trading.

*Q: Can I enter into a plan to purchase securities?*

A: Yes. Although most plans provide for the sale of an insider's securities, they also can be used to buy securities.

*Q: May I enter into other transactions to sell securities outside the Rule 10b5-1 Trading Plan?* 

A: Yes. However, you will need to comply with Rule 144 in connection with any such trade and you must comply with our regular insider trading policy on trading securities as well as securities laws generally.

*Q: Are there other limitations?*

A: Yes. You may not enter into multiple, overlapping trading plans, including 401(k) plans that are structured as Rule 10b5-1 Trading Plans, unless such plans qualify as "sell-to-cover" plans (i.e., plans that allow only sales that are necessary to satisfy tax withholding obligations that arise from the vesting of certain compensatory awards). In addition, if a plan is meant to effect a single transaction, you must not have had another single-trade plan (pursuant to Rule 10b5-1 or otherwise) during the prior 12-month period.

We strongly encourage you to consult with your own legal counsel, broker and/or investment advisor when determining whether a Rule 10b5-1 Trading Plan is best for you.

If you have any questions, please contact the Company's General Counsel.

------

Exhibit 19

**Annex 2** 

**<u>Rule 10b5-1 Trading Plans – Summary</u>**

&nbsp;&nbsp;&nbsp;&nbsp;1.All sales or purchases of IFF shares made pursuant to a trading plan by Company Insiders must be made pursuant to a trading plan that complies with Rule 10b5-1 under the Securities Exchange Act of 1934 (a "10b5-1 Plan" or "plan") and the guidelines set forth herein.

&nbsp;&nbsp;&nbsp;&nbsp;2.A 10b5-1 Plan must be put in place no later than one week following an earnings release (preferably as soon as the window opens).

&nbsp;&nbsp;&nbsp;&nbsp;3.Trading under 10b5-1 Plans by Section 16 Officers and Directors is subject to a cooling off period, i.e., a 10b5-1 Plan may not commence until the later of (1) 90 days following adoption or modification of such plan or (2) two business days following disclosure of the Company's financial results in a Form 10-Q or 10-K for the fiscal quarter in which the plan was adopted or modified (but not to exceed 120 days following plan adoption or modification). For all other employees of the Company, trading under a 10b5-1 Plan may not commence until 30 days following adoption or modification of such plan.

&nbsp;&nbsp;&nbsp;&nbsp;4.The length of the plan should be no less than 9 months in duration. Longer plans are permissible. Given the lengthy cooling off period between plans, longer plans may be preferred.

&nbsp;&nbsp;&nbsp;&nbsp;5.Any modifications to the amount, price or timing of the purchase or sale of securities under a 10b51 Plan will be deemed a termination of such plan and trigger a new cooling off period.

&nbsp;&nbsp;&nbsp;&nbsp;6.You may not enter into multiple, overlapping plans, including 401(k) plans that are structured as 10b5-1 Plans, unless such plans qualify as "sell-to-cover" plans (i.e., plans that allow only sales that are necessary to satisfy tax withholding obligations that arise from the vesting of certain compensatory awards). If you are considering a sell-to-cover plan, please discuss with legal to confirm it falls within the Rule.

&nbsp;&nbsp;&nbsp;&nbsp;7.If a plan is meant to effect a single transaction, you must not have had another single-trade plan (pursuant to Rule 10b5-1 or otherwise) during the prior 12-month period.

&nbsp;&nbsp;&nbsp;&nbsp;8.Any entry into a new 10b5-1 Plan, modification or termination of an existing plan by a Section 16 Officer or a Director must be pre-cleared by the Company's General Counsel and, in the case of the Company's General Counsel by the Company's Chief Executive Officer. You should only enter into a plan with the expectation that it will be in place for its entire term.

&nbsp;&nbsp;&nbsp;&nbsp;9.Plans can only be entered into if the person entering into such plan is not in possession of material nonpublic information and if such person is adopting the 10b5-1 Plan in good faith.

&nbsp;&nbsp;&nbsp;&nbsp;10.Shares that are tendered for an outstanding PRSU award may not be registered under a 10b5-1 Plan.

## Ex-21

Exhibit 21

**LIST OF SUBSIDIARIES OF INTERNATIONAL FLAVORS & FRAGRANCES INC.**

(the "Company")

---

| | |
|:---|:---|
| **Name of Entity** | **Jurisdiction** |
| Danisco Argentina S.A. | Argentina |
| International Flavors & Fragrances S.R.L. | Argentina |
| Solae Argentina S.A. | Argentina |
| Danisco Australia Pty Limited | Australia |
| Solae Australia Pty Limited | Australia |
| Nutrition & Biosciences Australia Pty Ltd | Australia |
| Enzymotec Australia Pty Ltd | Australia |
| IFF Australia Holdings Pty Limited | Australia |
| International Flavours & Fragrances (Australia) Pty Ltd | Australia |
| Bush Boake Allen Australia Pty Ltd | Australia |
| Taura Natural Ingredients Holdings Pty Limited | Australia |
| Danisco Austria GmbH | Austria |
| Frutarom GmbH | Austria |
| PTI-BEL TUE | Belarus |
| Genencor International BV | Belgium |
| Solae Belgium N.V. | Belgium |
| Frutarom Belgium N.V. | Belgium |
| Taura Natural Ingredients NV | Belgium |
| Danisco Ingredients Belgium N.V. | Belgium |
| TNI Investments NV | Belgium |
| Danisco Brasil Ltda. | Brazil |
| Solae Do Brasil Indústria E Comércio De Alimentos Ltda | Brazil |
| Solae Investimentos Ltda | Brazil |
| Solae Do Brasil Holdings Ltda | Brazil |
| Bremil S/A Industria de Produtos Alimenticios | Brazil |
| Bremil Industria E Comercio de Ingredientes Alimenticios Ltda | Brazil |
| Envoltec Industria de Embalagens Ltda | Brazil |
| Sabormax Industria de Alimentos E Representacao Ltda | Brazil |
| Frutarom do Brazil Industria e Comercio Ltda. | Brazil |
| IFF Essências e Frangrâncias Ltda. | Brazil |
| Bush Boake Allen Do Brasil Indústria e Comércio Ltda. | Brazil |
| IFF (BVI) Limited | British Virgin Islands |
| Fragrance Resources Asia Pacific Limited | British Virgin Islands |
| David Michael & Company (Canada) 1986 Ltd. | Canada |
| Danisco Canada Inc. | Canada |
| International Flavors & Fragrances (Canada) Ltd. | Canada |
| Danisco Chile S.A. | Chile |
| Frutarom Chile S.A. | Chile |
| International Flavors & Fragrances I.F.F. (Chile) Limitada | Chile |
| Bush Boake Allen Chile S.A. | Chile |
| Genencor (China) Bio-Products Co., Ltd. | China |
| Danisco (China) Holding Company Limited | China |

---

------

---

| | |
|:---|:---|
| **Name of Entity** | **Jurisdiction** |
| Danisco (Zhangjiagang) Textural Ingredients Co., Ltd. | China |
| Danisco Health Foods (Beijing) Co., Ltd. | China |
| Danisco (China) Co., Ltd. | China |
| Danisco Shineway Luohe Soy Industry Company Limited<sup>(1)</sup> | China |
| Solae Trading (Shanghai) Co., Ltd. | China |
| Danisco Shineway Luohe Food Company Limited<sup>(2)</sup> | China |
| Frutarom F&F Trading (Shanghai) Co., Ltd. | China |
| Tastepoint Flavors (Shanghai) Co., Ltd. | China |
| Frutarom Flavors (Kushan) Co., Ltd. | China |
| Inventive Food Technology (ZQ) Ltd. | China |
| Danisco Biosciences (Shanghai) Co., Ltd. | China |
| International Flavors & Fragrances (China) Ltd. | China |
| International Flavors & Fragrances (Hangzhou) Co., Ltd.<sup>(3)</sup> | China |
| International Flavors & Fragrances (Zhejiang) Co., Ltd. | China |
| International Flavors & Fragrances (ZhangJiagang) Co., Ltd. | China |
| IFF Bio Technology (Nanjing) Co., Ltd. | China |
| IFF Flavors & Fragrances (Hangzhou) Trading Co., Ltd. | China |
| Danisco Colombia Ltda. | Colombia |
| International Flavors And Fragrances Colombia S.A.S. | Colombia |
| Specialty Products Balkans d.o.o. | Croatia |
| Cupressus Limited | Cyprus |
| Vantodio Holdings Limited | Cyprus |
| Danisco Czech Republic, a.s. | Czech Republic |
| Tastepoint CZ, s.r.o. | Czech Republic |
| Solae Denmark ApS | Denmark |
| International N&H Denmark ApS | Denmark |
| Cometra ApS | Denmark |
| FYMSA del Caribe, S.R.L | Dominican Republic |
| Danisco Egypt Trading LLC | Egypt |
| MISR Company for Aromatic Products (S.A.E.) | Egypt |
| Aromco Ltd. | England |
| FoodBlenders Limited | England |
| Hagelin Flv (UK) Ltd. | England |
| Frutarom UK Investments Limited | England |
| International Flavours & Fragrances (CIL) Limited | England |
| Bush Boake Allen Enterprises Limited | England |
| Bush Boake Allen Limited | England |
| International Flavours & Fragrances (GB) Holdings Limited | England |
| International Flavours & Fragrances I.F.F. (Great Britain) Limited | England |
| A. Boake, Roberts And Company (Holding), Limited | England |
| Bush Boake Allen Holdings (U.K.) Limited | England |
| Frutarom (UK) Ltd. | England |
| Frutarom – Etol (UK) Limited | England |
| International Flavours & Fragrances (Pension Trustees) Limited | England |
| Savoury Flavours (Holding) Limited | England |

---

------

---

| | |
|:---|:---|
| **Name of Entity** | **Jurisdiction** |
| Savoury Flavours Ltd. | England |
| International N&H Manufacturing UK Limited | England |
| Solae (UK) Limited | England |
| Finnfeeds Oy | Finland |
| Genencor International Oy | Finland |
| Danisco Sweeteners Oy | Finland |
| Finnfeeds Finland Oy | Finland |
| Danisco France SAS | France |
| Atelier du Parfumeur IFF Grasse SAS | France |
| International Flavors & Fragrances IFF (France) SAS | France |
| Solae Deutschland GmbH | Germany |
| Danisco Deutschland GmbH | Germany |
| extrakt chemie Dr. Bruno Stellmach GmbH | Germany |
| Frutarom Germany GmbH | Germany |
| IFF Fragrance GmbH | Germany |
| International Flavors & Fragrances IFF (Deutschland) G.M.B.H. | Germany |
| Leagel GmbH | Germany |
| Walsroder CMC GmbH | Germany |
| Danisco Nutrition & Bioscience Greece Ltd | Greece |
| Danisco Guatemala S.A. | Guatemala |
| Danisco Centro America S.A. | Guatemala |
| Aroma S.A. | Guatemala |
| Manseg S.A. | Guatemala |
| Frutarom (Asia Pacific) Limited | Hong Kong |
| Prowin International Ltd. | Hong Kong |
| Inventive Technology Ltd. | Hong Kong |
| International Flavors & Fragrances (Hong Kong) Limited | Hong Kong |
| Nutrition & Biosciences Hungary Kft. | Hungary |
| IFF Hungary Global Korlátolt Felelősségű Társaság | Hungary |
| International Flavors & Fragrances I.F.F. (Hungary) Korlátolt Felelősségű Társaság | Hungary |
| Solae Company India Private Limited | India |
| Danisco (India) Private Limited | India |
| Danisco Nutrition and Biosciences India Private Limited | India |
| International Flavours & Fragrances India Private Limited<sup>(4)</sup> | India |
| P.T. Essence Indonesia | Indonesia |
| PT. INTERNATIONAL FLAVORS FRAGRANCES INDONESIA | Indonesia |
| International Flavors & Fragrances Irish Acquisition Company Limited | Ireland |
| IFF Capital Services | Ireland |
| Irish Flavours and Fragrances (CIL) Limited | Ireland |
| Aromatics Holdings Limited | Ireland |
| Cytisus Pharma Company Limited | Ireland |
| Seamair Pharma Company Limited | Ireland |
| Frutarom (UK) Holdings Limited | Israel |
| Frutarom Ltd. | Israel |
| Frutarom Trade & Marketing (1990) Ltd. | Israel |

---

------

---

| | |
|:---|:---|
| **Name of Entity** | **Jurisdiction** |
| Frutarom Industries Ltd. | Israel |
| International Flavors and Fragrances Ingredients Ltd | Israel |
| International Flavors & Fragrances I.F.F. (Israel) Ltd. | Israel |
| Frutarom Global Ltd. | Israel |
| BKF Vision Ltd | Israel |
| K - Vision Consulting and Investments Ltd | Israel |
| M.P. Equity Holdings Ltd | Israel |
| Nutra-Lease Ltd.<sup>(5)</sup> | Israel |
| Danisco Italy S.p.A. | Italy |
| International Flavors e Fragrances IFF (Italia) S.R.L. | Italy |
| Danisco Japan Limited | Japan |
| International Flavors & Fragrances (Japan) Ltd. | Japan |
| PTI Astana LLC | Kazakhstan |
| International N&H Kenya Limited | Kenya |
| Frutarom Kenya Limited | Kenya |
| Danisco Nutrition & Biosciences Korea Ltd. | Korea |
| IFF (Korea) Inc. | Korea |
| Frutarom Finance EUR AG | Lichtenstein |
| Nutrition & Bioscience (Luxembourg) Sàrl | Luxembourg |
| International Flavors & Fragrances (Luxembourg) S.a.r.l. | Luxembourg |
| International Flavors & Fragrances Ardenne S.a.r.l. | Luxembourg |
| L'Atelier Vanille Madagascar | Madagascar |
| Danisco Malaysia Sdn. Bhd. | Malaysia |
| International Flavors & Fragrances (Malaysia) Sdn. Bhd. | Malaysia |
| International Flavours & Fragrances (Mauritius) Ltd | Mauritius |
| Genencor Mauritius Ltd | Mauritius |
| IFF Nutrition Mexico SA de CV | Mexico |
| Solae De Mexico S. A. De C.V. | Mexico |
| Danisco Mexicana S.A. de C.V. | Mexico |
| International Flavors & Fragrances (Mexico), SA de CV | Mexico |
| Bush Boake Allen Controladora, S.A. DE C.V. | Mexico |
| PTI-MOL LLC | Moldova |
| ERELEM | Morocco |
| International Flavors & Fragrances (Myanmar) Limited | Myanmar |
| Bush Boake Allen Benelux B.V. | Netherlands |
| Danisco Zaandam BV | Netherlands |
| Genencor International B.V. | Netherlands |
| New Asia Holdco B.V. | Netherlands |
| N&B EMEA Holding B.V. | Netherlands |
| N&H LA Holding B.V. | Netherlands |
| Genencor International Holding B.V. | Netherlands |
| N&H EMEA Holding B.V. | Netherlands |
| IB EMEA Holding 2 B.V. | Netherlands |
| N&H International Holding 1 B.V. | Netherlands |
| N&H EMEA Holding 1 B.V. | Netherlands |

---

------

---

| | |
|:---|:---|
| **Name of Entity** | **Jurisdiction** |
| N&H EMEA Holding 2 B.V. | Netherlands |
| SP EMEA Holding 8 B.V. | Netherlands |
| Solae Overseas B.V. | Netherlands |
| Danisco Holland B.V. | Netherlands |
| Frutarom Netherlands B.V. | Netherlands |
| International Flavors & Fragrances I.F.F. (Nederland) B.V. | Netherlands |
| International Flavors & Fragrances (Nederland) Holding B.V. | Netherlands |
| N&B Services B.V. | Netherlands |
| N&B International Holding B.V. | Netherlands |
| MC (Netherlands) B.V. | Netherlands |
| Taura Natural Ingredients Limited | New Zealand |
| Danisco New Zealand Limited | New Zealand |
| International Flavours & Fragrances (NZ) Limited | New Zealand |
| IFF Nutrition Nigeria Limited | Nigeria |
| IFF West Africa Limited | Nigeria |
| Frutarom Nigeria Limited | Nigeria |
| Etol Skopje DRUŠTVO ZA TRGOVIJA ETOL UVOZ-IZVOZ DOOEL | North Macedonia |
| Ingrediants dooel Skopje | North Macedonia |
| Nutrition & Bioscience Pakistan (Private) Ltd | Pakistan |
| Danisco Perú S.A.C | Peru |
| IFF Perú S.A. (Montana Food activity) | Peru |
| IFF Nutrition Philippines, Inc. | Philippines |
| International Flavors & Fragrances (Philippines), Inc. | Philippines |
| Danisco Poland Sp. z.o.o | Poland |
| Tastepoint Polska Z.o.o. | Poland |
| International Flavors & Fragrances (Poland) Sp. z o.o. | Poland |
| Chemical Process Materials and Equipment S.A. | Republic of Panama |
| International Aroma Group | Republic of Panama |
| Mark Services Holdings Inc. | Republic of Panama |
| Frutarom Etol RO SRL | Romania |
| Frutarom (Marketing) S.R.L | Romania |
| ZAO Danisco (Closed Joint Stock Company "Danisco") | Russia |
| Tekhnomol Soya Products LLC | Russia |
| Platinum Absolut LLC | Russia |
| LLC PTI Group of companies (short name GK PTI) | Russia |
| PTI-NN LLC | Russia |
| "Tastepoint OOO" (Tastepoint Russia Ltd) | Russia |
| International Flavors & Fragrances I.F.F. (Rus) | Russia |
| Leagel S.r.l. | San Marino |
| Tastepoint JVE d.o.o. Novi Sad | Serbia |
| International Flavors & Fragrances (Greater Asia) Pte. Ltd. | Singapore |
| Enzymotec Singapore Pte Ltd | Singapore |
| Vaya Pharma Pte Ltd<sup>(6)</sup> | Singapore |
| Danisco Singapore Pte. Ltd. | Singapore |
| ETOL SK, s.r.o | Slovakia |

---

------

---

| | |
|:---|:---|
| **Name of Entity** | **Jurisdiction** |
| VITIVA proizvodnja in storitve d.d. (Short name: VITIVA d.d.) | Slovenia |
| Tastepoint d.o.o. | Slovenia |
| Etol Proizvodnja Arom D.O.O | Slovenia |
| Danisco South Africa (Pty) Ltd. | South Africa |
| Tastepoint SA (Pty) Ltd | South Africa |
| International Flavors and Fragrances IFF (South Africa) (Proprietary) Limited | South Africa |
| IFF Protein Technologies International Sales, LLC South Africa Branch | South Africa |
| IFF Nutrition and Biosciences Iberica S.L. | Spain |
| IFF Murcia Natural Ingredients, S.L.U | Spain |
| IFF Benicarló, S.L. | Spain |
| International Flavors & Fragrances I.F.F. (España), S.A. | Spain |
| IFF Latin American Holdings (España), S.L. | Spain |
| IFF Lanka Private Limited | Sri Lanka |
| Danisco Cultor Sweden AB | Sweden |
| International Flavors & Fragrances I.F.F. (Norden) AB | Sweden |
| Danisco Cultor (Switzerland) AG | Switzerland |
| Danisco Switzerland AG | Switzerland |
| Solae Europe Sarl | Switzerland |
| Frutarom Switzerland Finance USD AG | Switzerland |
| Frutarom Switzerland Finance CHF AG | Switzerland |
| Frutarom Switzerland Finance GBP AG | Switzerland |
| Frutarom Switzerland Finance MXN AG | Switzerland |
| Frutarom Switzerland Ltd. | Switzerland |
| International Flavors & Fragrances Taiwan Limited | Taiwan |
| International N&H (Thailand) Co. Ltd | Thailand |
| International N&H (Thailand) Co. Ltd- branch | Thailand |
| International Flavours & Fragrances (Thailand) Limited | Thailand |
| Danisco Dis Ticaret Limited Sirketi | Turkey |
| International NH Dis Ticaret Limited Sirketi | Turkey |
| Etol Aroma Ve Baharat Gida Ürünleri San.ve Tic.a.Ş. | Turkey |
| Frutarom Gida Ürünleri Sanayi Ve Ticaret Limited Sirketi | Turkey |
| WIBERG Baharat Sanayi Ve Ticaret Anonim Şirketi | Turkey |
| IFF Turkey Aroma ve Esans Ürünleri Satis Ticaret Anonim Sirketi | Turkey |
| IFF Aroma Esans Sanayi Ve Ticaret Anonim Şirketi | Turkey |
| Danisco Ukraine LLC | Ukraine |
| PARMA FA | Ukraine |
| PTI-Ukraine LLC | Ukraine |
| International Flavors & Fragrances (Middle East) FZ-LLC | United Arab Emirates |
| Agtech Products, Inc. | United States |
| Asian Investments, Inc. | United States |
| Bush Boake Allen, Inc. | United States |
| CitraSource Holdings, L.L.C. | United States |
| Columbia PhytoTechnology LLC | United States |
| Crestmont Investment Co. | United States |
| Danisco Holding USA Inc. | United States |

---

------

---

| | |
|:---|:---|
| **Name of Entity** | **Jurisdiction** |
| Danisco US Inc. | United States |
| Danisco USA Inc. | United States |
| IFF US Holding, LLC | United States |
| Eden Essentials, Inc. | United States |
| Enzymotec USA Inc. | United States |
| Finnsugar Bioproducts, Inc. | United States |
| Flavor Systems International, Inc. | United States |
| Frutarom USA Holding, Inc. | United States |
| Frutarom USA Inc. | United States |
| Genencor International Wisconsin, Inc. | United States |
| Genentech Ventures, Inc. GTVI | United States |
| Grow Company Inc. | United States |
| Health Wright Products, LLC | United States |
| iDrug Delivery, Inc.<sup>(7)</sup> | United States |
| IFF Acquisition, LLC | United States |
| IFF Augusta Holdings LLC | United States |
| IFF Chemical Holdings Inc. | United States |
| IFF Electronics Holding, LLC | United States |
| IFF International, Inc. | United States |
| IFF Protein Technologies International Sales, LLC | United States |
| IFF S&C Holding, LLC | United States |
| IFF US Holding, LLC | United States |
| International Flavors & Fragrances (Caribe) Inc. | United States |
| International Flavors & Fragrances Holdings, LLC | United States |
| International Frutarom Corporation | United States |
| MC (US) 1 LLC | United States |
| Neptune Merger Sub II LLC | United States |
| Nutrition & Biosciences USA 3, LLC | United States |
| Nutrition & Biosciences USA 4, Inc. | United States |
| PM Taiwan, LLC | United States |
| Pointer Specialty Chemicals, LLC | United States |
| Solae Holdings LLC | United States |
| Solae, LLC | United States |
| SP Holding IB, LLC | United States |
| SP Nutrition and Health (Singapore), Inc. | United States |
| Specialty Products N&H, Inc. | United States |
| Sweeteners (US) LLC | United States |
| Tastepoint Inc. | United States |
| Taura Natural Ingredients (North America) Inc. | United States |
| The Additive Advantage LLC | United States |
| The Foote & Jenks Corporation | United States |
| van Ameringen-Haebler, Inc. | United States |
| Vaya Pharma Inc | United States |
| Eigenbucket LLC | United States |
| Venezuelan Protein Technologies International - Pti, C.A. | Venezuela |

---

------

---

| | |
|:---|:---|
| **Name of Entity** | **Jurisdiction** |
| Nutrition & Biosciences Vietnam Company Limited | Vietnam |
| International Flavors & Fragrances (Vietnam) Limited Liability Company | Vietnam |
| Bush Boake Allen Zimbabwe (Private) Limited | Zimbabwe |
| International Flavors & Fragrances (Zimbabwe) (Private) Ltd. | Zimbabwe |

---

The companies listed above constitute all subsidiaries of the Company as of February 27, 2026. Except as otherwise indicated, such subsidiaries are wholly owned, directly or indirectly, by the Company.

____________________

&nbsp;&nbsp;&nbsp;&nbsp;(1)60% of the voting stock of Danisco Shineway Luohe Soy Industry Company Limited is owned indirectly by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;(2)52% of the voting stock of Danisco Shineway Luohe Food Company Limited is owned indirectly by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;(3)95% of the voting stock of International Flavors & Fragrances (Hangzhou) Co., Ltd. is owned indirectly by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;(4)93.36% of the voting stock of International Flavours & Fragrances India Private Limited is owned indirectly by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;(5)56.9% of the voting stock of Nutra-Lease Ltd. is owned indirectly by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;(6)80% of the voting stock of Vaya Pharma Pte Ltd is owned indirectly by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;(7)65% of the voting stock of iDrug Delivery, Inc. is owned indirectly by the Company.

## Ex-23

Exhibit 23

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-268580, No. 333-255780, No. 333-252650, No. 033-54423, No. 333-120158, No. 333-126421, No. 333-51436, No. 333-50752 and No. 333-277520) of International Flavors & Fragrances Inc. of our report dated February 27, 2026 relating to the financial statements, financial statement schedule and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.

---

| |
|:---|
| /s/ PricewaterhouseCoopers LLP |
| New York, New York |
| February 27, 2026 |

---

## Exhibit 31.1

Exhibit 31.1

**CERTIFICATION** 

I, J. Erik Fyrwald, certify that:

1. I have reviewed this Annual Report on Form 10-K of International Flavors & Fragrances Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 27, 2026

---

| | |
|:---|:---|
| By: | /s/ J. Erik Fyrwald |
| Name: | J. Erik Fyrwald |
| Title: | Chief Executive Officer |

---

## Exhibit 31.2

Exhibit 31.2

**CERTIFICATION** 

I, Michael DeVeau, certify that:

1. I have reviewed this Annual Report on Form 10-K of International Flavors & Fragrances Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 27, 2026

---

| | |
|:---|:---|
| By: | /s/ Michael DeVeau |
| Name: | Michael DeVeau |
| Title: | Executive Vice President, Chief Financial Officer |

---

## Ex-32

Exhibit 32

**CERTIFICATION OF CEO AND CFO PURSUANT TO 18 U.S.C. SECTION 1350,** 

**AS ADOPTED PURSUANT TO** 

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002** 

In connection with the Annual Report on Form 10-K of International Flavors & Fragrances Inc. (the "Company") for the fiscal year ended December 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), J. Erik Fyrwald, as Chief Executive Officer of the Company, and Michael DeVeau, as Chief Financial Officer, each hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: February 27, 2026

---

| | |
|:---|:---|
| By: | /s/ J. Erik Fyrwald |
| Name: | J. Erik Fyrwald |
| Title: | Chief Executive Officer |

---

---

| | |
|:---|:---|
| By: | /s/ Michael DeVeau |
| Name: | Michael DeVeau |
| Title: | Executive Vice President, Chief Financial Officer |

---

## Ex-97

Exhibit 97

**INTERNATIONAL FLAVORS & FRAGRANCES INC.<br>POLICY FOR THE<br>RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION**

1.<u>Purpose</u>. The purpose of this Policy is to describe the circumstances in which Executive Officers will be required to repay or return Erroneously Awarded Compensation to the Company in accordance with the Clawback Rules. Each Executive Officer shall be required to sign and return to the Company the Acknowledgement and Acceptance Form attached hereto as <u>Exhibit A</u> pursuant to which such Executive Officer will acknowledge that he or she is bound by the terms of this Policy; provided, however, that this Policy shall apply to, and be enforceable against, any Executive Officer and his or her successors (as specified in Section 11 of this Policy) regardless of whether or not such Executive Officer properly signs and returns to the Company such Acknowledgement and Acceptance Form and regardless of whether or not such Executive Officer is aware of his or her status as such.

2.<u>Administration</u>. Except as specifically set forth herein, this Policy shall be administered by the Administrator. Any determinations made by the Administrator shall be final and binding on all affected individuals and need not be uniform with respect to each individual covered by this Policy. Subject to any limitation under applicable law, the Administrator may authorize and empower any officer or employee of the Company to take any and all actions necessary or appropriate to carry out the purpose and intent of this Policy (other than with respect to any recovery under this Policy involving such officer or employee).

3.<u>Definitions</u>. For purposes of this Policy, the following capitalized terms shall have the meanings set forth below.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)"***Accounting Restatement***" shall mean an accounting restatement: due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements (a "Big R" restatement), or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (a "little r" restatement).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)"***Administrator***" shall mean the Committee or any other committee designated by the Board to administer the Policy, and in the absence of such designation, the Board.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)"***Board***" shall mean the Board of Directors of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)"***Clawback Eligible Incentive Compensation***" shall mean, with respect to each individual who served as an Executive Officer at any time during the applicable performance period for any Incentive-based Compensation (whether or not such individual is serving as an Executive Officer at the time the Erroneously Awarded Compensation is required to be repaid to the Company), all Incentive-based Compensation Received by such individual: (i) on or after the Effective Date; (ii) after beginning service as an Executive Officer; (iii) while the Company has a class of securities listed on the Listing Exchange; and (iv) during the applicable Clawback Period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)"***Clawback Period***" shall mean, with respect to any Accounting Restatement, the three completed fiscal years of the Company immediately preceding the Restatement Date and any transition period (that results from a change in the Company's fiscal year) of less than nine months within or immediately following those three completed fiscal years.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)"***Clawback Rules***" shall mean Section 10D of the Exchange Act and any applicable rules or standards adopted by the SEC thereunder (including Rule 10D-1 under the Exchange Act) or the Listing Exchange pursuant to Rule 10D-1 under the Exchange Act (including Section 303A.14 of the New York Stock Exchange Listed Company Manual), in each case as may be in effect from time to time.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)"***Committee***" shall mean the Human Capital & Compensation Committee of the Board.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)"***Company***" shall mean International Flavors and Fragrances Inc. (and as the Administrator determines is applicable, together with each of its direct and indirect subsidiaries).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)"***Effective Date***" shall mean October 2, 2023.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)"***Erroneously Awarded Compensation***" shall mean, with respect to each Executive Officer in connection with an Accounting Restatement, the amount of Clawback Eligible Incentive Compensation that exceeds the amount of Clawback Eligible Incentive Compensation that otherwise would have been Received had it been determined based on the restated amounts, computed without regard to any taxes paid.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)"***Executive Officer***" shall mean any individual who is or was an executive officer as determined by the Administrator in accordance with the definition of "executive officer" as set forth in the Clawback Rules and any other senior executive, employee or other personnel of the Company who may from time to time be deemed subject to the Policy by the Administrator. For the avoidance of doubt, the Administrator shall have full discretion to determine which individuals in the Company shall be considered an "Executive Officer" for purposes of this Policy. A list of senior executives, employees or other personnel of the Company Group who have been determined by the Administrator to be "Executive Officers" for purposes of this policy is set forth in <u>Exhibit B</u>, which may be revised from time to time at the sole discretion of the Administrator. 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l)"***Exchange Act***" shall mean the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m)"***Financial Reporting Measures***" shall mean measures that are determined and presented in accordance with the accounting principles used in preparing the Company's financial statements, and any measures that are derived wholly or in part from such measures. Stock price and total shareholder return shall for purposes of this Policy be considered Financial Reporting Measures. For the avoidance of doubt, a Financial Reporting Measure need not be presented within the Company's financial statements or included in a filing with the SEC.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n)"***Incentive-based Compensation***" shall mean any compensation that is granted, earned or vested based wholly or in part upon the attainment of a Financial Reporting Measure.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o)"***Impracticable***" shall mean, in accordance with the good faith determination of the Committee, or if the Committee does not consist of independent directors, a majority of the independent directors serving on the Board, that either: (i) the direct expenses paid to a third party to assist in enforcing the Policy against an Executive Officer would exceed the amount to be recovered, after the Company has made a reasonable attempt to recover the applicable Erroneously Awarded Compensation, documented such reasonable attempt(s) and provided such documentation to the Listing Exchange; (ii) recovery would violate the Company's home country law where that law was adopted prior to November 28, 2022, provided that, before concluding that it would be Impracticable to recover any amount of Erroneously Awarded Compensation based on violation of home country law, the Company has obtained an opinion of home country counsel, acceptable to the Listing Exchange, that recovery would result in such a violation and a copy of the opinion is provided to the Listing Exchange; or (iii) recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a) and regulations thereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(p)&nbsp;&nbsp;&nbsp;&nbsp;"***Listing Exchange***" shall mean the New York Stock Exchange or such other U.S. national securities exchange or national securities association on which the Company's securities are listed.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(p)"***Method of Recovery***" shall include, but is not limited to: (i) requiring reimbursement of Erroneously Awarded Compensation; (ii) seeking recovery of any gain realized on the vesting, exercise, settlement, sale, transfer, or other disposition of any equity-based awards; (iii) offsetting the Erroneously Awarded Compensation from any compensation otherwise owed by the Company to the Executive

------

Officer; (iv) cancelling outstanding vested or unvested equity awards; and/or (v) taking any other remedial and recovery action permitted by applicable law, as determined by the Administrator.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(q)"***Policy***" shall mean this Policy for the Recovery of Erroneously Awarded Compensation, as the same may be amended and/or restated from time to time.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(r)"***Received***" shall, with respect to any Incentive-based Compensation, mean deemed receipt and Incentive-based Compensation shall be deemed received in the Company's fiscal period during which the Financial Reporting Measure specified in the Incentive-based Compensation award is attained, even if the payment or grant of the Incentive-based Compensation occurs after the end of that period. For the avoidance of doubt, Incentive-Based Compensation that is subject to both a Financial Reporting Measure vesting condition and a service-based vesting condition shall be considered received when the Financial Reporting Measure is achieved, even if the Incentive-Based Compensation continues to be subject to the service-based vesting condition.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(s)"***Restatement Date***" shall mean the earlier to occur of: (i) the date the Board, a committee of the Board or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement; or (ii) the date a court, regulator or other legally authorized body directs the Company to prepare an Accounting Restatement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(t)"***SEC***" shall mean the U.S. Securities and Exchange Commission.

4.<u>Repayment of Erroneously Awarded Compensation</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)In the event the Company is required to prepare an Accounting Restatement, the Administrator shall reasonably promptly (in accordance with the applicable Clawback Rules) determine the amount of any Erroneously Awarded Compensation for each Executive Officer in connection with such Accounting Restatement and shall reasonably promptly thereafter provide each Executive Officer with written notice containing the amount of Erroneously Awarded Compensation and a demand for repayment or return, as applicable. For Clawback Eligible Incentive Compensation based on stock price or total shareholder return where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in the applicable Accounting Restatement, the amount shall be determined by the Administrator based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or total shareholder return upon which the Clawback Eligible Incentive Compensation was Received (in which case, the Company shall maintain documentation of such determination of that reasonable estimate and provide such documentation to the Listing Exchange). The Administrator is authorized to engage, on behalf of the Company, any third-party advisors it deems advisable in order to perform any calculations contemplated by this Policy. For the avoidance of doubt, recovery under this Policy with respect to an Executive Officer shall not require the finding of any misconduct by such Executive Officer or such Executive Officer being found responsible for the accounting error leading to an Accounting Restatement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)In the event that any repayment of Erroneously Awarded Compensation is owed to the Company, the Administrator shall recover reasonably promptly the Erroneously Awarded Compensation through any Method of Recovery it deems reasonable and appropriate in its discretion based on all applicable facts and circumstances and taking into account the time value of money and the cost to shareholders of delaying recovery. For the avoidance of doubt, except to the extent permitted pursuant to the Clawback Rules, in no event may the Company accept an amount that is less than the amount of Erroneously Awarded Compensation in satisfaction of an Executive Officer's obligations hereunder. Notwithstanding anything herein to the contrary, the Company shall not be required to take the actions contemplated in this Section 4(b) if recovery would be Impracticable. In implementing the actions contemplated in this Section 4(b), the Administrator will act in accordance with the listing standards and requirements of the Listing Exchange and with the applicable Clawback Rules.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Subject to the discretion of the Administrator, an applicable Executive Officer may be required to reimburse the Company for any and all expenses reasonably incurred (including legal fees) by the Company in recovering Erroneously Awarded Compensation in accordance with Section 4(b).

------

5.<u>Reporting and Disclosure</u>. The Company shall file all disclosures with respect to this Policy in accordance with the requirements of U.S. federal securities laws, including any disclosure required by applicable SEC rules.

6.<u>Indemnification Prohibition</u>. The Company shall not be permitted to indemnify any Executive Officer against the loss of any Erroneously Awarded Compensation that is repaid, returned or recovered pursuant to the terms of this Policy and/or pursuant to the Clawback Rules or to pay or reimburse any Executive Officer for the cost of third-party insurance purchased by an Executive Officer to cover any such loss under this Policy and/or pursuant to the Clawback Rules. Further, the Company shall not enter into any agreement that exempts any Incentive-based Compensation from the application of this Policy or that waives the Company's right to recovery of any Erroneously Awarded Compensation and this Policy shall supersede any such agreement (whether entered into before, on or after the Effective Date). Any such purported indemnification (whether oral or in writing) shall be null and void.

7.<u>Interpretation</u>. The Administrator is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate, or advisable for the administration of this Policy. It is intended that this Policy be interpreted in a manner that is consistent with the requirements of the Clawback Rules. The terms of this Policy shall also be construed and enforced in such a manner as to comply with applicable law, including the Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, and any other law or regulation that the Administrator determines is applicable. In the event any provision of this Policy is determined to be unenforceable or invalid under applicable law, such provision shall be applied to the maximum extent permitted by applicable law and shall automatically be deemed amended in a manner consistent with its objectives to the extent necessary to conform to any limitations required by applicable law.

8.<u>Effective Date</u>. This Policy shall be effective as of the Effective Date.

9.<u>Amendment; Termination</u>. The Administrator may modify or amend this Policy, in whole or in part, from time to time in its discretion and shall amend any or all of the provisions of this Policy as it deems necessary, including as and when it determines that it is legally required by the Clawback Rules, or any federal securities law, SEC rule, or Listing Exchange rule. The Administrator may terminate this Policy at any time, and this Policy shall remain in effect only so long as the Clawback Rules apply to the Company. Notwithstanding anything in this Section 9 to the contrary, no amendment or termination of this Policy shall be effective if such amendment or termination would (after taking into account any actions taken by the Company contemporaneously with such amendment or termination) cause the Company to violate the Clawback Rules, or any federal securities law, SEC rule, or Listing Exchange rule. Furthermore, unless otherwise determined by the Administrator or as otherwise amended, this Policy shall automatically be deemed amended in a manner necessary to comply with any change in the Clawback Rules.

10.<u>Other Recoupment Rights; No Additional Payments</u>. The Administrator intends that this Policy will be applied to the fullest extent permitted by applicable law. The Administrator may require that any employment agreement, equity award agreement, or any other agreement entered into on or after the Effective Date shall, as a condition to the grant of any benefit thereunder, require an Executive Officer to agree to abide by the terms of this Policy.<sup>1</sup> Executive Officers shall be deemed to have accepted continuing employment on terms that include compliance with the Policy, to the extent of its otherwise applicable provisions, and to be contractually bound by its enforcement provisions. Executive Officers who cease employment or service with the Company shall continue to be bound by the terms of the Policy with respect to Clawback Eligible Incentive Compensation. Any right of recoupment under this Policy is in addition to, and not in lieu of, any other remedies or rights of recoupment that may be available to the Company under applicable law, regulation or rule or pursuant to the terms of any similar policy in any employment agreement, cash-based bonus plan, equity award agreement or similar agreement and any other legal remedies available to the Company. To the extent that an Executive Officer has already reimbursed the Company for any Erroneously Awarded Compensation Received under any duplicative recovery obligations established by the Company or applicable law, it shall be appropriate for any such reimbursed amount to be credited to the amount of Erroneously Awarded Compensation that is subject to

------

recovery under this Policy, as determined by the Administrator in its sole discretion. Nothing in this Policy precludes the Company from implementing any additional clawback or recoupment policies with respect to Executive Officers or any other service provider of the Company. Application of this Policy does not preclude the Company from taking any other action to enforce any Executive Officer's obligations to the Company, including termination of employment or institution of civil or criminal proceedings or any other remedies that may be available to the Company with respect to any Executive Officer.

11.<u>Successors</u>. This Policy shall be binding and enforceable against all Executive Officers and their beneficiaries, estates, heirs, executors, administrators or other legal representatives to the extent required by the Clawback Rules or as otherwise determined by the Administrator.

\*&nbsp;&nbsp;&nbsp;&nbsp;\*&nbsp;&nbsp;&nbsp;&nbsp;\*

------

**Exhibit A**

**INTERNATIONAL FLAVORS & FRAGRANCES INC. POLICY FOR THE<br>RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION**

**ACKNOWLEDGEMENT AND ACCEPTANCE FORM**

Capitalized terms used but not otherwise defined in this Acknowledgement and Acceptance Form shall have the meanings ascribed to such terms in the International Flavors and Fragrances Inc. Policy for the Recovery of Erroneously Awarded Compensation (the "***Policy***"). By signing below, the undersigned executive officer (the "***Executive Officer***") acknowledges and confirms that the Executive Officer has received and reviewed a copy of the Policy and, in addition, the Executive Officer acknowledges and agrees as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)the Executive Officer is and will continue to be subject to the Policy and that the Policy will apply both during and after the Executive Officer's employment with the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)to the extent necessary to comply with the Policy, the Policy hereby amends any employment agreement, equity award agreement or similar agreement that the Executive Officer is a party to with the Company and shall apply and govern Incentive-based Compensation Received by any Executive Officer, notwithstanding any contrary or supplemental term or condition in any document, plan or agreement including without limitation any employment contract, indemnification agreement equity agreement, or equity plan document. The foregoing notwithstanding, unless otherwise expressly required to comply with the Clawback Rules, this Policy will not amend or otherwise modify or replace any other remedies or rights of recoupment that may be available to the Company under applicable law, regulation or rule or pursuant to the terms of any similar policy in any employment agreement, cash-based bonus plan, equity award agreement or similar agreement and any other legal remedies available to the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)the Executive Officer shall abide by the terms of the Policy, including, without limitation, by returning any Erroneously Awarded Compensation to the Company to the extent required by, and in a manner permitted by, the Policy;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)any amounts payable to the Executive Officer, including any Incentive-based Compensation, shall be subject to the Policy as may be in effect and modified from time to time in the sole discretion of the Administrator or as required by applicable law or the requirements of the Listing Exchange, and that such modification will be deemed to amend this acknowledgment;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) the Company may recover compensation paid to the Executive Officer through any Method of Recovery the Administrator deems appropriate, and the Executive Officer agrees to comply with any request or demand for repayment by the Company in order to comply with the Policy;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)the recovery of Erroneously Awarded Compensation under this Policy will not give rise to any right to voluntarily terminate employment for "good reason," or due to a "constructive termination" (or any similar term of like effect) under any plan, program or policy of or agreement with the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)the Company may, to the greatest extent permitted by applicable law, reduce any amount that may become payable to the Executive Officer by any amount to be recovered by the Company pursuant to the Policy to the extent such amount has not been returned by the Executive Officer to the Company prior to the date that any subsequent amount becomes payable to the Executive Officer; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;&nbsp;&nbsp;&nbsp;any assertion or application of any rights under federal, state, local or foreign law or in contract or equity that would otherwise conflict with or narrow the Company's authority to interpret,

------

apply and enforce the Policy to its fullest extent, including but not limited to, the Company's authority to withhold or divert wages pursuant to the Policy, is hereby waived by the Executive Officer.

This Acknowledgment may be electronically signed and any digital or electronic signatures (including pdf, facsimile or electronically imaged signatures provided by DocuSign or any other digital signature provider) appearing on this Acknowledgment are the same as handwritten signatures for the purposes of validity, enforceability and admissibility, and that delivery of any such electronic signature to, or a signed copy of, this Acknowledgment may be made by facsimile, email or other electronic transmission.

<u>&nbsp;&nbsp;&nbsp;&nbsp;</u><br> Signature

<u>&nbsp;&nbsp;&nbsp;&nbsp;</u><br> Print Name

<u>&nbsp;&nbsp;&nbsp;&nbsp;</u><br> Date

------

**Exhibit B**

**INTERNATIONAL FLAVORS & FRAGRANCES INC. POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION**

**EXECUTIVE OFFICERS**

Section 16 Officers (Employees Only)

<br>